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SUMMARY 
 
 Streptococcus suis serotype 2 is an important swine pathogen responsible for 
diverse infections, meningitis being its most striking feature. In addition, it is an emerging 
agent of zoonosis, which has gained worldwide attention due to important outbreaks in 
Asia. Understanding the pathogenesis of S. suis infections still represents a challenge. Up to 
present, the pro-inflammatory response due to S. suis has only been studied in vitro, and 
there is still a great need of appropriate experimental models for both septic shock and 
meningitis. In the present study, we successfully developed an in vivo model of S. suis 
infection in adult mice infected by the intraperitoneal route. This model served to 
investigate the pro-inflammatory events that take place at both the systemic and Central 
Nervous System (CNS) levels associated with this important pathogen. In addition, this 
model was useful to determine if susceptibility to S. suis infection may be influenced by the 
genetic background of the host. 
 The mouse model of S. suis infection was standardized in CD1 mice. Results showed 
sustained bacteremia during the 3 days post-infection (p.i.), accompanied by a quick and 
substantial release of different pro-inflammatory cytokines (TNF-α, IL-6, IL-12p40/p70, IFN-
ɣ)  and chemokines (KC, MCP-1 and RANTES) that lead to septic shock and 20% mortality in 
mice. Once the hallmark of the septic phase of S. suis infection was established in CD1 
mice, research continued with the objective to confirm the role of inflammation in 
mortality and to determine if the genetic background of the host may influence the 
inflammatory response toward this pathogen and the further outcome of the disease. For 
this, the mouse model of S. suis infection was used with two genetically different inbred 
mouse strains, this is, C57BL/6 (B6) and A/J mice,  which are considered as the prototype of 
Th1-type  and Th2-type mice, respectively. Results demonstrated a striking susceptibility to 
S. suis infection in A/J mice in comparison to B6 mice, with 100% mortality in the former 
mice strain at 20 h p.i., and 16 % mortality at 36 h p.i. for the latter. Very interestingly, and 
similarly to CD1 mice, bacteremia did not seem to be responsible for the death of mice, as 
both mice strains presented similar amounts of bacteria in blood and organs. Thus, it was 
postulated that the higher mortality in S. suis-infected A/J mice was due to uncontrolled 
septic shock. In fact, A/J mice presented very high levels of TNF-α, IL-12p40/p70, IL-1β and 
IFN-ɣ, that significantly exceeded those found in B6 mice. Remarkably, chemokine levels 
were similar between strains, suggesting their limited participation in the development of 
septic shock by S. suis. A greater survival of B6 mice was partially related to a better 
regulation of the pro-inflammatory cytokine cascade, as they showed a higher production 
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of the anti-inflammatory cytokine IL-10 than A/J mice. The potential beneficial role of the 
IL-10 in mice infected with S. suis was confirmed using two approaches: the first, by 
blockage of the cell receptor of IL-10 (IL-10R) with an anti-mouse IL-10R monoclonal 
antibody (Mab) in B6 mice and the second by administrating recombinant mouse (rm)IL-10 
(rmIL-10) to A/J mice. B6 mice that received the IL-10R MAb treatment before challenge 
with S. suis developed a clinical acute disease similar to that observed with A/J mice, with a 
striking and rapid increase in mortality and higher levels of TNF-α in comparison to those of 
infected mice that did not receive the treatment. Controversially, treatment with rmIL-10 
significantly delayed the onset of septic shock in A/J mice infected with S. suis. These 
results show that survival from S. suis septic shock requires a tight regulation of pro- and 
anti-inflammatory mechanisms, and that the latter should be activated at the same time or 
soon after the onset of the pro-inflammatory response. This part of the study may 
represent a
 
first step in the identification of host genes associated
 
with resistance against S. 
suis. 
 One of the most important achievements of the mouse model of infection 
described in this project is the development of distinct clinical signs of neurological disease 
in CD1 mice from 4 days p.i. Indeed, in CD1 mice that survived sepsis due to S. suis 
infection, clinical signs of neurological disease and vestibular syndrome, which are quite 
similar to those observed in clinical cases of S. suis meningitis in both pigs and humans, 
were observed. Studies of the brains of infected CD1 mice using in situ hybridization 
combined with immunocytochemistry, demonstrated that the CNS inflammatory response 
began with a significant increase in the transcription of Toll-like receptor (TLR)2 and CD14 
initially in the brain microvasculature and choroid plexuses, suggesting that S. suis may use 
these structures as portals of entry to the brain. There also was activation of NF-κB (as 
indicated by transcriptional activation of IκBα as a reporter system) and TNF-α, IL-1β and 
MCP-1, mainly in cells identified as microglia and to a lesser extent in astrocytes. These 
signals reached different brain structures, mainly the brain cortex, corpus callosum, 
hippocampus, choroid plexuses, thalamus, hypothalamus and meninges. All of these pro-
inflammatory events were associated with extensive areas of inflammation and necrosis, 
severe demyelination and presence of antigens of S. suis inside microglia. 
 In vitro studies were conducted in order to better understand the interactions of S. 
suis and microglia. For this, mouse microglia were infected with a virulent wild type (WT) 
strain of S. suis. Two isogenic mutants deficient in capsule (CPS) or hemolysin production 
(suilysin, SLY) respectively, were also included for comparative purposes. The CPS was 
important for S. suis resistance to phagocytosis, and it also modulated the inflammatory 
response by hiding pro-inflammatory components from the bacterial cell wall. On the other 
hand, the absence of SLY, a potential cytotoxic factor, did not have a major impact on S. 
suis interactions with microglia. Studies with microglia helped to confirm previous findings 
in vivo in mice, as the WT S. suis strain induced the up-regulation of TLR2 and the 
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production of several pro-inflammatory mediators, including TNF-α and MCP-1. As 
observed in mice, S. suis induced NF-kB translocation, which was more rapid for cells 
stimulated with the CPS-deficient mutant, suggesting that bacterial cell wall components 
are potent inducers of NF-kB. Moreover, WT S. suis promoted phosphotyrosine, PKC and 
different mitogen-activated protein kinase (MAPK) events. However, microglia infected 
with the CPS-deficient mutant showed overall stronger and more sustained 
phosphorylation profiles. Finally, the CPS also modulated S. suis-induced inducible nitrogen 
oxide synthase (iNOS) expression and further nitric oxide production in microglia, which 
could be related to neurotoxicity and vasodilatation in vivo. 
 
 We are confident that our results may help to more fully understand the 
mechanisms underlying S. suis induction of inflammation, leading to the design of more 
efficient anti-inflammatory strategies for sepsis and meningitis. Finally, we believe this 
experimental model of infection in mice could also be useful for studying the pathogenesis 
of infections of the CNS, due to other bacteria. 
 
 
Key words: Streptococcus suis, mouse, sepsis, meningitis, inflammation, cytokine, 
chemokine, microglia,TLR2, NF-κB, MAPK, nitric oxide.  
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RÉSUMÉ 
 
 Streptococcus suis de type 2 est un microorganisme pathogène d’importance chez 
le porc. Il est la cause de différentes pathologies ayant comme caractéristique commune la 
méningite. C’est également un agent émergeant de zoonose : des cas cliniques humains 
ont récemment été rapportés en Asie. Cependant, la pathogénèse de S. suis n’est pas 
encore complètement élucidée. Jusqu’à présent, la réponse pro-inflammatoire initiée par 
S. suis n’a été étudiée qu’in vitro. L’étude du choc septique et de la méningite requiert 
toujours des modèles expérimentaux appropriés. Au cours de cette étude, nous avons 
développé un modèle in vivo d’infection chez la souris qui utilise la voie d’inoculation intra-
péritonéale. Ce modèle a servi à l’étude de la réponse pro-inflammatoire associée à ce 
pathogène, tant au niveau systémique qu’au niveau du système nerveux central (SNC). Il 
nous a également permis de déterminer si la sensibilité aux infections à S. suis pouvait être 
influencée par des prédispositions génétiques de l’hôte. 
 Le modèle d’infection par S. suis a été mis au point sur des souris de lignée CD1. Les 
résultats ont démontré une bactériémie élevée pendant les trois jours suivant l’infection. 
Celle-ci était accompagnée d’une libération rapide et importante de différentes cytokines 
pro-inflammatoires (TNF-α, IL-6, IL-12p40/p70, IFN-ɣ) et de chémokines (KC, MCP-1 and 
RANTES), qui ont entraîné un choc septique et la mort de 20 % des animaux. Ensuite, pour 
confirmer le rôle de l’inflammation sur la mortalité et pour déterminer si les 
caractéristiques génétiques de l’hôte pouvaient influencer la réponse inflammatoire et 
l’issue de la maladie, le modèle d’infection a été étendu à deux lignées murines 
consanguines différentes considérées comme résistante : la lignée C57BL/6 (B6), et 
sensible : la lignée A/J.  
 Les résultats ont démontré une importante différence de sensibilité entre les souris 
A/J et les souris B6, avec un taux de mortalité atteignant 100 % à 20 h post-infection (p.i.) 
pour la première lignée et de seulement 16 % à 36 h p.i. pour la seconde. La quantité de 
bactéries dans le sang et dans les organes internes était similaire pour les deux lignées. 
Donc, tout comme dans la lignée CD1, la bactériémie ne semblait pas être liée à la mort des 
souris. La différence entre les taux de mortalité a été attribuée à un choc septique non 
contrôlé chez les souris A/J infectées par S. suis. Les souris A/J présentaient des taux 
exceptionnellement élevés de TNF-α, IL-12p40/p70, IL-1β and IFN- γ, significativement 
supérieurs à ceux retrouvés dans la lignée B6. Par contre, les niveaux de chémokines 
étaient similaires entre les lignées, ce qui suggère que leur influence est limitée dans le 
développement du choc septique dû à S. suis. Les souris B6 avaient une production plus 
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élevée d’IL-10, une cytokine anti-inflammatoire, ce qui suppose que la cascade cytokinaire 
pro-inflammatoire était mieux contrôlée, entraînant un meilleur taux de survie. Le rôle 
bénéfique potentiel de l’IL-10 chez les souris infectées par S. suis a été confirmé par deux 
approches : d’une part en bloquant chez les souris B6 le récepteur cellulaire à l’IL-10 (IL-
10R) par un anticorps monoclonal anti-IL-10R de souris et d’autre part en complémentant 
les souris A/J avec de l’IL-10 de souris recombinante. Les souris B6 ayant reçu le anticorps 
monoclonal anti-IL-10R avant d’être infectées par S. suis ont développé des signes cliniques 
aigus similaires à ceux observés chez les souris A/J, avec une mortalité rapide et élevée et 
des taux de TNF-α plus élevés que les souris infectées non traitées. Chez les souris A/J 
infectées par S. suis, le traitement avec l’IL-10 de souris recombinante a significativement 
retardé l’apparition du choc septique. Ces résultats montrent que la survie au choc 
septique dû à S. suis implique un contrôle très précis des mécanismes pro- et anti-
inflammatoires et que la réponse anti-inflammatoire doit être activée simultanément ou 
très rapidement après le début de la réponse pro-inflammatoire. Grâce à ces expériences, 
nous avons donc fait un premier pas dans l’identification de gènes associés à la résistance 
envers S. suis chez l’hôte. 
 Une des réussites les plus importantes du modèle d’infection de la souris décrit 
dans ce projet est le fait que les souris CD1 ayant survécu à la septicémie présentaient dès 
4 jours p.i. des signes cliniques neurologiques clairs et un syndrome vestibulaire 
relativement similaires à ceux observés lors de méningite à S. suis chez le porc et chez 
l’homme. L’analyse par hybridation in situ combinée à de l’immunohistochimie des 
cerveaux des souris CD1 infectées a montré que la réponse inflammatoire du SNC débutait 
avec une augmentation significative de la transcription du Toll-like receptor (TLR)2 et du 
CD14 dans les microvaisseaux cérébraux et dans les plexus choroïdes, ce qui suggère que 
S. suis pourrait se servir de ces structures comme portes d’entrée vers le cerveau. Aussi, le 
NF-κB (suivi par le système rapporteur de l’activation transcriptionnelle de IκBα), le TNF-α, 
l’IL-1β et le MCP-1 ont été activés, principalement dans des cellules identifiées comme de 
la microglie et dans une moindre mesure comme des astrocytes. Cette activation a 
également été observée dans différentes structures du cerveau, principalement le cortex 
cérébral, le corps calleux, l’hippocampe, les plexus choroïdes, le thalamus, l’hypothalamus 
et les méninges. Partout, cette réaction pro-inflammatoire était accompagnée de zones 
extensives d’inflammation et de nécrose, de démyélinisation sévère et de la présence 
d’antigènes de S. suis dans la microglie. 
 Nous avons mené ensuite des études in vitro pour mieux comprendre l’interaction 
entre S. suis et la microglie. Pour cela, nous avons infecté des cellules microgliales de souris 
avec la souche sauvage virulente (WT) de S. suis, ainsi qu’avec deux mutants isogéniques, 
un pour la capsule (CPS) et un autre pour la production d’hémolysine (suilysine). Nos 
résultats ont montré que la capsule était un important mécanisme de résistance à la 
phagocytose pour S. suis et qu’elle modulait la réponse inflammatoire, en dissimulant les 
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composants pro-inflammatoires de la paroi bactérienne. Par contre, l’absence 
d’hémolysine, qui est un facteur cytotoxique potentiel, n’a pas eu d’impact majeur sur 
l’interaction de S. suis avec la microglie. Ces études sur les cellules microgliales ont permis 
de confirmer les résultats obtenus précédemment in vivo. La souche WT a induit une 
régulation à la hausse du TLR2 ainsi que la production de plusieurs médiateurs pro-
inflammatoires, dont le TNF-α et le MCP-1. S. suis a induit la translocation du NF-kB. Cet 
effet était plus rapide dans les cellules stimulées par le mutant déficient en CPS, ce qui 
suggère que les composants de la paroi cellulaire représentent de puissants inducteurs du 
NF-kB. De plus, la souche S. suis WT a stimulé l’expression de la phosphotyrosine, de la PKC 
et de différentes cascades liées à l’enzyme mitogen-activated protein kinase (MAPK). 
Cependant, les cellules microgliales infectées par le mutant déficient en CPS ont montré 
des profils de phosphorylation plus forts et plus soutenus que celles infectées par le WT. 
Finalement, la capsule a aussi modulé l’expression de l’oxyde nitrique synthétase inductible 
(iNOS) induite par S. suis et par la production subséquente d’oxyde nitrique par la 
microglie. Ceci pourrait être lié in vivo à la neurotoxicité et à la vasodilatation. 
 Nous pensons que ces résultats contribueront à une meilleure compréhension des 
mécanismes sous-tendant l’induction de l’inflammation par S. suis, ce qui devrait 
permettre, d’établir éventuellement des stratégies plus efficaces de lutte contre la 
septicémie et la méningite. Enfin, nous pensons que ce modèle expérimental d’infection 
chez la souris pourra être utilisé dans l’étude de la pathogénèse d’autres bactéries ayant le 
SNC pour cible. 
 
Mots-clefs : Streptococcus suis, souris, septicémie, méningite, inflammation, cytokine, 
chémokine, cellules microgliales, TLR2, NF-κB, MAPK, oxyde nitrique. 
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Streptococcus suis is one of the most important pathogens affecting the swine 
industry worldwide, and it also is a relevant agent of zoonosis. In pigs, the most frequently 
reported pathologies include septicemia and central nervous system (CNS) infection, leading 
to meningitis, endocarditis, pneumonia and arthritis. In humans, S. suis infection has been 
considered as a work-related infection, as most of the cases described have occurred in 
people working in close relationship with pigs or raw pork products. In 2005, an important S. 
suis human outbreak in China, attracted worldwide attention to this pathogen, highlighting 
the menace it represents for human health. In this episode of S. suis infection, more than 
two hundred people were affected, including thirty nine deaths. Furthermore, in several 
Asian countries, cases of zoonotic infections by S. suis have escalated, and it is currently 
considered as the most important agent of adult meningitis in Vietnam. To date, thirty five 
S. suis serotypes have been reported, however, serotype 2 is still by far the most frequently 
isolated from both diseased animals and humans (at least in Europe and Asia), and it is also 
considered as the most virulent.  
The mechanisms that S. suis exploits to invade and colonize the host and cause 
disease and the response of the host to such aggression have only been partially clarified. 
The capsular polysaccharide (CPS) of S. suis is known to play a crucial role in the progression 
of disease, as it hampers phagocytosis and helps bacteria to persist in the blood, allowing 
them to multiply and disseminate throughout the body, leading to septicemia and/or CNS 
disease. However, although all virulent S. suis strains are well capsulated, the presence 
alone of capsule does not warrant disease as most avirulent strains are also well 
encapsulated, indicating that other virulence factors are also essential. Many virulent strains 
of S. suis also possess a hemolysin (suilysin -SLY-, a member of thiol-activated cytolysin 
family of hemolysins) that may also participate in the development of the disease, although 
it does not seem to be a critical trait. Another proposed virulence factor is the serum 
opacity factor (OFS) which proved to be a relevant trait for the virulence of S. suis, as an 
isogenic mutant was greatly attenuated in virulence but not in colonization. However, the 
OFS is not present in all virulent strains. Recently, many putative virulence factors have 
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been described, amongst which, the ᴅ-alanylation of lipoteichoic acid (LTA) and N-
acetylation of peptidoglycan (PG) have proved to be determinant for the virulence of this 
pathogen, as their respective isogenic mutants are not only more susceptible to the killing 
effect of different components from the innate immune sytem, but are also less virulent in 
pig and mouse infection models. Other potential S. suis proteins associated with virulence 
have been described, although they are not always present in all virulent strains. These 
include the extracellular protein factor (EF), the muramidase-released protein (MRP), a 
fibronectin/fibrinogen-binding protein (FBPS), a hialuronidase, different adhesins, and 
several proteases. 
Despite much effort, elucidation of the pathogenesis of both systemic and CNS 
infections
 
caused by S. suis remains a challenge. In the natural host, S. suis enters through 
the respiratory route and colonizes the tonsils, whereas in humans, the entrance is mainly 
through skin abrasions. Bacteria subsequently reach the bloodstream where the CPS will 
contribute to resistance to phagocytosis. Dissemination occurs as bacteria multiply and 
spread either freely or as cell-bound bacteria attached to monocytes/macrophages (the 
“modified Trojan horse” theory). This bacteremia often results in fatal septicemia and toxic 
shock-like syndrome. Several studies have demonstrated that S. suis induces the up-
regulation of different adhesion molecules, as well as the production of diverse cytokines 
and chemokines in monocytes, which may trigger the inflammatory response and enhance 
the recruitment of leukocytes at sites of infection. However, all of these studies have been 
done in vitro. 
If the host is able to resist septicemia, it may still develop meningitis, which is the 
most striking clinical feature of S. suis infection. In order to gain access to the CNS and 
provoke meningitis, S. suis should trespass the blood brain barrier (BBB). It has been 
demonstrated that S. suis is able to adhere to and to invade porcine brain microvascular 
endothelial cells (PBMEC), and that SLY is cytotoxic for these cells. There is also evidence of 
the relevance of the blood-cerebrospinal fluid barrier (CSF) as a possible gate for S. suis 
entry into the central nervous system. Indeed, S. suis is capable of invading porcine choroid 
plexus epithelial cells (PCPEC, the single-cell layer comprising the blood–CSF barrier), with 
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the activation of different intracellular signaling pathways involved in cellular uptake. Once 
in the brain, S. suis must face the local defense system, represented principally by microglia, 
which are the brain’s macrophages. These cells are designed to respond quickly to 
pathogens and injury and to produce a wide variety of pro-inflammatory molecules. 
However, if stimulation is exaggerated, there will be an exacerbated local inflammatory 
response with negative consequences for the host.  Studying the interactions between S. 
suis and microglia is necessary to have a better understanding of the development of the 
inflammatory response against this pathogen in the CNS and the possible pathological 
consequences. 
As mentioned previously, certain of the pro-inflammatory events associated to S. 
suis have been studied in vitro only. Hence, and there is no in vivo confirmation of the 
machinery triggered by S. suis for the development of the inflammatory response at a 
systemic level or in the CNS, upon infection. Furthermore, to date, there is no available data 
on potential immune factors associated with genetic susceptibility to S. suis infection.  The 
use of the mouse or murine cells as experimental models of S. suis infection is justified, 
since previous studies in the mouse showed that this animal species is susceptible to 
infection by this pathogen. However, these previous efforts were used to assess mainly 
disease outcomes and compare them to those observed for experimentally infected pigs.   
In addition, in vivo research on S. suis infection permit the evaluation of the 
importance of different putative virulence factors. Increased knowledge on the mechanisms 
underlying S. suis induction of inflammation in the brain would be useful for the design of 
more efficient anti-inflammatory strategies in cases of meningitis that may be used in both 
swine and humans.  
The main overall objective of this research project is to strengthen the current 
knowledge on the pathogenesis of S. suis infection by focusing on the development of the 
inflammatory response triggered by this important pathogen at both systemic and CNS 
levels.  
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The specific objectives of this research are: 
1. To study the in vivo progression of S. suis infection at both the systemic and 
CNS levels using a standardized model. This objective focuses on the 
characterization of the inflammatory hallmark of systemic infection, 
including the development of clinical signs and measurement of a panel of 
pro-inflammatory markers at the systemic level.  
2. To dissect in vitro some of the pro-inflammatory machinery activated by S. 
suis in murine microglia. This objective focuses on TLRs recognition, ability of 
microglia to phagocyte S. suis, as well as different intracellular signalling 
pathways that may lead to the production of different pro-inflammatory 
mediators and messenger molecules involved in inflammation.  
3. To identify possible genetic immune traits associated with host susceptibility 
to S. suis infection.  For this objective, the mouse model of infection will be 
used to compare the severity of infection between two genetically different 
inbred mouse strains. Different sepsis-clinical parameters and inflammatory 
mediators are evaluated to dissect possible immune factors associated with 
genetic susceptibility.  
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1. Streptococcus suis  
 
1.1. General aspects of S.  suis 
 S. suis is currently considered as one of the most important  pathogens of the swine 
industry worldwide, responsible for substantial economical losses. The most frequent 
pathologies include meningitis, septicemia, arthritis, pneumonia and endocarditis [6]. It is also 
a zoonotic agent responsible for meningitis, septicemia, toxic shock-like syndrome and 
endocarditis [7, 8]. S. suis is a Gram-positive, facultatively anaerobic coccus, possessing cell wall 
antigenic determinants related to Lancefield group D, although it is genetically unrelated to 
other members of this group [6, 9]. S. suis occurs singly, in pairs and, rarely, in short chains, 
forming small, grey, colonies. Although some strains are β-hemolytic and produce a hemolysin 
on agar plates containing horse blood agar, all strains of this species are α -hemolytic when 
grown on blood agar plates containing sheep blood [10]. S. suis is characterized by absence of 
growth in 6.5 % NaCI agar, a negative Voges-Proskauer test, production of acid in trehalose and 
salicin broth and production of amylase [11, 12]. The NaCI (6.5%) test clearly differentiates 
between S. suis and Streptococcus bovis from the genus Enterococcus. The Voges-Proskauer 
test is critical and the most reliable for differentiating S. suis from S. bovis [12].  
S. suis was first reported by veterinarians in the early 1950’s from piglets and adult 
swine,  from which α-hemolytic streptococci were isolated [13, 14]. Early classification of these 
bacteria determined that they belonged to groups R, S, R, S and T, according to Lancefield 
classification of streptococci [15]. However, this classification was inaccurate, as Elliot (1966) 
demonstrated that they belonged to group D. Misclassification was due to the fact that the 
LTA, the antigen from the cell wall that allows classification of streptococci into group D, was 
masked by antigens from the CPS used by de Moor [16]. S. suis was officially recognized as a 
species in 1987, when Kilpper-Bälz and Scheleifer used DNA hybridization and cell wall analysis 
to demonstrate that S. suis is not closely related to group D streptococci and that it constitutes 
a genetically homogeneus species [17].  
Current classification of S. suis is based on its CPS antigens, and 35 serotypes, namely 1, 
1/2, 2 - 34 have been described (Fig. 1) [6]. However, recent evidence suggested that serotypes 
32 and 34 should be excluded from the S. suis species and re-designated as Streptococcus 
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orisratti [18]. Moreover, the 16S rRNA gene sequence analysis of the 35 reference strains of S. 
suis demonstrated that serotypes 32, 33 and 34 might belong to a different species [19]. In S. 
suis serotype 2, the antigen epitope portion corresponds to the N-Acetylneuraminic acid [20]. 
Some of the reference strains of these serotypes originated from diseased pigs whereas others 
were isolated from the nasal cavities of clinically healthy pigs [6]. Reference strains of serotypes 
20, 31 were recovered from diseased calves, whereas serotype 33 was isolated from a lamb 
and reference strain of serotype 14 from a case of human meningitis [12, 21, 22]. The number 
of untypeable isolates is, in general, relatively low. These isolates are mostly recovered from 
sporadic cases of disease and it seems that there is no justification at the present time fot the 
characterization of new capsular types [23]. Some serotypes cross-react, indicating that some 
capsular antigenic determinants are shared. This is the case for serotype 1/2 cross-reaction 
with serotype 1 and serotype 2 antisera [24].  
 
Fig. 1. Transmission electron microphotograph of thin sections of S. suis serotype 2 reference 
strain S735, which shows a thick capsule characteristic of this serotype. Original magnification 
37,500×. Taken from [25]. 
Among all capsular types, S. suis serotype 2 is the most frequently isolated and is 
considered as the most virulent in several European and Asian countries [26-30].  In Japan, the 
prevalence of S. suis serotype 2 is around 28% [31], whereas in Spain and France it is of 51% 
and 69%, respectively [26, 27]. In North America, serotype distribution greatly differs from that 
reported in several European countries. In fact, recent data show that the incidence of S. suis 
serotype 2 strains recovered from diseased animals in Canada is relatively low (less than 25%) 
[32], whereas in the United States (US), most of S. suis field strains belong to serotype 3 (20% 
of the isolates) and serotype 2 (17%). The similarities between the results from Canada and US 
suggest a  common status in North America [33]. 
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1.2. S. suis infection and transmission 
 
1.2.1. In swine 
S. suis can affect pigs of all ages. However, the disease is most common following 
weaning and mixing, and the majority of cases occur between 3 and 12 weeks of age [34]. The 
incidence of the disease varies from herd to herd and also within a herd over a period of time. 
No seasonal incidence has been noted in pigs [35, 36]. Different management practices and/or 
the presence of other pathogens have been suggested as predisposing factors [37]. In fact, S. 
suis infection is associated with stressful management practices, such as excessive temperature 
fluctuation, high relative humidity, poor ventilation, crowding, an age spread of > 2 weeks 
between pigs in the same room, weaning and/or moving animals [37].  
The natural habitat of S. suis is the upper respiratory tract (particularly the tonsils and 
nasal cavities) and the genital and alimentary tracts of pigs [6], although it can also be isolated 
from the lungs, the vagina, and the prepuce of pigs [38, 39]. In this species, S. suis is responsible 
for meningitis, meningoencephalitis, septicemia, arthritis and endocarditis [6]. Onset of 
infection is characterized by anorexia, depression and high fever, up to 42°C, glazed eyes, and 
reddening of mucous membranes. [6, 40-42]. After several days, diseased animals develop 
neurological signs, including opisthotonus, lateral recumbency, paddling, convulsions, and 
ataxia (Fig. 2) [40-43]. Some animals may also present lameness in one or more legs as arthritis 
develops [41, 42]. 
 
Fig. 2. Experimental infection with S. suis serotype 2 in a piglet. Typical clinical signs of S. suis 
meningitis: lateral recumbency and front limb-paddling.  
In animals that have died due to septicemia, gross findings include bronchopneumonia, 
arthritis (Fig 3A) and diffuse inflammation of the heart (Fig. 3B), spleen, liver and serosae. 
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Histopathological examination of these organs usually reveals suppurative or fibrinopurulent 
inflammation [6, 43, 44]. In some cases, even though meningoencephalitis is evident, isolation 
of the pathogen from brain and meninges is negative, indicating that isolation of S. suis from 
other organs should be attempted to confirm the etiology [43].  
  
Fig. 3. Experimental infection with S. suis serotype 2 in a piglet. (A) Rear limb articulation, 
demonstrating that the synovial membrane is thickened (arrow), and that there is a fibrino-
haemorragic exudate. (B) Heart, fibrinous exudate on the epicardium.  
In the CNS, findings include meningeal haemorrhages, congestion and thickening of the 
dura mater, with flattening of gyri as a result of compression of the swollen
 
brain by the dura 
mater and inner surface of the skull, shallowing of cerebullar sulci and increase in the volume 
of yellowish cerebrospinal fluid [42, 43]. Microscopically, the meninges are hemorrhagic, 
infiltrated by neutrophils
 
and macrophages (Fig. 4A).  Encephalitis is associated with marked 
cerebral edema characterized
 
by broadening of perivascular spaces, massive
 
infiltration of 
neutrophils, focal proliferation of
 
microglial cells and gliosis (Fig. 4B). The choroid plexuses of 
the lateral,
 
third, and fourth ventricles may show marked congestion associated
 
with scant 
cellular exudates [42]. 
A B 
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Figure 4. Clinical case of S. suis infection in a piglet. (A) Brain, showing severe thickening of the 
meninges, due to the massive infiltration of leukocytes (arrow). (B) Edema and infiltration of 
leukocytes in the perivascular space (arrow) and gliosis (arrow head).  
Infected pigs generally have clinical signs and lesions referable to either the respiratory 
system or to the CNS, but not both [43]. S. suis is commonly isolated from the respiratory tract 
of pigs with respiratory disease. However, it is unclear whether the organism is a primary agent 
of pneumonia. Indeed, S. suis is often isolated in combination with other respiratory 
pathogens, such as Pasteurella multocida, Actinobacillus pleuropneumoniae, Haemophilus 
parasuis, Bordetella bronchiseptica and others [45, 46], suggesting that, in these cases, S. suis 
may act as an opportunistic pulmonary pathogen. This hypothesis is supported by the difficulty 
to reproduce respiratory clinical signs in experimentally infected animals. In fact pre-infection 
with B. bronchiseptica is needed for the induction of S. suis pneumonia during experimental 
trials [47]. In contrast, in pigs with meningitis or meningoencephalitis, S. suis is considered a 
primary pathogen since it is the only bacterial species isolated from the brain of these pigs [46]. 
Viral infections such as Aujeszky's disease virus, porcine reproductive and respiratory syndrome 
(PRRS) virus and porcine circovirus (PCV) may predispose pigs to infection with S. suis [48-50].  
S.suis can be both vertically and horizontally transmitted. Piglets born from sows with 
uterine and/or vaginal infections are either infected or become infected at birth [51]. They can 
also acquire the bacterium after birth due to close contact with the sow, her feces and contact 
with piglets from other litters and the surrounding environment [6, 52]. Strategies for the 
elimination of S. suis based on off site production or early weaning have not been successful 
because many piglets are carriers of S. suis within the first days of life. Entrance of S. suis  to 
naïve pig production facilities is through asymptomatic infected animals carrying pathogenic 
strains [6, 34]. It has been proposed that once a pig is infected with S. suis serotype 2, it may 
B A 
12 
 
remain a carrier for life [53]. Pigs may harbor different S. suis strains (even of different 
serotypes) in their nasal cavities and tonsils with no relationship with a specific pathological 
condition [54]. Multiple S. suis serotypes have also been isolated from diseased animals within 
the same herd [6, 46].  
1.2.2. In humans  
Human S. suis infections are most often reported from countries where pig-rearing is 
common. It has traditionally been considered as an occupational disease, as most of the cases 
are reported in people working with pigs or pig-derived products [55, 56]. Since the first report 
of human S. suis infection in Denmark in 1968 [57], many cases have been reported in several 
European countries (The Netherlands, Italy, Spain, United Kingdom, Belgium, Croatia, Austria, 
Sweden, Germany, Ireland, Hungary, France, Greece, Italy, Hungary, Portugal) and Asian 
countries (Japan, China, Hong Kong, Taiwan, Thailand, Singapore) as well as in Canada, the US, 
Australia, New Zealand, and Argentina [7, 58-61]. Most cases of S. suis infection have been 
attributed to serotype 2 strains [7]. However, cases due to serotype 4 [62], serotype 14 [63-65], 
and serotype 16 [66] have also been reported. Two human cases have been attributed to 
serotype 1, although the isolates from these cases were not confirmed with a serologic reaction 
using specific antisera [67]. 
However, the classical picture of S. suis infection as an occupational disease has 
drastically changed, as large outbreaks took place in China in 1998 and 2005 (see description 
below 1.2.2.1) [7, 68]. Currently, S. suis infection has become an important public health 
concern in several Asian countries but rate of S. suis human infection may not be precise, as in 
developing countries with intense pig farming, such as those in Southeast Asia, disease due to 
S. suis infection is not notifiable and under diagnosis is common [69]. In fact, S. suis is currently 
the primary cause of adult meningitis in Vietnam as well as the third most common cause of 
community-acquired bacterial meningitis in Hong Kong [69-72] .  
S. suis causes a systemic infection in humans that affects several systems; meningitis is 
the most common clinical manifestation. The presenting features of S. suis meningitis are 
generally similar to those of other bacterial pyogenic meningitis and include frontal headache, 
fever, diaphoresis, vomiting, a stiff neck, confusion and generalized tonic clonic seizures. Sick 
people are often admitted to the hospital 2–5 days after the onset of clinical signs [56]. Besides 
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meningitis, patients may also present endocarditis, cellulitis, peritonitis, rhabdomyolysis, 
arthritis, spondylodiscitis, pneumonia, uveitis and endophthalmitis [69, 73-75]. In some cases 
pulmonary embolism, lumbar epidural abscesses, aortic aneurisms and brain stem 
ophthalmoplegia leading to persistent dipoplia have also been reported [61, 76-78]. An 
association between S. suis infection and colon carcinoma has also been suggested [79].  
Deafness and/or vestibular dysfunction, which may be permanent and disabling, are 
the most common sequela of S. suis meningitis, recorded in up to one-half of patients at 
presentation or a few days later. This hearing loss may be the result of damage to the eight 
craneal nerve or secondary to cochlear sepsis, resulting from passage of the organism from the 
sub-arachnoid space to the perilymph via the cochlear aqueduct [78, 80]. For unknown 
reasons, the recorded incidence of deafness following infection caused by S. suis is higher than 
that reported for other meningitis-causing bacteria, such as Streptococcus pneumoniae, 
Neisseria meningitidis and Haemophilus influenzae, and can reach 50% and 65% in Europe and 
Asia, respectively [75]. Deafness, however, has never been reported in non-meningitis cases of 
S. suis human infection [7]. The overall case fatality rate from S. suis infection reaches near 13% 
in Europe and 20% in Asia [74]. Interestingly, only five human cases of meningitis have been 
reported in North America (three in Canada and two in the US). However, recent information 
suggest that human infection with S. suis is more common in the US than currently thought, as 
swine-exposed persons had higher titers of antibodies to S. suis than did non–swine-exposed 
persons [81]. As S. suis can be mistaken for enterococci, Listeria spp., viridans streptococcus, or 
S. pneumoniae, it should be considered in the differential diagnosis of septicemia, especially 
when complicated by meningitis in adults with a recent history of contact with pigs or 
unprocessed pork [82]. 
The route of infection differs from the natural host, as in humans, entry of the 
organism occurs through small cuts in the skin, mucosa of the mouth and nasal cavity [7, 83]. 
Additionally, infection through ingestion by contaminated food has been proposed [84]. In 
general, high exposure to S. suis may lead to a colonization of the upper respiratory tract 
without producing any health consequences. In certain cases clinical disease will follow [7]. The 
bacterium may colonize the gastrointestinal tract, as suggested by the presence of diarrhea as 
a prodromal symptom [85]. The incubation period ranges from a few hours to two days [85]. 
Almost all cases of human infection can be assigned to close contact with pigs or to a high 
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degree of exposure to unprocessed pork meat, which in certain markets, has been found to be 
contaminated with S. suis [71, 86]. With few exceptions, most cases (in general adult males) are 
pig farmers, abattoir workers, people transporting pork, meat inspectors, butchers and 
veterinary practitioners [74, 75, 87]. Splenectomy, alcoholism and diabetes mellitus have been 
suggested as important predisposing factors for the development of serious S. suis disease [74, 
88, 89]. Most studies showed that strains isolated from humans are phenotypically and 
genotypically similar to those recovered from swine within the same geographical region [90-
95]. In addition, the virulence properties of strains isolated from pigs or humans appear to be 
similar [7]. 
1.2.2.1.    Human outbreak in China 
 The first important outbreak  of human S. suis serotype 2 infection took place in 1998, 
in the province of Jiangsu, China, resulting in fourteen deaths [96]. In the summer of 2005, 
another mores substantial episode of human infection was recorded in the province of Sichuan, 
China, with two hundred-fifteen cases of acute disease and a total of thirty-nine deaths. In the 
Sichuan episode, all infections occurred in backyard farmers who were directly exposed to 
infection during the handling of pigs that had died of unknown causes or been killed for 
comsumption,  even if they were ill. In addition, the oral route of infection can not be ruled out 
[95].  These Chinese outbreaks did not follow the classical clinical presentation of S. suis 
infection, as they were characterized by a high incidence of systemic disease with elevated 
rates of mortality and a proportionally low number of cases of meningitis [82]. In all cases, 
there was no evidence of human to human infection. At first, Chinese cases were misdiagnosed 
as streptococcal toxic shock syndrome (STSS) as patients presented a sudden onset of disease, 
with high fever, diarrhea, hypotension, blood spots and petechia, clear erythematous blanching 
rash and dysfunction of multiple organs, such as acute respiratory distress syndrome, liver and 
heart failure, disseminated intravascular coagulation and acute renal failure [87, 95]. However, 
the presence of superantigens could not be demonstrated in the strains isolated during the 
Sichuan outbreak [28, 87, 95]. S. suis serotype 2 sequence type 7 strains emerged in 1996 and 
caused a STSS in the 1998 and 2005 Chinese outbreaks. The comparison between sequence 
type (ST) 7 strain SC84, isolated from a patient with STSS during the 2005 outbreak, and the 
sequence type 1 strain 31533, demonstrated some of the differences in their mechanisms for 
cytokine production. It was found that S. suis ST 7 strain SC84 possesses a stronger capacity to 
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stimulate T cells, naive T cells and peripheral blood mononuclear cell proliferation than does S. 
suis sequence type 1 strain 31533. The T cell response to both strains is dependent upon the 
presence of antigen-presenting cells and on their mitogenic effect over T cells [97]. 
 Post-mortem examination of chinese patients revealed features of disseminated 
intravascular coagulation. Evidence of multiple organ damage was observed, involving several 
organs. Histologic findings included microthrombosis (hyaline thrombus) in organ capillaries; 
necrosis of parenchymal cells; and congestion, exudate, and hemorrhage of interstitial vessels 
of kidneys, lungs, and other organs [98]. Biochemical and Polymerase Chain Reaction (PCR) 
tests confirmed that all isolates from the 2005 outbreak were S. suis serotype 2 [28, 87, 95]. 
Phylogenetic analysis by Multilocus Sequence Typing (MLST) of S. suis strains isolated from 
both sick humans and pigs, showed  that all strains belonged to the same clone responsible for 
the 1998 outbreak in the Jiangsu province [28, 87, 95]. MLST studies also showed that all but 
two strains from the 2005 outbreak belonged to the ST 7 (ST 1 complex) [28]. 
1.2.3. In other animal species   
S. suis has been isolated from different animal species, including ruminants (calves and 
lambs), horses, cats, dogs, birds and hamsters [6, 99-106]. This suggests that S. suis may be 
pathogenic for more than one animal species. Similarly to the situation in pigs, it seems that S. 
suis colonizes the tonsils of these species [100, 107, 108]. Moreover, it is believed that hunters 
and poachers are at risk of infection as wild boars are a possible reservoir for S. suis [7, 109, 
110]. Indeed, the prevalence of S. suis serotype 2 among wild boars (11%) is similar to that 
among domestic pigs (14%) in Germany [111].  
1.3. Treatment and prevention of the infection 
 
1.3.1. In swine  
Control of S. suis infections in swine facilities is based on efficient management 
practices, such as use of chemoprophylactic agents, early weaning and vaccination [112]. The 
economic and zoonotic significance of this organism highlights the importance to monitor its 
drug resistance trends [113]. Sensibility to antimicrobial agents depends not only on the 
geographic origin of the strain, but also on the serotype and year of isolation [114]. In pigs, the 
most efficient antimicrobial drugs against S. suis infection include amoxicillin, ampicillin, 
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gentamicin, ceftiofur and enrofloxacin [37].   Antimicrobial resistance is observed against 
tetracyclines, sulphonamides, macrolides and clindamycin, and many isolates can develop a 
multi-resistance pattern [114]. However, continuous surveillance of the susceptibility pattern 
of clinical isolates and prudent use of antimicrobial agents is highly advised, as recent studies 
indicate that there is increasing resistance to penicillin, ampicillin and ceftiofur. Moreover, the 
resistance of S. suis to ceftiofur also poses potential health risks in humans since third-
generation cephalosporins have been primary drugs used for the treatment of human 
meningitis in recent years [115]. As clinical signs of meningitis are associated to inflammation 
of the CNS, administration of anti-inflammatory drugs may be useful [6]. 
 Different strategies of vaccination have been developed or are presently under 
investigation. First attempts of immunization included the use of autogenous bacterins, 
preparations from purified CPS or poorly encapsulated strains. Unfortunately, these 
approaches delivered, in general, unsatisfactory results [116]. In addition, autogenous vaccines 
may include extra disadvantages, such as lack of vaccine safety, efficacy of data and severe 
adverse reactions to oil adjuvants which are often added to this kind of vaccines. A further 
difficulty is that multiple strains belonging to different serotypes are often present in a single 
herd [117]. More recent vaccination strategies have included the use of S. suis isogenic mutants 
lacking putative virulence factors [118] and a purified SLY vaccine which induced good 
protection in swine experimentally infected with a serotype 2 strain [119]. This SLY-based 
vaccine may not be useful against North American S. suis strains that do not produce SLY [120]. 
Other possible vaccine candidates are purified bacterial cell wall components with putative 
immunogenic characteristics, such as the recently described HP0197 and 6-Phosphogluconate 
dehydrogenase (6PGD) proteins which confer protection in pigs and mice [121, 122]. Another 
potential vaccine candidate is Sao, a protein present on the surface of S. suis. The immunization 
of piglets with recombinant Sao resulted in development of a significant humoral antibody 
response. Nevertheless, this antibody response was not reflected in protection of pigs that 
were intratracheally challenged with a virulent S. suis serotype 2 strain [123]. However, 
administration of recombinant Sao together with a Quil A, provides cross-protection against S. 
suis serotype 2 disease in mouse and pig vaccination models [124]. The use of some other 
bacterial components as vaccine candidates, such as S. suis enolase (SsEno), a recently 
described S. suis adhesin with fibronectin-binding activity, has been controversial. In fact, one 
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study demonstrated that although subcutaneous immunization of mice with recombinant 
SsEno elicited strong immunoglobulin G (IgG) antibody responses, SsEno-vaccinated and 
nonvaccinated control groups showed similar mortality rates after challenge with highly 
virulent S. suis [125] (See annex, Article IV).  In contrast to these results, other researchers 
showed that SsEno can confer complete protection against S. suis infection to mice, suggesting 
that enolase has potential as a vaccine candidate [126].  
1.3.2.  In humans  
 
 In humans suffering from S. suis infection, treatment is based on the use of 
antimicrobial agents. Penicillin G administrated by intravenous route is generally the first 
choice, as most S. suis isolates are susceptible to this antimicrobial [127-129]. Antimicrobial 
therapy also includes ampicillin, chloramphenicol, aminoglicosides and third generation 
cephalosporins, such as ceftriaxone [69, 70, 129]. Similarly to the pig, most human S. suis 
isolates are resistant to tetracycline and erythromycin [128]. Antimicrobial agents are 
administrated for up to four weeks [69]. Early administration of antimicrobials does not appear 
to have any influence on the development of post-meningitis hearing-loss [127]. 
 Use of  anti-inflammatory drugs such as dexamethasone as an adjunct treatment to 
reduce mortality and improve the outcome of meningitis remains controversial [130]. Based on 
results of individual cases, dexamethasone therapy may or may not be associated with 
protection against severe hearing loss [59, 131]. However, in a recent controlled trial (with 
treated and placebo groups), it was clearly shown that dexamethasone treatment during the 
first four days of hospitalization can significantly reduce the rate of severe hearing loss due to 
S. suis. Nevertheless, there was no difference in clearance of bacterial DNA between patients 
treated with dexamethasone and patients treated with placebo [128]. 
 Currently, a human vaccine is not available, but simple preventive measures, such as 
wearing gloves during processing of pig meat or slaughtering, hand washing after handling raw 
pig meat, and thorough cooking of pork, should prevent the majority of cases. Travelers should 
be aware that dietary habits in some countries may pose a risk for infectious diseases, including 
S. suis infection [56]. 
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1.4. Virulence factors of S. suis 
One of the problems in identification of virulence factors of S. suis is the lack of 
agreement on virulence for this pathogen, as different parameters are used to define whether 
a strain is virulent or avirulent [6]. Different S. suis components have been proposed as 
virulence factors. However, most of them are either not critical for virulence or are present in 
virulent and avirulent strains. Besides, virulence of a certain number of these factors can not be 
completely ascertained, as there are no “knock-out” (KO) strains available for some factors. 
Moreover, most studies on S. suis virulence factors have been performed using serotype 2 
strains, and there is a lack of information concerning possible virulence factors of other 
serotypes.  
 To decide if a field strain is virulent or avirulent, different research groups have 
proposed different criteria, such as the clinical condition of the animal from which the strain 
was isolated (clinically diseased or healthy animals); the presence of virulence-related proteins; 
and the virulence in pigs from high-health-status herds, specific-pathogen-free (SPF) pigs, and 
colostrum-deprived pigs or piglets of different ages from either conventional or SPF herds [132-
135]. In fact, results of experimental infections of pigs with S. suis may depend, among other 
considerations, on the immunological status of the animals, the route of infection, the size of 
the inoculum and the presence of the organism as normal inhabitant of the upper respiratory 
tract of animals prior to the experimental infection [6, 136]. In addition, large discrepancies 
exist in the literature regarding even the virulence of the same strain of S. suis [137, 138]. To 
date, the CPS remains as the only factor that is considered to be decisive for S. suis virulence, 
although recent research has highlighted the importance of  several components from the cell 
wall. 
 
1.4.1. The capsular polysaccharide (CPS) 
S. suis is a well-encapsulated bacterium [139], and it has been proposed that the CPS 
confers antiphagocytic properties [140-142]. The CPS of S. suis serotype 2 is composed of five 
different sugars: galactose (Gal), glucose (Glc), N-acetyl glucosamine (GlcNAc), rhamnose (Rha) 
and N-acetyl neuraminic (sialic) acid (NeuNAc) [20, 143]. The cps locus coding for the CPS of S. 
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suis serotype 2 has been cloned and characterized. This locus contains several genes that 
encode potential glucosyl-, galactosyl-, N-acetylglucosaminyl- and rhamnosyltransferase 
activities, as well as genes involved in the synthesis of sialic acid [144, 145]. 
The CPS is still considered as the only proven critical virulence factor, based on the 
studies with nonencapsulated isogenic mutants. The absence of CPS correlates with increased 
hydrophobicity and phagocytosis by murine and porcine phagocytes [140, 144, 146]. 
Comparable results were obtained with porcine neutrophils [147]. Indeed, it is now known that 
the CPS modulates the activation of relevant intracellular signalization pathways implicated in 
phagocytosis in murine macrophages [148]. Moreover, surface adhesion, without phagocytosis, 
of S. suis to murine macrophages is mediated, at least in part by the sialic acid component of 
the CPS [149]. The relevance of the CPS has also been evaluated in vivo, as nonencapsulated 
mutants were shown to be avirulent and cleared from circulation rapidly in both mouse and pig 
models of infection [140, 150].  
Some research also proposes that thickness of the capsule has a positive correlation 
with virulence. In fact, isolates of S. suis serotype 2 recovered from diseased animals have been 
shown to possess a thicker capsule than those isolated from clinically healthy animals [151]. An 
increase of capsular thickness following in vivo growth has been noted for virulent but not for 
avirulent strains, and this increase in capsular thickness of virulent strains is also associated 
with resistance to killing by pig polymorphonuclear leukocytes [152]. However, other reports 
did not demonstrate any correlation between the thickness of capsular material and virulence 
[6]. Nevertheless, cells of serotype 2 reference strain are not covered by a thicker layer of CPS, 
compared to other serotypes [6]. It has been suggested that the invasive ability of strains of 
this serotype may depend on the composition of the capsular material which contains sialic 
acid [139], as this component has been associated with virulence of other bacterial agents of 
meningitis [153]. However, it has been shown that virulent and avirulent strains possess a 
capsule of similar size with similar concentrations of sialic acid [154].  Finally, factors other than 
the CPS would also be critical for virulence of S. suis, as most of non virulent strains are 
capsulated [6]. 
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1.4.2. ᴅ-Alanylation of Lipoteichoic Acid (LTA)  
 
 LTA is an amphilic molecule found in most Gram-positive bacteria, and is considered as 
the equivalent of the lipopolysaccharide (LPS) in Gram-negative bacteria [155]. LTA is 
associated with development of shock by Gram-positive bacteria, as it activates
 
leukocytes, 
stimulates an exacerbated generation of proinflammatory cytokines and cytotoxic molecules, 
 
and hence, causes a systemic inflammatory response
 
syndrome that may lead to multiple organ 
failure and death [155]. This molecule is a polymer of polyphosphoglycerol substituted with a 
ᴅ-alanyl (ᴅ-Ala) ester or a glycosyl residue and anchored in the membrane by a terminal 
glycolipid moiety [156]. The ᴅ-alanylation of LTA allows Gram-positive bacteria to modulate 
their surface charge, regulate ligand binding and control the electromechanical properties of 
the cell wall [157]. Genetic studies of the biosynthesis of LTA in various Gram-positive bacteria, 
such as Lactobacillus caseii and Bacillus subtilis have shown that the incorporation of ᴅ-Ala 
residues requires the activity of four gene products, which are encoded by the dlt operon [158, 
159]. However, there are few research data available dealing with the importance of ᴅ-
alanylation of LTA and virulence of streptococci. Studies using isogenic mutants lacking a 
functional dlta operon (ᴅ-dltA-), have shown that in GBS, this operon is needed to resist the 
killing by defensins and phagocytic cells [157], whereas in Group A Streptococcus (GAS), S. 
gordonii and S. pneumoniae,  it confers resistance to the killing effect of lysozyme and 
antimicrobial peptides (AMPs) [160-162]. 
 The importance of ᴅ-alanylation of LTA in the virulence of S. suis serotype 2 has been 
recently evaluated. Use of a S. suis ᴅ-dltA- strain, demonstrated that, similarly to other 
streptococci, lack of LTA ᴅ-alanylation resulted in increased susceptibility to the action of 
cationic antimicrobial peptides. In addition, the ᴅ-dltA- mutant was efficiently killed by porcine 
neutrophils and showed diminished adherence to and invasion of porcine brain microvascular 
endothelial cells.  Moreover, virulence of the ᴅ-dltA- mutant, in comparison to the parental 
strain, was attenuated in mouse and porcine models of infection, an effect that may be 
associated with a decrease in the ability to escape immune clearance mechanisms, a lower 
capacity to activate the inflammatory cascade and an impaired competence to move across 
host barriers [163] (See annex, Article V).  
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1.4.3. N-deacetylation of Peptidoglycan (PG) 
 
 The main cell wall component of Gram-positive bacteria is peptidoglycan (PG), which 
provides stress resistance and
 
shape-determining properties to bacterial cell walls [155]. This
 
polymer contains long sugar chains of two alternating sugar
 
derivatives, N-acetylglucosamine 
(NAG) and N-acetylmuramic acid
 
(NAM), which are highly cross-linked by peptide subunits and
 
bridges [155, 164]. Among different bacterial species, the structure of
 
the sugar chains is highly 
preserved, while the composition
 
of the peptide subunits varies. PG synergizes with LTA to 
trigger the inflammatory response in the host and cause shock [165]. However, the host takes 
advantage of this rather invariant structure to recognize bacteria, through the nucleotide-
binding oligomerization domain (NOD)1 and NOD2 proteins, which recognize muropeptides 
released during cell wall turnover, and also to kill the microorganisms through the hydrolytic 
activity of lysozyme [166, 167].  In order to circumvent the host’s defenses, bacteria have 
developed specific mechanisms to modify the structure of their PG. For example, the pgdA 
gene from S. pneumoniae and L. monocytogenes N-deacetylate the NAG residues into 
glucosamine or muramic acid. This N-deacetylation of PG will help bacteria to avoid NOD1 and 
NOD2 recognition and will also increase the resistance to lysozyme [168, 169]. 
 Similarly to the aforementioned bacteria, S. suis is able to N-deacetylate its PG by 
means of the pgdA gene. Studies demonstrated that expression of the pgdA gene was 
increased upon interaction of the bacterium with neutrophils in vitro as well as in vivo in 
experimentally inoculated mice, suggesting that S. suis may enhance PG N-deacetylation under 
these conditions. Virulence of an isogenic pgdA mutant was highly attenuated in comparison to 
its parental strain in mouse and pig models of infection, confirming that relevance of N-
deacetylation of PG in the pathogenesis of S. suis infection.  In addition, the pgdA- mutant was 
not able to persist in blood or to escape immune clearance mechanisms mediated by 
neutrophils [40] (See annex, Article VI). 
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1.4.4. Opacity Factor  (OFS) 
 
The presence of an Opacity Factor (OF) associated with virulence of S. suis (OFS) has 
been described [170]. This OFS, encoded by the ofs gene, shares structural homologies with 
members of the microbial surface components recognizing adhesive matrix molecules 
(MSCRAM) family and a C-terminal LPXTG sorting signal [171]. The N-terminal region of OFS is 
homologous to the respective regions of fibronectin-binding protein A of Streptococcus 
dysgalactiae and the serum opacity factor of GAS. Similar to these two proteins, the N-terminal 
domain of OFS was able to opacify horse serum [171]. The role of OFS in the pathogenesis of S. 
suis was evaluated in pigs experimentally infected with an isogenic mutant lacking the ofs gene. 
The mutant was severely attenuated in virulence but not in colonization [171]. These results 
encouraged further research on this mutant as a possible candidate for vaccination. However, 
experimental trials in pigs demonstrated that although pigs inoculated with the ofs mutant 
elicited humoral immune responses against different putative virulence factor of S. suis, the 
mutant strain failed to induce sufficient opsonizing activity and significant systemic protection 
against the parental strain [118].  The prevalence and variations of the ofs gene among 
different S. suis isolates from diseased and healthy pigs and human patients was further 
investigated. Regardless of their origin, only approximately 30 % of the isolates possessed a 
functional OFS [172].  
1.4.5. Muramidase-released protein (MRP) and extracellular protein factor (EF) 
These two proteins, known as muramidase-released protein (MRP) and extracellular 
factor (EF) protein, are among the first putative virulence factors described for S. suis serotype 
2 [173]. MRP is a 136-kDa protein, present in the cell wall fraction and also released into the 
culture supernatant during bacterial growth. MRP is encoded by the mrp gene, is an LPXTG 
protein, and is therefore expected to be anchored to the cell wall PG by sortase A [173, 174]. 
On the other hand, EF is a 110-kDa protein only present in culture supernatants [173]. Serotype 
2 strains with the phenotype MRP
+
EF
+
 induce severe clinical signs of disease in pigs, but strains 
with the phenotype MRP
-
EF
-
 do not [47, 175]. These proteins possesses different variants. 
Higher and lower molecular weight variants of MRP, respectively called MRP* (> 136-kDa) and 
MRP
s
 (< 136-kDa), and higher molecular weight EF proteins, called EF* (> 150-kDa) can be 
found in phenotypes such as MRP*EF
-
, MRP
s
EF
-
, MRP
s
EF
+
, MRP
-
EF*, and MRP
+
EF* [27, 120, 
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176]. Also, it has been suggested that European S. suis serotype 2 strains that present MRP, EF 
and SLY (another putative virulence factor, see description below), that is,  with a MRP
+
EF
+
SLY
+
 
phenotype, are more virulent than North American strains which do not possess such proteins 
[9]. However, when isogenic mutants were used to experimentally inoculate newborn germfree 
piglets, they proved to be as pathogenic as their parental strain [177]. Recent data have shown 
that the most common phenotypes in North American strains are MRP
+
EF
-
SLY
-
 (40%) and MRP
-
EF
-
SLY
+
 (35%), but that the presence of the gene did not always correlate with actual expression 
of the respective protein [33]. Unfortunately, as the specific roles of MRP and EF in the 
pathogenesis of S. suis have not been fully clarified, they should be considered as virulence-
associated markers. 
 
1.4.6. Hemolysin (suilysin, SLY) 
Hemolysins have often been implicated as virulence factors in infections caused by 
various bacterial species. In 1994, a 54-kDa hemolysin, designated as suilysin (SLY), was 
identified and purified from culture supernatants of S. suis serotype 2 [178]. Subsequently, a 
65-kDa hemolysin from the same serotype was described.  In fact, these two proteins are the 
same toxin and the molecular mass difference are due to purification methods [179]. SLY is 
found among different serotypes of S. suis, including 1, 1/2, 3, 4, 5, 7, 8, 9, 14, 15, 17, 18, 19, 23 
and 28, and it belongs to the formely named group of thiol-activated toxins that are now 
known as cholesterol-binding cytolytic toxins [180-182]. The hemolysin from S. pneumoniae 
(pneumolysin) is the most closely related orthologous gene known [182]. Other members of 
the same group include the streptolysin O (Group A Streptococcus -GAS-), listeriolysin (Listeria 
monocytogenes) and perfringolysin (Clostridium perfringens) [183]. SLY shares several 
characteristics with these toxins, such as loss of activity upon oxidation, reactivation upon 
reduction, inhibition by small amounts of cholesterol, formation of transmembrane pores and a 
multi-hit mechanism of action [179]. Cholesterol in the membrane of eukaryotic cells is thought 
to be the toxin-binding site [183, 184].  
As with other putative virulence factors, the role of SLY in the pathogenesis of S. suis 
has not been fully elucidated. It has been demonstrated that it is cytotoxic to endothelial and 
epithelial cells, as well as neutrophils, monocytes and macrophages [147, 185-188]. In addition, 
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purified SLY induces the production of several pro-inflammatory cytokines by human and 
porcine BMEC [189-191], by porcine peripheral blood cells [192] and by pig alveolar 
macrophages [193]. SLY also enhances the upregulation of adhesion molecules in human 
monocytes [194] and it is implicated in the secretion of arachidonic acid, a precursor of 
prostaglandin, in human endothelial cells [195]. Together, this data provid evidence that 
indeed SLY plays an important role in bacterial dissemination, host inflammation and invasion 
of different tissues by S. suis. Nevertheless, some data are controversial, such as the failure to 
cause death following systemic administration to mice of a culture supernatant from a SLY-
positive S. suis strain [196]. On the other hand, an allelic-replacement mutant of the sly gene 
was non-toxic for murine macrophage and also avirulent in a mouse infection model, whereas 
its virulence was only slightly attenuated in a porcine model of systemic infection [197]. 
Conversely, other researches showed that both the parental strain and a sly knockout mutant 
were resistant to bactericidal factors present in whole pig blood. Furthermore, in a pig 
challenge model, the mutant strain induced disease similarly to the wild type strain, with 
presence of clinical signs of disease and isolation of bacteria from different tissues [193]. 
Finally, similarly to MRP and EF, whereas SLY is present in most of Asian and European S. suis 
serotype 2 strains, it is only present in a limited number of North American serotype 2 strains 
[7, 26, 33, 47, 108, 120, 181]. 
1.4.7. Adhesins 
 
1.4.7.1. Fibronectin-fibrinogen binding protein (FBPS) 
 Different strains of S. suis are able to bind to extracellular matrix (ECM) proteins, such 
as fibronectin [198]. S. suis serotype 2 possesses a 64 kDa protein with fibronectin (FN) and 
fibrinogen (FB)-binding activities (FBPS). This protein is the product of the fbps gene and is 
expressed by strains of serotype 2. However, the expression of the 64 kDa protein by all the 
serotypes of S. suis has not been studied. Therefore, it is possible that not all serotypes express 
the FBPS [199]. As this FBPS can bind to proteins from the extracellular matrix, it is possible 
that it may participate in tissue colonization by S. suis. Experimental infection of piglets with a 
fbps mutant showed that FBPS protein was not required for colonization of the tonsils but that 
it played a role in the colonization of the specific organs commonly involved in S. suis infection. 
Therefore, the fbps mutant was considered partly attenuated. The induction of specific 
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antibodies in piglets was observed following infection, suggesting that this protein might be an 
interesting candidate for a subunit vaccine [199].  
1.4.7.2. Glyceraldehyde-3-phosphatase dehydrogenase 
(GAPDH) 
 S. suis possesses a 39 kDa glyceraldehide-3-phosphatase dehydrogenase (GAPDH) that 
can bind to albumin and results in increased adhesion of the pathogen to epithelial cells [200, 
201]. Furthermore, the presence of albumin enhances the virulence of S. suis in mice [200].  It 
has been also demonstrated that GAPDH is implicated in binding to plasminogen of pig and 
human origin [202]. Moreover, adhesion and activation of plasminogen may be implicated in 
invasion and damage of tissues by S. suis [202]. The gene encoding the GAPDH of S. suis has 
been cloned and sequenced [203]. The gapdh gene has been found in isolates of serotypes 1, 9 
and 7, in addition to serotype 2 [201]. However, the role of GAPDH in the pathogenesis of S. 
suis is not completely understood, as GAPDH is present in both virulent and non-virulent strains 
[200]. Interestingly, it has been reported that S. suis highly upregulates the expression of this 
gene in vivo in different porcine organs [204] and GAPDH is highly immunogenic in pigs [205]. 
 
1.4.7.3. Alpha-enolase  
A 52 kDa protein with capacity to bind to the Fc fraction of IgG has been found in S. suis 
serotype 2 strains. This protein can interact with IgG from different species of mammals, 
including the human, pig, cow, rabbit and mouse, as well as with human IgA and chicken IgY 
[206, 207]. Also, a 60-kDa heat-shock protein with  IgG binding protein has been characterized 
from S. suis serotype 2 [208]. Subsequent studies confirmed that these proteins were in fact 
identical [209]. This IgG-binding protein represents a common antigen found in all the S. suis 
serotypes including both virulent and avirulent strains of S. suis serotype 2, and it is found 
either associated with the cell surface or released in a soluble form during bacterial growth. It 
was found that this protein is indeed a S. suis α-enolase, designated as SsEno, that is expressed 
in all known serotypes of this pathogen. This enolase has fibronectin- and fibrinogen-binding  
activities and has proved to be relevant for the adhesion to and invasion of PBMEC, suggesting 
that it may contribute to the pathogenesis of S. suis meningitis [210].  In fact, Gram positive α-
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enolases are cytoplasmic enzymes critical for sugar metabolism. However, they have been 
shown to be also surface located. Among other contributions to virulence, α-enolases are able 
to drive binding of pathogens to plasminogen [211, 212]. Hence, it was an exceptional finding 
that recombinant S. suis α-enolase expressed in E. coli was also able to bind fibronectin [207, 
210]. Moreover, surface plasmon resonance demonstrated that S. suis α-enolase binds 
fibronectin with high (low nanomolar) affinity [210]. Since abolition of anchoring to the S. suis 
cell wall of LPXTG proteins does not result in full impairment of fibronectin binding by this 
pathogen [213], it might be hypothesized that α-enolase is one of the most important 
fibronectin-binding proteins. Interestingly, S. suis α-enolase has been shown to be expressed in 
vivo in pigs and is highly immunogenic, as demonstrated by the use of an immunoproteomic 
approach [214].  
 The potential of SsEno as a vaccine candidate has been studied. A research group 
demonstrated that SsEno is highly immunogenic in mice and elicits a strong immune response 
mediated by different subclasses of IgG. However, SsEno-vaccinated and nonvaccinated control 
groups showed similar mortality rates after challenge with a highly virulent S. suis strain. 
Similar results were obtained upon passive immunization of mice with hyperimmunized rabbit 
IgG anti-SsEno antibodies, not increasing the ability of mouse phagocytes to kill S. suis in vitro. 
It was concluded that although recombinant SsEno triggers a strong antibody response, it does 
not confer effective protection against infection with S. suis serotype 2 in mice [125] (see 
annex, Article IV). Alternatively, another research group identified the enolase gene from S. suis 
serotype 2, showing it to be an important trait for bacterial adherence. Moreover, they 
demonstrated that SsEno confers complete protection in mice and therefore it has potential as 
a vaccine candidate [126]. Further studies are needed to determine if indeed SsEno is a good 
vaccine candidate. 
 
1.4.7.4. Pili 
 
 Pili have been shown to contribute to the virulence of different Gram-positive 
pathogenic species. These structures participate in adherence to host cells, colonization and 
systemic virulence [215]. Electron microscopy studies demonstrated that S. suis serotypes 1 to 
8 and 1/2 present peritrichous, thin, and flexible pilus-like structures on their surface, that 
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measured up to 250 nm with a diameter of around 2 nm [139]. Morphologically similar 
structures were observed on hemagglutinating as well as on nonhemagglutinating strains of S. 
suis [216]. S. suis possesses four gene clusters encoding putative pili [217, 218]. Recent 
research evaluated the functionality of one of these clusters, known as the S. suis pilus srtF 
cluster. It was demonstrated that pili expressed by genes of this cluster are composed of the 
major pilin subunit but lack the ancillary protein (a putative adhesin). This phenotype is 
common among field isolates and results from nonsense mutations that prevent expression of 
the gene encoding the ancillary protein. Besides, as in other Gram-positive pathogens, the srtF 
cluster pilus is polymerized by the action of a dedicated sortase and anchored to the cell wall 
by the housekeeping sortase. However, S. suis pili are atypical compared to other Gram-
positive pili, as it seems that their contribution to virulence of S. suis may be limited. In fact, 
abolishment of the expression of srtF cluster encoded pili does not impair interactions of S. suis 
with PBMEC. Furthermore, non-piliated mutants are as virulent as their WT strain in a murine 
model of S. suis infection [219]. 
  
1.4.8. Proteases 
Bacterial proteases play a critical role in colonization and evasion of host immune 
defenses, acquisition of nutrients for growth and proliferation, facilitation of dissemination, or 
tissue damage during infection [220]. Several proteases have been described for S. suis, 
including an Arg-aminopeptidase, a dipeptidyl peptidase (DP) IV, a chymotrypsin-like, a 
caseinase, a phospholipase C and a hyaluronate lyase [195, 221, 222].  
The Arg-aminopeptidase of S. suis (55 kDa) can be found both extracellularly and cell-
associated. It was suggested that its presence may be associated with production of ATP and 
other essential metabolic precursors via the arginine deiminase pathway [223].  
The DPP IV protease (70 kDa) was found in the culture supernatant and on the cell 
surface of S. suis [223]. It is a specific protease that may cleave proteins after the X-Pro and X-
Ala residues at the N-terminus of polypeptide chains [224]. Many cytokines have a proline in 
the second position in their polypeptide chains [225]. The S. suis DPP IV may result in local 
changes to host responses during the course of certain S. suis-associated infections. On the 
other hand, the removal of dipeptides from the N-termini of peptides can generate new 
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biologically active peptides. DPP IV may thus contribute significantly to the deregulation of 
inflammatory processes during meningitis. The S. suis DPP IV may also contribute to tissue 
destruction and systemic bacterial dissemination. [224]. It was recently demonstrated that DPP 
IV can interact with human fibronectin [226]. Moreover, inactivation of DPP IV appears to 
attenuate greatly the virulence of highly pathogen S. suis serotype 2 strains [226].  
Caseinase (36 kDa), which putatively belongs to the class of metalloproteases, may 
have a nutritional function or participate in the maturation of different protein precursors. In 
fact, it may help in maturation of SLY [223]. The chymotrypsin-like protease, which belongs  to 
the class of serine proteases, was detected in European, but not in North American, strains of 
serotype 2 tested [223].  
A phospholipase C was detected in the culture supernatant and on the cell surface of S. 
suis serotype 2. This protease hydrolyses phosphatidylcholine into phosphate choline and 
diacylglycerol, a messenger molecule that activates protein kinase C, the latter participating in 
the production of arachidonic acid in target cells [224].  
A hyaluronate lyase is also found in S. suis [221]. This enzyme catalyses the degradation 
of hyaluronic acid (HA), which is a glycosaminoglycan commonly found in different tissues, such 
as connective, epithelial and nervous tissues. S. suis may take advantage of this hyaluronate 
lyase to obtain growth factors or to facilitate tissue colonization [221]. This enzyme has been 
detected in S. suis serotypes 1, 1/2, 2, 3, 7, 9, 14 and 15 [227].  
More recently, a novel serine protease that degrades porcine IL-8 was identified in S. 
suis serotype 2 [228]. S. suis can induce an exacerbated release of inflammatory mediators by 
swine endothelial cells that could cause a massive recruitment of leukocytes and subsequent 
BBB breakdown facilitating the pathogenesis of S. suis-induced meningitis [229]. Therefore, S. 
suis may secrete this IL-8 protease in order to delay recruitment of killer-neutrophils to the site 
of inflammation, allowing this pathogen to survive upon its arrival at CNS central nervous 
system [228].  
In addition, S. suis produces an IgA1 protease. The purified recombinant protein shows 
good cleaving activity in IgA1 and is highly immunoreactive with convalescent sera. As the 
respective gene was found in most pathogenic strains but rarely in non-invasive isolates, the 
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IgA1 protease may play a crucial role in the pathogenesis of S. suis [230]. However, further 
studies are needed to prove this hypothesis. 
S. suis also possesses a cell-surface subtilisine-like proteinase that plays a role in 
virulence. Mutants devoid of subtilisin-like proteinase activity have longer generation times, 
are more susceptible to killing by whole blood and are also less virulent in a mouse model of 
infection in comparison to their WT parental strain [231]. Moreover, it was found that the  
surface-associated subtilisin-like serine protease of S. suis, designated as SspA is also necessary 
for the development of disease in pigs, as an SspA isogenic mutant (sspA-) is less virulent in 
comparison to its WT parental strain [232]. 
 
1.4.9. Sortases 
 Many surface proteins which are covalently linked to the PG of Gram-positive bacteria 
have a consensus C-terminal motif Leu-Pro-X-Thr-Gly (LPXTG). In all Gram-positive bacteria 
examined so far, this sequence is cleaved, and the processed protein is attached to an amino 
group of a cross-bridge in the PG by enzymes known as housekeeping sortases [174, 233]. 
Moreover, many of these cell surface proteins possessing LPXTG motif have been reported to 
mediate bacterial interaction with host cells, namely the extracellular matrix, and thus play an 
distinguished role in virulence [234].  
 At first, five sortases were described for S. suis serotype 2, named as SrtA, SrtB, SrtC, 
SrtD and SrtE [233]. Complementary studies showed that SrtA belongs to the subtype A, 
whereas SrtB to D belong to group C [235]. Another sortase, also belonging to subtype C has 
been described [236]. SrtA is a transpeptidase associated to the membrane that clives LPXTG 
proteins between their T and G motifs.  The relevance of SrtA in the pathogenesis of S. suis was 
examined using a srtA mutant. Interactions with host cells and extracellular matrix proteins, as 
well as virulence in a mouse infection model were investigated. It was found that the mutant 
was impaired in its interactions with porcine BMEC compared to the wild-type strain. In 
addition, it showed lower levels of adherence to plasma fibronectin, cellular fibronectin and 
collagen type I. However, disruption of srtA had little effect on the virulence of S. suis in a 
mouse intraperitoneal model of infection [213] (See annex, Article VII). These results suggest 
that surface proteins anchored by SrtA are required for a normal level of bacterial binding but 
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are not essential for S. suis virulence. However, different results were obtained in a parallel 
study carried out using an isogenic srtA mutant of a highly virulent Chinese S. suis serotype 2 
strain. In this study,  deletion of srtA attenuated the full virulence of the virulent strain and 
impaired its colonizing potential in specific organs in challenged pigs. Furthermore, the srtA 
mutant displayed significant reduction in adherence to human cells (Hep-2 and human 
umbilical vein endothelial cells) [217].  
 
1.4.10. Other proteins associated with virulence 
Several other putative virulence factors have been ascribed to S. suis. Among them, we 
found the: 
1) Surface antigen one (Sao) protein, located at the surface and exhibiting typical features 
of membrane-anchored surface proteins of Gram-positive bacteria, such as a signal 
sequence and an LPVTG membrane anchor motif [123]. Sao is a potential vaccine 
candidate as it elicits strong IgG and protective responses in mice and pigs [124].  
2) Glutamate deshydrogenase (GDH), which is a 45 kDa protein exposed at the bacterial 
surface. The gene coding for GDH is conserved in all strains of S. suis serotype 2 
tested [237]. As highly virulent strains produce electrophoretic types and sequence 
types of GDH distinct from those of moderately virulent and nonvirulent strains, it 
has been recently propose this may serve as useful markers in predicting the 
pathogenic behavior of strains of S. suis serotype 2 [238]. 
3) Lipoprotein signal peptidase (SP-ase), named as Lsp. SP-ase II is involved in the removal 
of the signal peptide from glyceride-modified prolipoproteins [239]. An isogenic 
mutant of S. suis serotype 2 unable to produce Lsp was constructed and shown to 
process lipoproteins incorrectly, including an S. suis homologue of the pneumococcal 
PsaA (pneumococcal surface protein A) lipoprotein [239]. In S. pneumoniae the PsaA 
lipoprotein interferes with complement-dependent host defense mechanisms [240]. 
However, in vivo trials carried out in pigs demonstrated that the lsp mutant is as 
virulent as its parental strain. 
4)  Putative phosphoglycerate mutase (38 kDa protein). This protein is found at the cell 
surface of S. suis. It is present in all known serotypes, except for serotypes 20, 26, 32 
31 
 
and 33 and shares a high degree of homology with sequences of unknown function 
from S. pneumoniae, S. mutans,  L. monocytogenes and Clostridium perfringens. 
[241]. The recombinant protein was reactive with serum from pigs experimentally 
infected with virulent strains of S. suis serotype 2, suggesting that the protein is 
immunogenic and may serve as an antigen of diagnostic importance for the 
detection of most S. suis infections. Pigs immunized with the recombinant 38 kDa 
protein mounted antibody responses to the protein and were completely protected 
against challenge with a wild type strain of a homologous serotype, suggesting that 
it may be a good candidate for the development of a S. suis vaccine [241]. 
5) Superoxide dismutase (SOD). Superoxide ions (O2
-
) are a major antibacterial free radical 
in macrophage phagolysosomes. Thus, the capacity to secrete superoxide 
dismutases (SodA), which convert superoxide ions to molecular oxygen and H2O2, 
may be relevant in virulence. Indeed, these enzymes constitute one
 
of the major 
defense mechanisms of cells against oxidative stress [242, 243]. The presence of a 
gene (sodA), encoding SodA as well as SOD activity was reported in S. suis serotype 2 
strains [244].  
6) Ssna nuclease. This is a 108 kDa protein located at the cell wall of S. suis serotypes 1 to 
9. Its substrate specificity is for single- and double-stranded linear DNA. Screening of 
porcine clinical isolates from surface (nasal mucosa or palatine tonsil) or internal 
(joint, brain or other internal organ) locations revealed a significant relationship 
between expression of Ssna and isolation from an internal site [245].  
7) Transmembranal 44 kDa protein. This protein of unknown function has been proposed 
as a virulence factor as well as an important immunogen of S. suis serotype 2 after 
two avirulent mutants were produced from a highly virulent S. suis strain [246]. It 
was demonstrated that the 44-kDa native protein, present in the parent strain, was 
absent in both mutants. Besides, complementary studies demonstrated that the 
protein was strongly immunogenic. However, the real contribution of this protein 
has not been further verified. [246].  
8) Arginine deiminase system (ADS). In S. suis two cell wall-associated proteins
 
with 
homologies to proteins from the ADS system of GAS were identified [247]. One of 
these proteins, of 47 kDa, is encoded by the octS gene and shares homologies with a 
orthine carbamoyl transferase, whereas the other protein, of 53 kDa, is encoded by 
32 
 
the adiS gene and is homologous to the streptococcal acid glycoprotein from S. 
pyogenes [247]. The ADS system catalyzes the conversion of arginine to ornithine, 
ammonia, and carbon dioxide. ADS are widely distributed among prokaryotic 
organisms and, in oral streptococci and GAS, they seem to provide protection 
against acidic stress by the production
 
of ammonia to increase pH [248, 249]. 
Furthermore, it has been shown that the ADS of GAS is involved in adhesion to and 
invasion of
 
epithelial cells [249]. Stgudies using an adiS mutant (called arcA mutant 
in the study), in which expression of the arcABC operon (from the ADS system) was 
abolished, demonstrated that this operon contributes to survival under acidic 
conditions [250]. 
9) Proteins binding to the extracellular matrix (ECM) and to plasmatic proteins. The ECM is 
a complex, structural  network that gives support to epithelial and endothelial cells 
and surrounds connective tissue. The ECM is composed of different biomolecules, 
the most important being several glycoproteins, including collagen, fibronectin, 
elastin and laminin and glycosaminoglycans, such as heparin and heparan sulfate 
[251]. Following an injury or trauma, the ECM of the host is exposed and its 
components may serve as potential receptors for pathogen bacteria. In addition, 
bacteria may bind to different plasmatic and tissular, hiding their own immunologic 
epitopes with the aim to avoid recognition by the immune system. Recently, 
adherence of S. suis serotype 2 to different proteins from the ECM and from plasma 
was demonstrated [198]. In fact, all tested strains of S. suis bound to plasma and 
cellular fibronectin and collagen types I, III, and V, and some strains bound to fibrin, 
vitronectin, and laminin. An unencapsulated isogenic mutant bound to ECM proteins 
better than its parental encapsulated strain, suggesting that the CPS interferes with 
binding. On the other hand, pre-incubation with plasma fibronectin increased 
binding to collagen IV, suggesting that S. suis might use fibronectin as a bridging 
molecule. The results of heat treatment and proteolytic digestion suggest that 
adhesins for these ECM proteins are proteinaceous in nature [198]. However, the 
specific mechanisms implicated in these interactions remain to be studied. 
10) Very recently, using a comparative proteomic approach with S. suis serotype 9 isolates 
from diseased and healthy pigs, several novel proteins that may be considered as 
putative virulence-associated factors were identified. These proteins are a DNA 
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nuclease (which seems to be different from Ssna nuclease), o-acetylserine lyase, PG-
binding LysM, phosphoglycerate mutase, and putative 5’-nucleotidase [252]. More 
studies are needed in order to evaluate their respective role in the pathogenesis of 
S. suis. 
   
1.5. Pathogenesis of S. suis infection  
Most of the studies concerning the pathogenesis of S. suis have been carried out using strains 
from serotype 2 [6], and although exhaustive reseach has been performed, the knowledge on 
the mechanisms implicated in the development of the infection is still limited.  
 
1.5.1. Portal of entry and colonization of tonsils 
 
 Both vertical and horizontal transmission of S. suis have been demonstrated in pigs [6]. 
In the case of horizontal transmission, most researchers believe that S. suis probably enters the 
host via the upper respiratory tract and resides within the palatine [253] or pharyngeal tonsils 
[254, 255]. Palatine tonsils in pigs are penetrated by numerous crypts which extend into, and 
branch extensively within, the lymphoid tissue. Stratified squamous non-keratinised epithelium 
covering the oropharyngeal surface is continuous with that lining the neck of crypts. 
Lymphoepithelium covers the tonsillar lymphoid tissue within the crypts. It consists of non-
keratinised epithelial cells, M cells, goblet cells and many intraepithelial lymphoid cells [256]. 
The tonsils have been described as one of the primary sites of invasion by bacteria, with 
subsequent spread to the superpharyngeal lymph nodes [257]. In fact, S. suis antigens were 
identified by a specific fluorescent marker, and whole bacteria were frequently observed in the 
crypt lumen, but were also present in the epithelium and immediate sub-epithelial zone. In the 
inter-follicular tissue, the S. suis antigen was sometimes closely associated with cell nuclei and 
small amounts of particulate fluorescence were seen within a minority of tonsillar germinal 
centres [253]. Bacteria were found in association with cells of the myeloid lineage. Expression 
of CD16 and CD163 on these leukocytes suggested an association with mature macrophages in 
tonsils, which may lead to clearance or control of the micro-organism [253]. Other studies have 
confirmed that the presence of S. suis at the tonsillar crypts leads to an increase in the CD4 and 
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CD8 lymphocytes, suggesting the initiation of both humoral and cellular responses against S. 
suis might start within the crypt epithelium of the tonsils [258]. 
 
 Once colonized by S. suis, some animals may remain as clinically healthy carriers, 
whereas others may develop bacteremia, septicemia and/or meningitis. For these events to 
happen, S. suis must first be able to disseminate from tonsils and/or other mucosal surfaces 
and reach the circulation (both blood and lymph). As mentioned above, in humans, the portal 
of entry is mainly through skin wounds [56] with access to blood circulation.  
 
1.5.2. Trespassing of mucous membranes 
S. suis is present at low levels on mucosal surfaces, and the mechanisms that this 
pathogen uses to traverse the first mucosal barriers to develop disease are still not completely 
understood. In fact, bacteria would need to breach mucosal epithelia in the upper respiratory 
tract to reach blood circulation [9]. It has been reported that virulent S. suis strains can adhere 
to epithelial cell lines of pig and human origin [186, 187]. The adhesin(s) involved seem(s) to be 
partially masked by the
 
CPS and are a part of the cell wall [186]. In addition, S. suis isolates 
recovered from diseased animals adhere to frozen sections of the pig lung, whereas isolates 
from clinically healthy animals show a weak adherence. The thickness of the capsular material 
seems to influence the adherence activity, but is probably not the only mechanism involved 
[259]. As examples of new putative mechanisms involved in epithelial adhesion, we found the 
orphan transcriptional regulator, designated RevSC21 and the gene coding for glutamine 
synthetase (GlnA) [260, 261]. In the former case, deletion of the revSC21 gene of S. suis 
serotype 2 yielded a mutant strain which exhibited a significant decrease in adherence to 
human laryngeal epithelial cells, and lacked hemolytic activity. Complementary studies 
revealed that RevSC21 influences the expression of MRP, EF, SLY and CPS, among other 
virulence-associated factors [260]. In the latter example, and similarly to the revSC21 mutant, 
an isogenic mutant exhibited a significant decrease in adherence to the human laryngeal 
epithelial cells. Furthermore, it seems that GlnA plays a role in the colonization of the specific 
organs involved in S. suis infection [261]. 
In addition, S. suis may damage epithelial barriers to advance invasion of multiple 
tissues. In this regard, SLY positive strains may use cell disruption to reach the bloodstream as it 
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has been reported that suilysin is toxic for epithelial cells [186, 187, 262]. However, strains not 
producing this hemolytic toxin are also able to reach the circulation and disseminate [6]. The 
possibility that S. suis may be capable of traversing epithelial barriers without cytotoxicity is still 
under debate, as invasion of epithelial cells by receptor-mediated endocytosis has only been 
demonstrated for non-capsulated and non-typeable S. suis strains [263]. 
 
 
1.5.3. Blood dissemination: bacterial uptake and importance of phagocytic cells 
In order to disseminate throughout the body and cause bacteremia, and septicemia, S. 
suis must be able to survive in blood. Development of septicemia is a critic step prior to the 
development of meningitis [9]. To survive in blood and resist the army of phagocytic cells, S. 
suis is equipped with a thick CPS that serves as a shield and hampers neutrophil and 
monocyte/macrophage-mediated killing  [6, 264]. In fact, many studies support this theory, as 
contrary to capsulated strains, isogenic non-capsulated strains are highly sensitive to 
phagocytosis by murine and porcine macrophages [140, 141] and porcine neutrophils [264].  
Still, resisting phagocytosis is not the same as dissemination. In order to cause a 
generalized infection and meningitis, S. suis must facilitate its travel throughout the 
bloodstream. Early findings suggested a “Trojan Horse” strategy, in which bacteria are taken up 
by monocytes (in the absence of specific antibodies), surviving within phagocytic cells, thus 
facilitating invasion of the CNS [265]. Studies carried out with flow cytometry also indicated 
uptake of S. suis by swine and human phagocytes [266]. In fact, this bacterial uptake could take 
place directly at the tonsils by macrophages or once the bacteria are in the bloodstream [9]. 
Nevertheless, most of the studies in the last decade regarding this subject demonstrate that S. 
suis may use different strategies to circulate, more precisely, either free or adhered to the 
surface of monocytes, a theory that is known as the “Modified Trojan Horse” [9]. Indeed, 
instead of being phagocytised, virulent capsulated S. suis remains attached  to  phagocytic cells 
[142, 149]. This phenomenon appears to be mediated by the presence of S. suis CPS that down-
regulates central signaling pathways involved in macrophage phagocytosis [148].  
In addition, S. suis possesses other weapons that can damage phagocytic cells. More 
precisely, SLY appears to affect complement-dependent killing by decreasing the opsonization 
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of S. suis and the bactericidal capacity of neutrophils and macrophages [149, 264] and thus, 
affecting the efficiency of the innate immune system.  
 
1.5.4. S. suis and the development of the inflammatory response: In vitro studies 
Interactions between S. suis and phagocytic cells are crucial for the development of the 
inflammatory response. In fact, S. suis is capable of up-regulating important adhesion 
molecules involved in inflammation, such as intercellular adhesion molecule-1 (ICAM-1, CD54), 
CD11a/CD18 and CD11c/CD18 in human monocytes. This may result in an increased leucocyte 
recruitment into sites of infection, thus providing a possible mechanism for some of the 
inflammatory features of meningitis caused by this pathogen [267]. Once in contact with 
murine and human macrophages, S. suis induces the secretion of different pro-inflammatory 
cytokines and chemokines, including tumor necrosis factor-alpha (TNF-α), Interleukin (IL)-6, IL-
1β, IL-8 and monocyte chemotactic protein (MCP-1) [268, 269]. Porcine whole blood stimulated 
by live S. suis also releases high levels of TNF-α, IL-1β and IL-6 and intermediate levels of IL-8 
and MCP-1. The bacterial cell wall is the major cytokine-inducing component [192]. Other 
studies support these findings, as porcine macrophages stimulated with a S. suis CPS mutant 
express a higher activation of pro-inflammatory genes, including TNF-α, IL-1β and MIP-2, in 
comparison to the well capsulated parental strain [270]. 
 Moreover, stimulation of human monocytes by whole encapsulated S. suis or purified 
cell wall components triggers the release of a similar profile of cytokines and chemokines [271]. 
In experimentally infected pigs, S. suis induces the systemic production of IL-6 and IL-8 [272] 
(See annex, Article VIII). This production of pro-inflammatory mediators will have many 
systemic effects, contributing to the recruitment of leucocytes to the site of infection, 
enhancing haematopoiesis and inducing fever [273]. However, although inflammatory 
cytokines and chemokines contribute to the anti-infectious process, their production has 
severe side-effects, which will be discussed below. 
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1.5.5. Reaching the Central Nervous System (CNS) 
 
1.5.5.1. Blood-brain barrier (BBB) disruption 
To date, we know that in order to cause meningitis, S. suis colonizes the mucosa of the 
upper respiratory tract, with further invasion of the intravascular space, where it 
survives/multiplies to cause bacteremia and induces the inflammatory response. S. suis must 
then reach and invade the CNS. But how does S. suis induce meningitis? It is generally accepted 
that once in circulation (either free or in association with monocytes), meningitis-causing 
bacteria traverse the blood-brain barrier (BBB) and survive and multiply in the subarachnoid 
space to elicit inflammatory responses from the host, inciting pathophysiological alterations 
such as pleocytosis and BBB disruption [274]. However, in order to completely understand the 
development of the infection, we need to focus on the specific mechanisms that S. suis elicits 
to arrive and traverse the BBB. It is necessary to elucidate the strategy elicited by S. suis to get 
access to the CNS and study the interactions with endothelial cells from the BBB. It is also 
necessary to identify possible alternative portals of entry, such as the blood-cerebrospinal fluid 
(CSF) barrier (BCSFB) and compare the mechanisms of invasion elicited by S. suis with those 
used by other Gram-positive meningitis bacteria. 
The BBB is a structural and functional barrier formed by brain microvascular 
endothelial cells (BMEC). BMECs possess distinct features such as tight junctions with a high 
electrical resistance between them, and low rates of pinocytosis [274-276]. These microvessels 
are covered by pericytes and outgrowths of astrocytes, which are referred to as astrocytic end-
feet [277, 278] (Fig. 5). Pericytes are a very important cellular constituent of the BBB. They play 
a regulatory role in brain angiogenesis, endothelial cell tight junction formation, BBB 
differentiation, and contribute to the microvascular vasodynamic capacity and structural 
stability [279]. On the other hand, astrocytes provide the cellular link to the neurons and 
support the integrity of tight junctions [280]. The BBB functions as a high-resistance barrier to 
circulating macromolecules, protecting the brain from any microbes and toxins circulating in 
the blood. Disruption of the blood-brain barrier is a hallmark event in the pathophysiology of 
bacterial meningitis  [274, 275]. 
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Fig. 5: The blood brain barrier. Taken from [278]. 
 
 Several studies have addressed the interactions between S. suis and brain 
microvascular endothelial cells (BMEC) of either human (HBMEC) or porcine origin (PBMEC). 
Early studies demonstrated that this pathogen is capable of adhering to HBMEC, although cell 
invasion could not be confirmed. Moreover, as SLY was cytotoxic for HBMEC, it was suggested 
that SLY-positive S. suis strains use adherence and SLY-induced HBMEC injury, as opposed to 
direct cellular invasion, to proceed from the circulation to the central nervous system [281]. 
Interestingly and contrary to observations in epithelial cells, S. suis attachment to HBMEC 
seems to be independent of the CPS, as a noncapsulated mutant adhered similarly compared 
to its wild-type strain [281]. Once attached to HBMEC, bacterial cell wall components stimulate 
the production of several pro-inflammatory cytokines from HBMEC, including IL-6, IL-8 and 
MCP-1 [282], and stimulate the expression of adhesion molecules, such as soluble intercellular 
adhesion molecule-1 (sICAM-1) [283], whereas SLY induces the secretion of arachidonic acid 
[195]. Moreover, this bacterial attachment to BMEC seems to be specific, as S. suis does not 
adhere nor stimulate the production of pro-inflammatory cytokines from other types of 
endothelial cells, such as human umbilical vein endothelial cells [281]. Furthermore, bacterial 
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challenge stimulates production of different pro-inflammatory cytokines and chemokines, as 
well as that of pro-inflammatory mediators, including prostaglandin E(2) (PGE(2)), and matrix 
metalloproteinase 9 (MMP-9) in co-cultures of HBMEC and macrophages infected with S. suis 
[284]. The pro-inflammatory cytokine production along with the release of other pro-
inflammatory mediators and expression of adhesion molecules may play a main role in 
initiating changes in permeability or adhesion properties of the same BMEC. This may provoke 
local hemodynamic changes, such as edema accumulation and hemorrhages and may allow the 
immune cells to infiltrate the CNS, and possibly influencing the activity of nearby cells, such as 
astrocytes and glial cells. [195, 282, 285]. 
 Further studies revealed the ability of S. suis to adhere, and most importantly, to 
invade porcine BMEC (PBMEC) (Fig 6). In fact, viable bacteria were recuperated from PBMEC 
after several hours of incubation. In addition, the CPS of S. suis seemed to partially interfere 
with the adhesion and invasion abilities of the bacterium. This study also showed that invasion 
of S. suis in PBMEC requires actin microfilaments but not microtubular cytoskeletal elements.  
SLY proved to be a key element, as SLY-positive strains are toxic for PBMEC.  Other researchers 
claim that S. suis adhesion to PBMEC is greatly influenced by the presence of CPS and by serum 
components. Surprisingly, and in disagreement with the previous results, they found that none 
of the S. suis tested was able to invade the PBMEC [286] 
 
 Other research examing molecular means by which S. suis interacts with PBMEC 
revealed that once in contact with these cells, S. suis will induce the expression of several 
putative virulence genes, including dltA, pgdA and srtA [236]. As mentioned in their respective 
sections (1.4.2 and 1.4.3), different in vitro and in vivo studies have confirmed the importance 
of dltA and pgdA genes in the pathogenesis of S. suis infection. In fact, their respective isogenic 
S. suis mutants are more susceptible to the killing effect of leukocytes and clinical presentation 
Fig. 6. S. suis invades PBMEC. The pathogen is 
observed forming small chains within invagination 
structures (arrow). Bars = 1.5 μm. Adapted from [4]. 
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of meningitis is significantly reduced in comparison to their parental strain An isogenic mutant 
lacking the srtA gene has a reduced capacity to adhere and invade PBMEC in comparison to its 
wild type strain (section 1.4.9) [287]. 
1.5.5.2. Possible entry through the blood-cerebrospinal 
fluid barrier (BCSFB) 
 
 The choroid plexus (CP) epithelium (CPe) is a villous organ that produces and secretes 
the bulk of the CSF into the ventricles of the brain. The CP consists of a single-layered cuboidal 
epithelium, which surrounds a highly vascular connective tissue core, and its surface is greatly 
increased by many villous projections. BBB barrier properties are present at the CPe/CSF 
interface, as the CPe presents apical tight junctions between cells, inhibiting paracellular 
diffusion of water-soluble molecules across this barrier. This barrier is known as the blood-
cerebrospinal fluid (CSF) barrier (BCSFB). Besides its barrier function, CPe has a secretory 
function and produces the CSF. The barrier and secretory function of the CPe is maintained by 
the expression of numerous transport systems allowing the directed transport of ions and 
nutrients into the CSF and the removal of toxic agents out of the CSF [276, 288]. 
 
 Transwell models of in vitro infection have demonstrated that the CPe is capable of 
restricting growth of S. suis upon activation with proinflammatory cytokines by creating an 
unfavorable microenvironment for the bacteria [289]. However, in contrast, S. suis seemed to 
affect the porcine CPe barrier function and integrity, as hemolytic strains of S. suis  were 
cytotoxic for the CPe, and other death-cell mechanisms, such as apoptosis seemed to be 
involved [290, 291].  However, the development of an “inverted” Transwell filter system of 
porcine choroid plexus epithelial cells (PCPEC) from the same research group, permitted the 
investigation of possible bacterial invasion and translocation from the “blood side” (basolateral 
side) to the apical (CSF) side of the BCSFB, which better reproduces the normal physiological in 
vivo conditions. The basolateral cell membrane of the PCPEC is a significant obstacle that the 
bacteria encounter before they penetrate the BCSFB, the endothelium of the CP being 
fenestrated and having only minor barrier functions. In contrast, the PCPEC are firmly attached 
to each other by tight junctions and represent the structural basis of the BCSFB [292]. In this 
study, there was specific invasion and translocation of S. suis across the PCPEC exclusively from 
the basolateral side. This process seems to be influenced by bacterial viability, the presence of 
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the CPS and cytoskeletal regulation of PCPEC. Interestingly, and in striking contrast to previous 
research, no cell injury nor loss of barrier function was observed [293].  
  
 Anatomapathological findings at the CP of pigs infected by S. suis show disruption of 
the plexus brush border, a decrease in the number of Kolmer cells, and exudation of fibrin and 
inflammatory cells into the ventricles, reaching the arachnoid villi and olfactory nerve sheaths  
[265, 294]. Once in the CSF, S. suis may be free to survive and gain acccess to the brain 
parenchyma. Bacterial multiplication may be favored as the CSF contains almost no 
immunoglobulins, only a few leukocytes are present and no components of the Complement 
System are normally found  [295].  
 
 
1.6. Animal models for experimental infection with S. suis 
 
 Animal experimentation is an essential tool for the study of infectious diseases, 
including meningitis. These animal models may be useful to clarify mechanisms of disease 
pathogenesis, test novel drugs and vaccine candidates and characterize the role of bacterial 
and host factors and genetic susceptibility to infection [296]. Different animal species, including 
the pig, its natural host, have been used as animal models of S. suis infection. Results from 
these studies are very valuable and have set the reference for future research. However, to 
date, most of these studies have been performed with S. suis serotype 2. They have focused 
mainly on clinical aspects of the disease, comparison of the virulence of different S. suis strains, 
testing the relevance of different bacterial components, and evaluation of efficacy of vaccine 
candidates and of antimicrobials. Currently, S. suis is considered to be not only an important 
swine etiologic agent, but also a relevant emerging human pathogen. Therefore, there is an 
urgent need for suitable animal models that mimic clinical features found in infected swine and 
humans and that allow more comprehensive research on the activation and development of 
host immune responses to this important pathogen. 
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1.6.1. Swine 
 
 As the pig is the natural host of S. suis, early animal experimentation took place in this 
animal species. Experiments have been carried out using pigs of different ages and with diverse 
genetic background, testing different inoculation routes or amount of inoculum, and 
considering different parameters to determine virulence. In addition, availability of many of the 
techniques and reagents necessary to identify host factors associated with the development of 
the infection are not standardized for pig samples. Quality of animal facilities is also crucial to 
obtain trustworthy results. It is advisable that animals are housed in separate units into which 
air is forced through absolute filters (0.3 µm pore size) to prevent any contact of these animals 
with infectious agents [133]. 
 
 The intranasal (IN) route of infection in pigs has been used to demonstrate that natural 
horizontal transmission of S. suis occurs by this means, and to draw attention to the tonsils as 
first site of colonization [255]. This route has also served to underline the possible association 
between S. suis and viruses. In fact, pigs infected experimentally with PRRSV and S. suis are 
more susceptible to develop pneumonia and bacteremia due to S. suis in comparison to pigs 
infected only with the bacterium. PRRSV-induced suppression of pulmonary intravascular 
macrophage function may in part explain PRRSV-associated increased susceptibility to S. suis 
infection [297]. Similar data were obtained in pregnant sows intranasally infected with PRRSV, 
whose piglets were more susceptible to S. suis infection than those born to non-infected sows 
[48]. IN infected pigs sometimes only develop subclinical infection, although this is 
transmissible among litters [298]. Treatment of these animals with acetic acid (also by the IN 
route) favors inducing the disease [299]. Infection of Göttingen minipigs with aerosolized S. 
suis, following exposure to acetic acid also by aerosol has also been proposed as an 
experimental model of infection. Since this breed is defined as free of S. suis and a range of 
other endemic porcine pathogens, this experimental model might be useful in the study of this 
infection[300]. 
 On the other hand, the intravenous (IV) route of infection has been used in most of the 
experimental research with S. suis in pigs. This route is more advantageous as there is better 
control of the amount of bacteria inoculated, and it better reflects the septicemic and CNS 
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phases of disease. This latter advantage has facilitated the elucidation of virulence of several S. 
suis strains. In fact, the use this route in SPF piglets has been proposed as a standard model for 
S. suis infection. This standardized method proposes the use of 7-week old SPF piglets kept in 
isolation rooms with controlled air flow [133]. It allows the differentiaton of virulence of S. suis 
strains, based on clinical signs, zootechnical performance, lesions, and bacteriological findings 
[133, 301]. Some studies report that no clinical signs nor lesions are found in animals 
inoculated by the IV route [299]; however, this may be due to the amount of inoculum and size 
of experimental group.  In general, IV infected animals develop several clinical signs, including 
depression, fever, lameness, seizures and paddling  [40, 42, 133, 163, 272, 301]. Moreover, 
lesions at the CNS reflect for the most part those found in naturally infected pigs [42]. The IV 
route of S. suis infection has also been used for other purposes: 
1) To identify immunogenic bacterial proteins that are induced or upregulated in vivo, and 
differences of their expression among S. suis strains  [302]. 
2)  To evaluate the importance of several putative virulence factors, such as the CPS,  SLY, 
ᴅ-alanylation of LTA, N-acetylation of PG, FBPS and sortase A in the pathogenesis of 
infection [40, 119, 120, 122, 163, 199, 217, 272, 303].  
3) To test the protective capacity of live vaccines or possible immunogenic molecules that 
may serve as vaccine candidates [116, 122, 205, 303-305]. 
 In swine, the intracisternal (IC) model of infection has also been used, in particular for 
comparison with the IV route, obtaining similar results [294]. However, as this route bypasses 
several steps of the natural infection and handling of animals is more difficult, it has not been 
used for S. suis research in recent years. 
 
1.6.2. Mouse 
 
 Experimental S. suis disease has also been investigated by using the mouse as model of 
infection. However, as encountered for the pig, it has been difficult to establish a standard 
model of mouse infection due to variability. Experiments have been performed with either 
outbred or inbred mouse strains infected with different S. suis strains and with dissimilar 
inoculum size. Moreover, as criteria for experimental S. suis infections in mice have not been 
established, it is difficult to compare the results among studies.  
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 Nevertheless, S. suis experimentation in mice be more advantageous than the pig 
model of infection as manipulation of animals is easier and there is a wide selection of 
laboratory reagents, equipment and techniques available for use with mouse samples. To date, 
these studies have been performed with outbred mouse strains, such as CD1, BALB/c and CF-1, 
inoculated in most of the cases by the intraperitoneal (IP) route. The use of outbred mice 
strains offer phenotypic diversity that may be important to imitate the natural variation in 
response to infection. However, the inclusion of mouse inbred strains as models of S. suis 
infection should be considered.  Inbred mice offer more uniform responses to experimental 
treatments due to their uniformity in the immune system. In addition, there is now a wide 
array of inbred “knock-out”(KO) mice available, with inactivation of specific genes that could 
facilitate the identification of host’s factors participating in infection and may help understand 
the mechanisms of the host’s susceptibility or resistance to infection. 
 S. suis research in mice has been performed to determine if the behavior of S. suis in 
this animal species resembles that in pigs [306, 307]. Moreover, as in the pig, mouse models 
have served to test the immunogenic potential of S. suis proteins or the use of S. suis strains as 
vaccine candidates [305, 308]. The mouse has also been used to assess the virulence of 
different S. suis strains or the importance of certain bacterial components for the development 
of the disease (CPS, SLY) [141, 197].  Kunming mice, which are the most popular outbred colony 
in China, have been used to test the efficacy of adjuvants to boost resistance against infection. 
Interestingly, in this case, infection with S. suis was performed by the oral route [309]. 
 
1.6.3. Others  
 
 Other animal species have been used in the research for S. suis with different purposes.  
For example, the hamster was used to determine the possible anatomical origin of hearing loss, 
a common sequela in humans that have suffered S. suis meningitis. In this case, the IP, 
intracranial and intrabullar routes of infection were examined, with 47%, 100% and 80% of 
successful reproduction of clinical meningitis, respectively (criteria of meningitis are not 
specified). In vivo studies of audiometry suggested there was hearing loss, and further 
histological examination of affected tissues allowed establishing that hearing loss is possibly 
associated to cochlear sepsis [310].  
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2. The innate immune response (IIR) 
 
2.1. Components of the IIR 
 
 Immune systems in vertebrates are divided into two basic categories: innate and 
adaptive immunity. Adaptive immunity relies on antigen-specific receptors expressed on 
clonally expanded T and B lymphocytes that are generated by gene rearrangements and hyper 
mutations [311]. The innate immune system (IIS) is an evolutionarily ancient part of the host 
defense mechanism [312]. It constitutes the first line of host defense against pathogens and 
therefore plays a crucial role
 
in the early recognition and subsequent triggering of a pro-
inflammatory
 
response [311, 313]. The IIS consists of physical and
 
chemical barriers to 
infection, as well as of different cell
 
types recognizing invading pathogens and activating 
antimicrobial
 
immune responses. Physical and chemical defense mechanisms
 
are represented 
by the epidermis, ciliated respiratory epithelium,
 
vascular endothelium, and mucosal surfaces 
with antimicrobial
 
secretions. Similarly, the cellular components of innate
 
immunity include 
macrophages
 
and granulocytes, cytotoxic natural killer cells (NK), antigen-presenting cells 
(APCs), that is, dendritic cells (DCs) and γδ T lymphocytes [314, 315]. In fact, one of the key 
components of the IIS lies behind the inflammatory response triggered by these cells [312].  
 The innate immune response (IIR) is not completely nonspecific, as was originally 
believed, as it is able to discriminate between self and a variety of pathogens. The IIR is 
activated through a limited number of germline-encoded pattern recognition receptors (PRRs) 
that can be expressed on the cell surface, in intracellular compartments, or secreted into the 
bloodstream and tissue fluids (Table 1). The principal functions of PRRs include opsonization, 
activation of complement and coagulation cascades, phagocytosis, induction of apoptosis and 
activation of proinflammatory signalling pathways [312-317]. These PRRs are designed to 
recognize specific arrangements of key molecules called pathogen-associated molecular 
patterns (PAMPs). The PAMPs are vital structures of the microbial cell that have altered little 
over evolutionary time-spans and include LPS, lipoproteins, LTA, PG, lipoarabinomannan and 
oligosaccharides, among others [312, 317]. PAMPs are generated by microbes and not by the 
host, suggesting that PAMPs are good targets for innate immunity to discriminate between 
self- and nonself [312]. Among PRRs, TLRs have been highlighted as the key recognition 
structures of the IIS [312, 317].  
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2.2. Pattern recognition receptors: Family of Toll-like receptors (TLRs)  
 
 The family of TLRs, which are localized either to the cell surface or within endosomes,  
is the major and most extensively studied
 
class of PRRs (Fig 7) [315, 318]. The Toll gene was 
identified as a gene essential for the dorsal-ventral development during embryogenesis as well 
as in the antifungal response in Drosophila melanogaster [315]. Structurally, TLRs are integral 
glycoproteins characterized
 
by an extracellular or luminal ligand-binding domain containing
 
leucine-rich repeat (LRR) motifs and a cytoplasmic signaling
 
Toll/interleukin-1 (IL-1) receptor 
homology (TIR) domain. Ligand binding to TLRs through PAMP-TLR interaction induces
 
receptor 
oligomerization, which subsequently triggers intracellular
 
signal transduction [313, 315, 317, 
319]. The TLR family now consists of thirteen mammalian members [313]. To date, ten TLRs 
have been identified in
 
humans (hTLRs) while in the mouse twelve TLRs (mTLRs) have been 
recognized [319]. The genes corresponding to all ten TLRs genes identified in humans have 
been fully cloned in pigs [320]. Individual TLRs are differentially distributed within the cell.
 
TLR1, TLR2, TLR4 and TLR6 are expressed on the cell surface (Fig 7), as demonstrated
 
by 
positive staining of the cell surface by specific antibodies.
 
In contrast, TLR3, TLR7, TLR8 and 
TLR9 have been shown to be
 
expressed in intracellular compartments such as endosomes (Fig. 
7) [5, 313]. Each TLR recognize distinct PAMPs derived from
 
various microbial pathogens, 
including viruses, bacteria, fungi,
 
and protozoa (Table 2 and Fig. 7) [5, 315, 321]. In addition to 
the recognition of PAMPs, TLRs may also be able to recognize endogenous signals such as heat 
shock proteins and products of necrotic cells and thus may be involved in auto-immune 
phenomena or activation of tissue repair [317]. 
 TLRs are preferentially –but not exclusively- expressed in APCs, including macrophages 
and B lymphocytes [315, 317]. TLR signaling causes DCs to become APCs by the induction of co-
stimulatory molecules (such as CD80 and CD86), the up-regulation of major histocompatibility 
complex (MHC) molecules and the secretion of cytokines and chemokines [319]. In fact, TLRs 
have been identified in most cell types,
 
expressed either constitutively or in an inducible 
manner in
 
the course of infection [315]. 
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 As aforementioned, TLRs play a central role in the recognition of a wide array of 
microbial components. Actually, most Gram-positive and -negative bacteria can activate 
additional TLRs via alternative PAMPs present in the cell membrane, cell wall, or intracellularly 
[315].  As general rule, it is considered that the lipid A portion of LPS from Gram-negative 
bacteria is recognized through the TLR4/MD2/CD14 complex [313, 322]. When LPS is present in 
the blood stream, it is immediately captured by LBP, which converts oligomeric micelles of LPS 
to a monomer for delivery to CD14. Then, CD14 concentrates LPS for binding to the TLR4/MD2 
complex (Fig. 7) [313, 323]. 
Fig. 7. TLRs and their ligands. TLR2 is essential in the recognition of microbial lipopeptides. 
TLR1 and TLR6 cooperate with TLR2 to discriminate subtle differences between triacyl and 
diacyl lipopeptides, respectively. TLR4 is the receptor for LPS. TLR9 is essential in CpG DNA 
recognition. TLR3 is implicated in the recognition of viral dsRNA, whereas TLR7 and TLR8 are 
implicated in viral-derived ssRNA recognition. TLR5 recognizes flagellin. TLR11 participates in 
recognition of uropathogenic bacteria (ligand still unknown). Thus, the TLR family members 
recognize specific patterns of microbial components. Adapted from [5]. 
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2.3. Importance of TLR2 
 
 TLR2 is a versatile receptor, as it recognizes a variety of microbial components, 
including lipoproteins/lipopeptides from Gram positive/negative bacteria and PG, LTA from 
Gram-positive bacteria. These two last components can trigger a toxic shock syndrome similar 
to that induced by LPS [313, 314, 317]. MD2 enhances TLR2-mediated recognition, as it is 
physically associated with this receptor, but this association is weaker than with TLR4 [323].  
Two characteristics have been proposed as mechanisms that could explain
 
why TLR2 recognizes 
a wide spectrum of microbial components.
 
The first explanation is that TLR2 forms heterophilic 
dimers
 
with other TLRs such as TLR1 and TLR6, to discriminate subtle differences between 
triacyl and diacyl lipopeptides, respectively (Table 2, Fig. 7) [5]. The second
 
explanation involves 
the ability of TLR2 to recognize fungal-derived components. Indeed, TLR2 collaborates with 
distinct types of receptors such as dectin-1,
 
that is a lectin family receptor for the fungal cell 
wall component
 
β-glucan [5, 324].  
 In the case of Gram-positive cocci responsible for meningitis, it is now known that TLR2 
is involved in the recognition of S. pneumoniae and in the expression of the pro-inflammatory 
response. In this case, TLR2 is the receptor for pneumococcal cell wall, including PG  [325]. 
However, pneumolysin, a crucial virulence factor of S. pneumoniae virulence, triggers the 
inflammatory response via TLR4 [326], denoting that the host can synergistically activate 
different TLRs for S. pneumoniae recognition. As for GBS, researchers have found that this 
pathogen elicits cell recognition through TLR2 and a MyD88-dependent pathway, events that 
lead to cytokine and nitric oxide (NO) production, molecules that have a direct negative impact 
on neurons, as there is induction of apoptosis in these cells via a caspase-8 pathway [327, 328].   
Moreover, GBS cell-recognition also requires CD14 and TLR6, that may act synergistically with 
TLR2 and function as co-receptors for secreted microbial products. It also seems that neither 
TLR1 nor TLR4 participate in GBS recognition [329]. Further downstream signaling pathways are 
by both MyD88 –dependent and –independent pathways. Whereas the former is necessary for 
NF-κB expression, bacterial uptake depends on the later mechanism [330]. In addition, Gram-
positive bacteria can also trigger cytosolic PRRs, including NOD1/2 and the NALP1 
inflammasome, both activated by PG [315, 331].  
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2.4. Pro-inflammatory signaling pathway  
 The net result of TLR engagement of a relevant
 
PAMP is the triggering of downstream 
signaling pathways, ultimately
 
resulting in the generation of an antimicrobial proinflammatory
 
response [315]. This includes the production of inflammatory cytokines and chemokines, 
antimicrobial peptides, costimulatory molecules, MHC molecules, and other effectors 
necessary to arm the host cell against the invading pathogen [312]. Importantly, TLRs activate a 
common signaling pathway that will provoke the production of pro-inflammatory cytokines as 
well as alternative pathways that will induce appropriate and effector responses against 
different types of pathogens. In particular, TLR3, TLR4, TLR7, TLR8 and TLR9 induce antiviral 
responses by inducing type I IFN [311]. Interestingly, septic patients present an increased 
expression of CD14, TLR2 and TLR4 on monocytes, and death is associated with downregulation 
of TLR2 and CD14 expression on monocytes [332]. 
 The activation of TLR signaling pathways originates from the cytoplasmic TIR domains. 
This allows them to use the same signaling components as IL-1R. Four TIR domain-containing 
adaptors (MyD88, TIRAP/MAL, TRIF, and TRAM) play a relevant role in TLR signaling pathways. 
Each TLR mediates distinctive responses in association with a different combination of these 
adapters [313]. To date, evidence indicates that TLR signaling pathways consist of a minimum 
of a MyD88-dependent pathway that is common to all TLRs, except for TLR3, and a MyD88-
independent pathway (also known as TRIF-dependent pathway) that is restricted to TLR3 and 
TLR4 [5, 311, 315, 333]. 
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2.4.1.  MyD88 dependent pathway 
 
 In the MyD88 dependent pathway (Fig. 8), upon ligand binding TLRs/IL-1Rs dimerize (a), 
thereby undergoing conformational changes required for the recruitment of the adaptor 
molecule MyD88 (b). The TIR domain-containing adapter MyD88 possesses a TIR domain in its 
C terminus and a death domain in its N terminus. Upon stimulation, MyD88 recruits IL-1 
receptor kinase (IRAK) to TLRs through the interaction of both molecules’ death domains. Two 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The IKK complex phosphorylates the inhibitor of IκB (i), which becomes ubiquitinated 
and destroyed by the proteosome. IκB itself is a NF-κB target gene, and its de novo synthesis is 
a crucial auto-regulatory loop.  Once released from its inhibitor, the NF-κB (j) moves to the 
nucleus, binds to specific DNA regions and up-regulates a number of pro-inflammatory genes 
involved in host defense (k). This signaling pathway is essential, for the expression of 
members of the IRAK family, IL-1 receptor-
associated kinase (IRAK-1) and IRAK-4 (c) are 
activated by phosphorylation, dissociate from 
MyD88 and associate with TRAF6 (d). This last 
adaptor forms a complex with ubiquitin-
conjugating enzymes (e) to activate TAK1 (f). 
TAK1 forms a complex with TAB1, TAB2 and 
TAB3. TAK1 leads to the activation of NF-κB 
(IκB) and activator protein-1 (AP-1) through 
the canonical IκB kinase (IKK) (g) complex and 
the MAPK respectively (h). AP-1 activation in 
TLR signaling is mostly mediated by MAP 
kinases such as c-Jun N-terminal kinase (JNK), 
p38 and extracellular signal-regulated kinase 
(ERK). Many TLR ligands activate these MAPK 
in similar kinetics. 
Fig. 8. MyD88 signalisation pathway. For details, 
see text. Adapted from [3]. 
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inflammatory cytokine genes, including TNF-α, IL-6, IL-12, and IL-1β, free radicals, stressors and 
costimulatory molecules. In the case of the TLR2 and TLR4 signaling pathways, additional 
adapters TIRAP/MAL adaptors are also required for the activation of the MyD88- dependent 
pathway [3, 311-313, 317, 321]. 
 
 
2.4.2. MyD88 independent pathway 
 
 Triggering of IL-1R or TLR recruits IRAK to the receptor complex via adaptor MyD88, 
followed by TRAF6 activation, which finally leads to the activation of NF-κB and MAPK (Fig. 7). 
MyD88 KO macrophages are unresponsive to LPS and other bacterial components including PG, 
lipoproteins and CpG DNA, which proves the essential role of MyD88 in the response to all 
pathogen-derived immunostimulatory molecules [321]. However, although LPS-induced 
production
 
of pro-inflammatory cytokines is not observed; activation
 
of MAPK and NF-κB is still 
present but with delayed kinetics [5, 321].This indicates that the LPS response may be 
mediated by both MyD88-dependent and -independent pathways, each of which leads to the 
activation of MAPK and NF-κB [321]. The MyD88-independent pathway involves activation of 
the transcription factor IRF-3, and induction of IFN-β, which in turn, activates Stat1, leading to 
the induction of several IFN-inducible genes [321]. Viral infection or dsRNA, which are TLR3 
ligands,
 
also activate IRF-3 and thereby induce IFN-β
 
in a MyD88-independent manner. Hence, 
TLR3 and TLR4 utilize
 
the MyD88-independent component to induce IFN-β [5]. Nevertheless, 
the MyD88-dependent pathway is essential for the inflammatory response mediated by LPS 
[321].  
 
 
2.4.3. Pro-inflammatory gene expression 
 
 Many proteins have NF-κB binding sites in their promoters. Indeed, once transcription 
factors such as NF-κB or AP-1 are upregulated, the cell responds in some way: either by 
phagocytosis, up-regulation of co-stimulatory molecules, maturation of APCs and transcription 
of genes producing pro- or anti-inflammatory cytokines. Adhesion molecules, such as 
intracellular adhesion molecule 1 (ICAM-1), E-selectin and vascular cell adhesion molecule 
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(VCAM), are also up-regulated on the endothelium. Other enzymes that are part of the global 
response are cyclo-oxygenase-2 (COX-2) and inducible nitric oxide synthetase (iNOS), all of 
which contribute to the IIR against the invading pathogen. [317]. In addition, NF-κB has a 
crucial role in regulating the expression of anti-apoptotic proteins and affecting the 
susceptibility of cells to apoptosis [315, 317, 334, 335]. Moreover, the up-regulation of co-
stimulatory molecules that enhances maturation of APC provides the link between the innate 
and acquired immune system [317].  
 
 
2.5. MAPK signaling pathway 
 
 As mentioned, MAPK along with NF-κB are involved in signal transduction of genes 
associated with the control of many immune responses. Indeed MAPK are a family of kinases 
involved in numerous cellular processes which are activated by a dual phosphorylation 
mechanism involving phosphorylation of both Tyrosine- and Serine/Threonine residues [336]. 
MAPK pathway is activated not only through TLRs, but also through G-protein-coupled 
receptors, growth-factor receptors, cytokine receptors and receptors associated with 
environmental and genotoxic stress [337]. To date, four subfamilies of MAPK have been 
recognized: ERK1/ERK2, which is phosphorylated by the mitogen-activated/erk kinases (MEK or 
MKK) 1 and 2; the p38/regulated kinases (RK) subfamily, which is activated by MEK 3 and 4; the 
family of c-jun N-terminal kinases (JNK)/stress activated protein kinases (SAPK) that is activated 
by MKK4 and the recently discovered MEK/MKK6 [336]. These kinases stimulate AP-1 activity, a 
pivotal transcription factor that regulates T-cell activation, cytokine production, and the 
production of matrix metalloproteinases (MMP) [337]. Thus, MAPK are responsible for most 
cellular responses to cytokines and external stress signals and crucial for regulation of the 
production of inflammation mediators, such as COX2 and iNOS expression and NO production 
[338-341]. Moreover, MAPK signaling cascades regulate important cellular processes including 
cell proliferation, cell survival and death [342]. Numerous immunogenic molecules can trigger 
the MAPK signaling pathway, including LPS, double-stranded RNA, lipoproteins and cell wall 
components from Gram-positive bacteria, in particular LTA [336, 340, 341, 343-345].
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3. Septic shock 
 
3.1. Definition 
  
 The normal reaction to infection involves a series of complex immunologic processes. 
Activation of the immune system during microbial invasion is generally protective. A deficient 
immunologic defense may allow infection to become established. However, in certain 
circumstances, this response may be excessive because of a poorly regulated immune response 
to the invading pathogen. Consequently, the patient may experiment a wide spectrum of 
immunologic events, ranging from sepsis and severe sepsis to septic shock and death (Fig. 9) [2, 
346]. 
 
 Sepsis is defined as infection with evidence of systemic inflammation, consisting of two 
or more of the following: increased or decreased temperature or leucocyte count, tachycardia, 
and rapid breathing (Fig. 9) [2, 347-349]. Severe sepsis is sepsis complicated by organ 
dysfunction, tissue/organs hypoperfusion or hypotension, while septic shock is the syndrome 
characterized by a persistent arterial hypotension in a septic patient that persists after 
resuscitation with intravenous fluid (Fig. 9) [1, 2, 347-350]. This process is characterized by a 
massive release of pro-inflammatory mediators such as TNF-α, IL-6 and IL-1β. In addition, 
neutrophil apoptosis is significantly delayed by these inflammatory mediators. This allows them 
to function more effectively at sites of inflammation, thus leading to enhanced surveillance 
against infectious agents and a prolonged recruitment of other pro-inflammatory cells by the 
release of cytokines and chemokines [1]. Organ dysfunction in septic shock usually includes 
acute lung injury; coagulation abnormalities; thrombocytopenia; altered mental status; renal, 
liver, or cardiac failure; or hypoperfusion with lactic acidosis [348]. 
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3.2. Development of septic shock 
 
3.2.1. Cellular phase of the acute inflammatory response 
 
 A series of systemic pathogenic events are behind the transition from sepsis to severe 
sepsis/septic shock. This process begins with a neurohumoral, generalized pro- and anti-
inflammatory response. The first set of events involves the cellular phase of the acute 
inflammatory response, in which leukocytes are delivered into exudates at the site of injury 
[351]. This phase is characterized by recruitment, rolling, firm adhesion to the endothelial 
surface, activation, aggregation, and subsequent transmigration of leukocytes to sites of 
inflammation through the endothelial cell junctions into the interstitium toward a 
chemoattracting gradient [1, 2, 348]. Leukocyte rolling is mediated through the expression of 
cell-adhesion molecules, such L-selectin and β2 integrins (LFA-1 [CD11a/CD18]; Mac-1 
[CD11b/CD18]; p150,95 [CD11c/CD18]; αdβ2 [CD11d/CD18]) on leukocytes and  E- and P-
selectin, ICAM-1 and VCAM-1 on endothelium. Once leukocytes are attached to the vascular 
endothelium, they adhere to platelet-endothelial cell adhesion (PECAM-1) molecules present at 
Fig. 9. Development of sepsis: The excessive inflammatory response to infectious agents 
can lead to septic shock. Following the release of pro-inflammatory mediators, 
compensatory anti-inflammatory mechanisms will appear. However, if pro- and anti- 
inflammatory mechanisms do not reach a balance, the disproportionate inflammatory 
response to microbial products finally may lead to tissue damage, haemodynamic changes, 
multiple organ failure and ultimately death. Adapted from [1, 2]. 
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the endothelial cell junction and transmigrate through the junction into the perivascular tissue. 
Pseudopodia from neutrophils and other leukocytes extend between endothelial cells and 
come into contact with and bind to the basement membrane, where they express β1 integrins 
(VL-1 to -6) that promote adhesion to extracellular matrix proteins such as laminin, fibronectin, 
vitronectin and collagen. This process is modulated by complement fragments (C5a), vasoactive 
amines, cytokines (TNF-α, IL-1β, IL-6), chemokines and membrane-derived mediators such as 
platelet-activating factor(PAF), platelet-derived growth factor (PDGF) and leukotrienes [1, 2, 
348, 351]. This transendothelial migration of leukocytes leads to the accumulation of 
inflammatory cells in the connective tissue stroma and is accompanied by vascular leakage and 
injury [351]. These changes result in occlusion of post-capillary venules causing tissue ischemia. 
Neutrophil-derived proteases and toxic oxygen products can act synergistically on the 
endothelial surface, leading to endothelial injury, intercellular gap formation, and increased 
vascular permeability [2]. In addition, the level of endogenous activated Protein C, which 
modulates coagulation, controls inflammation and supports fibrinolysis is also decreased. The 
hallmarks of sepsis are excessive inflammation, excessive coagulation and suppression of 
fibrinolysis, leading to tissue hypoxia and ischemia with resultant organ dysfunction and death 
[350].  
 
3.2.2. Disordered inflammation: Participation of the cytokine and chemokine pro-
inflammatory network 
 
 As aforementioned, sepsis is characterized by a massive release of pro-inflammatory 
mediators including TNF-α, IL-1β, IL-6, IL-8, and macrophage chemotactic protein-1 (MCP-1) [1, 
352-355] In addition, neutrophil apoptosis is significantly delayed by these inflammatory 
mediators. This allows them to function more effectively at sites of inflammation, thus leading 
to enhanced surveillance against infectious agents and a prolonged recruitment of other pro-
inflammatory cells by the release of cytokines and chemokines [1].  
 
3.2.2.1. Participation of cytokines 
 
 Cytokines are soluble, low molecular weight glycoproteins which act to regulate both 
innate and specific immune responses and act as inflammatory mediators. Individual cytokines 
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can be produced by multiple cells and are pleiotropic acting on multiple target cells in different 
ways depending on timing and concentration. At low concentrations cytokines have a paracrine 
effect, whereas at higher concentrations, such as in sepsis, cytokines have endocrine effects 
and act systemically [349]. During sepsis, a wide spectrum of pro-inflammatory cytokines are 
released, the following being the most relevant: 
 
a) TNF- α 
 TNF- α (25 kDa) is a pleiotropic cytokine that plays a pivotal role in the pathogenesis of 
inflammation, cachexia, toxic shock and tissue injury [356]. It is released by cells of the 
monocyte/macrophage lineage, glial cells in brain, Kupffer cells in the liver, keratinocytes in the 
skin, mast cells, NK cells, T cells and B cells. TNF-α stimulating factors include LPS, enterotoxins, 
toxic shock syndrome toxins, bacterial cell wall, and products of the complement activation 
[357]. Circulating TNF-α interacts with at least two membrane-associated receptors named 
TNF-R1 and TNF-R2. Both TNF-Rs are widely expressed, as they are found in virtually all types of 
cells, excluding erythrocytes and they also exist in soluble forms in the serum [357]. TNF-R1 is 
mainly responsible for the induction of pro-inflammatory responses via NF-kB but can also 
induce apoptosis. The outcome of TNF-R1 engagement seems to depend on the association 
with certain membrane microdomains rich in cholesterol and sphingolipids, the so-called lipid 
rafts. The translocation of TNF-R1 after triggering lipid rafts seems to be essential for NF-kB 
activation, whereas interference with lipid raft organization leads to apoptosis. In contrast, 
TNF-R2 is less well defined and seems to be involved in supporting TNF-R1-mediated functions 
[1]. Pathologic manifestations of TNF-α production include hypotension, acute renal tubular 
necrosis, pulmonary edema, disseminated intravascular coagulopathy, and a cascade of 
cytokine and stress hormone release [356].   
 
b) IL-1 
 
 IL-1 (17kDa) is a major inflammatory mediator produced primarily by monocytes and 
activated macrophages. The activity of IL-1 is mediated by two proteins, known as IL-1α and IL-
1β, which are the products of separate genes. A high-affinity activating receptor (IL-1RI) for IL-1 
is expressed by lymphocytes and fibroblasts, whereas a low-affinity decoy receptor (IL-1RII) is 
expressed on several other cell types. An unique feature of IL-1 is the existence of a naturally 
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occurring antagonist, IL-1Ra, which is expressed in neutrophils and monocytes [1]. Because IL-
1α and IL-1β bind to the same receptor, there are no differences between the biological actions 
of IL-1α and IL-1β. However, IL-1α is a cell-associated cytokine that can also act as a 
transcription factor, whereas IL-1 β is secreted and, therefore, more likely to play a role in 
systemic inflammation [358]. In septic shock, IL-1 acts directly on the blood vessels to induce 
vasolilatation through the rapid production of small mediator molecules such as PAF, 
prostaglandins, and NO, which are potent vasodilatators. Other systemic effects of IL-1 are the 
ability to induce fever, sleep, anorexia and hypotension [359]. 
 
c) IL-6 
 
The biological activities of IL-6 partially 
 Many cells, in particular fibroblasts, cells of the monocyte/macrophage lineage, and 
endothelial cells can secrete IL-6, a 26 kDa protein. This is a multi-functional cytokine that plays 
a central role in host defense mechanisms, regulation of immune responses, B cell 
differentiation, and is also a mediator for immunoglobulin class switching and hematopoiesis 
[360]. The biological activities of IL-6 partially overlap those of IL-1. Some of the pleiotropic 
effects of IL-1 are actually caused by IL-6 or by synergistic actions of IL-1 and IL-6. This cytokine 
stimulates hepatic protein synthesis during acute-phase responses and acts as an endogenous 
pyrogen. Because of these functions, IL-6 has been described as an alarm hormone: it is 
released by damaged tissues and induces the synthesis of acute-phase proteins in the liver that 
protect the host against inflammatory reactions [361, 362].  
 
 
3.2.2.2. Participation of chemokines 
 
 The chemokines are small 8-to-10 kDa proteins. Two major subfamilies, CXC and CC 
chemokines, have been extensively investigated in sepsis and in endotoxemia. In the CXC 
chemokines, the first two cysteine residues are separated by a single amino acid and they are 
typically chemotactic for neutrophils, whereas in the CC chemokines, the first two cysteine 
residues are adjacent to each other, and they attract and activate mononuclear cells [363].  
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a) IL-8 
 
 IL-8, a CXC chemokine, is produced by a wide array of cells, including endothelial cells, 
monocytes/macrophages and neutrophils. IL-8 plays a role in the pathophysiology of sepsis 
because this cytokine is able to activate and degranulate neutrophils. In fact, IL-8 is released 
into the circulation in animal models for septic shock and upon intravenous administration of 
endotoxin. Moreover, plasma levels of IL-8 are increased in up to 89% of in patients with sepsis, 
with no significant differences between those with Gram-positive or Gram-negative infections. 
IL-8 is able to induce shape change, release of lysosomal enzymes, and degranulation of 
neutrophils. It also elicits respiratory burst, and activates arachidonate-5-lipoxygenase in 
neutrophils, processes that enhance inflammation. IL-8 may promote adherence of neutrophils 
to the endothelium by increasing, β2-integrin expression and may regulate transendothelial 
migration of these cells. Moreover, when produced at local sites, IL-8 elicits edema formation 
due to neutrophil-mediated endothelial damage and subsequent plasma leakage [364, 365].  
 
b) MCP-1(CCL2) 
 
 MCP-1, a prototype of CC chemokines, is a potent chemoattractant and a regulatory 
mediator involved in a variety of inflammatory diseases. This chemokine is secreted mainly by 
monocytes, although MCP-1 expression is also found in different types of cells, including 
fibroblasts, endothelial and epithelial cells. Similarly to IL-1 and IL-6, MCP-1 stimulates 
monocytes/macrophages to elicit respiratory burst, expression of β2-integrins, release of 
lysosomal enzymes, induction of production of different cytokines and attraction of T cells and 
NK cells [352, 365]. More precisely, MCP-1 has been implicated
 
as a remarkable mediator of 
monocyte and lymphocyte infiltration
 
of tissues in a wide variety of inflammatory diseases, 
such
 
as glomerulonephritis, rheumatoid arthritis, and bacterial meningitis. It has been shown 
that inhibition of
 
MCP-1 expression results in reduced transmigration of monocytes
 
through 
blood vessels and in diminished recruitment of T
 
lymphocytes, suggesting a critical role in acute 
inflammation [363]. 
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3.2.3. Anti-inflammatory response  
 
 During sepsis, the anti-infectious agemt response is closely linked to an overwhelming 
pro-inflammatory process. All mediators contribute in synergy to tissue injury, organ 
dysfunction, and possibly to lethality. The early hyper pro-inflammatory phase of sepsis is 
followed by counterregulatory mechanisms, and the hyper- and anti-inflammatory states 
alternate during the following course of sepsis or the two may co-exist at the same time.  The 
anti-inflammatory response relies on a few cytokines, mainly IL-10, IL-4 and transforming 
growth factor-beta (TGF-β) and some soluble factors, including soluble TNF-receptor (sTNF-αR) 
and IL-1 receptor antagonist (IL-1Ra). There is also participation of glucocorticoids, 
neuromediators (adrenalin, acetylcholine), and some other factors (heat shock proteins, 
adenosine). These mediators modify the immune status of circulating leukocytes or they 
reduce pro-inflammatory cytokine production in response to Toll-like receptor agonists [1, 
366].  
 
a) IL-10  
 
 Plasma IL-10 concentrations in patients with septic shock are significantly higher than 
those with only sepsis. It is believed that the magnitude of the IL-10 response appears to 
correlate both with the severity of the inflammatory insult and the plasma concentration of 
pro-inflammatory cytokines. In fact, it is known that IL-10 production in sepsis is a direct 
consequence of pro-inflammatory cytokine production, predominantly TNF-α. IL-10 (18 kDa) is 
produced by TH2 lymphocytes, monocytes and epithelial cells. Being a TH2 cytokine, IL-10 
mainly inhibits gene expression and synthesis of pro-inflammatory cytokines and chemokines 
from macrophages. More precisely, it suppresses the synthesis of IL-1α, IL-1β, TNF-α, IL-6, IL-8, 
IL-12, IL-18, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-
stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), macrophage 
inflammatory protein (MIP)-1α, regulated upon activation—normal T cell expressed and 
secreted (RANTES), leukemia-inhibiting factor (LIF), and IL-10 itself.  In addition, IL-10 induces 
neutrophil apoptosis during the resolution of inflammation. Cell signaling after the engagement 
of IL-10 to its receptor includes phosphorylation of JAK1 and TYK2 and phosphorylation of 
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STAT-3, very similar to that of interferon-α/β. IL-10 also inhibits the synthesis of NO and the 
synthesis of gelatinase and collagenase [1, 355, 367].  
b) IL-4 
 IL-4 is a 15 kD protein produced by activated T cells, mast cells, and basophils. IL-4 
stimulates the TH2 cell differentiation and proliferation, and enhances B cell secretion of IgE. 
Moreover, it suppresses production of IL-1β and other monocyte-derived cytokines, including 
TNF-α, IL-6 and IL-8, although it enhances IL-1Ra synthesis. IL-4 also induces fibroblast 
proliferation and production of extracellular matrix proteins [368, 369].  
 
c) TGF-β 
 
 TGF-β is a pleotrophic cytokine expressed in the vessel wall that promotes several anti-
inflammatory effects, such as the production of anti-inflammatory cytokines and the inhibition 
of leukocyte adhesion to the endothelium. In addition, TGF-β also inhibits the migration of 
neutrophils through
 
endothelial monolayers activated by TNF-α. This cytokine achieves its anti-
 
inflammatory properties by inhibiting the expression of at least two genes,
 
E-selectin and IL-8, 
which are essential in the inflammatory pathway [1, 370]. 
 
d) sIL-1Ra 
 
 IL-1Ra receptor is one of the three members of the IL-1 gene family, and it functions as 
a specific receptor agonist. Processing of IL-1α or IL-1β, to “mature” forms require specific 
cellular proteases. In contrast, IL-1Ra evolved with a signal peptide and is readily transported 
out of the cells and termed secreted IL- 1Ra (sIL-1Ra).  The major function of sIL-1Ra is to 
regulate the pleiotropic effects of IL-1 by competitively blocking its binding to cell surface 
receptors. Thus, sIL-1Ra functions as a major naturally occurring anti-inflammatory protein; 
when the balance between IL-1 and IL-1Ra is upset, inflammatory disease and tissue damage 
may ensue. Maintenance of a balance between IL-1 and IL1-Ra is important in preventing the 
development or progression of inflammatory disease in certain organs. Recently, three 
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intracellular isoforms for IL-1Ra have been described, and identified as icIL-1Ra1, 2, and 3, 
although their role is still poorly defined [371, 372]. 
 
 There are two IL-1 receptors (IL-1R), the type I receptor (IL-1RI) transducing a signal, 
whereas the type II receptor (IL-1RII) binds IL-1 but does not transduce a signal. In fact, IL- IRII 
acts as a sink for IL-18 and has been termed a “decoy” receptor.  When IL-1 binds to IL-1R1, a 
complex is formed that then binds to the IL-1R accessory protein (IL-1R-AcP), resulting in high-
affinity binding. The extracellular or ‘‘soluble’ ’ portions of the IL-1RI (IL-1sRI) and IL-1RII (IL-
1sRII) circulate in health and disease functioning as natural “buffers” binding IL-1α, IL-1β, or IL-
IRa. In addition, several cytokines exert a negative influence on both the production and 
activity of IL-1 [371, 372].  
 
e) sTNF-αR 
 TNF-α has two receptors, TNF-α receptor I (TNF-αRI) (55kDa) and TNF-αRII (75 kDa). 
The TNF-αRI is the main mediator of the TNF-α signaling to cells, whereas the TNF-αRII, which 
has a secondary role in signaling, serves also for “ligand passing,” this is, for channeling TNF-α 
to the TNF-αRI, thus facilitating its binding to it. Both receptors for TNF-α exist also in soluble 
forms, probably derived by proteolytic cleavage from the cell surface forms. Once released, 
soluble receptors (sTNF-αRI and sTNF-αRII) inhibit TNF-α activity by binding to TNF-α and 
preventing binding of the ligand to TNF-α cell receptors. This regulatory process may modulate 
TNF-α activity in response to inflammation. Interestingly, these soluble receptors  are found in 
the circulation of patients with sepsis and in response to endotoxemia and their rise indicates 
worsening of sepsis. In addition, renal insufficiency may contribute to the persistently high 
levels by inhibiting the elimination of soluble receptors [373, 374].  
 
f) Glucocorticoids and neuromediators  
 One of the more intriguing subjects of investigation is the connection between the 
central nervous system, the adrenal cortex and the resolution of inflammation. Glucocorticoids 
(GCs), which are produced by the adrenal cortex, are main players in this concept. GCs are the 
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most powerful endogenous inhibitors of the innate immune reaction throughout the organism. 
The secretion of cortisol in humans, or corticosterone in animals, occurs as the result of the 
hypothalamic-pituitary-adrenal (HPA) axis activation. Inflammatory and stress-related sensory 
information triggers corticotropin-releasing factor (CRF)-secreting neurons in the 
paraventricular nucleus (PVN) of the hypothalamus. This leads to the release of ACTH from the 
pituitary, which then stimulates the release of GCs from the zona fasciculata of the adrenal 
cortex. Numerous studies have suggested that IL-1β, IL-6, TNF-α and other pro-inflammatory 
cytokines, lead to an increased pituitary release of adrenocorticotrophic hormone into the 
serum, which mediates increased cortisol/corticosterone production in the adrenal cortex, 
ultimately decreasing the inflammatory response.  In the ‘cholinergic anti-inflammatory 
pathway’, vagus nerve stimulation with a subsequent release of acetylcholine attenuates 
systemic inflammatory responses by the inhibition of the release of TNF-α and other cytokines 
from macrophages. It was recently demonstrated that the nicotinic acetylcholine receptor α7 
subunit is essential for inhibiting cytokine synthesis by the cholinergic anti-inflammatory 
pathway. In addition, the adenosine A2a receptor also seems to be necessary for down-
regulation of the pro-inflammatory immune response [1, 375].  
 
 
3.3. Toxic shock syndrome (TSS) and toxic shock like syndrome(TSLS) 
 
 
 Infections of the chest, abdomen, genitourinary system, and primary bloodstream 
(including meningitis) result in more than 80% of cases of sepsis. Interestingly, it has been 
observed that the occurrence of sepsis due to Gram-negative bacterial infections has 
diminished over the years to 25–30%, while sepsis caused by Gram-positive infections accounts 
for 30–50% of cases [347]. However, several Gram-positive species are also capable of 
producing disease through toxin production in addition to classic sepsis syndromes. Toxic shock 
syndrome (TSS) is an acute, multi-system, toxin-mediated illness, typically resulting in shock 
and multi-organ failure early in its clinical course. It represents the most fulminant expression 
of a spectrum of diseases caused by toxin-producing strains of S. aureus and S. pyogenes (GAS).  
In addition to these pathogens, some Gram-negative bacteria, Mycoplasma spp, and certain 
viruses are known to produce toxins known as superantigens (SAgs). These SAgs bypass 
conventional mechanisms of MHC-limited antigen processing, whereby antigens are processed 
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into peptide fragments within APCs. In fact, SAgs share the ability to trigger excessive and non-
conventional T-cell activation, this is, on CD4
+
 and CD8
+
 T cells, which bear the T cell receptor 
(TcR) αβ and sometimes on those bearing the ɣδ TcR.  The staphylococcal and streptococcal 
SAgs identified to date are single-chain proteins expressed as precursor molecules, which are 
then cleaved to release the functional extracellular toxin. Unlike conventional peptide antigens, 
SAgs bind most often to invariant regions of the MHC class II molecules at the surface of APCs 
outside the classical antigen-binding groove. They are presented as unprocessed proteins to T 
cells that express appropriate motifs on the variable domain of the β chain (Vβ) of the TcR. This 
process results in the formation of ternary MHC class II molecule-SAg-TcR complexes leading to 
the proliferation of the targeted T cells in a Vβ-restricted fashion. Streptococcal and 
staphylococcal SAgs exhibit a remarkable spectrum of biological and pharmacological activities. 
These activities include the pyrogenic effects elicited by these toxins as a consequence of the 
release of IL-1 and TNF-α, and their action on the hypothalamus; blockade of the 
reticuloendothelial system (monocytes/macrophages located in the reticular connective tissue) 
and enhancement of host susceptibility to lethal shock by endotoxin; and immunosuppression 
of humoral and cell-mediated responses, deletion of T cell repertoire, anergy and apoptosis of 
lymphocytes. Moreover, T cell activation leads to recruitment of further T and B cells to the site 
of infection. Clonal T cell expansion continues, as well as activation of APCs, further amplifying 
the release of pro-inflammatory mediators. A complex interplay exists between the cytokines 
released during this pro-inflammatory cascade, with IFN-γ rapidly inducing TNF-α and IL-6 
expression. [346, 376]. 
 
 Toxic shock-like syndrome (TSLS), caused by GAS is a syndrome with a rapid and 
fulminant course closely resembling the TSS caused by S. aureus and GAS SAgs. The 
streptococcal TSLS has a rapid course and frequently fatal outcome. GAS produces a variety of 
extracellular substances that have different antigenic and biologic activities. These exotoxins 
are often associated with severe suppurative soft-tissue infection, such as skin or muscle and 
other soft tissue, and may cause a syndrome of fever, shock, a rash that later desquamates, 
hypotension and multi-organ-system dysfunction. Although streptococcal TSLS is most often 
associated with exotoxin A-producing infections of soft tissues, the syndrome has also been 
reported in association with exotoxin types B and C, and with strains producing combinations 
of the exotoxins. Streptococcal pyrogenic exotoxins  types A, B, and C, are responsible for the 
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fever and rash of scarlet fever, and each has potent toxin properties that alter host defense by 
increasing susceptibility to endotoxin shock, decreasing antibody response, inhibiting 
macrophage function, and activating lymphocytes. TSLS has been associated with the 
reappearance of highly mucoid exotoxin-producing strains of streptococci that have a greater 
tendency to produce potent exotoxins than previous strains. In fact, the observed increase in 
the incidence and severity of invasive group A streptococcal infections coincides with the 
resurgence of genetically related, highly virulent strains of GAS that express an invasive 
phenotype and carry a specific gene for pyrogenic exotoxin A [377, 378]. 
 
 It is thought that S. suis ST7 has recently acquired putative virulence factors responsible 
for TSLS. Indeed, as mentioned in section 1.3.2.1, S. suis ST 7 strains possesses a stronger 
capacity to stimulate T cells, naive T cells and peripheral blood mononuclear cell proliferation 
than S. suis ST1. As explained, S. suis ST7 infection in humans is characterized by acute onset of 
fever, chills, headaches, dizziness, malaise, abdominal pain, diarrhea, organ function 
impairment, and death [97, 98]. 
 
 
3.4. Genetic influence of the host on the development of sepsis 
 
 Variation in responses to pathogens is influenced by exposure history, environment 
and the host's genetic status. There is now evidence that specific genetic factors influence a 
host's susceptibility or immunity to many infectious agents, and modulate severity and 
outcome of infectious diseases, which may have important clinical implications. Thus, variation 
in key innate immunity genes may explain variation in individuals' responses to infection. If so, 
it would be useful to evaluate genotypes of critically ill patients to understand individual 
susceptibility and response to infection, which could lead ultimately to specific patient-tailored 
therapy based on genotype [379]. Investigation of single nucleotide polymorphisms (SNPs) in 
candidate genes associated with sepsis and septic shock may provide valuable clues to 
understand the origin of such variability. 
 
 In humans, TNF-α polymorphism (-308A allele) is associated with increased secretion of 
TNF-α from macrophages in vitro and elevated TNF-α blood concentration in vivo. There is 
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evidence that the TNF-α-308A allele is associated with adverse outcome in a variety of 
infectious and inflammatory diseases including cerebral malaria and meningococcal disease. 
The TNF-α promoter gene is in linkage disequilibrium with several alleles that may be involved 
with the control of TNF-α secretion, or that may be independent risk factors for the 
development of meningococcal disease or other forms of sepsis [379]. On the other hand, SNPs 
in CD14, mannose-binding lectin (MBL) and hTLR2 are associated with increased prevalence of 
sepsis associated with positive bacterial cultures, but not with altered prevalence of septic 
shock or decreased survival. Furthermore, CD14 SNPs are associated with Gram-negative 
bacterial infections, and TLR2 with Gram-positive bacterial infections, MBL not being associated 
with a particular organism class [380]. These results reinforce the theory that SNPs in innate 
immune receptors may alter recognition and clearance of bacteria without changing outcomes 
in critically ill adults with systemic inflammatory response syndrome. Morevoer, hTLR4 
mutations are associated with an increased incidence of Gram-negative infections and 
development of sepsis [381]. However, results may be contradictory, as other research has 
provided evidence that there is no association between SNPs of hTLR4 and outcome of Gram 
negative sepsis. This would also be the case for SNPS of TNF-α, IL-1β, plasminogen activator-1 
(PAI-1), urokinase plasminogen activator (uPA) and CD14 [382]. Allelic variation in HLA class II 
molecules plays a major role in modulating severity of GAS sepsis, primarily because they serve 
as binding and signaling receptors for superantigens, which are the primary trigger of the 
severe inflammatory responses that can lead to organ failure and shock [383]. 
 
 In the case of meningitis-associated bacteria, some patients may develop meningitis, 
whereas others may present with sepsis or even septic shock. This variability of clinical 
presentations of the same disease among affected individuals may be associated with host 
genetic factors. For example, in the case of infection by N. meningitidis, complement 
deficiencies and defects in sensing or opsonophagocytic pathways, such as SNPs of TLR4 and 
combinations of inefficient variants of Fcγ-receptors, seem to have the most important role in 
genetically susceptibility  [384]. In the case of S. pneumoniae infections, homozygotes for MBL 
codon variants, could be at substantially increased risk of invasive pneumococcal disease in 
humans [385]. Moreover, and similarly to N. meningitidis infection, genetic variability in the 
TLR4, CD14 and Fcγ-receptors genes is associated with an increased risk of developing invasive 
disease in patients who are infected with S. pneumoniae [386]. To date, there are no studies 
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regarding the possible influence of host’s genetic factors on the development of S. suis 
infection. 
 
 In order to systematically identify additional gene variants that modulate susceptibility 
to severe sepsis or other infections, and to elucidate how they influence disease outcome, 
researches take advantage of animal experimental models of the disease with attributes that 
incorporate roughly the same level of genetic variation as that of human populations [383]. 
Different inbred mouse lines have been used to study differential susceptibility to several 
infections; unfortunately, these models are limited in their genetic variability and cannot be 
used to map modifier loci. However, the generation of genetically diverse mouse reference 
population of recombinant inbred strains, which can be linked to an immortal population of 
human monozygotic twins, is considered as the ideal model for many studies. Recombinant 
inbred strains are generated by the crossing of two inbred strains followed by at least twenty 
consecutive generations mating among siblings.
 
 These types of strains are frequently used for 
studying genetic variation and mapping quantitative trait loci (QTL) influencing disease [383].  
 
4.   The innate immune response in the brain 
 
 For a long time, the CNS has been considered as an immune privileged organ, as, unlike 
the peripheral organs, it exhibits a relative absence of lymphatic drainage of the parenchyma, 
has a limited number of APCs, and the BBB meticulously filtrates circulating elements. Although 
this is partly true, the CNS has its own innate immune system, which is activated in response to 
both cerebral and systemic immune challenges. On one hand, activation of the innate immune 
system and cytokine production controls infections, remove debris and promote repair in the 
CNS, but on the other hand, they may promote various CNS pathologies, ranging from acute 
injuries to chronic degeneration. As in peripheral tissues, the brain contains a resident set of 
bone marrow derived mononuclear phagocytes that include the microglia in the parenchyma, 
perivascular macrophages and macrophages in the meninges and choroid plexus. However, 
unlike most other tissues, the CNS contains very few mast cells or DCs. In certain immune-
mediated lesions within the CNS, DCs can be found in the brain parenchyma and may 
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contribute to the chronicity of the disease. However, the absence of DCs in the normal brain is 
likely to be a major contributor to the particular immunological status within the brain 
parenchyma [387, 388].  
  
4.1. Triggering of the inflammatory response in the brain 
 Most of the research on the development of the inflammatory response in the brain 
has been developed using LPS, a TLR4 ligand widely known for its rapid and potent induction of 
cytokine production. The use of LPS in animal models of brain inflammation has been of great 
help for depicting the spatio-temporal expression of genes involved in this response. Indeed, 
the intraperitoneal injection of LPS in mice leads to a robust induction of IkBα (index of NF-κB 
activation) in cells of endothelial type along the blood vessels of the entire brain. The same 
effect is observed when animals are injected with either IL-1β or TNF-α, but not IL-6. Moreover, 
the IkBα transcript is also found in scattered small cells, which are positive for microglia 
markers (using ant-OX-42 antibodies).  These results indicate that the brain responds to 
systemic inflammatory insults and that specific cells of the CNS are involved in such a response 
[389]. Interestingly, complementary studies suggested that the inflammatory response in the 
brain starts in the circumventricular organs (structures devoid of BBB), and notably, that TLR4 
may be the recognizing molecule for Gram-negative bacterial
 
components only in response to 
systemic infection, whereas CD14
 
may have a more complex role in the pro-inflammatory signal 
transduction
 
events in the brain parenchyma. These conclusions were made as the systemic 
inoculation of LPS in mice lead to an up-regulation of TLR4 mainly in the leptomeninges, 
choroid plexus, and circumventricular organs (subfornical organ, organum vasculosum of the 
lamina terminalis, median eminence, and area postrema), but only scattered small cells 
displayed a convincing positive signal within the brain parenchyma. These brain structures also 
exhibited constitutive expression of CD14, which was up-regulated in different cells of myeloid
 
origin throughout the entire brain parenchyma. However, and in contrast to the strong up-
regulation of the gene encoding CD14, neither LPS nor the challenge with IL-1β caused a 
convincing increase in the TLR4 mRNA levels throughout the CNS [390]. Nevertheless, IL-1β is 
not the only cytokine that has a direct effect on the inflammatory response in the brain. In fact, 
TNF-α has a similar effect, as rats that are intracerebroventricularly challenged with 
recombinant rat TNF-α, show a strong up-regulation of IkBα, TNF-α, and CD14 mRNA in 
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parenchymal microglial cells localized in different regions of the brain. In the case of CD14 
mRNA, the signal is mainly detected at the right
 
caudoputamen, cerebral cortex, hippocampal 
and septal formation,
 
and parenchymal elements around the third ventricle, beneath the
 
leptomeninges, and near the central canal and the fourth ventricle, whereas IkBα and TNF-α 
signals are observed in regions near the ventricles. These findings provide the evidence that 
microglial-derived TNF-α is responsible for the production of the CD14 during endotoxemia. 
This autocrine/paracrine stimulatory loop may be of great importance in controlling the 
inflammatory events that take place in the CNS during innate immune response as well as 
under pathological conditions [391]. 
 
 Mice that receive a systemic challenge with LPS, show a robust up-regulation of TLR2 
within cerebral tissue, which is first detected in regions devoid of BBB and few blood vessels 
and microcapillaries and then in brain parenchyma in cells identified as microglia. Moreover, 
LPS-challenge also induces a rapid induction of IκBα and up-regulation of MyD88, suggesting 
that LPS-induced TLR2 transcription may be dependent on the NF-κB pathway. However, mice 
challenged with bacterial components that are considered as TLR2 ligands (LTA, PG or a 
combination of both), failed to induce the up-regulation of the receptor [392].  
 
  Similar studies more recently confirmed the relevance of chemokine up-regulation in 
the brain. The systemic challenge with LPS provokes up-regulation of MCP-1 mRNA particularly 
in endothelial cells of the microvasculature and in brain areas devoid of BBB,  indicating that 
MCP-1 may therefore play a critical role in the cerebral innate immune response and 
contribute to the early chemotaxic events during cerebral inflammation [393].  
 
4.2. Central role of microglia 
 The term microglia refers to cells that reside within the
 
parenchyma of the CNS, that 
share many if not all
 
the properties of macrophages in other tissues. Moreover, although 
microglia are "brain macrophages," they are distinguished due to their parenchymal location 
and certain functional differences,
 
from other types of brain macrophages such as meningeal 
and
 
perivascular macrophages and perivascular cells
 
or pericytes, which are enclosed by a 
perivascular
 
basement membrane within blood vessels and are not part of the
 
CNS 
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parenchyma. Besides, they are ontogenetically related to cells of the mononuclear phagocyte 
lineage, unlike all other cell types in the CNS [388, 394-397]. 
 Microglia account for up to 10% of the overall number of brain cells. They are present 
within all brain regions including both grey and white matter [398]. One of the characteristics 
of microglia is their activation at a very early stage in response to injury. Microglia activation 
often precedes reactions of any other cell type in the brain. In
 
their non-activated or resting 
state, they have a characteristic "ramified"
 
morphology not seen in resident macrophages of 
other organ systems, adapted to the specialized microenvironment of the CNS. Certain cell 
surface markers of importance
 
in immune regulation, such as MHC class II molecules and 
complement type-3 receptor (CR3; CD11b/CD18 complex) are constitutively
 
expressed on 
ramified microglia in the normal adult brain.
 
Microglia are able to respond selectively to 
molecules involved in neurotransmission, as they have receptors for CNS signaling molecules 
such as adenosine triphosphate (ATP) and calcitonin gene-related peptide (CGRP), and can 
react both with changes in their extracellular ionic milieu and by activation of transcriptional 
mechanisms. This allows them in their ‘resting’ state to continuously monitor the physiological 
integrity of their micro-environment and to react rapidly in the event of pathological events 
[388, 394-398].  
 Ramified microglia have the capacity to dramatically
 
change their morphology in 
response to a variety of CNS insults such as microbial
 
invasion; they retract processes and 
round cell body, acquiring a reactive “amoeboid” form. In addition, they quickly up-regulate a 
large number of receptor types and
 
secrete innumerable products that are thought to 
contribute
 
to the defense and, potentially, damage of the infected brain. Signs of microglial 
activation include increased expression of CR-3, up-regulation of MHC class I and II antigens, 
which enable microglia to interact directly with immunocompetent cells such as T cells and 
presence of phagolysosomes, which denotes transition into phagocytic cells. There also is 
synthesis of a variety of potentially harmful soluble factors, including reactive oxygen and 
nitrogen intermediates, proteolytic enzymes, arachidonic acid metabolites and pro-
inflammatory, potentially cytotoxic cytokines such as TNF-α and IL-1 [388, 394-397]. 
 Microglia can unequivocally be distinguished from other resident, non-neuronal cells in 
the CNS by immunocytochemistry or immunofluorescence or confocal microscopy by using 
anti-serum against the CR3 (OX-42 antibody). In addition, these cells constitutively express 
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galactose-containing glycoconjugates that bind isolectin B4 from Griffonia simplicifolia (Fig 10) 
[395]. 
 
 
 
 
 
 
 Bsibsi et al [399], performed cultures of primary microglia from human postmortem 
brain tissues obtained from healthy donors with the aim of investigating the expression of TLRs 
by these cells. They found that microglia express mRNA encoding a wide range of different TLR 
family members, with a marked expression of both TLR2 and TLR3. In addition, microglia also 
express TLR1, TLR4, TLR5, TLR6, TLR7, and TLR8 and lower but detectable levels of TLR9. 
Immunocytochemical studies demonstrated that both TLR3 and TLR4 are exclusively localized 
in vesicular structures inside microglia and not on the surface of the cells. In addition, as only a 
minority of cultured microglia cells express sufficient levels of TLRs to be detectable by 
immunocytochemical staining, microglial TLR expression may be regulated and dependent on a 
certain level of activation that is reached only in a minority of cells in culture [399]. It was later 
confirmed that, similarly to human microglia, mouse microglia express mRNA for TLR1-9 [400]. 
Furthermore, cell activation was investigated after stimulation of inactive microglia with 
various TLR agonists, including LPS (TLR4), PG (TLR2), polyinosinic-polycytidylic acid (TLR3), CpG 
DNA (TLR9), and infection with viable Theiler's murine encephalomyelitis virus (which 
interestingly, activated TLRs 2, 3, 5, and 9). It was also observed that microglia
 
stimulated with 
the different TLR agonists expressed pro-inflammatory cytokines, including IL-12, IL-18, and 
TNF-α,
 
denoting a Th1-type pro-inflammatory response. In addition,
 
there also was expression 
of chemokines (MIP-1α,
 
MCP-1, and RANTES), which in vivo may be required for attracting 
peripheral
 
macrophages and T cells to the CNS. Most importantly, microglia
 
activation via TLR 
agonists up-regulated expression of co-stimulatory
 
molecules (B7-1, B7-2, CD40, and ICAM-1) 
and MHC class II, which
 
may render the cells functionally capable to present Ag to CD4
+
 Th1 
Fig. 10. Primary microglia from newborn 
C57BL/6 mice. Immunofluorescence microscopy. 
Microglia were identified by fluorescein 
isothiocyanate (FITC)-labeled G. simplicifolia 
isolectin B4 (Vector Laboratories). Nuclei were 
labeled with Propidium Iodide (SIGMA). 
(Domínguez-Punaro, et al; unpublished data).  
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cells [400].
 
Moreover, microglia stimulated with different TLRs agonists (LPS, CpG, 
oligodesoxynucleotide, and Tripalmitoyl-S-glyceryl-cysteine), release substantial amounts of NO 
[401].   
 The accessibility to microglia obtained from KO mice lacking selected genes involved in 
the innate immune response, has allowed the dissection of some of the mechanisms used by 
microglia to mount an inflammatory response against meningitis-causing bacteria, which at the 
same time may have negative consequences for the host. For example, experiments using co-
cultures of microglia and neurons or neurons alone infected with GBS, demonstrated that GBS 
induces neuronal injury only in the presence
 
of microglia. Moreover, experiments using TLR2
 -/-
 
and MyD88
-/-
 microglia indicate that this microglial activation and neuronal
 
apoptosis induced 
by GBS require these signal
 
transduction molecules. Furthermore,
 
NO, a molecule that is largely 
responsible for GBS-induced neuronal injury, was produced  only in the wild type, but not in 
TLR2
–/–
 or MyD88
–/– 
 cells [327]. Complementary studies revealed that both TLR2 and MyD88 
are involved in GBS-induced apoptosis in microglia via caspase-8 activation [328].  
  Purified components from S. pneumoniae are strong inducers of the inflammatory 
response in microglia. Indeed, when microglia are stimulated with purified cell walls from S. 
pneumoniae, another important meningitis agent, there is release of different pro-
inflammatory cytokines and chemokines, including TNF-α, IL-6, IL-12, MIP-1α and MIP-2. In 
addition, the use of a ERK1/2 inhibitor (tyrphostin AG126) blocks this cytokine release, 
revealing the participation of the MAPK pathway in the production of pro-inflammatory 
molecules in microglia [344, 402]. In addition, pneumolysin is mainly responsible for the release 
of NO and TNF-α from mouse microglia and it also induces apoptosis of these cells. In this case, 
apoptosis is attributed to damage to mitochondria, followed by the release of apoptosis-
inducing factor (AIF) from the mitochondria  [401, 403, 404]. In additional studies, mouse 
microglial cultures were pre-stimulated with different TLRS agonists, such as Pam3CSK4 
(TLR1/2), LPS and CpG and then exposed to either encapsulated or nonencapsulated strains of 
S. pneumoniae. Results revealed that those cells pre-stimulated with TLR1/2, 4 and 9 agonists, 
ingested and killed more bacteria than non-stimulated cells, suggesting the participation of 
several TLRs in the inflammatory response against this pathogen [405]. Both bactericidal 
activity and secretory response  from microglia are significantly influenced by a Pneumococcal 
surface protein C (PspC) molecule, present on the bacterial surface. Lack of PsPC renders S. 
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pneumoniae more susceptible to the phagocytic and killing activities of microglia and also 
stimulates the release of TNF-α, MIP-2, IL-10 and NO [406]. 
  S. aureus is the main causal agent of brain abscesses in humans. Mouse microglia 
exhibit bactericidal activity against this pathogen. In addition, microglia show an increase in the 
up-regulation of TLR1, TLR2, TLR6, and CD14 following stimulation with heat-inactivated S. 
aureus or PGN. The increase in the expression of these TLRs and in CD14 following bacterial 
stimulation might serve as a mechanism to potentiate the antibacterial immune response in 
the brain prior to leukocyte recruitment in vivo. Moreover, up-regulation of the mentioned 
receptors is accompanied by enhanced of MHC Class II, CD40, CD80, and CD86 expression. 
These later findings suggest that the ability of microglia to present antigens may be enhanced 
following stimulation with S. aureus and this could serve as a means to amplify the expansion 
of antigen-specific T cells to quell CNS infections initiated by this pathogen. Finally, microglia 
respond to heat-inactivated S. suis or its PG by secreting substantial quantities of  IL-1α, IL-1β, 
TNF-α, IL-6, IL-1Ra, MIP-1α, MIP-2, and MCP-1 [407]. The importance of TLR2 in the recognition 
of S. aureus was further evaluated by comparing the inflammatory response from TLR2
-/-
 and 
wild type microglia. TLR2 was found to play a pivotal role in PG recognition and subsequent 
activation in primary microglia, as demonstrated by the attenuated expression of  pro-
inflammatory cytokines and chimokines in PG-treated TLR2
-/-
 microglia compared with wild 
type cells. In contrast, the responses of TLR2
-/-
 and wild type microglia to S. aureus were 
qualitatively similar, indicating that alternative receptors are responsible for recognizing intact 
bacteria [408]. Moreover, the pro-inflammatory response against S. aureus is partially 
attenuated when using specific agonist of PPAR-γ, a Peroxisome proliferator-activated receptor 
(PPARs), member of the nuclear receptor superfamily of proteins that regulate the expression 
of genes involved in reproduction, metabolism, development, and immune responses. More 
precisely, the use of the prostaglandin metabolite 15-deoxy-Δ12,14- prostaglandin J2 (15d-
PGJ2), which is a natural agonist for PPAR-γ, inhibits cytokine and CC chemokine production by 
microglia stimulated with heat-killed S. aureus. Moreover, 15d-PGJ2 also selectively inhibited 
the S. aureus-dependent increase in microglial TLR2, CD14, MHC class II, and CD40 expression. 
These findings suggest that 15d-PGJ2 may exert beneficial effects during the chronic stage of 
brain abscess by minimizing damage to normal brain parenchyma that is a common sequelae of 
disease [409]. 
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 The remarkable participation of microglia in mounting the inflammatory response 
against Gram-negative bacteria responsible for meningitis has also been studied with Borrelia 
burgdorferi, the causative agent of Lyme disease. In fact, microglia react rapidly when infected 
with this pathogen, producing different pro-inflammatory mediators, such as IL-6, TNF-α, and 
PGE2. This reaction is associated with up-regulation of TLR2 and CD14 and further induction of 
NF-κB [410]. However, B. burgdorferi, as well as N. meningitidis induce a delayed production of 
IL-10 from microglia, which in vivo, may be associated with the suppression of inflammation 
seen within the brain parenchyma during chronic bacterial infections. Moreover, it would also 
indicate a decrease in the bactericidal capacity of these cells and may serve to demonstrate the 
ability of microglia to limit potentially damaging inflammation within the CNS in response to 
invading pathogens [411]. 
 Microglia express functional NOD2 proteins, which may represent a potentially 
distinguished mechanism by which this cell type can respond to bacterial infections of the CNS. 
In fact, NOD2 protein expression is elevated following exposure to specific bacterial ligands for 
TLRs. These findings are supported by the observation that muramyl dipeptide (MDP), which 
elicits cellular responses via NOD2, can also elevate levels of this receptor, and by the 
demonstration that microglia express Rip2 kinase and GRIM-19, essential downstream effector 
molecules for NOD2-mediated cell responses. Finally, NOD2 is also up-regulated after exposure 
to B. burgdorferi, as well as N. meningitidis [412]. Moreover, recent data demonstrate that 
NOD2 is required, at least in part, for the astrogliosis, demyelination, behavioral changes, and 
elevated inflammatory cytokine levels observed following in vivo infection with these two 
pathogens [413]. To date, there are no published reports on the participation of these 
important intracellular receptors in the development of meningitis by S. suis. 
4.3. Participation of other glial cells 
 Astrocytes are the major glial cell type in the CNS. In the human brain, astrocyte bodies 
and processes cover around 11% of the cortex area, 0.80% of this value being represented by 
astrocyte processes, which form perivascular sheaths [414]. The principal method for 
identifying astrocytes is immunohistochemistry or immunofluorescence and confocal 
microscopy with antisera raised against glial fibrillary acidic protein (GFAP) an intermediate 
filament present in the cell body and processes of all astrocytes [414-416] (Fig. 11). 
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 Traditionally,
 
astrocytes have been considered to have a supportive or
 
structural role in 
the brain. However, they are also a remarkable source for neuroactive
 
substances, such as 
growth factors, eicosanoids, and neurosteroids,
 
which may subsequently influence neuronal 
development, survival
 
and neurosecretion [415]. In addition, in recent years, astrocytes have 
been recognized as potentially important contributors to inflammatory immune responses 
within the brain.  In fact, production of pro-inflammatory cytokines in the brain, such as IL-1β 
and TNF-α increases dramatically in neuropathological states,  as they contribute to the 
breakdown of  the BBB and recruitment of leukocytes into the CNS.  Furthermore, expression 
of adhesion molecules (VCAM-1 and ICAM-1) make a major contribution to the extravasation of 
leukocytes across the BBB. Interestingly, IL-1β induces sustained expression of IL-8 and VCAM-1 
and ICAM-1 in astrocytes. This suggests that astrocytes may participate in the development of 
chronic inflammatory lesions in the brain. Moreover, IL-1β is able to induce a sustained 
activation of NF-κB in astrocytes, which may also lead to a chronic inflammatory state [417, 
418]. 
 Primary murine astrocytes express mRNA encoding for different members of the TLR 
family. In fact, these cells have a low basal expression of mRNA for TLR2-5 and 9. These 
receptors are functional, as binding to their specific ligands leads to the translocation of NF-κB 
to the nucleus and up-regulation of the expression of mRNA-encoding IL-6 [419]. In addition, 
these cells express only basal levels for TLR2-3 [327, 399]. As opposed to microglia, which 
mainly express TLR3 in intracellular compartments, astrocytes appear to have both a high 
intracellular and a high surface expression of TLR3. This possibly reflects the fact that astrocytes 
 
Fig. 11. Primary astrocytes from newborn 
C57BL/6 mice. Confocal microscopy. 
Astrocytes were identified with rabbit anti-
GFAP antibody (Abcam) and Alexa-Fluor 488 
goat anti-rabbit IgG (Invitrogen). The staining 
demonstrates the network of intermediate 
filaments in the cytoplasm (Zheng and 
Domínguez-Punaro, et al, unpublished data).  
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are not professional phagocytes and thus would require a high surface expression of TLR3 for 
an efficient detection of extracellular pathogens [420]. Moreover, astrocyte response to LTA 
includes activation of PI3K/Akt and ERK1/2 MAPK pathways and activation of the IKK/NF-κB 
cascade. Once activated and translocated to the nucleus, NF-κB binds to κB-binding site of 
MMP-9 promoter, turning on transcription of MMP-9 [421]. 
 The participation of astrocytes to the development of meningitis associated with Gram-
positive bacteria also has been studied. In the case of S. pneumoniae, purified pneumococcal 
cell walls are able to induce tyrosine phosphorylation and activation of ERK1/2 and p38 MAPK 
pathways in a dose-dependent fashion. Inhibitors of tyrosine phosphorylation are able to 
alleviate this effect and block cytokine production of astrocytes. Moreover, these responses of 
astrocytes require the presence of sCD14 present in serum [336]. It seems that astrocytes may 
play a key role in the initial antibacterial immune response against S. aureus or its purified cell 
walls, an event that involves TLR2, with further production of pro-inflammatory cytokines and 
chemokine production [422]. In addition, up-regulation of GFAP expression in the brain is 
noteworthy to contain the development of S. aureus abscesses. GFAP
-/-
 mice develop, in 
comparison to wild type mice, larger and more poorly demarcated inflammatory lesions, as 
well as a significantly increased intracerebral bacterial load, a diffuse leukocytic infiltration of 
the contralateral hemisphere, purulent ventriculitis, vasculitis, and severe brain edema. Wild 
type mice also present activated astrocytes showing a strong up-regulation of their GFAP 
expression in the abscesses [423]. Finally, S. aureus or its PG are able to modify the structure of 
gap junctions, that are formed by the hexameric organization of protein subunits called 
connexins (Cx). These gap junctions establish communication among astrocytes, and they may 
influence neuron homeostasis at sites distant from the primary focus of infection. This event is 
partially dependent on the p38 MAPK pathway [424]. 
 Astrocytes also possess functional NOD receptors. It has been found, that similarly to 
microglia, NOD2, in association with its downstream effector molecule, Rip2 kinase, participate 
in the inflammatory response N. meningitidis and B. burgdorferi, that lead to the production of 
different pro-inflammatory cytokines [412, 413]. 
 Some of the mechanisms involved in regulation of the inflammatory response in 
astrocytes are being elucidated. It was recently found that in rat astrocytes, down-regulation 
mechanisms of TLR2-4 include the participation of monomeric GTPases of the Rho family. Rho 
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proteins are activated by signals emanating from different surface receptors, including TLRs 
and act as molecular turn-off switches to control a variety of cellular processes, e.g., membrane 
trafficking, endocytosis, cytoskeletal remodeling, cell growth and differentiation, transcription, 
and apoptosis [425]. As these results demonstrated the importance of astrocytes in mounting 
the inflammatory response in the CNS, it will be necessary to evaluate their role in the 
meningitis caused by S. suis. 
 Studies evaluating the participation of oligodendrocytes in the development of the CNS 
inflammatory response are scarce, but it is known that oligodendrocytes can at least express 
mRNA encoding for TLR2-3. Oligodendrocytes seem to be very sensitive to pro-inflammatory 
events in their microenvironment. For example, up-regulation of TLR4 from microglia 
stimulated with LPS provokes death of oligodendrocytes, an effect that may be associated with 
the release of pro-inflammatory molecules from microglia. This finding may be associated with 
the demyelination observed in chronic lesions of meningitis [327, 399, 426]. 
 
4.4. Animal models of meningitis 
 There is an urgent need for animal models in the field of infectious diseases, 
particularly in the research on meningitis and septic shock. The usefulness of an animal model 
of meningitis/septic shock will vary depending on:  1) if the objective of the study is to focus on 
bacterial factors of virulence that may facilitate colonization and invasion of tissues, 2) if the 
main goal is to reproduce the development of pathogenic events leading to inflammation 
(either generalized or at the CNS), 3) if we want to analyze the host immune response and the 
progress of possible negative consequences or 4) if we want to test new therapeutic drugs or 
vaccines. There is no substitute for using animal studies if we want to understand in depth the 
dynamics of host–pathogen interactions or the complex interactions between the different cell 
types and organs that are involved in the host response to a pathogen.  Numerous animal 
models have been developed; including monkeys, rats, mice and rabbit models [427-429]. 
Nevertheless, mice are an attractive organism in which to understand human or zoonotic 
infectious diseases. Despite some differences, the immune systems of mice and humans are 
similar and they can often be challenged with the same, or similar, pathogens [427-429].   
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 One of the most important concerns in developing a model of infection 
(meningitis/septic shock) is the site of bacterial inoculation. On one hand, the pathogen is 
inoculated into animals intranasally, intraorally, subcutaneously, intravenously, or 
intraperitoneally. This methodology allows, depending on the chosen route, study of 
nasopharyngeal colonization, mucosal invasion, intravascular survival, bacterial multiplication 
and tissue invasion, including the CNS.  Therefore, these types of models allow researchers to 
focus on bacterial and host factors that determine the development of septicemia and the 
potential of a pathogen to invade the CNS. Because it is considered that adult animals will not 
reliably develop meningitis after intranasal or intraperitoneal challenge with live organisms, 
infant animals must be used for these models. On the other hand, adult animals are infected by 
direct inoculation of the pathogen into the CSF (intracisternal route), and in the case of mice, 
also by the intracranial route (IC) or by direct intracerebral instillation (through the right orbital 
surface of the zygomatic bone, at the posterior corner of the right eye). These models can 
reliably produce lethal infections with a predictable time course. However, these types of 
experimental infections bypass the natural dissemination of bacteria from the intravascular 
compartment to the CNS. Nevertheless, these models are considered to be useful for studying 
pathogen and host factors leading to brain and meningeal inflammation, for studying 
complications resulting from CNS inflammation, and for evaluating potentially useful agents for 
therapy of bacterial meningitis [427-429]. 
1) The adult rabbit model 
 This model has been developed for the most part using New Zealand white rabbits (2 - 
3 kg weight). Animals are anesthetized, and a helmet formed with dental acrylic is attached to 
the skull by screws. This helmet secures the anesthetized animal in a stereotactic frame that 
holds a geared electrode introducer with a spinal needle and facilitates puncture of the cisterna 
magna. Animals are infected by direct injection of a bacterial suspension into the cisterna 
magna [430-432]. The size of the inoculum that induces lethal infection depends mainly on the 
infecting microorganism, and it varies depending whether the objective of the study is to 
develop fatal disease or meningitis. For example, with S. pneumoniae, a dose of 1 × 10
6
 CFU/ml 
produces meningitis in all animals, although as much as 1 × 10
9
 CFU/ml is needed in order to 
produce a fatal disease. As a rule, only encapsulated bacteria are capable of establishing a 
productive infection in the subarachnoid space, whereas unencapsulated pathogens induce a 
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transient meningeal inflammation but are ultimately cleared from the CSF. In addition to live 
organisms, heat-killed bacteria, purified bacterial products, or host factors (cytokines) can be 
instilled into the CSF with the object of evaluating their inflammatory activity [432]. 
2) The adult rat model 
 This model uses adult Wistar rats and requires anesthesia of animals (usually a 
combination of ketamine/xylazine). Then there is removal of 75 µl of CSF via intracisternal 
puncture using a micromanipulator fitted to a 25-gauge needle, followed by inoculation of 50 
µl of the challenge organism (1 × 10
6
 CFU/ml). This model has been tested with S. pneumoniae, 
E. coli and H. influenza. After inoculation, meningitis is allowed to develop for defined 
durations. This model has been useful to determine bacterial and leukocyte counts in CSF, as 
well as bacterial counts in the blood, although for short periods, not longer than 8 hours after 
inoculation, as well as to assess possible differences in pathogenicity between capsulated and 
non capsulated strains. Moreover, brains from sick animals have been used to analyze possible 
changes at the cerebral capillary endothelium and integrity of the BBB [433].  This same model, 
with some modifications, has been useful in the study of the pathogenesis of meningitis by S. 
pneumoniae, providing the following advantages: (1) it allows the continuous measurement of 
multiple pathophysiologic parameters, such as temperature, cerebral blood flow and 
intracranial pressure (measured by Laser-Doppler flowmetry), (2) it is performed under 
standardized, controlled conditions, such as monitoring of mean arterial blood pressure and 3)  
animals can be equipped with a cranial window for the visualization of pial vessels, to 
determine their diameter and integrity by  light microscope and video equipment. The 
advantages of the adult rat model is that it allows taking repetitive samples of blood and CSF, 
although quantities are smaller than these in the rabbit model [428, 429, 434].  
3) The adult mouse model 
 In adult mice, meningitis is reproduced using mainly the intracerebral, the 
intracisternal, and the intracranial routes of infection. The intraperitoneal route has been used 
to a lesser extent. However, as mentioned above, the three mentioned approaches bypass 
several steps of the disease, and development of clinical signs is very rapid, making the design 
of long-term studies difficult, and it may be necessary to provide antimicrobial treatment so 
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that animals can survive longer. Moreover, manipulation of animals is complicated, as 
anesthesia is necessary, and precise handling is required to locate the best site of inoculation.  
 
 The intracerebral route has been used in particular for the study of the 
pathophysiology of L. monocytogenes meningoencephalitis. It has also proved useful for 
cytokine-induced meningitis. In this case, mice are anesthetized, and a superficial dorsal skin 
incision is made on the lower back to visualize the underlying lumbar vertebrae. Pro-
inflammatory cytokines (such as IL-1β) are then injected via lumbar puncture at vertebrate 
level L-1 or L-2. Mice injected with pro-inflammatory cytokines develop significant CSF 
pleocytosis and disruption of the BBB within 4 hours after injection [435, 436].  
 
 The intracisternal route is an approach widely used for the research in S. pneumoniae 
meningitis. For this, mice should be under short-term anesthesia with halothane and then, they 
receive a 15 μl intracisternal injection containing 1 × 10
7
 CFU/ml of S. pneumoniae. All animals 
surviving for more than 24 h after infection receive antimicrobial therapy with ceftriaxone. At 
specific time points, mice are anaesthetized for a second time (ketamine/xylazine) and a 
catheter is placed into the cisterna magna to determine leukocyte counts in the CSF and to 
measure the intracranial pressure. On necropsy, brain samples are taken to determine bacterial 
counts, to evaluate histopathological lesions and to measure the presence of cytokines. In this 
approach, all infected animals develop meningitis. Under antimicrobial therapy, about 80–90% 
of infected mice recover from the disease. However, motor residues and hearing impairment 
can still be observed in recovered mice. Histopathological alterations such as leukocyte 
infiltration, vasculitis and abscess formation may be observed from 24 h after inoculation [437]. 
Moreover, this route is also used to infect rats/mice with S. pneumoniae and study the 
mechanisms underlying meningitis-associated hearing loss by means of auditory brainstem 
response audiometry. Infected animals present deafness, which may be mild and partially 
reversible during the acute stage or severe with permanent hearing loss. Suppurative 
labyrinthitis is accompanied by BBB disruption, which correlates closely with hearing loss 
during the acute stage but not after recovery. In chronic lesions, there is hair cell damage, and 
fibrocytic occlusion of the cochlea; spiral ganglion neuronal density is markedly decreased and 
correlates with the severity of permanent hearing loss [438, 439]. 
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   The intracranial route is considered as an alternative method to the intracisternal 
route, in particular in research concerning S. pneumoniae. Bacteria are usually inoculated into 
the right forebrain of adult mice. Observed parameters (blood and CSF bacterial titers, CSF 
leukocyte counts and meningeal inflammation) increase gradually and all animals die within 
45 h. Therefore, antimicrobial treatment with ceftriaxone must be started at around 21 h after 
infection, because treatment at later time points is associated with high mortality (44% in case 
of treatment at 24 h). Examination of brain sections of intracranially infected animals revealed 
a purulent infiltrate surrounded by reactive astrocytes and microglia that developed within 
36 h at the site of infection, corresponding to early stage of cerebritis. However, an advantage 
of the model is its practicability with secure injection of the whole inoculum into the brain [440, 
441]. 
 Recently, the intracranial subarachnoidal route of infection was proposed as a variation 
for the intracranial route. Adult mice are placed under anesthesia (ketamine/xylazine) and 
infected with S. pneumoniae into the subarachnoid space through a soft point located 3.5 mm 
rostral from the bregma. The bregma is the intersection of the coronal and sagittal sutures of 
the skull and can be recognised in mice by visual examination of the exposed skull.  The 
stereotaxic coordinates of such inoculation point are 0 mm (× plane), 3.5 mm rostral (y plane) 
and 2 mm ventral (z plane) from the bregma. In moribund mice, systemic dissemination of 
pneumococci to blood and spleen was observed. Histological analysis of the brain of animals 
infected with S. pneumoniae confirmed the induction of meningitis closely resembling the 
disease in humans [296, 442]. 
 The intraperitoneal route has been used to study the pathogenesis of meningitis 
caused by H. influenzae, although two in-vivo passages to enhance virulence of bacteria are 
required, and a minimum dose of 1 x 10
4
 CFU/ml is necessary to cause disease. Many of the 
animals display hind leg paralysis, become moribund and/or convulse at around 12 h post-
infection [443]. Moreover, adult mice infected by the intraperitoneal route with N. 
meningitidis, produce a rapid but transient bacteremia and symptoms of infection (inactivity, 
lachrymation) that last only during 9 h post-infection. Bacteria were not recovered from the 
blood at 18 h post-infection [444]. Mice infected with S. pneumoniae by this route, show 
bacteremia that lasts up to 24 h, and cerebral deposition of S. pneumoniae can be found from 6 
h of infection. However all animals die from septic shock thirty-six hours after infection, before 
81 
 
the development of meningitis. Antimicrobial treatment of animals with cefazolin (an 
antimicrobial agent without CNS penetration) is required to stabilize peripheral bacterial titers, 
resulting in animal survival for at least 5 days [445]. 
4) The infant rat model 
 This model has been extensively used for the study of the pathogenesis of meningitis 
caused by H. influenza and E. coli. The experimental model uses albino Sprague-Dawley 
COBS/CD suckling rats (around 5 days old), caged with their mothers.  Bacteria are 
atraumatically instilled into the nose. The inoculum per animal varies between 1 × 10
3
 and 10
9
 
CFU/ml. This approach results in development of bacteremia after 2 days (73% of animals), 
depending on the dose. When the inoculum size is decreased, the incidence of bacteremia 
decreases [446]. This model has demonstrated that intranasal inoculation can result in 
bacteremia and meningitis, and that the magnitude of bacteremia is directly proportional to 
the inoculum size. However, this model has several limitations, including the size of the 
animals, which only results in small sample volumes, variability in the time course, modest 
brain damage and low case-fatality rate [429].  
5) The infant mouse model 
 This model consists of 11 day-old mice infected by the intracranial route with S. 
pneumoniae. All mice develop meningitis sixteen hours after infection, as documented by 
positive bacterial cultures of the CSF, although no clear signs of CNS disease are observed. 
Development of brain lesions depends not only on the bacterial strain used, but also on mouse 
strain selected, as at 40 h post-infection, there is 60% of survival in infected C57BL/6, 50% in 
CD1 mice, and 0% in BALB/c. Histological evaluations of brain sections reveal apoptosis in the 
dentate gyrus of the hippocampus in 27% of infected C57BL/6 and in 5% of infected CD1 mice 
[447]. The infant mouse model has also been used in N. meningitidis research. In this case, 
bacteria are inoculated into the nostrils of infant mice and the numbers of organisms in the 
nasal passages, lungs, blood and brains are determined. Intranasal instillation results in 
consistent nasal colonisation, which usually develops into a lung infection. In many cases, the 
lung infection precedes bacteremia, which occasionally results in death of the mice. The 
severity of the infection and the transition to bacteremia is enhanced by intraperitoneal 
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treatment of the mice with iron dextran or human transferrin. The requirement for lung 
colonization to precede bacteremia and the need for injection of iron compounds limit the use 
of this model of meningitis [448].  
  
4.5. Studying meningitis with KO mice: The example of Streptococcus pneumoniae 
 Despite the use of antimicrobial agents, the prognosis of bacterial meningitis is still 
poor due to central CNS complications. Experimental studies with animal models have given 
new insights into its pathophysiology during the acute phase of the disease. Targeted gene KO 
in mice have been used to characterize the mechanism of gene action during infectious 
processes, including meningitis, representing a gold tool for this research. Most mouse mutants 
with a defective immune system have a broad vulnerability to infection and show signs of 
immunodeficiency. By using KO mice, new knowledge of the roles of the different receptors, 
adaptor molecules, cytokines, proteases, and oxidants involved in the inflammatory cascade 
has emerged. It is believed that in the future, temporal and cell type-specific control of gene 
expression will provide even more information on the impact of a particular gene on 
meningitis-induced brain damage [449]. 
 
 The generation of a KO mice requires a targeted insertion of DNA into embryonic stem 
cells by homologous recombination [450]. Typically, a targeting vector is designed in a way that 
a positive selectable marker gene (for example, neomycin resistance gene, neo
r
) is flanked by 
large sequences of cloned genomic DNA homologous to the endogenous target gene. The 
homologous sequences enable insertion of the vector into the target gene by homologous 
recombination, while the neo
r
 gene disrupts the wild type DNA sequence, replacing  the 
original allele by a non-functional one (“null” allele, gene
+/–
). Mating of heterozygous mice with 
one “null” allele will produce a strain of KO mice homozygous for the non-functional gene 
(gene
–/–
). To date, hundreds of KO mice have been genetically engineered and numerous 
animals have been designed with specific mutations of genes related to the immune or CNS, 
offering new tools for research on bacterial meningitis [427]. 
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 S. pneumoniae is a leading cause of bacterial pneumonia, meningitis, and sepsis in 
children worldwide. In pneumococcal meningitis, the most common form of bacterial 
meningitis in adults, death occurs in 25–30% of all patients and neurological and 
neuropsychological sequelae are reported to affect up to 50% of survivors. Clinical and 
neuropathological studies have shown that the fatal outcome of the disease is mainly a result 
of complications secondary to bacterial meningitis. These complications include hearing loss, 
intracranial hypertension due to brain edema or hydrocephalus, arterial and venous 
cerebrovascular alterations (cerebral ischemia, venous thrombosis), intracranial hemorrhage, 
and systemic spread of bacteria leading to septic shock and multi-organ failure [451]. 
 
 The use of KO mice in S. pneumoniae research was used firstly to confirm that TLR2 is 
involved in the host immune response, initiating the recognition of the pathogen and triggering 
mechanisms involved in bacterial killing and production of pro-inflammatory mediators. 
Interestingly, the use of TLR2
-/-
 mice allowed establishing that the host reaction against S. 
pneumoniae does not depend solely on this receptor. More precisely, infected TLR2
-/-
 mice 
show an increase in disease severity, higher brain and blood bacterial titers and aggravated 
intracranial complications in comparison to wild type mice. However, expression of different 
pro-inflammatory mediators is similar between TLR2
-/-
 mice and wild type mice, indicating that 
there should be receptors other than TLR2 that still sense infection with S. pneumoniae and 
trigger the inflammatory response [325, 452]. In this regard, it is now accepted that 
pneumolysin recognition is TLR4-dependent, and once the receptor is bound to its ligand, there 
is release of TNF-α and IL-6, and may induce apoptosis of cells of the myeloid/monocytic 
lineage [453]. Furthermore, it was found that TLR9 plays a protective role in the lungs at an 
early stage of infection prior to the entry of circulating inflammatory cells, as TLR9
-/-
 mice are 
more susceptible to the intranasal challenge with S. pneumoniae, showing impaired 
pneumococcal uptake and in pneumococcal killing [454].  
 
 The use of KO mice has also been useful to determine the importance of MyD88 as an 
adaptor molecule to induce the inflammatory response against S. pneumoniae. MyD88- 
deficient mice display a markedly diminished inflammatory host response in the CNS, as 
evidenced by reduced CSF pleocytosis and expression of cytokines, chemokines and 
complement factors, accompanied by a decreased of intracranial complications. Nevertheless, 
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MyD88 deficiency is associated with a worsening of disease that seems to be attributable to 
severe bacteremia. Surprisingly, the role of MyD88 or even other adaptor molecules or 
receptors may depend on the site of the infection, as, although MyD88-deficient mice showed 
a reduced inflammatory response in the CNS, they were able to mount an exacerbated 
inflammatory response in the lung, in comparison to wild-type animals [455].  The relevance of 
the transcription factor NF-κB was also evaluated by a similar approach, comparing the 
susceptibility to pneumococcus infection between wild type mice and KO mice deficient in the 
subunit p50 of NF-κB. It was observed that p50 KO mice  have an impaired bacterial clearing, 
along with an enhanced inflammatory host response and increased mortality, thus confirming 
the importance of NF-κB activation in the pro-inflammatory response of the host [456].  
 
 Many in vitro and in vivo studies have highlighted the relevance of different cytokines 
(IL-1β, TNF-α  and IL-6) in the pro-inflammatory response towards S. pneumoniae. Studies with 
mice deficient in one of these cytokines or their receptors have provided a deeper insight into 
their role during bacterial meningitis. In a murine model of pneumococcal CNS inflammation, 
the lack of TNF-α was associated with worse clinical outcome and shorter survival time 
compared with wild type mice, but meningeal inflammation was not distinguishable between 
the groups. However, bacterial titers were significantly higher in the blood and spleen of TNF-
α
–/– 
mice, indicating that the clearance of S. pneumoniae from the bloodstream was severely 
affected. By contrast, mice with targeted disruption of the two TNF receptors p55 and p75 
showed decreased meningeal inflammation with reduced leukocyte infiltration. These results 
indicate that other TNF receptor ligands than TNF-α  may contribute to the inflammatory 
reaction in pneumococcal meningitis [457]. In IL-6-deficient mice, infection with pneumococci 
caused a marked increase in CSF leukocyte counts compared with wild type mice. This was 
associated with a higher expression of IL-1β, TNF-α and MIP-2 in IL-6
–/–
 mice, indicating that in 
wild type animals these pro-inflammatory mediators are down-regulated by IL-6 [458]. 
 
 Finally, the importance of different reactive molecules, including nitrogen 
intermediates, such as NO, in the pathogenesis of S. pneumoniae have also been studied using 
KO mice. NO is produced by three different NO synthases (NOS): two constitutive isoforms, 
which are present in endothelial cells (eNOS) and neuronal cells (nNOS), and one inducible 
isoform iNOS, which is expressed in many cells, including neutrophils, macrophages, microglia 
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and astrocytes, in response to stimulation with cytokines or bacterial cell-wall components. The 
significance of pharmocological studies using NOS inhibitors is limited by three major problems: 
1) NOS inhibitors are not completely selective for one isoform, 2) their bioavailability is 
questionable, and 3) they may exert additional pharmacological effects unrelated to the NOS 
system. Therefore, mice deficient in one distinct isoform have offered a powerful tool to 
elucidate the role of eNOS and iNOS in experimental bacterial meningitis [449]. In 
pneumococcal meningitis, iNOS
–/–
 mice showed significantly lower concentrations of pro-
inflammatory cytokines and also a reduction in the BBB disruption in comparison to wild type 
mice. However, iNOS-deficient mice presented increased CSF leukocyte counts in reponse to 
pneumococcal challenge. There is not a clear explanation for this effect, but it provides 
evidence that NO is able to modulate the adhesiveness of leukocytes to the endothelium [459].
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Table 1. Pattern recognition receptors (PRRs): Soluble receptors 
Soluble 
receptors: 
Members Role Ref. 
Collectins Surfactant proteins A & D (SP-A, 
SP-D) and the mannose-binding 
lectin (MBL) and MBL-
associated proteins (MASPs) 
SP-A and SP-D act as opsonins, increasing 
the clearance of the organism. The bacterial 
targets of both molecules are LTA and PG. 
MBL and MASPs bind poly-mannose 
components of microbial cell walls. They 
also activate the complement  cascade. 
[460] 
Complement 
cascade (CC) 
CC is activated by three 
pathways: the classical, 
alternative, and lectin pathways.  
CC eliminates bacteria by a direct attack, 
forming a membrane attack complex and 
producing opsonins C3b and iC3b for 
opsonophagocytosis. 
[317, 
461] 
Pentraxins It includes the short pentraxins 
such as C-reactive protein and 
serum amyloid P (SAP) and the 
long pentraxins. C-reactive 
protein and SAP are acute phase 
proteins synthesised by the liver 
as part of the acute inflammatory 
response. 
C-reactive protein binds phosphorylcholine 
and mannose residues found on bacterial or 
fungal cell walls and both CRP and SAP act 
as opsonins. They can activate the classical 
pathway of CC. The short pentraxins are 
also taken up by Fcγ receptors on phagocytic 
cells. 
[317] 
Others  Lipopolysaccharide-binding 
protein (LBP) and 
soluble/membrane associated 
CD14 
 
LBP is an acute phase protein produced in 
the liver and bounds LPS present in the 
serum. It increases the transfer of LPS to a 
receptor, CD14, a glycosylphosphatidyl 
inositol anchored cell surface glycoprotein 
found on macrophages that functions as a 
binding receptor for LPS. In CD14-negative 
cells such as endothelial cells and 
fibroblasts, the soluble form of CD14 
present in serum can functionally replace 
membrane-bound CD14. This LBP/CD14 
complex then links TLR4, which ultimately 
leads to intra-cellular signalling and cytokine 
secretion by the macrophage.  
[321, 
462] 
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Table 1. Pattern recognition receptors (PRRs). Continuation: Cell-associated and intracellular 
receptors. 
Cell-associated 
receptors: 
Members Role Ref. 
Membrane-bound 
receptors 
 
TLRs 
 
TLRs are explained in detail in the text  
 
CD14  CD14 role is explained in the text  
 
MD2 160-amino acid protein that is associated with TLR2/4 on 
the cell surface. 
[323, 
463] 
Scavenger receptors 
SR-AI, SR-
AII and 
MARCO 
They bind LPS, LTA as well as whole bacteria. They 
clear tissue of invading organisms by acting as receptors 
for phagocytosis. 
[317, 
464] 
C-type lectin family 
Mannose 
receptors 
(MR) 
Mannose-binding lectin (MBL) binds repeating arrays of 
sugar groups on microbial surfaces with its lectin 
domains. MBL activates the “alternative,” or lectin, 
complement pathway in an antibody-independent manner. 
MBL also is an opsonin that enhances phagocytosis. 
MBL binds yeasts, viruses, and Gram-negative bacteria 
and Gram-positive bacteria with low affinity. 
MR are present on macrophages. Their main function is 
phagocytosis of microbial pathogens, and their delivery 
into the lysosomal compartment where they are destroyed 
by lysosomal enzymes. 
[465] 
Complement 
receptors 
 
 Organisms coated with complement components are 
bound to complement receptors and also ingested by 
phagocytosis. 
[317, 
461] 
Formyl-peptide 
receptors 
 Found on neutrophils and monocytes. They are in part 
responsible for chemotaxis of neutrophils to sites of 
infection. 
[466] 
Intra-cellular 
receptors 
Members Role Ref. 
Nucleotide binding 
and oligomerization 
domain (NOD) 
receptors 
NOD1 and 
NOD2 
Sense the cytosolic presence of the PG fragments meso-
DAP and muramyl dipeptide, respectively and activate 
the inflammatory response.  
[312] 
Others  Protein 
kinase R 
(PKR) 
Activated by double stranded RNA. PKR also upregulates 
NF-κB and MAP kinases, leading to the production of 
interferons. 
[312, 
317] 
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Table 2. TLRs recognize molecular patterns associated with a broad range of pathogens 
including bacteria, fungi, protozoa, and viruses. Adapted from [311, 313, 318, 321, 467]. 
 
TLR Ligand 
TLR1 Triacyl lipopeptides (bacteria) 
TLR2 
PG, LTA (from Gram positive bacteria), lipoprotein, lipopeptides, 
atypical LPS, lipoarabinomannan (mycobacteria) 
Zymosan, phospholipomannan (fungi) 
GPI anchor (protozoa) 
Envelope protein (virus) 
TLR3 Poly (I:C), dsRNA (virus) 
TLR4 
LPS from Gram negative bacteria (bacteria) 
RSV fusion protein (virus) 
Glycoinositolphospholipids (protozoa) 
Mannan, glucuronoxylomannan (fungi) 
TLR5 Flagellin (bacteria) 
TLR6 Diacyl lipopeptides (bacteria) 
TLR7/TLR8 
Synthetic imidazoquinoline-like molecules, ssRNA (virus)  
Immune function of TLR8 remains unknown in mice 
TLR9 
CpG DNA (bacteria, protozoa, virus) 
Hemozoin (protozoa) 
TLR10 
(pseudogene  
in mouse) 
Unknown, however, it heterodimerizes with TLR1and TLR2 
TLR11 
(pseudogene 
 in human) 
Unknown components of uropathogenic bacteria  
Profilin like molecule (protozoa) 
TLR12 
(mouse) 
Unknown 
TLR13 
(mouse) 
Unknown 
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Abstract 
 
Streptococcus suis, an important swine and human pathogen, causes septic shock and 
meningitis. The pathogenesis of both systemic and central nervous system (CNS) 
infections caused by S. suis is poorly understood. A hematogenous model of infection in 
CD1 mice was developed to study the systemic release of cytokines during the septic 
shock phase and the pro-inflammatory events in the CNS associated with this 
pathogen. Using a liquid array system, high levels of systemic TNF-α, IL-6, IL-12, IFN-γ, 
CCL2, CXCL1 and CCL5 were observed 24 h after infection and might be responsible for 
the sudden death of 20% of animals. Infected mice that survived the early sepsis later 
developed clinical signs of meningitis and exhibited lesions in the meninges and in 
numerous regions of the brain, such as the cortex, hippocampus, thalamus, 
hypothalamus and corpus callosum. Bacterial Ags were found in association with 
microglia residing only in the affected zones. In situ hybridization combined with 
immunocytochemistry showed transcriptional activation of TLR2 and TLR3 as well as 
CD14, NF-κB, IL-1β, CCL2 and TNF-α, mainly in myeloid cells located in affected cerebral 
structures. Early transcriptional activation of TLR2, CD14 and inflammatory cytokines in 
the choroid plexus and cells lining the brain endothelium suggests that these structures 
are potential entry sites for the bacteria into the CNS. Our data indicate an important 
role of the inflammatory response in the pathogenesis of S. suis infection in mice. This 
experimental model may be useful for studying the mechanisms underlying sepsis and 
meningitis during bacterial infection. 
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Introduction 
Infections caused by Streptococcus suis serotype 2 are a problem worldwide in the 
swine industry. In swine, S. suis infection is associated with meningitis, septicemia, 
endocarditis and arthritis (1). Moreover, S. suis is an agent of zoonosis, afflicting people 
in close contact with infected pigs or pork-derived products (2). The clinical 
presentation of S. suis infection may vary from asymptomatic bacteremia to fulminant 
systemic disorder. Meningitis is the most striking feature; the presence of fibrin, 
oedema and cellular infiltrates in the meninges and choroid plexus along with adjacent 
encephalitis are the most frequently observed histopathological characteristics (3). 
People who survive the infection may develop important sequelae such as permanent 
deafness (2, 4). Recently, a serious S. suis outbreak in China resulted in more than 200 
human cases with a fatality rate of nearly 20%. Symptoms reported in this outbreak 
include high fever, malaise, nausea and vomiting, followed by nervous symptoms, 
subcutaneous hemorrhage, septic shock, and coma in severe cases (5). Virulence 
factors associated with S. suis are poorly defined. To date, the antiphagocytic capsular 
polysaccharide (CPS)
3
 as well as other putative virulence factors, such as the hemolysin 
(suilysin), cell-wall associated and extracellular proteins, fibronectin-binding proteins 
and a serum opacity factor, have been described (6, 7). 
Elucidation of the pathogenesis of both systemic and CNS infections caused by 
S. suis remains a challenge. It is believed that pigs are infected with S. suis via airborne 
transmission and that bacteria, once in the blood, interact with different leukocyte 
populations as well as endothelial cells and then migrate to different organs and cause 
tissue damage (8). In the event, for unknown reasons, that bacteria fail to cause acute 
fatal septicemia, S. suis is able to reach the CNS through mechanisms that are only 
partially understood (9). It has been demonstrated that S. suis adheres to human brain 
microvascular endothelial cells (BMEC) and exerts a cytotoxic effect that involves 
suilysin (9). In addition, interactions between S. suis and epithelial cells from the 
choroid plexus have been observed using an in vitro model in which this pathogen 
induces a loss of blood-cerebrospinal fluid barrier function (10). Both mechanisms 
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might lead to a breakdown of the blood brain barrier (BBB), as described for other 
pathogens (11, 12).  
Clinical and neuropathological studies with meningitis-associated bacteria have 
shown that a fatal disease outcome can be attributed to the host inflammatory 
response which leads to intracranial complications, including brain edema, increased 
intracranial pressure and cerebrovascular insults. Indeed, up-regulation of pro-
inflammatory mediators and increased leukocyte trafficking may contribute to the 
breakdown of the BBB (13). S. suis induces BMEC to release arachidonic acid and 
different pro-inflammatory cytokines and chemokines, which might help bacteria 
migrate through the BBB and modulate local inflammation (14, 15). Additionally, S. suis 
induces phagocytes to secrete cytokines, chemokines, PGE2 and matrix 
metalloproteinase-9, mediators which are also implicated in the disruption of the BBB 
(16-19). Lastly, S. suis up-regulates the expression of adhesion molecules by 
monocytes, consequently increasing adherence to endothelial cells (20). Although the 
exact mechanisms underlying the inflammatory response induced by S. suis are 
unknown, in vitro experiments showed that cytokine and chemokine production by S. 
suis-activated phagocytes is mediated through CD14-dependent and independent 
pathways (18). More recently, we demonstrated in vitro that TLR2 plays an important 
role in the recognition of S. suis through a MyD88-dependent mechanism (21). 
The CNS, although commonly considered an immunologically privileged site, is 
capable of mounting a coordinated innate immune response along with the expression 
of different immunomodulatory mediators (22). Different types of cells may play an 
inflammatory role. Microglial cells, the macrophage-like population within the CNS, 
represent the first line of defense against invading pathogens and have pro-
inflammatory effector functions (23). Astrocytes, the major glial cell type in the CNS, 
also contribute to the inflammatory response in the brain. Both types of cells express 
constitutively low levels of mRNA encoding different TLRs which can be notably 
increased following the binding of specific ligands (23, 24). To date, the inflammatory 
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activities in the brain as well as the pro-inflammatory role of both microglia and 
astrocytes during CNS infections associated with S. suis have not been studied.  
The recently documented increase in severity of S. suis infection in humans 
underscores the critical need to better understand factors associated with 
pathogenesis of S. suis infection (5). In the present study, we developed an adult 
mouse model of streptococcal meningitis and encephalitis after i.p. infection with a 
virulent S. suis serotype 2 strain. Using this model, we studied the systemic release of 
different cytokines during the septic shock phase observed within hours after infection. 
In addition, the cerebral innate immune response in mice that survived the septic 
phase, but developed clinical signs of meningitis at later stages of the infection, was 
studied using mRNA in situ hybridization. To our knowledge, this is the first report of a 
streptococcal meningitis/encephalitis model using an i.p. infection route in adult mice.  
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Materials and methods  
 
Bacterial strain, growth conditions and production of antiserum 
S. suis serotype 2 strain 31533 was used for the experimental infection. This is an 
encapsulated, suilysin-positive virulent strain that has been widely used in several cell 
stimulation studies (15, 17-19, 25). Bacteria were grown overnight onto sheep blood 
agar plates at 37°C and isolated colonies used as inocula for 5 ml of Todd-Hewitt broth 
(THB) (Difco Laboratories), which was incubated for 8 h at 37°C with agitation. Working 
cultures were prepared by transferring 10 μl of 1/1000 dilutions of 8 h-cultures into 30 
ml of THB which was incubated for 16 h at 37°C with agitation. Stationary-phase 
bacteria were washed twice in PBS (pH 7.3). Bacterial pellet was then resuspended in 
THB until an OD600nm value of 0.4 was achieved, which corresponded to 5 x 10
8
 CFU/ml. 
The inoculum for experimental infection was prepared with a 1:10 dilution of the 
resuspended bacteria in THB to obtain a final concentration of 5 x 10
7
 CFU/ml. This final 
suspension was plated onto blood agar to accurately determine the CFU/ml. Specific 
polyclonal antiserum against S. suis serotype 2 was obtained as previously described 
(26). 
 
Experimental infection 
Female, 6-week-old CD1 mice (Charles River) were acclimated to standard laboratory 
conditions of 12-h light/12-h dark cycle with free access to rodent chow and water. All 
experiments involving mice were conducted in accordance with the guidelines and 
policies of the Canadian Council on Animal Care and the principles set forth in the 
Guide for the Care and Use of Laboratory Animals by the Animal Welfare Committee of 
the Université de Montréal. A total of 145 animals were included in the study. On the 
day of the experiment, 1 ml volume of the bacterial suspension (5 x 10
7
 CFU/ml) or the 
vehicle solution (sterile THB) was administrated by i.p. injection. Three series of 
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preliminary and independent trials were performed for both systemic and CNS 
infection studies to establish optimal bacterial dose and time points. Preliminary data 
obtained in these pre-studies showed results consistent with those obtained in the 
major experiments described bellow. 
Study of the systemic innate immune response  
A total of 36 infected and 12 non-infected mice were assigned to the bacteriological 
and histopathological studies as well as the systemic measurement of pro-
inflammatory molecules. Samples were taken at 3, 6, 12, 24, 30 and 36 h and at 3, 6, 9 
and 12 days (d) post infection (p.i.) and the following studies performed: 
 A. Clinical parameters of disease and mortality. A group of 10 mice were 
monitored three times daily for mortality and clinical signs of septic disease, such as 
depression, swollen eyes, rough hair coat, lethargy, and nervous signs of meningitis.   
B. Determination of viable bacteria in organs. At each designated time, 3 
infected and 1 non-infected mice were anaesthetized with CO2. Blood was collected by 
cardiac puncture and the brain, liver and spleen were obtained aseptically. The organs 
(0.05g/organ) were trimmed, placed in 500 μl of PBS (pH 7.3) and homogenized with a 
vortex. Then, 50 μl of 10
-2
 and 10
-4
 dilutions of the homogenate in PBS was plated onto 
blood agar plates. Blood samples (50 μl) were also plated. All samples were plated 
using an Autoplate 4000 Automated Spiral Plater (Spiral Biotech). Blood agar plates 
were incubated overnight at 37°C. Colonies were counted and expressed as CFU/0.05g 
for organ samples or CFU/ml for blood samples. In addition, a 5 ml THB tube was 
inoculated with 300 l of the remaining supernatant from homogenates or with 10 μl 
of blood and cultured at 37°C overnight with agitation. These THB cultures were plated 
only when the cultures plated with the Spiral Plater were negative due to low numbers 
of viable bacteria in the organs. Although not quantitative, a positive THB culture 
indicates the presence of bacteria in the organ. 
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C. Histopathological studies. Samples from the brain, heart, liver and spleen 
were fixed in 10% buffered formalin. After paraffin embedding, 4-mm–wide tissue 
sections were stained with hematoxylin-eosin according to standard protocol and 
examined under light microscopy.  
D. Plasma collection and measurement of cytokines and chemokines. Blood from 
CO2-anaesthetized mice was collected by cardiac puncture into heparinized tubes and 
centrifuged at 10,000 x g for 10 min to obtain plasma. Samples were preserved at -80°C 
until analysis. Levels of IL-1β, IL-6, IL-10, IL-12 (p40/p70), TNF-α, IFN-γ, CCL2 (MCP-1), 
CXCL1 (KC) and CCL5 (RANTES) in plasma were determined using a liquid multi-array 
system (Luminex Co.). Commercial multiplex coated beads, biotinylated antibodies and 
Beadlyte microtiter 96 well filter plates were obtained from Upstate Group Inc. Each 
multiplex assay was performed in duplicate following the manufacturer’s specifications. 
Data were collected using the Luminex-100 system Version IS 2.2 and analyzed by 
MasterPlex Quantitation Software (MiraiBio Inc.). Standard curves for each cytokine 
and chemokine were obtained using the reference concentrations supplied by the 
manufacturer. Results are the mean of two independent experiments. 
 
Study of the cerebral innate immune response 
A total of 55 infected and 22 non-infected mice were analyzed in this set of 
experiments. For all studies, samples were taken at 3, 6, 12, 24, and 36 h as well as at 2, 
3, 5, 7, 9 and 14 d p.i. At each designated time, 5 infected and 2 non-infected mice 
were deeply anaesthetized with an i.p. injection of a mixture of ketamine hydrochloride 
(Bimeda-MTC) and xylazine (Bayer), and then rapidly perfused transcardially with 0.9% 
saline, followed by 4% paraformaldehyde (PFA) in 0.1 M borax buffer (pH 9.5 at 4°C). 
Brains were rapidly removed from the skulls, post-fixed for 2-8 d, and placed in a 
solution containing 10% sucrose diluted in 4% paraformaldehyde-borax buffer 
overnight at 4°C. The frozen brains were mounted onto a microtome (Reicher-Jung, 
Instruments Company) and cut into 25 μm coronal sections from the olfactory bulb to 
98 
 
 
the end of the medulla. The sections were collected in a cold cryoprotectant solution 
(0.05 M sodium phosphate buffer, pH 7.3, 30% ethylene glycol, 20% glycerol) and 
stored at -20°C.  
 
cRNA probes  
Plasmids for the synthesis of the cRNA probes have described previously (27, 28). 
Plasmids were linearized, and the sense and antisense riboprobes were synthesized as 
reported (27, 28). Radioactive cRNA copies were obtained by incubating 250 ng of 
linearized plasmids in 6 mM MgCl2, 40 mM Tris (pH 7.9), 2 mM spermidine, 10 mM 
NaCl, 10 mM ATP/GTP/CTP, 100 μCi of α-
35
S-UTP (Dupont-NEN; #NEG 039H), 20 U 
RNAsin (Promega), and 10 U of either T7, SP6 or T3 RNA polymerase for 60 min at 37°C. 
Unincorporated nucleotides were removed using ammonium acetate precipitation 
method, and 100 μl of DNase solution (1 μl DNase, 5 μl of 5 mg/ml tRNA, 94 μl of 10 
mM Tris/ 10 mM MgCl2) was added 10 min before phenol-chloroform extraction. The 
cRNA was precipitated with 80 μl of 5 M ammonium acetate and 500 μl of 100% 
ethanol for 20 min on dry ice. The pellet was dried and resuspended in 50 μl of 10 mM 
Tris/1 mM EDTA. A probe containing 10
7 
cpm was mixed into 1 ml of hybridization 
solution (500 μl formamine, 60 μl 5 M NaCl, 10 μl 1 M Tris (pH8.0), 2 μl 0.5 M EDTA (pH 
8.0), 50 μl 20x Denhart’s solution, 200 μl 50% dextran sulphate, 50 μl 10 mg/ml tRNA, 
10 μl 1M DDT, (118 μl DEPC water – volume of probe used). This solution was mixed 
and heated for 10 min at 65°C before being spotted on slides (27, 28). 
 
In situ hybridization histochemistry 
Histochemical localization of TLR2, TLR3, TLR4, CD14, IκB (an index of NF-κB 
activation), IL-1β, IL-6, TNF-α, CCL2 (MCP-1) and mouse proteolipid protein (PLP) mRNA 
was performed on every twelfth section of the whole rostro-caudal extent of each 
brain using in situ hybridization with 
35
S-labeled cRNA probes as described previously 
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(27-29). All solutions were treated with DEPC and sterilized to prevent RNA 
degradation. Briefly, tissue sections mounted onto poly-L-lysine-coated slides were 
desiccated overnight under vacuum, fixed in 4% PFA for 30 min, and digested with 10 
μl/ml of proteinase K in 0.1 M Tris HCl (pH 8.0) and 50 mM EDTA (pH 8.0) at 37°C for 25 
min. Brain sections were rinsed in sterile DEPC water, followed by a solution of 0.1 M 
triethanolamine (TEA, pH 8.0), acetylated in 0.25% acetic anhydride in 0.1 M TEA, and 
dehydrated through graded concentrations of ethanol (50, 70, 95, and 100%). After 
vacuum drying for a minimum of 2 h, 90 μl of hybridization mixture (10
7
 cpm/ml) was 
spotted onto each slide, sealed under a coverslip, and incubated at 60°C overnight 
(~15-20 h) in a slide warmer. Coverslips were then removed and the slides rinsed in 4X 
standard saline citrate (SSC) at room temperature (SSC 1X is composed of 0.15 M NaCl 
and 15 mM trisodium citrate buffer at pH 7.0). Sections were digested with 20 μg/ml of 
RNase A at 37°C for 30 min, rinsed in descending concentrations of SSC (2X, 1X, 0.5X 
SSC), washed in 0.1X SSC for 30 min at 60°C, dehydrated with graded concentrations of 
ethanol, and vacuum-dried for 2 h. Sections were exposed at 4°C to X-ray films 
(Biomax, Kodak) for 1-3 days. Slides were defatted in xylene, dipped in NTB-2 nuclear 
emulsion (Kodak; diluted 1:1 with distilled water), exposed for 7 (IκBα and IL-1β 
transcripts), 8 (PLP transcript), 14 (CD14, TNF-α and CCL2 transcripts), 15 (TLR2 and 
TLR3 transcripts), 19 (TLR4) or 31 d (IL-6), then developed in a D19 developer (Kodak) 
for 3.5 min at 14-15°C, washed 15 s in water, and fixed in rapid fixer (Kodak) for 5 min. 
Tissues were rinsed in running distilled water for 1-2 h, counterstained with thionin 
(0.25%), dehydrated with graded concentrations of ethanol, cleared with xylene, and 
sealed with distrene plasticizer xylene mounting medium. 
 
Qualitative analysis 
The anatomical identification of brain structures was based on the Paxinos and 
Franklin’s Atlas (30). The relative intensity of TLR2, TLR3, TLR4, CD14, IκBα, IL-1β, IL-6, 
TNF-α, CCL2 and PLP mRNA expression throughout the brain of each infected animal 
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was determined on x-ray film images and graded according to the scale of undetectable 
(-), low to undetectable (+/-), low (+), moderate (++), strong (+++), or very strong (++++) 
signal  (31).  
 
Combined immunohistochemistry and in situ hybridization 
In situ hybridization was combined with immunohistochemistry to identify the cellular 
sources expressing TLR2, IκBα, and CCL2 (MCP-1) in the brain parenchyma of mice after 
systemic injection of S. suis. Every twelfth section of the brain was processed by the 
avidin–biotin method with peroxidase as a substrate. Microglial cells were labeled with 
an Ab against the anti-ionized calcium binding adapter molecule 1 (iba1, kindly 
provided by Dr. Y. Imai, Nationale Institute of Neuroscience, Kodaira, Japan), as 
previously described (32). Astrocytes were labeled with an Ab against glial fibrillary 
acidic protein (GFAP) (DAKO). Briefly, sections were rinsed with Potassium-PBS (KPBS; 
2.2 mM K2H2PO4, 1.8 mM KH2PO4 and 138 mM NaCl in milliQ water at pH 7.4), 
incubated with primary Ab, washed once with KPBS before incubation with biotinylated 
secondary Abs (Vector Laboratories), and then rinsed again with KPBS before a final 
incubation with an avidin-biotin-peroxidase complex (Vectastain ABC Elite kit, Vector 
Laboratories). After several washes in KPBS, brain sections were reacted in 0.05% 3,3’-
diaminobenzidine (DAB) and 0.003% hydrogen peroxide. Thereafter, sections were 
rinsed in KPBS, mounted, desiccated, fixed in 4% PFA, and digested by proteinase K. 
Pre-hybridization, hybridization, and post-hybridization steps were performed as 
described above, but shorter dehydration times (ethanol 50, 70, 95, 100%) were used 
to prevent discoloration of immunoreactive cells. The slides were dried and then 
exposed and developed as described above. 
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Immunohistochemistry for S. suis 
Immunohistochemical localization of S. suis was also performed on every twelfth 
section of the whole rostro-caudal extent of each brain. Brain sections were washed 3 
times for 15 min each in KPBS, followed by 20 min incubation at room temperature 
with solution A (0.4% Triton X, 4% goat serum and 1% BSA in KPBS). The sections were 
incubated with a primary polyclonal Ab against S. suis (1:6000 in solution A) for 18 h at 
4°C, followed by three 5-min washes with solution B (0.02% Triton X and 0.05% BSA in 
KPBS), incubation with the secondary Ab diluted 1:500 in solution B of a commercial 
biotinylated anti-rabbit IgG (Vector Laboratories) for 90 min, and three 15-min washes 
with solution B.  Immunoreaction was displayed by the addition of ABC labeled polymer 
and the substrate DAB (Vector Laboratories) as per the manufacturer’s instructions. 
The sections were washed 3 times for 15 min each in KPBS and then counterstained 
with Nissl stain (0.25% thionine solution) to obtain a general index of cellular 
morphology. The tissues were mounted onto slides and observed under light 
microscopy. 
 
Determination of acute demyelination 
The myelin content was determined via Sudan black B staining (SBB) as described 
before (29). Briefly, brain sections mounted onto poly-L-lysine-coated slides were 
dehydrated with graded concentrations of ethanol (50 and 70%; 2 min each) and 
incubated for 1 h in SBB solution (Sigma, 0.3% saturated solution in 70% ethanol). The 
sections were rinsed in 70% ethanol until the desired contrast was reached and then 
washed with water. Tissues were dehydrated with graded concentrations of ethanol 
(50 and 70%; 2 min each), cleared with xylene for 1 min (two times), and cover slipped.  
In addition, the level of demyelination was correlated to the level of PLP mRNA 
expression in specific areas of the brain using in situ hybridization as described above.  
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Results  
 
Systemic and CNS symptoms appear at different times after i.p. infection 
During the course of infection, clinical signs of sepsis were depression, rough hair coat, 
swollen eyes, weakness, and death. Mortality of 20% due to septicemia was observed 
before 48 h p.i. The appearance of clinical signs of meningitis was observed in 40% of 
remaining infected mice between days 4 and 9 p.i. These mice exhibited normal 
characteristics before the sudden appearance of nervous signs, which consisted of 
hyperexcitation, episthotonus, opisthotonus (video1.mov), bending of the head 
towards one side, walking in circles (video2.mov), and strong locomotive problems of 
mainly paresis of the forelimbs. Some mice displayed sudden spinning while in lateral 
recumbence (video3.mov). In addition, mice developed unilateral or bilateral 
exophthalmia, with corneal opacity, probably in association with increased intracranial 
pressure.  
 
Bacteria survive several days in mice after i.p. infection  
After i.p. infection with S. suis, mice developed bacteremia which lasted for several 
days. S. suis was isolated from all infected mice that were tested. Bacteria were found 
in the blood, liver, spleen, and brain. From 3 h to day 3 p.i., bacterial counts in the 
blood exceeded 1 x 10
8
 CFU/ml, then decreased between days 6 and 9 p.i. to a median 
of 2 x 10
2
 CFU/ml, and finally disappeared at day 12 p.i. (Fig. 1A). Viable counts in the 
liver and spleen were comparable and presented similar kinetics. From 3 h to day 3 p.i., 
bacterial counts from these organs were higher than 1 x 10
7
 CFU/organ in all sampled 
animals. Counts diminished drastically at day 6 p.i., and by day 12 p.i. were negative in 
the spleen or qualitatively positive in the liver (growth after broth enrichment) (Fig. 
1A). In contrast, bacterial counts in the brain showed a different pattern. While in other 
organs viable counts were very similar and showed well-defined kinetics among 
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sampled mice, bacterial loads in the brain were highly variable between individual mice 
and between sampling times (Fig. 1B). No clear kinetic pattern of bacterial counts could 
be identified in the brain. Nevertheless, bacterial counts were relatively high as early as 
3 h p.i., ranging from 10
4
 to 10
8
 CFU/0.05 g of brain. This range of bacterial load was 
observed throughout the different p.i. time points up to day 3 day p.i. Although 
bacterial loads decreased by day 6 p.i., the presence of S. suis in the brain could be 
detected qualitatively at day 12 p.i. (Fig. 1B).  
  
S. suis- associated lesions were correlated with CNS symptoms 
Although it was possible to isolate bacteria from various tissues at different p.i. time 
points, histopathological lesions associated with the infection were found in the brain 
of infected mice that developed clinical signs of meningitis. These mice presented 
bacterial loads ranging from 10
3
 to 10
4
 CFU/0.05 g of tissue. No significant 
histopathological changes in the brain, heart, liver or spleen were observed in mice 
that succumbed during the early phase of sepsis, which occurred during the first 48 h 
p.i. From day 6 p.i., the most important changes in the brain of mice with clinical 
nervous symptoms comprised the presence of neutrophils across blood vessel walls, 
hemorrhagic foci and malacia mainly at the somatosensory cortex, striatum, 
hippocampus, thalamus and hypothalamus, together with gliosis and the presence of 
inflammatory foci composed primarily of neutrophils. At these time points, it was 
possible to observe great numbers of bacteria inside blood vessels (bacterial emboli), 
surrounded by a rim of neutrophils (Fig. 2A). As the infection progressed, by day 9 p.i., 
there was complete destruction of the corpus callosum, including the external capsule, 
where numerous neutrophils and cellular debris were observed (Fig. 2B). In several 
mice, the meninges were thickened and severely infiltrated by a mixture of neutrophils, 
macrophages and lymphocytes (Fig. 2C). Occasionally, in severely affected mice, a 
moderate dilation of the aqueduct was apparent. Outside the brain, histopathological 
lesions were observed only in the heart of some mice that developed clinical nervous 
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symptoms. These lesions, consisting of dense infiltrates of neutrophils in the 
myocardium of the interventricular septum (suppurative myocarditis), and thrombi 
composed of fibrin, great numbers of neutrophils and bacteria, were found on the wall 
of the right atrio-ventricular valves (valvular endocarditis).  
 
Intraperitoneal infection with S. suis induces a rapid pro-inflammatory systemic 
response in mice 
Results showed that the systemic cytokine and chemokine production in mice after 
infection with S. suis varied over time and among different cytokines. Production of 
pro-inflammatory TNF-α, one of the most important host mediators in the 
pathogenesis of septic shock, showed a high but transitory peak at 6 h p.i. and a drastic 
return to basal levels at 12 h p.i, regardless of the infection outcome (Fig. 3A). This 
rapid TNF-α production in plasma may indicate an important early participation of 
phagocytic cells during the onset of the inflammatory response against S. suis and the 
initiation of an amplification loop leading to the production of several other pro-
inflammatory cytokines. Along with TNF-α, IL-6 and IL-12(p40/p70) were also rapidly 
induced. IL-6, an important inducer of acute phase proteins (33, 34), was expected to 
be elevated in the later phase of infection (35, 36) but, similar to TNF-α, its systemic 
levels were significantly high only during the first 12 h p.i., peaking at 97,000 pg/ml at 6 
h p.i. (Fig. 3B). Th1-promoting IL-12, which mediates the transition to adaptive 
immunity, was also induced early after S. suis systemic infection. Levels of IL-12p40 in 
plasma increased abruptly and also returned rapidly to basal levels of non-infected 
controls as early as 6 h p.i. (Fig. 3C). Interestingly, IL-12p40 production preceded the 
appearance of biological IL-12p70 as suggested previously (37). Indeed, the pattern of 
IL-12p70 expression was similar to the aforementioned pro-inflammatory cytokines, 
peaking at 6 h p.i and gradually returning to baseline by 30 h p.i. (Fig. 1D). In contrast, 
production of IFN-γ, a critical Th1 cytokine, was rapidly induced at 6 h p.i., remained at 
high levels, and reached a plateau at 24 to 36 h p.i. (Fig. 3E). Surprisingly, IL-1β, known 
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to play an important role in inflammation (38), was induced only slightly after systemic 
S. suis infection (Fig. 3F). It should be noted that these cytokines were no longer 
detected at day 6 p.i. (data not shown).  
We also measured the production of the chemokines CXCL1 (KC), CCL2 (MCP-1) 
and CCL5 (RANTES) in mice infected with S. suis. While CXCL8 (IL-8) has not been 
identified in the mouse, CXCL1 is one of the CXCL8 homologs believed to be important 
in the trafficking and activation of neutrophils in mice (39, 40). Levels of this key 
chemotactic factor were extremely high and rapidly induced, reaching peak production 
between 6 and 12 h p.i. and returning to baseline at day 3 p.i. (Fig 3G). The expression 
of CCL2 (MCP-1), a prototypic
 
inflammatory chemokine which mainly targets 
monocytes and T lymphocytes (40), was increased at 3 h p.i., peaking between 3 h and 
24 h p.i, and gradually decreasing thereafter (Fig. 3H). Since very little is known 
regarding the role of CCL5 (RANTES), a highly potent chemoattractant for both 
monocytes and T cells (41), in Gram-positive systemic infections, we measured its 
production during the septicemic phase of S. suis infection in mice. Results showed that 
CCL5 was also induced as early as 3 h p.i., reaching maximal expression at 6 h p.i. and 
slowly diminishing to levels of non-infected mice at day 3 p.i. (Fig. 3I). No significant 
levels of any chemokines were observed after day 6 p.i. (data not shown). 
We also assessed the expression of anti-inflammatory IL-10. In infected mice, IL-
10 in plasma was apparent at 6 h p.i. and gradually increased to peak levels between 24 
and 30 h p.i., with values greater than 6000 pg/ml (Fig. 3J). Thereafter, it disappeared 
rapidly and was undetectable after day 6 p.i. (data not shown). 
 
S. suis up-regulates the expression of genes encoding for several pro-inflammatory 
mediators at different structures of the brain  
In situ hybridization was used to examine the spatiotemporal expression of different 
pro-inflammatory genes after i.p. infection of mice with S. suis at different p.i. time 
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points (Table I). This technique was combined with immunohistochemistry to study the 
ability of microglia/macrophages and astrocytes to express diverse pro-inflammatory 
genes as described below.  
 
Expression of TLR2, TLR3 and TLR4 
A modest constitutive TLR2 hybridization signal (+/-) was observed at the 
choroid plexus of the lateral ventricles in all vehicle-treated mice from 3 to 12 h p.i. In 
infected mice, transcriptional activation of TLR2 gene was first detected at 24 h p.i. in 
the meninges as well as in different areas of the somatosensory cortex, striatum, the 
choroid plexus, hippocampus, thalamus and hypothalamus. The spatiotemporal 
intensity of the hybridization signal varied from weak but positive (-/+ or +) at 24 h p.i. 
to moderate (++) at 3-4 days p.i. TLR2 mRNA expression was bilateral and in most cases 
symmetrical (Table I and data not shown). As the infection progressed, the signal 
became stronger, reaching peak expression at day 5 p.i. (+ to ++++, Fig. 4A). As 
depicted in Fig. 5A, TLR2 gene expression was particularly intense in the corpus 
callosum, hippocampus, and thalamus, coinciding with findings from histopathological 
studies also showing that similar structures were the most affected. Such a robust 
signal in small-scattered cells indicated that microglia/macrophages were probably the 
type of cells expressing this innate immune receptor (Fig. 6A). TLR2 hybridization signal 
was also present in cells lining the endothelium of the brain capillaries (Fig. 6A). 
Participation of microglia/macrophages was confirmed by dual labeling (TLR2 mRNA in 
iba1-immunoreactive cells). These data provide evidence that systemic S. suis infection 
activates transcription of TLR2 of either resident or blood-derived microglia (Fig. 7A). 
TLR2 signal started to diminish after day 9 p.i., returning to basal levels of control mice 
at day 14 p.i. (Table I). 
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It is notable that S. suis was able to induce the transcriptional activation of TLR3, 
which was not expressed constitutively in non-infected mice. Although TLR3 signal was 
generally weaker in comparison with the expression of other genes studied here, it 
followed a pattern of expression similar to TLR2 (Table I). In infected animals, a weak 
positive (-/+) TLR3 hybridization signal was detected at 24 h p.i., mainly in the choroid 
plexus of the lateral ventricles as well as the thalamus and hypothalamus. Peak TLR3 
hybridization signal (+ to ++) in mice with clinical signs of cerebral inflammation was 
observed between days 5 and 7 p.i. The brains of these animals showed a weak to 
moderate scattered pattern of TLR3 at the cortex, thalamus, hypothalamus, choroid 
plexus of lateral ventricles, hippocampus and corpus callosum. In contrast to TLR2, 
TLR3 expression was not observed in the meninges. From day 9 p.i. the expression of 
TLR3 decreased to normal levels (Table I). Finally, TLR4 hybridization signal was not 
detected in any group at any time during the experiment (data not shown). Previous 
studies showed that the TLR4 probe accurately recognizes its target gene (42) and is 
therefore not induced in the brain of S. suis-infected mice. 
  
Expression of CD14  
In contrast to constitutive expression that was nearly undetectable, S. suis-infected 
mice showed spatiotemporal expression of CD14 at levels similar to some degree as 
other pro-inflammatory transcripts (Table I). A modest positive bilateral signal was 
observed as early as 3 h p.i. (-/+) and peaked at day 5 p.i. (+ to ++). At this time point, 
CD14 expression was detected in the corpus callosum, thalamus, hypothalamus and 
meninges (Fig. 4B). In the corpus callosum, CD14 signal was lower compared to that of 
TLR2 (Fig 5B), although it could be detected in the cells of blood vessels (Fig. 5B and 
6B). In contrast to TLR2 and TLR3, expression of this receptor was weaker in the 
choroid plexus, cortex and hippocampus.  
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Expression of IκBα 
Basal expression (+/-) of IκBα, an indirect marker of NF-κB activity, was found mainly in 
the choroid plexus. In S. suis-infected mice, however, the signal increased in this 
structure at 3 h p.i. and reached maximal expression levels at day 5 p.i. (+ to +++, Fig. 
4C and Table I). IκBα distribution resembled that of TLR2, especially in the corpus 
callosum, hippocampus and hypothalamus (Fig. 5C). The message was also found in the 
cortex, thalamus and meninges (Fig. 4C and Table 1), as well as in blood vessels (Fig. 5C 
and 6C). IκBα mRNA was detected in both myeloid cells (data not shown) and 
astrocytes (Fig. 7B).  Following peak expression, the signal gradually decreased to basal 
levels by 14 d p.i. (data not shown). 
 
Expression of pro-inflammatory cytokines and chemokines in the brain 
There was no constitutive expression of TNF-α, IL-1β, IL-6 and CCL2 (MCP-1) in brains of 
control mice.  However, the expression levels of these immune mediators were up-
regulated to different extents in the brain of S. suis-infected mice (Table I). IL-1β was 
detected in the choroid plexus and cortex as early as 24 h p.i. and gradually increased 
by day 5 p.i. in mice that exhibited clinical signs. At this time point, IL-1β signal was 
clear in the choroid plexus, cortex, corpus callosum, and meninges (++) (Table I). On the 
other hand, IL-6 gene expression was found in the CNS of only a few mice and it was 
not considered significant (Table I). It should be noted that we previously 
demonstrated that this IL-6 probe hybridizes IL-6 in the brain of LPS-treated mice (43). 
For TNF-α, a weak (+) mRNA expression appeared at 24 h p.i. in the corpus callosum. At 
day 5 p.i., TNF-α signal increased and was confined to the entire corpus callosum and 
the choroid plexus, while other brain structures and blood vessels failed to express 
TNF-α (Table I).  
A weak positive (-/+) signal for CCL2 (MCP-1) was observed in the choroid plexus 
at 3 h p.i. One day following inoculation, the signal intensified (+ to ++) in the cortex, 
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choroid plexus, hippocampus, thalamus, corpus callosum and meninges (Table I). 
Similar to other transcripts, CCL2 expression levels peaked by day 5 p.i. (Fig. 4D and 
5D). Given the particularly widespread and strong levels of expression of this 
chemokine, we also evaluated the participation of microglia and astrocytes in its 
production. Dual labeling provided anatomical evidence that cells expressing CCL2 
transcript were mainly of the microglia/macrophage subset (Fig. 7C), although a 
modest participation of astrocytes was also observed (Fig. 7D). Strong expression of 
CCL2 mRNA was also observed in cells lining the endothelium of the brain capillaries 
(Fig. 6D). CCL2 expression decreased considerably after day 5 p.i. and was similar to 
control mice at day 14 p.i. 
 
Presence of S. suis in different anatomical sites as detected by immunohistochemistry 
S. suis Ags were detected by immunohistochemistry in different structures of the brain 
in mice showing nervous clinical signs. No antigenic labeling was observed in control 
mice (Fig. 8A and 8B). Although S. suis Ags were observed in different areas of the 
brain, their presence was more striking at the corpus callosum and cerebral cortex, 
where histopathological lesions and expression of inflammatory mediators were 
observed (Fig. 8C and 8D). Interestingly, both Nissl and hematoxylin-eosin staining 
indicated degeneration of the corpus collosum of infected mice (Fig. 2B and 8D). The 
presence of S. suis Ags was largely associated with large, elongated cells with oval 
nuclei that had morphological characteristics compatible with macrophages (Fig. 8E).  
 
The inflammatory response to S. suis provokes demyelination 
PLP, synthesized by oligodendrocytes, is the most abundant protein of CNS myelin (44). 
As the infection progressed, the inflammatory response to S. suis correlated with a 
decrease in the expression of PLP mRNA in specific areas of the brain, indicating 
demyelination. At day 5 p.i., this loss in myelin content was observed in the corpus 
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callosum (Fig 9D-F), whereas vehicle-treated mice did not exhibit any significant 
changes in PLP mRNA expression (Fig 9A-C). To confirm the loss of myelin, brain 
sections were stained with SBB. While control mice showed no alterations (Fig. 9G-I), 
histological examination of infected mice revealed an acute loss of myelin staining (Fig. 
9J-K). As observed with the PLP mRNA probe, this loss of myelin was restricted to the 
corpus callosum (Fig. 9L). 
 
Discussion 
 
To successfully induce meningitis, a pathogen must be able to invade and survive in the 
intravascular space, cross the BBB, survive and multiply in the cerebrospinal fluid (CSF) 
and then cause damage to the CNS (45). Different animal models have been used to 
study infections caused by meningeal bacterial pathogens, specifically the pathogenesis 
of meningitis, the host immune response induced after infection, and the efficacy of 
novel drugs and vaccines. Most models use infant animals because adult animals do 
not reliably develop brain pathology after intranasal, i.v. or i.p. challenge with live 
microorganisms (45). In addition, models using i.v. or i.p. challenges in adult animals 
typically result in bacteremia and septicemia, leading sometimes to rapid death of 
infected animals with modest, if any, brain pathology. Experimental infections leading 
to meningitis are usually performed by direct inoculation of the pathogen into the CSF 
or by direct intracerebral instillation (46, 47). However, this model bypasses several 
steps, such as bacterial dissemination and increased permeability of the BBB, which is 
the natural portal of entry into the CNS for most meningeal pathogens. In the present 
study, we used a CD1 mouse model of S. suis infection to study the two phases of 
disease: an early septic shock-like syndrome leading to death and a second late phase 
that induces evident brain damage. Using this model we consistently reproduced 
clinical signs of affected nervous system and damage to the CNS in adult animals by 
means of a hematogenous infection with a Gram positive bacterial pathogen. 
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Interestingly, CD1 mice appear to be specifically and consistently susceptible to CNS 
infections by S. suis, although this pathogen does not induce clinical signs of meningitis 
in other mouse strains (BALB/c, C57BL/6 and A/J) tested (unpublished observations). 
The i.p. route may confer certain advantages compared with direct inoculation into the 
CNS. First, the technique causes minimal trauma and anesthesia is not required. 
Second, it better represents the natural route of infection since most pathogenic 
bacteria cause bacteremia before reaching the CNS via mechanisms that are only 
partially understood. 
In the model used in the present study, a virulent S. suis strain caused 20% 
mortality within 48 h p.i. The number of CFU in the blood, liver and spleen was 
routinely high in all infected mice until day 3 p.i, although the presence of high levels of 
bacteremia was not always fatal. Variable numbers of bacteria were found in the brain, 
indicating a pattern of S. suis colonization that is unique to this organ. Surprisingly, 
more than 100 CFU/sample were found in the brain of some mice after 6-9 days p.i. in 
the absence of clinical signs; however, animals were sacrificed at specified time points 
in our kinetics study and therefore it is not known whether these mice would have 
developed nervous disease at a later time. 
 The use of a multiplex system in this study allowed us to quantitatively measure 
the kinetics of several cytokines simultaneously in a small volume of plasma. High levels 
of TNF-α, IL-6, IL-12, IFN-γ, CCL2 (MCP-1), CXCL1 (KC) and CCL5 (RANTES) were 
observed in vivo within 24 h p.i. and might be responsible in part for the sudden death 
of 20% of animals. In fact, the presence of high number of bacteria and the lack of 
specific lesions in mice that died during the first 24-48 h suggest that the exacerbated 
inflammatory response might be the cause of death. It is not clear why some animals 
succumbed while others survived this acute phase. A general analysis of cytokine 
patterns suggests that infection with S. suis serotype 2 induces a Th1-type immune 
response. TNF-α, the first cytokine observed in the systemic inflammatory cascade 
following S. suis infection, has been previously implicated in the pathogenesis of Gram-
positive septic shock-like syndrome (36, 48). It is important to note the remarkably high 
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levels of IL-6 production in S. suis-infected mice. Indeed, high levels of both TNF-α and 
IL-6 correlate inversely with survival time in patients with sepsis (49). Previous studies 
of mice infected with S. pneumoniae, Group A (GAS) or Group B streptococci (GBS) 
have reported elevated IL-6 in plasma, albeit at lower levels than those found here (48, 
50). Likewise, IFN-ɣ contributes to the immune control of invading pathogens but also 
may cause pathology leading to death when its production is excessive or uncontrolled 
(50). It has been shown that high levels of IL-12 produced early during GAS infection, as 
those observed in this study with S. suis, may influence NK cells and others to produce 
IFN-ɣ, suggesting a positive feedback regulation in the pro-inflammatory cytokine 
cascade (50, 51). Levels of IL-1β were not as high as those observed for other type 1 
cytokines; however, this finding does not necessary preclude a causative role for IL-1 
in S. suis disease, as already suggested for other pathogens (52).  As for the 
chemokines, high levels of CXCL1 (KC) and CCL2 (MCP-1) were detected during the first 
36 h p.i. in the sepsis phase of infection, and their presence in plasma lasted longer 
than most of the pro-inflammatory cytokines tested. Although there are very few 
studies on the activity of CCL5 (RANTES) in sepsis (39), it has been shown that its levels 
in plasma during meningococcal disease show a different pattern than those of other 
chemokines (53). However, in our study, CCL5 followed a pattern similar to other 
chemokines. It has been shown that different meningitis-causing bacteria induce 
distinct inflammatory responses, including either high or low levels of CCL5 folowing 
interaction with cells of the human meninges (54). Finally, the relatively delayed IL-10 
up-regulation might indicate a negative feedback mechanism to control the extent of 
the inflammatory response, as described in experimental pneumococcal meningitis 
(55). Given that numbers of viable bacteria remained constant during the first 3 d p.i., 
IL-10 production did not appear to influence bacterial clearance from the blood or 
various organs and instead likely contributed to mouse survival by preventing 
immunopathology associated with excessive pro-inflammatory cytokines.  
We showed that most S. suis-infected mice that survive septicemia later 
developed CNS clinical signs such as locomotion problems, episthotonus, opisthotonus, 
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bending of the head laterally and walking in circles, which could be considered 
characteristic of brain inflammation. S. suis infection clearly induced inflammation and 
suppurative and necrotizing lesions in specific anatomical sites of the brain 
parenchyma, such as the meninges, cortex, hippocampus, thalamus, hypothalamus, 
and corpus callosum. In addition, a strong activation of TLR2 in the same regions of the 
brain parenchyma was observed several days after the presence of S. suis bacteremia. 
Previous studies showed that mice systemically inoculated with peptidoglycan (PGN), 
lipoteichoic acid (LTA) or a combination of both fail to modulate TLR2 expression in the 
CNS (27). However, intracisternal injection of live or killed S. pneumoniae, PGN and LTA 
triggers an immune reaction via TLR2 (56). These conflicting results may reflect 
different routes of inoculation. We hypothesize that local multiplication of S. suis, 
which might expose or release high amounts of PGN, LTA and other surface 
components, might be responsible for TLR2 up-regulation. The role of this receptor in 
protective immunity and immunopathology in Gram positive meningitis is controversial 
(57). Indeed, it has been demonstrated that TLR2 plays a dual role in GBS infection 
depending on the bacterial dose, that is, it has a protective role at low doses but exerts 
detrimental effects, such as causing septic shock-like syndrome, at high doses (48). 
In our model, results show that TLR2 activation coincided with up-regulated 
expression of CD14 receptor and activation of IκBα (index of NF-κB activation), IL-1β, 
TNF-α and MCP-1 in similar anatomical regions among mice with CNS symptoms. 
However, it is not possible to ascertain that the increased mRNA expression of 
inflammatory mediators was directly related to TLR2 signaling pathway. In fact, there 
was also a moderate induction of TLR3 mRNA expression which followed a pattern 
similar to TLR2. Thus, we cannot rule out the possibility that S. suis can activate other 
TLRs besides TLR2 and possibly other components of the innate immune system, as 
previously reported by our in vitro studies (18, 21). In agreement with these findings, 
mice with S. pneumoniae-induced meningitis have increased TLR2, TLR4 and TLR9 
mRNA expression while hippocampal cultures exposed to the same bacteria also trigger 
up-regulated TLR2 and TLR3 mRNA expression. In addition, TLR2-deficient mice 
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infected intracraneally with S. pneumoniae express different pro-inflammatory 
cytokines in the CNS, indicating TLR2-independent recognition pathways (56, 58, 59). 
Finally, we confirmed previous data that support no involvement of TLR4 in this 
response (21). The pneumolysin of S. pneumoniae was reported to activate TLR4 (60). 
Although S. suis produces a toxin, named suilysin, with high homology to pneumolysin 
(6), it appears that these two toxins do not engage the same activation pathways. It 
should be noted that no correlation could be established between positive in situ 
hybridization signals and bacterial loads in the brain. In fact, the technique requires 
perfusion of mice with paraformaldehyde and such a treatment does not allow further 
sampling for other types of studies, such as bacteriology. However, results from 
immunohistochemistry showed the presence of high loads of bacterial Ags in 
association with cells which morphologically resembled microglia residing only in the 
affected zones, indicating a high concentration of bacteria in these regions. 
 Transcriptional activation of cytokine mRNA in the CNS at a time coincident 
with the presence of clinical signs may indicate an important role of inflammation in 
the development of S. suis-related meningitis. Based largely on in vitro data, it has been 
suggested that CSF cytokines are secreted predominantly by microglia or astrocytes 
within the brain parenchyma (61). In this study, we showed that, in general, 
microglia/macrophage (or infiltrating monocyte) cells and, to a lesser extent, astrocytes 
were activated and these cell types were probably the cellular sources of cytokine 
induction in the brain parenchyma. This hypothesis is supported by the strong 
transcriptional activation of NF-κB and MCP-1 mRNA in these cells. Infiltrating 
monocytes would contribute not only to in situ inflammation but also to bacterial 
infiltration into the CNS given that monocytes carry externally associated bacteria, as 
suggested by the “modified Trojan Horse” theory for S. suis invasion of the CNS (6). 
Finally, endothelial and ependymal cells might also play a supporting role in inducing 
inflammation in the CNS (61).  
S. suis does not appear to induce the expression of pro-inflammatory mediators 
in leaky areas of the brain (regions excluding the BBB) and does not affect the so-called 
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circumventricular organs, as previously reported for LPS (22, 27, 62, 63). Indeed, 
microscopic analysis of brain sections showed that cells expressing transcripts for TLR2, 
CD14, IκBα and CCL2 (MCP-1) were associated with microvascular vessels early after 
infection, suggesting that endothelial cells play an important role in the pathogenesis 
of S. suis-related meningitis. Furthermore, previous in vitro reports from our laboratory 
show that the BBB may be the portal of entry for the bacteria into the brain (9, 25) and 
that BMEC might also contribute to the initiation of inflammatory process by 
producing, among others, IL-6, CXCL8 (IL-8) and CCL2 after contact with S. suis. (15). 
Interestingly, these in vitro studies showed an absence of TNF-α and IL-1β activation in 
S. suis-infected BMEC (15), a finding that is consistent with the lack of a positive 
transcription signal for these cytokines in microvascular vessels as demonstrated here 
and in other studies (64). In this study, shortly after infection, TLR2 and CD14 mRNA up-
regulation was observed in cells lining the brain microvasculature. Although data are 
limited, TLR2 expression in brain endothelial cells has been reported (64) while 
endothelial cell expression of CD14 is controversial (65-67). On the other hand, both 
TLR2 and CD14 may be induced in perivascular microglia and monocytes, which 
participate in many inflammatory events in  the CNS (68, 69). Finally, it has also been 
suggested that S. suis, which can affect the viability of porcine choroid plexus epithelial 
cells, may also invade the CNS through the choroid plexus (10). In agreement with this 
hypothesis, the present study showed robust and rapid expression of TLR2, TLR3, CD14, 
IκBα, IL-1β, TNF-α, and CCL2 (MCP-1) in the choroid plexus early after S. suis infection. 
 In conclusion, results obtained in the present study provide important insights 
into the mechanisms underlying the innate immune response against the infection 
caused by S. suis at both systemic and CNS-specific levels. This is the first report of an 
hematogenous infection model that consistently reproduces clinical signs of an 
affected nervous system and damage to the CNS in adult animals with a bacterial 
pathogen. The adult model of CNS infection developed in this study may be useful to 
further study mechanisms involved in bacterial invasion of the CNS and brain 
inflammation caused by Gram positive bacteria.   
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Table I. mRNA expression of different receptors and pro-inflammatory mediators in the brain 
of mice intraperitoneally infected with S. suis
a  
 
Expression at 3 h p.i. 
Structure TLR2 TLR3 CD14 IκBα IL-1β IL-6 TNF-α CCL2 
Meninges - - - - - - - - 
Choroid plexus +/- - +/- + - +/- - +/- 
Blood vessels - - - - - - - - 
Cortex - - - - - - - - 
Hippocampus - - - - - - - - 
Corpus callosum - - - - - - - - 
Thalamus - - - - - - - - 
Hypothalamus - - - - - - - - 
 
Expression at 24 h p.i. 
Structure TLR2 TLR3 CD14 IκBα IL-1β IL-6 TNF-α CCL2 
Meninges + - +/- + - - - + 
Choroid plexus + +/- + + + +/- - + 
Blood vessels +/- - ++ ++ - +/- - + 
Cortex + - + + + +/- - ++ 
Hippocampus + - +/- + - - - + 
Corpus callosum +/- - ++ + - - + ++ 
Thalamus + +/- + + - - - + 
Hypothalamus + +/- + + - - - +/- 
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Expression at 5 d p.i. 
Structure TLR2 TLR3 CD14 IκBα IL-1β IL-6 TNF-α CCL2 
Meninges + - ++ ++ ++ v - + 
Choroid plexus ++ ++ + ++ ++ v ++ ++ 
Blood vessels ++ - ++ +++ - v - ++ 
Cortex ++ ++ + + ++ v - +++ 
Hippocampus +++ ++ +/- +++ + v - + 
Corpus callosum ++++ ++ ++ +++ ++ v ++ ++++ 
Thalamus +++ + ++ ++ +/- v - ++ 
Hypothalamus + + ++ +++ +/- v - +/- 
 
Expression at 9 d p.i. 
Structure TLR2 TLR3 CD14 IκBα IL-1β IL-6 TNF-α CCL2 
Meninges +/- - +/- +/- +/- +/- - - 
Choroid plexus +/- +/- +/- + +/- +/- +/- +/- 
Blood vessels +/- - +/- + - +/- - +/- 
Cortex +/- - +/- +/- +/- +/- - +/- 
Hippocampus + - +/- +/- +/- +/- - +/- 
Corpus callosum + - +/- + +/- +/- +/- + 
Thalamus + - +/- +/- +/- +/- - +/- 
Hypothalamus +/- - +/- +/- +/- +/- - +/- 
a 
++++, very strong signal; +++, strong signal, ++, moderate signal; +, low but positive signal; +/-, 
low to undetectable; -, undetectable; for an average of 3 mice per group at each post-infection 
time (p.i.). v: variable results in different mice. CCL2: MCP-1 
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ARTICLE I. FIGURES.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 1. Bacterial distribution in 
different organs from mice 
infected i.p. with S. suis. (A) 
Bacterial loads in the liver and 
spleen are expressed as CFU/0.05 
g of tissue and in the blood as 
CFU/ml. Results are expressed as 
mean ± SEM of at least 3 infected 
mice per time point. (B) Bacterial 
counts in the brain. Results are 
expressed as CFU/0.05 g of tissue. 
Each ▲ represents one mouse. 
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bv 
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◄ hc 
Fig. 2. Histopathological findings in the brains of 
mice with clinical signs of meningitis. (A) Micrograph 
of a brain from an infected mouse at day 6 p.i. 
showing a blood vessel (bv) surrounded by a rim of 
neutrophils (n) with bacteria partially occluding the 
lumen (white arrow head). Areas of malacia (m) are 
observed nearby. Hippocampus (hc). (B) Micrograph 
of a brain from an infected mouse at day 9 p.i. 
showing complete destruction of the corpus callosum 
(cc). The normal tissue was replaced by numerous 
infiltrating neutrophils (black arrow head). Some 
hemorrhagic foci are also observed (+). (C) 
Micrograph of a brain from a mouse at day 9 p.i. 
showing the meninges (me) severely thickened and 
diffusely infiltrated by numerous macrophages and 
neutrophils (black arrow heads). Hematoxilin-eosin 
staining, 400X  magnification. Bacterial loads in these 
mice ranged from 10
3
 to 10
4
 CFU/0.05 g of brain 
tissue. 
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Fig. 3. S. suis infection induces production of inflammatory mediators in a time-dependent 
manner. (A) TNF-α, (B) IL-6, (C) IL-12p40, (D) IL-12p70, (E) IFN-γ, (F) IL-1β, (G) CXCL1/KC, (H) 
CCL2/MCP-1, (I) CCL5/RANTES and (J) IL-10. Cytokine concentrations were assayed by a liquid 
multi-array system (Luminex), as described in the Material and Methods. Data are expressed as 
mean ± SEM pg/ml and are representative of two independent experiments. Time 0 h 
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represents the mean (SEM) results from negative mice. Median bacterial loads in the blood of 
mice used for cytokine measurements are presented in Figure 1A. 
 
 
Fig. 4. Coronal sections showing the in situ hybridization results from S. suis-infected mice 
and non-infected (negative) controls. The dark-field microphotographs of nuclear emulsion-
dipped coronal sections show the spatial expression of TLR2 (A), CD14 (B), IκBα (C), and 
CCL2/MCP-1 (D) mRNA at day 5 p.i. The positive hybridization signal appears as an 
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agglomeration of silver grains in specific structures of the brain, such as the hippocampus (hc), 
corpus callosum (cc), thalamus (th), and meninges (me). 
 
Fig. 5. S. suis is able to induce strong transcriptional activation of genes encoding TLR2 (A), 
CD14 (B), IκBα (C), and CCL2/MCP-1 (D) in various structures of the brain. These dark-field 
microphotographs are magnifications of coronal sections depicted by Figure 4 and are 
representative examples of the expression patterns of the different transcripts in the 
hippocampus (hc), corpus callosum (cc) and blood vessels (bv) at day 5 p.i. 
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Fig. 6. S. suis infection induces transcriptional activation of genes encoding pro-inflammatory 
molecules in the brain and blood vessels (bv) of mice. The dark-field photomicrographs of 
nuclear emulsion-dipped coronal sections from infected mice at day 5 p.i. show the presence of 
positive hybridization signal in parenchymal cells and also in cells lining the endothelium of the 
brain capillaries, as clearly indicated by corresponding bright-field photomicrographs. 
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Hybridization signals are depicted for TLR2 (A), CD14 (B), IκBα (C), and CCL2/MCP-1 (D) 
transcripts.  
 
Fig. 7. Combined immunohistochemistry and in situ hybridization labeling suggests a key role 
of microglia/macrophages in the inflammatory response provoked by i.p. S. suis infection in 
mice. Microglial cells were labeled with an antibody against ionized binding adapter molecule 1 
(iba1) and glial fibrillary acidic protein (GFAP) antisera was used to stain astrocytes (brown cell 
bodies and ramifications). In situ hybridization was thereafter performed for TLR2, IκBα or 
CCL2/MCP-1 mRNA (silver grains). All microphotographs are representative of infected mice at 
day 5 p.i. The presence of mRNA encoding either TLR2 (A) or CCL2/MCP-1 (C) within 
parenchymal microglia appears as an agglomeration of silver grains inside the cell cytoplasm 
(black arrow heads). Few positive astrocytes for IκB (B) and CCL2/MCP-1 (D) transcripts were 
also detected.  
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Fig. 8. S. suis Ags were labeled by immunoperoxidase using a polyclonal antiserum. (A and B) 
Nissl-stained coronal section from a control mouse showing the absence of bacterial Ags or 
tissue degeneration. (C) Representative section of an infected mouse at day 5 p.i. showing the 
bilateral localization of S. suis Ags in the brain. (D) Localization of S. suis Ags occurred in specific 
areas of the brain parenchyma, mainly the cortex (co) and corpus callosum (cc). (E) S. suis Ags 
were largely found in associated with cells with morphological resemblance to 
macrophages/microglia. Nissl staining revealed areas of corpus collosum degeneration (C and 
D) as indicated by black arrow heads. 
 
Fig.9. PLP transcript expression was diminished in the brain of S. suis-infected mice. (A-C) 
Brain sections from control mice showing normal levels of PLP expression. (D-F) Brain sections 
of infected mice at day 5 p.i. showing the reduced expression of PLP mRNA, mainly in the 
corpus callosum (cc). In (E) and (F), the regions with a decreased level of PLP transcript in the 
corpus callosum are indicated by white arrow heads. Please note that PLP mRNA expression 
levels remain similar to control mice in other areas of the brain. (G-I) SBB-stained brain sections 
from control mice showing absence of histological changes. The presence of myelin in the (cc) 
is apparent. (J-L)  SBB-stained brain sections of infected mice at day 5 p.i. showing a clear and 
localized loss of myelin at the level of the corpus callosum (cc). In (K) and (L) the localized 
demyelination in the (cc) is indicated by black arrow heads. 
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SUPPLEMENTAL DATA LEGENDS 
 
Video 1. 
A CD1 mouse presenting clinical signs of CNS inflammation (episthotonus and 
opisthotonus) which suddenly appeared at day 6 after i.p. infection with a virulent 
strain of S. suis serotype 2. Animals were immediately and humanely sacrificed after 
the video was recorded as approved and recommended by The Animal Welfare 
Committee of the Université de Montréal, Canada. 
 
Video 2. 
A CD1 mouse presenting clinical signs of CNS inflammation (locomotion problems, 
bending of the head laterally and walking in circles) which suddenly appeared at day 5 
after i.p. infection with a virulent strain of S. suis serotype 2. Animals were immediately 
and humanely sacrificed after the video was recorded as approved and recommended 
by The Animal Welfare Committee of the Université de Montréal, Canada. 
 
Video 3. 
A CD1 mouse presenting serious clinical signs of CNS inflammation (locomotion 
problems, 360° rotation of the body) at day 9 after i.p. infection with a virulent strain of 
S. suis serotype 2. Animals were immediately and humanely sacrificed after the video 
was recorded as approved and recommended by The Animal Welfare Committee of the 
Université de Montréal, Canada. 
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Abstract 
 
Streptococcus suis is an important swine and human pathogen responsible for 
septicemia and meningitis. In vivo research in mice suggested that in the brain, microglia 
may be involved in activating the inflammatory response against S. suis. The aim of this 
study was to better understand the interactions between S. suis and microglia. Murine 
microglial cells were infected with a virulent wild type strain of S. suis. Two isogenic 
mutants deficient either at capsule or hemolysin production were also included. The 
capsular polysaccharide (CPS) contributed to S. suis resistance to phagocytosis and 
regulated the inflammatory response by hiding pro-inflammatory components from the 
bacterial cell wall, while the absence of hemolysin, a potential cytotoxic factor, did not 
have a major impact on S. suis interactions with microglia. Wild-type S. suis induced 
enhanced expression of Toll-like receptor 2 by microglial cells, as well as 
phophotyrosine, PKC and different mitogen-activated protein kinase (MAPK) events. 
However, cells infected with the CPS-deficient mutant showed overall stronger and 
more sustained phosphorylation profiles. Moreover, S. suis-induced inducible nitrogen 
oxide synthase (iNOS) expression and further nitric oxide production from microglia was 
also modulated by CPS. Finally, S. suis-induced NF-kB translocation was faster for cells 
stimulated with the CPS-deficient mutant, suggesting that bacterial cell wall 
components are potent inducers of NF-kB. These results contribute to our knowledge on 
the mechanisms underlying S. suis induction of inflammation in the brain and would be 
useful to design more efficient anti-inflammatory strategies for meningitis.   
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 Introduction 
Streptococcus suis is one of the most important swine pathogens worldwide as 
well as an important agent of zoonosis. Up today, 35 serotypes have been described, 
although serotype 2 is still the most frequently isolated from both, swine and humans. 
In swine, meningitis is the most striking feature of the infection, although other 
pathologies such as septicemia, endocarditis, pneumonia and arthritis have been 
described (3, 31, 66). The most common pathology associated to S. suis infection in 
humans is also meningitis, although cases of septicemia with septic shock, endocarditis, 
and several other clinical manifestations have been reported (65, 67, 69). As a zoonotic 
agent, S. suis infection has been traditionally considered as an occupational hazard, 
since most of the cases described in Western countries have occurred in people working 
in close relationship with pigs or raw pork products. The situation in Asian countries is 
completely different. In addition to an important human Chinese outbreak caused by S. 
suis in 2005 (69),  this pathogen has recently been reported as the third most common 
culture-confirmed cause of community-acquired bacterial meningitis in Hong Kong (33) 
and  the most frequent cause of bacterial meningitis in adults in Vietnam (44). People 
who survive S. suis infection may be handicapped as severe post-infection sequels, such 
as deafness, may develop (65, 66).  
In recent years, an important number of studies describing the proposed 
virulence factors of S. suis serotype 2 have been published (5, 26). However, few 
candidates have been shown to be critical for virulence. Among them, the capsular 
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polysaccharide (CPS) has been considered as an important anti-phagocytic factor (13). 
Although not essential for virulence, a hemolysin (suilysin) produced by most virulent 
strains in Eurasia has also been shown to be toxic for cells of murine, human, and swine 
origins (12, 14, 54, 64).  
The pathogenesis of infection of S. suis has been partially elucidated. In swine, 
infection occurs through the respiratory route with subsequent colonization of the 
tonsils while in humans, the access is mainly through skin cuts and/or the oral route (4, 
25, 26). Once S. suis reaches the bloodstream, it travels either free or associated to 
monocytes (24), with invasion of different tissues and organs.  High mortality observed 
at this stage of the disease may be associated to septic shock with an exacerbated 
release of pro-inflammatory cytokines (17, 18). However, if the host overcomes 
septicemia, S. suis may still invade the central nervous system (CNS) and cause 
meningitis and, in some cases, encephalitis. Mechanisms used by the pathogen to gain 
access to the brain and induce local inflammation are still under debate. It is likely that 
access is by transcytose and/or toxicity to microvascular endothelial cells (64) and/or 
the choroid plexus epithelial cells that are part of the blood-brain barrier (BBB) (63). 
Increase of BBB permeability due to inflammation cannot be ruled out (24). 
Recently, our laboratory developed an in vivo mouse model of 
meningitis/encephalitis after S. suis infection via the intraperitoneal route (17). Using 
this model, an important inflammatory response in the CNS with the expression of 
different pro-inflammatory genes, including Toll-like receptor (TLR)-2, CD14, IκBα (an 
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index of NF-ĸB expression), IL-1β, TNF-α, and MCP-1 was observed. Interestingly, the 
expression of these genes and bacterial antigens were found by  immunohistochemistry 
to be probably associated with microglia and astrocytes (17). Microglia, the 
macrophage-like population within the
 
CNS, represents the first line of defense against 
invading pathogens
 
and has proinflammatory effector functions (48). Although previous 
findings draw attention to the implication of these cells in the development of 
meningitis and encephalitis, it is critical to dissect how these cells initiate key pro-
inflammatory mechanisms in order to respond to S. suis infection.  
The goal of this study was to explore the murine microglial response to a virulent 
strain of S. suis as well as isogenic mutants defective in either capsule or suilysin 
production.  The ability of microglia to phagocyte S. suis, to activate TLRs, to secrete 
different pro-inflammatory mediators as well as to activate important inflammatory 
intracellular signaling pathways was evaluated.  
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Materials and methods 
Cell culture. The murine microglial cell line BV-2 was kindly provided by Dr S. Rivest 
(Université Laval, QC, Canada). This cell line exhibits morphological and functional 
characteristics of microglia (7, 8). It has been recently shown that this cell line is a valid 
substitute for primary microglial cells (34). BV-2 microglia was maintained in vitro in 
DMEM high-glucose medium (Wisent Inc., St-Jean Baptiste, QC, Canada) containing 10% 
of heat-inactivated fetal bovine serum and 2% penicillin-streptomycin (both from 
Invitrogen, Carlsbad, CA). Cells were kept in 75 cm
2
 Falcon flasks at 37°C in a humidified 
atmosphere containing 5% CO2. Experiments were performed in 24-well plates unless 
specified, with a concentration of  5 × 10
5 
cells/well. Absence of cell toxicity with 
different S. suis strains and concentrations tested was evaluated by measuring the 
release of lactate dehydrogenase enzyme with the Cyto Tox 96 Non-Radioactive 
Cytotoxicity Assay (Promega, Madison, WI) as previously described (66).  
 
Bacterial strains and growth conditions. Three strains of S. suis capsular serotype 2 
were used, the virulent wild-type suilysin-positive strain 31533 (WT) originally isolated 
from a case of porcine meningitis and widely used in previous studies (18, 19, 42, 58, 
59),  as well as two isogenic mutants obtained by allelic exchange, the suilysin-negative 
mutant SX911 (SLY-) (45) and the non-capsulated mutant B218 (CPS-) (23). Bacteria 
were grown overnight on sheep blood agar plates at 37°C and isolated colonies were 
inoculated into 5 ml of Todd-Hewitt broth (THB; Difco Laboratories, Detroit, MI), which 
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was incubated for 8 h at 37°C with agitation. Working cultures were prepared by 
transferring 10 µl of 1/1000 dilutions of 8 h-cultures into 30 ml of THB, which was 
incubated for 16 h at 37°C with agitation. Stationary-phase bacteria were washed twice 
in phosphate-buffered saline pH 7.3 (PBS). For experiments, the bacterial pellet was 
resuspended and diluted in cell culture medium to a final concentration of 1 × 10
6
 
CFU/ml, unless specified.  When necessary, the WT and CPS- S. suis strains were heat 
killed as previously described at 60°C for 45 min (minimal experimental conditions 
required for S. suis killing) (57).  
 
Phagocytosis assays. Phagocytosis assays were performed as already described (60) 
with some modifications. Briefly, microglial cells were infected by removing culture 
medium and adding different S. suis strains resuspended in cell culture media at a MOI 
of 2:1. In selected experiments, bacterial opsonization was performed by incubating 
bacteria in the presence of 20% (v/v) of complete normal or heat inactivated mouse 
serum in PBS for 30 min at 37°C with shaking prior to cell infection. Mouse serum from 
C57BL/6 mice was inactivated by incubation for 30 min at 56°C. After 15, 30 and 60 min 
of infection, cell monolayers were washed twice with warm culture media, and 
reincubated for 1 h with medium containing penicillin G (5 μg/ml) and gentamicin (100 
μg/ml) to kill extracellular bacteria (both antibiotics were from Sigma-Aldrich, Oakville, 
ON, Canada). Previous studies with S. suis showed that this concentration of antibiotics 
is able to kill any remaining extracellular bacteria (56, 60). In addition, supernatant 
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controls were taken in every test to confirm antibiotic efficacy. After antibiotic 
treatment, cell monolayers were washed three times and the medium was replaced 
with 1 ml of sterile distilled water to lyse microglial cells. After vigorous pipetting to 
ensure complete cell lysis, viable intracellular streptococci were determined by 
quantitative plating of serial dilutions of the lysates on THB agar. All samples were 
plated using an Autoplate 400 Automated Spiral Plater (SpiralBiotech Inc., Norwood, 
MA). Each test was repeated four times in independent experiments, and the number of 
CFU recovered per well (mean number ± SEM) was determined.  
 Phagocytosis was confirmed by confocal microscopy. Microglial cells were plated 
on coverslips and infected with S. suis WT and CPS- strains. After 2 h of bacteria-cell 
contact, coverslips were washed with culture media to remove non-associated bacteria, 
and cells fixed with methanol/acetone (80:20) for 20 min at -20
°
C, washed and blocked 
with PBS containing 2% fetal bovine serum for 10 min. Coverslips were incubated for 1 h 
with optimal dilutions of rabbit hyperimmune anti-S. suis serum, produced as described 
previously (36), and with rat anti-LAMP1 antibody (Developmental Studies Hybridoma 
Bank, Iowa, IA). After washing, coverslips were incubated with the secondary antibodies 
Alexa-Fluor 488 goat anti-rabbit IgG and Alexa-Fluor 568 goat anti-rat IgG (Invitrogen) 
for 30 min, washed and mounted on glass slides with mowiol containing DABCO and 
DAPI to stain the nuclei. Samples were observed with an IX-80 confocal microscope 
integrated into the FV-1000 imagery system and analysed using the fluoview software 
(Olympus, Markham, ON, Canada).  
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Cytokine and chemokine detection by ELISA. Microglial cells were infected with S. 
suis WT and mutant strains included in the study at a MOI of 2:1. Purified Escherichia 
coli lipopolysaccharide (LPS) at 1µg/ml (Sigma-Aldrich) was used as positive control. 
After 12 h incubation (optimal incubation time as observed in kinetic studies, data not 
shown), the supernatant was recovered to measure levels of  IL-1β, IL-6, TNF-α, MCP-1 
and the chemokine interferon-inducible protein of 10 kD/CXC chemokine ligand 10 
(CXCL10/IP-10) by a sandwich ELISA, using commercially available antibody pairs 
(R&D Systems, Minneapolis, MN), as previously described (58). Standard curves were 
included in each ELISA plate (Nunc, Ville Mont Royal, QC, Canada) as two-fold 
dilutions of recombinant (R&D Systems) mouse IL-1β (1000 to 39 pg/ml), IL-6 (1250 to 
39 pg/ml), TNF-α (1000 to 8 pg/ml), MCP-1 (500 to 8 pg/ml) or IP-10 (4000 to 31 
pg/ml). Supernatant dilutions giving optical density readings in the linear portion of the 
appropriate standard curve were used to determine the level of each cytokine in the 
samples. Standard and sample dilutions were added in duplicate wells to each ELISA 
plate. 
 
Analysis of TLRs gene expression by real time reverse transcriptase-quantitative 
PCR. Microglial cells were infected with WT and CPS- S. suis strains at a MOI of 2:1 for 
0, 1, 2, 4 and 8 h. Following infection, medium was removed and cells were washed with 
cell culture medium. Total cellular RNA was prepared from cells using Trizol 
(Invitrogen) following standard procedures. Next, 1 µg of total RNA was reverse-
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transcribed with the QuantiTect reverse transcription kit (Qiagen, Mississauga, ON, 
Canada) and the resulting cDNA was amplified using the SsoFastTM EvaGreen® 
Supermix kit (Bio-Rad, Hercules, CA). The PCR amplification program for all cDNA 
samples consisted of an enzyme activation step of 3 min at 98°C, followed by 40 cycles 
of a denaturing step for 3 s at 98 °C and an annealing/extension step for 5 s at 57 °C. 
Each 10 µl reaction contained 250 nM each of forward and reverse primers. The primers 
used for amplification of the different target cDNA are listed in Table 1 and were all 
tested to achieve an amplification efficiency between 90% and 110%. The primer 
sequences were all designed from NCBI GenBank mRNA sequence using web-based 
software primerquest from Integrated DNA technologies 
(http://www.idtdna.com/Scitools/Applications/Primerquest/). The Bio-Rad CFX-96 
sequence detector was used for amplification of target cDNA of various TLRs and 
quantitation of differences between the different groups was calculated using the 2−∆∆Ct 
method. β-actin and β2 microglobulin (β2m) were used as normalizing genes to 
compensate for potential differences in cDNA amounts between the various samples. 
These two genes were selected from candidate normalizing genes using the “Normfinder 
V19” algorithm (2) as their expression was found to be the most stable in these 
experimental conditions. The non-infected BV-2 microglia group was used as the 
calibrator reference in the analysis. 
 
Measurement of nitric oxide production. Microglia cells were seeded and stimulated 
with killed bacteria as previously described (56), with some modifications. Briefly, heat-
killed S. suis WT and CPS- strains (concentration equivalent to 1 ×109 CFU/ml) were 
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incubated with cells (5 × 105 cells/well) for 6, 12, 24, and 48 h. LPS (1µg/ml) was used 
as positive control. Nitric oxide (NO) production was determined by measuring nitrite, a 
stable end product of NO. Microglial culture supernatant was assayed by mixing with 
Griess reagent (Promega, Madison, WI). Sulfonamide (1%) and N-1 (1-naphthyl)-
ethylenediamine dihydrochloride (0.1%) were added to the supernatant. After 30 min of 
incubation at room temperature, the absorbance was read at 540 nm. The nitrite 
concentration (expressed as µM/ml) was calculated using standard solutions of sodium 
nitrite prepared in culture medium. 
 
Signaling pathway analysis by immunoblotting. Western blotting was performed to 
analyze the phosphorylation state of protein kinase C (PKC) pathway, several mitogen-
activated protein kinases (MAPKs), including stress-activated protein kinase/c-Jun NH2-
terminal kinase (SAPK/JNK), extracellular signal-regulated kinase (ERK) and p38, as 
well as total tyrosine (Tyr) phosphorylation and inducible nitric oxide synthase (iNOS) 
expression, as previously described (38, 50). Briefly, cells were plated in a 6-well plate 
and stimulated with S. suis WT and CPS- strains at a MOI of 2:1. LPS (1µg/ml) was used 
as positive control. After different incubation times (see Results), cells were lysed in cold 
buffer containing 0.5 M Tris (pH 6.8), 0.5 M EDTA, 1% β-mercaptoethanol (v/v) 
(Biorad, Mississauga, ON, Canada), 10 mM EGTA, 10% IGEPAL (v/v), 1 mM sodium 
orthovanadate (Na3VO4)  (all from Sigma-Aldrich) and protease inhibitors aprotinin (10 
µg/ml) (Sigma-Aldrich) and leupeptin (5 µg/ml) (Roche, Mississauga, ON, Canada). The 
lysates (60µg/lane) were separated by SDS-PAGE and proteins transferred to 
polyvinylidene difluoride membranes (Millipore, Bedford, MA). Membranes were 
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blocked in Tris-buffered saline/0.1% Tween containing 1% bovine serum albumin (or 5% 
skim milk for anti-α-actin), for 1 h at room temperature. Membranes were then washed 
and incubated overnight at 4°C with one of the following antibodies: anti-phospho-ERK 
1/2 (Thr202/Tyr204), anti-phospho-p38 (Thr180/Tyr182), anti-phospho-(Ser) PKC substrate 
antibody (all from Cell Signaling, Danvers, MA), anti-phospho SAPK/JNK 1/2  
(Thr183/Tyr185) (Invitrogen), anti-phospho-Tyr  (clone 4G10, Upstate, Lake Placid, NY) 
or anti-iNOS (BD Systems, San Jose, CA).  After washing, membranes were incubated 
with anti-rabbit or anti-mouse HRP-conjugated antibodies (Sigma-Aldrich) for 1 h, and 
proteins were visualized with ECL Plus Western Blotting reagent (Amersham, Arlington 
Heigths, IL). Membranes were then stripped using the Restore Western Blot Stripping 
Buffer (Pierce, Rockford, IL), and blotting was repeated using anti-protein antibodies 
(per the manufacturer of the anti-phospho-protein). Blotting with anti-α-actin antibody 
(Sigma-Aldrich) was used as loading control for p-Tyr, p-PKC and iNOS blots. 
 
MAPK inhibition assays. In selected experiments, microglial cells were pretreated with 
the ERK inhibitor Apigenin (50 µM), the SAPK-JNK inhibitor SP600125 (50 µM) or the 
p38 inhibitor SB203580 (75 µM) 1 h prior to infection (all from Biomol Research 
Laboratories, Plymouth Meeting, PA). Western blot analysis of the corresponding 
phosphorylated proteins was done as described above after 2 h or 4 h incubation in 
presence of bacteria. Cytokine measurement was performed as aforementioned after 12 h 
incubation. Inhibitors were used at maximal subcytotoxic concentrations as determined 
by the Cyto Tox 96 Non-Radioactive Cytotoxicity Assay. An inhibitor was considered 
cytotoxic if viability was < 90% of untreated control after 12 h.  
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NF-kB binding. Electrophoretic mobility-shift assay (EMSA) was performed as 
previously described (50), with some modifications. Briefly, microglial cells were placed 
in a 25-cm2 flask and let to adhere overnight prior to infection with either S. suis WT or 
CPS- strains at a MOI of 2:1. LPS (1µg/ml) was used as positive control. Cells were 
washed with ice-cold culture medium and scraped in 1 ml of culture medium. After 
centrifugation, cells were resuspended in 400 µl of ice-cold buffer A (10 mM HEPES pH 
7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and 1 mM PMSF), and 
incubated on ice for 15 min. Twenty-five µl of 10% IGEPAL were then added. Tubes 
were vortexed for 10s and centrifuged at maximum speed for 30s. Nuclear fractions were 
resuspended in 50 µl of ice-cold buffer C (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM PMSF) and incubated at 4°C on a shaking 
platform for 15 min. After centrifugation at 12,000 × g for 5 min at 4°C, the supernatants 
were stored at –70°C until further use. Then, 7 µg of these nuclear protein extracts were 
mixed with a γ-32P-labeled oligonucleotide containing a consensus binding sequence for 
NF-κB (Santa Cruz, Biotechnology, Santa Cruz, CA). Complexes were resolved by 
electrophoresis on a 4% nondenaturing polyacrylamide gel. The gel was dried and 
visualized by autoradiography. The consensus sequence for NF-κB was 5'-AGT-TGA-
GGG-GAC-TTT-CCC-AGG-C-3'. 
 
Statistical analysis. Each test was done at least in triplicate biological repetitions. 
Differences were analyzed for significance by using the Student unpaired t test (two-
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tailed P value). A P value of <0.05 was considered significant. All data are presented as 
mean ± SEM. All statistical analyses were performed using Sigma Plot software (v.11; 
Systat Software, San Jose, CA). 
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RESULTS 
Ability of murine microglia to phagocytose S. suis is modulated by CPS. Fig. 1A shows 
the kinetics of S. suis phagocytosis by murine microglia. The WT strain and its SLY- 
mutant were relatively poorly phagocytosed throughout the experiment and no 
statistically significant differences were found between them (P > 0.05). This indicates 
that under non-opsonic conditions, the absence of suilysin, which is considered a 
putative S. suis virulence factor, does not have a major impact on phagocytosis by 
microglia. On the other hand, the CPS- mutant was quickly phagocytosed and levels of 
ingested bacteria in comparison to the WT strain significantly increased with incubation 
time, from 15 (P = 0.01) to 60 min (P = 0.002) (Fig. 1A). The possible effect of 
opsonization on S. suis phagocytosis by murine microglia was also assessed. All strains 
were pre-opsonized by incubation in the presence of 20% (v/v) of complete normal or 
heat inactivated serum in PBS for 30 min prior to microglia cell infection for 30 min. As 
shown in Fig. 1B, S. suis opsonization with mouse serum increased phagocytosis levels of 
all three strains in comparison to non opsonizing conditions (P < 0.05). However, it is 
likely that factors present in the serum other than complement are responsible for this 
phenomenon, as levels of phagocytosis for each strain opsonized with inactivated 
mouse serum were similar to those obtained with normal complete serum (P > 0.05).  
To confirm the intracellular location of bacteria, confocal microscopy was 
performed using hyperimmune serum against S. suis and an antibody specific for 
LAMP1, a protein enriched in phagolysosomes. Confocal analysis showed that only few 
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numbers of WT S. suis were internalized by microglia (Fig. 2). However, the CPS- mutant 
was found in higher numbers not only attached to the cell membrane, forming small 
chains, but also inside the cytoplasm and associated to numerous phagolysosomes of 
microglial cells (Fig. 2).  
 
S. suis induces production of pro-inflammatory cytokines and chemokines by murine 
microglia. In S. suis meningitis, microglia have been suggested as being, at least in part, 
responsible for the high inflammatory reaction in the CNS (18). Therefore, microglial 
cells were stimulated with S. suis WT strain and its isogenic mutants for 12 h and levels 
of TNF-α, IL-1β, IL-6, MCP-1 and IP-10 production analyzed by ELISA. Cell culture 
medium alone was used as a negative control, and purified E. coli LPS was used as 
positive control. LPS induced high production levels of the aforementioned pro-
inflammatory cytokines and chemokines (data not shown). S. suis induced different 
patterns of cytokine release by microglial cells (Fig. 3). The S. suis WT strain induced 
significantly higher levels of TNF-α and MCP-1 than non-infected cells, but failed to 
induce IP-10 production over basal levels (Fig. 3). The presence of suilysin was not 
involved in modulation of TNF-α, MCP-1 and IP-10 release as the SLY-mutant induced  
comparable levels of cytokines to those observed for the WT strain (P > 0.05). On the 
other hand, the CPS- mutant induced significantly higher secretion of all three cytokines 
compared to S. suis WT strain (P > 0.01).  
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Different results were obtained for IL-1β, as microglial cells produced low levels 
of this cytokine after the infection with all S. suis strains tested (Fig 3), albeit these levels 
were significantly higher that those observed with non infected cells (P < 0.001). 
Interestingly, the production of IL-1β seemed not to be influenced by the absence of the 
capsule, as levels observed for the CPS- mutant were not significantly different from 
those found with the WT strain (P > 0.05). In the case of IL-6 (Fig. 3), microglia cells did 
not produced this cytokine after infection with the WT strain or the SLY- mutant. Only 
the CPS- mutant (and the positive control LPS, data not shown) was able to induce the 
release of IL-6 from these cells (P < 0.001).  
As a whole, results obtained with microglial cells for both phagocytosis and 
cytokine production were similar between the WT strain and the SLY- mutant. Important 
differences were observed only between the parental strain and its CPS- mutant. 
Therefore, we used only these two strains for further characterization of receptor 
activation and intracellular signaling pathways related to S. suis-induced inflammatory 
response by murine microglia.  
 
S. suis infection induces TLR2 gene expression. TLRs are receptors that play a key role in 
the innate immune response. Having observed differences in expression of cytokine 
levels following infection of microglia by the WT strain and the CPS- mutant, we were 
interested in examining whether gene expression of different TLRs was modified. To this 
effect, microglia cells were infected with WT and CPS- strains of S. suis for different 
151 
 
 
times and TLR1, TLR2, TLR4, TLR6, and TLR9 gene expression analyzed by real-time PCR. 
Microglial cell infection by both S. suis strains failed to increase TLR1, TLR4, TLR6, and 
TLR9 gene expression over basal levels (data not shown). However, TLR2 gene 
expression was significantly increased in microglia between 4 and 8 h of incubation by 
either the WT strain or its CPS- mutant, when compared to non-infected cells (P < 0.05) 
(Fig. 4). Interestingly, the CPS- mutant was able to induce TLR2 gene expression in 
microglial cells at a higher level than the WT S. suis strain (P < 0.001). This finding is in 
agreement with the fact that CPS- mutant was also associated with a general higher 
cytokine production by these cells. 
 
S. suis induces iNOS expression and NO production in mouse microglia. In the brain, 
activated microglia releases NO following induction of iNOS that might lead to tissue 
destruction and degeneration (15, 46). Therefore, we sought to determine whether S. 
suis induces iNOS expression and NO release from murine microglia over time. Western 
blot analysis showed a strong iNOS expression in microglial cells stimulated with both S. 
suis strains tested. iNOS expression was observed as soon as 6 h of bacterial-cell contact 
and reached a plateau at 24 h of incubation. The activation of iNOS was higher after 
microglia infection with the CPS- mutant strain at all incubation times (Fig. 5). 
Accordingly, NO production increased over time and reached a plateau at 24 h of 
incubation. In agreement with iNOS results, NO production was significantly higher with 
the CPS- mutant strain (Fig. 5) (P < 0.05). 
152 
 
 
 
Microglial cell profile of tyrosine phosphorylation is modulated during S. suis 
infection. Studies with different pathogens have demonstrated that bacterial
 
attachment can lead to activation of host signal transduction
 
cascades, predominantly 
through Tyr phosphorylation of
 
proteins that contribute to different signal transduction 
mechanisms, including internalization of pathogens
 
into host cells (22). Thus, 
modulation of protein phosphotyrosine residues in response to S. suis infection and the 
effect of CPS in this process were assessed. As shown in Fig. 6A, the Tyr phosphorylation 
response towards S. suis is considerably down-modulated by the presence of the 
capsule. Indeed, the WT strain induces a modest Tyr phosphorylation of some proteins, 
which is more apparent at 2h post-infection, while the CPS- mutant leads to dramatic 
changes in the phosphorylation state of numerous proteins. These changes occur not 
only earlier in comparison to the WT strain (15 min), but also the level of 
phosphorylation is stronger and generally increases over time. It is interesting to note 
that during the course of infection, the phosphorylation level of some proteins of ~ 110, 
70-75 and 25-30 kDa temporarily decreased, suggesting that either different bacterial 
components and/or different steps of the infection (adhesion vs internalization) may 
influence Tyr phosphorylation patterns (Fig. 6A).  
Murine microglial cells display PKC activity after S. suis infection. PKC represents a 
family of serine/threonine kinases that play central roles in multiple signaling events, 
such as regulation of the immune response by MAPKs and gene transcription activation 
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(62). Using an antibody specific to PKC substrates containing phospho-serine, 
phosphorylation levels of several proteins in microglial cells was shown to be different 
after infection with the WT strain compared to the CPS- mutant (Fig. 6B). In fact, the WT 
strain showed a discrete phosphorylation of several proteins, ranging from ~ 25 to 60 
kDa that occurred at different times post-infection depending on the protein. In 
contrast, the phosphorylation pattern of PKC substrates observed for the CPS- mutant 
was particularly stronger and more stable reaching maximal phosphorylation at 2 h 
post-infection for most of the proteins. Similarly to that observed for phosphotyrosine 
(Fig. 6A), PKC-dependent phosphorylation of some proteins showed a shift between de 
phosphorylated and the non-phosphorylated state over the infection period.  
 
S. suis infection activates MAPK phosphorylation in murine microglia. It is known that 
MAPK signal transduction pathways are involved in microglial activation leading to 
production of different pro-inflammatory mediators that play an essential role in host 
response against pathogens (6, 51). To this end, the time-course phosphorylation of the 
three MAPK signaling pathways, ERK 1/2, SAPK/JNK and p38, in microglial cells was 
investigated after stimulation with S. suis WT strain and CPS- mutant (Fig 7). A specific 
phosphorylation pattern was observed for each MAPK evaluated, that seemed to be 
influenced also by the strain tested. ERK 1/2 activation in response to the WT strain was 
observed as soon as 15 min; however, this phosphorylation was down-regulated 
between 30 min and 1 h post-incubation, though a second phase of phosphorylation 
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was found at 2 h. No activation of this MAPK was found when using longer incubation 
times (data not shown). A similar ERK 1/2 activation pattern was detected with the CPS- 
mutant. Similarly to the WT strain, there was dephosphorylation of ERK 1/2 at 1 h and a 
second and final pick of phosphorylation at 2 h. When cells were stimulated with WT S. 
suis the phosphorylated form of JNK was also found at 15 min post-stimulation, but 
similarly to ERK 1/2, phosphorylated JNK was down-regulated from 30 min to 1 h. A 
second phase of activation was found at 2 h that extended up to 4 h of bacteria-cell 
contact. Interestingly, when using the CPS- mutant, a prompt and lasting JNK 
phosphorylation was detected, from 15 min to 4 h of stimulation. This phosphorylation 
seemed to be slightly down-regulated from 30 min to 1 h. In the case of p38, a very 
slight activation was found in WT strain-infected migroglial cells between 30 min and 2 h 
post-infection. However, when microglial cells were stimulated with the CPS- mutant, 
p38 phosphorylation was more marked and extended from 1 h to 4 h post-infection. 
These results show that S. suis is not only capable of inducing activation of different 
MAPK signaling pathways, but also that cell wall components seem to be mainly 
implicated in this phenomenon.  
 The involvement of ERK 1/2, JNK and p38 in regulation of microglial production 
of pro-inflammatory cytokines and chemokines in response to S. suis infection was 
confirmed using specific inhibitors. For this purpose, microglial cells were treated with 
subcytotoxic doses ERK 1/2 (Apigenin), JNK (SP600125) or p38 (SB203580) inhibitors, 
and then infected with either S. suis WT strain or its CPS- mutant. Fig. 8A shows Western 
blot results of this selective MAPK inhibition, with an evident abrogation in 
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phosphorylation of all three MAPKs. In parallel, it was possible to confirm that MAPK 
activity was involved in cytokine and chemokine production, as microglia treated with 
MAPK inhibitors prior to S. suis infection showed a strong diminution of TNF-α and MCP-
1 production (Fig. 8B and 8C), for either the WT strain or its CPS- mutant.  
S. suis infection of murine microglia induces NF-κB activation. NF-ĸB is one of the most 
prominent transcription factors involved in the inflammatory response. As our previous 
in vivo research suggested NF-ĸB activation in microglia of mice infected with S. suis 
(18), the ability of this pathogen to stimulate NF-ĸB in microglial cells was studied. Cells 
were incubated with either S. suis WT or CPS- strains and time-course of NF-ĸB 
translocation and its DNA binding activity were studied by EMSA. LPS, a potent inductor 
of NF-ĸB activity, served as positive control. A basal DNA binding activity of NF-ĸB was 
observed in non-infected cells; however, in response to S. suis WT infection, an 
important induction of NF-ĸB binding activity was recorded at 4 h which increased over 
time reaching its maximum at 12 h post-infection (Fig. 9). Although S. suis CPS- mutant 
induced NF-ĸB translocation and DNA binding activity with a similar time-course, this 
activity was overall stronger than the one recorded for the WT strain. The specificity of 
NF-κB DNA binding was confirmed by competition analysis with an excess of unlabeled 
specific or unspecific oligonucleotides. 
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DISCUSSION 
S. suis is an important swine and human agent of meningitis. Although research 
has significantly increased in recent years (29), knowledge on the pathogenesis of the 
infection is still scarce. Once S. suis arrives to the CNS, it will encounter microglia (as 
well as meningeal and perivascular macrophages), major brain resident innate immune 
effector cells. In fact, microglia play an ambiguous role since they may protect neurons 
by preventing the entry of pathogens into the brain, but they can also be toxic to 
surrounding neurons by releasing NO, glutamate, and pro-inflammatory cytokines (10, 
31, 72). In addition, activated microglia have been implicated in neurodegeneration 
resulting from bacterial meningitis (47). Using a well standardized mouse model, it has 
been shown that most S. suis-infected mice that survive septicemia,
 
later developed CNS 
clinical signs such as locomotion problems,
 
episthotonus, opisthotonus, bending of the 
head laterally and
 
walking in circles, which could be considered characteristic
 
of brain 
inflammation. S. suis infection clearly induced inflammation
 
and suppurative and 
necrotizing lesions in different anatomical
 
sites of the brain parenchyma (18). Results 
from immunohistochemistry
 
studies showed the presence of high bacterial antigen load 
in association
 
with cells which morphologically resembled microglia (18). It was 
hypothesized that these cells would be critically implicated in the CNS inflammatory 
response induced by S. suis (18).   
Microglial cells have recently been shown to be able to phagocytose and kill 
Gram-positive bacteria, including well encapsulated pathogenic S. pneumoniae (52). In 
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the case of S. suis, previous studies carried out with murine, porcine and human 
phagocytes indicated that S. suis capsule is critical for bacterial resistance to 
phagocytosis (12, 56, 61).  Similarly, phagocytosis and confocal microscopy results from 
the present study show that microglial cells hardly ingest well encapsulated S. suis, 
whereas the  CPS- mutant was significantly more ingested than the WT strain.  The 
absence of the suilysin, a virulence factor present mainly in Eurasian strains (54), has 
already been associated to a partial susceptibility of encapsulated S. suis to killing by 
neutrophils and dendritic cells in the presence of complement (5)12) (M. P. Lecours, M. 
Gottschalk, M. Houde, P. Lemire, N. Fittipaldi, and M. Segura, submitted for 
publication). Since components from the complement cascade can be found in the brain 
(26), their possible effect on phagocytosis of S. suis by microglia was evaluated. 
Although the presence of serum significantly increased the phagocytosis rate of S. suis, 
complement components do not seem to be implicated in such a process. In addition, 
the capsulated S. suis SLY- mutant behaved similarly to the WT strain, indicating a 
particular behavior of the microglial cells, different from other phagocytes (5, 12). The 
observed increased rate of phagocytosis in the presence of serum might be due to other 
proteins, such as albumin and fibronectin (9).  
Results of cell activation by S. suis provide support to the relevance of microglia 
in the development of the inflammatory response against this pathogen, as shown by 
the production of pro-inflammatory cytokines and chemokines. This confirms previous 
in vivo findings in the brain of mice where high mRNA expression levels of different pro-
inflammatory mediators were observed in cells suspected to be microglia (18). Indeed, 
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high levels of TNF-α and MCP-1 but relatively low levels of IL-1β were observed after in 
vitro S. suis activation of microglial cells. Interestingly, the WT encapsulated strain did 
not induce IL-6 production. It has been previously shown that, although highly secreted 
in the bloodstream during the septicemic phase, IL-6 mRNA was not expressed in the 
brain of S. suis infected mice (18). Results obtained in this study confirm this 
observation. For so far unknown reasons, the lack of IL-6 production by microglia differs 
from what was observed with other phagocytic cells and S. suis (30, 57, 58) as well as 
with other streptococci and microglial cells (44).   
The pneumolysin produced by S. pneumoniae, which presents a high homology 
with the suilysin, was shown to play an active role in inflammation (37). This does not 
seem to be the case for the suilysin, since the S. suis SLY- mutant induces similar 
cytokine levels than the WT strain. On the other hand, the capsule seems to be critical 
for modulating production of pro-inflammatory mediators, as the CPS- mutant induced 
the release of significant higher levels of all pro-inflammatory mediators. These findings 
support the assumption that several cell wall components, such as lipoteichoic acid 
(LTA), peptidoglycan (PG) and lipoproteins, partially masked by the capsule, are potent 
pro-inflammatory inducers, as recently suggested (24, 25, 70). Finally, as a humble 
production of IP-10 for capsulated S. suis strains in comparison to the CPS- mutant was 
also noted, we might hypothesize that the CPS might influence the onset of the adaptive 
inflammatory response, as recently shown for dendritic cells (M. P. Lecours, M. 
Gottschalk, M. Houde, P. Lemire, N. Fittipaldi and M. Segura, submitted for publication). 
As a consequence, less T lymphocytes would be attracted to the site of infection.  
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It has recently been demonstrated that TLRs, which are crucial pattern 
recognition receptors in innate immunity, are expressed in microglia (49). TLR activation 
will set in motion a broad spectrum of intracellular events to initiate the inflammatory 
response, including MAPK signaling pathways, activation of NF-κB and cytokine 
production (1). In the present work, it was observed that S. suis induces significant 
microglial TLR2 mRNA upregulation in a time-dependent fashion. As expected, and in 
agreement with cytokine results, up-regulation of TLR2 is influenced by direct exposition 
of cell wall components, as a significantly higher level of TLR2 expression was observed 
with the CPS- mutant. These findings confirm previous studies from our laboratory, 
where in vitro recognition of this pathogen by professional macrophages was shown to 
be through TLR2 (30). In vivo, S. suis infected mice showed a clear up-regulation of TLR2 
in specific parts of the brain, where microglial cells were present (18). Interesting, our 
results slightly differ from those recently reported by Wichgers Schreur et al. (70), since 
these authors could observe TLR2 upregulation after culturing human transfected 
epithelial cells with extracted lipoproteins but not with live or heat-killed S. suis. It 
should be noted, however, that interactions between S. suis and epithelial cells can 
highly differ from those observed with phagocytic cells. The fact that no upregulation of 
TLR1, TLR6, TLR4 and TLR9 was observed should be taken with caution, since relatively 
high constitutive expression levels of these mRNA were observed, and no further up-
regulation could be observed using respective positive controls (data not shown). 
A sustained and therefore uncontrolled production of toxic products released 
from microglia may cause irreversible damage to neurons. NO plays a significant role in 
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macrophage bactericidal functions, however, it is also involved in a variety of brain 
insults, including neurotoxicity, increase of intracranial pressure and meningeal 
inflammation (41). It was observed that both S. suis WT and CPS- strains efficiently 
enhance the expression of iNOS in a time-dependent manner, that transformed in the 
release of NO from microglia, although levels were again higher with the CPS- mutant. 
Cell wall components of other Gram positive bacteria, such as LTA, have already been 
reported to be involved in NO production by microglial cells (15). 
In the present study, the modulation of classical PKC and Tyr phosphorylation 
events, which are involved in different processes of macrophage activation, such as 
phagocytosis, NO production and cytokine production (11, 21, 32, 48) was examined.  
Results demonstrated a low and biphasic pattern of phosphorylation of PKC substrates 
and Tyrosyl residues in microglial cells infected with S. suis WT strain, while cells 
infected with the CPS- strain showed a stronger pattern of phosphorylation. This may 
indicate that once in contact with microglia, virulent encapsulated S. suis is able to 
modulate intracellular signaling events most likely to avoid phagocytosis and delay the 
activation of the inflammatory response. These findings support previous research on S. 
suis modulation of murine macrophage functions, in which it was concluded that the 
capsule was responsible for weak activation of Akt and PKCα kinases as well as 
activation of protein tyrosine phosphatases, which correlated with low levels of 
phagocytosis (56).  
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It was also examined whether S. suis activates the three classical MAPK 
intracellular signaling pathways and if their phosphorylation was involved in the 
production of pro-inflammatory mediators. As expected, the CPS- mutant proved to be 
particularly potent in MAPK activation, as phosphorylation patterns were stronger and 
more sustained than those obtained with the WT strain. MAPK phosphorylation levels, 
in particular p-ERK 1/2 and p-JNK, followed a biphasic pattern. This noticeable 
dephosphorylation of MAPK proteins highlights the intimate cross-talk between these 
signaling pathways and pathogen derived components and likely has an impact on 
microglia proliferation and/or activation (20). Interestingly, phosphorylation levels of 
p38, a MAPK that plays an important role in activation of inflammatory responses (53), 
were subtly increased by WT S. suis, but more noticeable with the CPS- mutant, 
emphasizing  the relevance of CPS in regulation of pro-inflammatory events. It is likely 
that, again, hidden cell wall components are the principal mediators of MAPK pathway 
activation. In fact, recent studies revealed that a capsule deficient mutant of S. suis was 
able to induce higher levels of transcriptional expression of different putative genes 
from the MAPK pathway than the parental strain (17). Furthermore, purified cell wall 
preparations from S. suis and other meningitis-causing bacteria were shown to trigger 
the phosphorylation of MAPK signal transduction pathway (15, 63). EstA cell surface 
protein is a recently described S. pneumoniae virulence factor that induces MAPK 
phosphorylation and NF-κB translocation (39). The estA gene is also found in S. suis (40), 
so we may hypothesize that MAPK and other intracellular signaling pathway activation 
do not depend solely on a few S. suis constituents, but that many of them participate in 
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the activation of the pro-inflammatory machinery. The use of pharmacological MAPK 
inhibitors, revealed an almost complete abrogation in cytokine release from microglia 
infected with either S. suis WT or CPS- strains, confirming the importance of ERK 1/2, 
JNK and p38 in the inflammatory response against this pathogen. MAPK pathways are 
molecular targets for drug development, and their inhibitors will undoubtedly be one of 
the next group of drugs developed for the treatment of human diseases (53), so these 
results may open the door to future studies, using animal models of S. suis meningitis to 
evaluate the in vivo efficiency of such drugs. 
NF-κB is a central mediator critical for driving the innate immune response 
against many pathogens that infect the brain (43). Both strains of S. suis tested were 
able to increase this DNA binding activity in a time-dependent fashion, yet this activity 
was faster and more apparent when cells were infected with S. suis CPS- mutant. 
Similarly to other reports, it is likely that cell wall components, in particular LTA, will 
influence the activation of NF-κB (15). Moreover, these findings support previous 
research stating that the in vivo inflammatory response towards S. suis in the brain of 
infected mice, as well as in vitro infection of porcine alveolar macrophages, involve NF-
κB activation (17, 18). Activation of NF-κB in murine microglial cells infected with S. suis 
would lead to the production of different cytokines and chemokines, as well as 
production of neurotoxic products, such as NO, as previously demonstrated for other 
brain pathogens (39, 43).  
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Finally, it might also be argued that activation of microglial cells may be a direct 
consequence of phagocytosis. In fact, cytochalasin treatment significantly reduced 
cytokine release by S. suis infected cells (data not shown). However, levels of cytokines 
produced by treated cells infected with the non phagocytosed well encapsulated WT 
strain were also significantly reduced, suggesting that phagocytosis alone was not 
responsible for cell activation. Rearrangement of the actin cytoskeleton may be 
necessary to for the formation of a fully active receptor  (16)complex, which may indeed 
be affected by cytochalasin treatment as reported in other systems (16, 33, 65). In fact, 
the regulation of inflammatory cytokine production is very complex and is controlled at 
transcriptional, post-transcriptional, and post-translational levels. Alteration of cell 
receptors and/or actin networks could conceivably affect most of these levels of 
regulation by altering cell surface-mediated events. However, it is also possible that 
additional distinct mechanisms exist that are not related to alterations in receptor 
complexes and are probably mediated by phagolysosome ‘in-out’ signals. Further 
studies are needed to address this issue. 
In conclusion, results obtained in the present study demonstrate that S. suis 
phagocytosis by microglia and consequent activation of these cells is highly influenced 
by the presence of the capsule, and probably involves recognition of cell wall 
components that requires participation of TLR2-dependent pathway, activation of 
different signaling pathways, translocation of NF-κB and production of different pro-
inflammatory mediators and neurotoxic metabolites. The results obtained may 
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contribute to understand the participation of microglia in the meningitis caused by S. 
suis and the genesis of brain injury associated to this pathogen. 
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Table 1: Primers used in real-time quantitative PCR for the amplification and detection of TLRs 
Gene Forward Primer Reverse Primer Amplicon 
size 
TLR1 CACAGCTCCTTGGTTTTAATG TGGGTATAGGACGTTTCTGTAG 102 bp 
TLR2 TGGAGCATCCGAATTGCATCACCG GAGCGGCCATCACACACCCC 193 bp 
TLR3 CGGGGGTCCAACTGGAGAACCT GGGCGTTGTTCAAGAGGAGGGC 198 bp 
TLR4 GCCTCCCTGGCTCCTGGCTA AGGGACTTTGCTGAGTTTCTGATCCA 139 bp 
TLR6 CCGTCAGTGCTGGAAATAG CGATGGGTTTTCTGTCTTGG 108 bp 
TLR9 CAGTTTGTCAGAGGGAGC ACTTCAGGAACAGCCAATTG 198 bp 
β-Actin CCAACCGTGAAAAGATGACC AGCATAGCCCTCGTAGATG 170 bp 
 β2m ATGGCTCGCTCGGTGACCCT TTCTCCGGTGGGTGGCGTGA 110 bp 
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ARTICLE II. FIGURES.  
 
FIG. 1. Phagocytosis of S. suis by murine microglial cells. (A) Kinetics of phagocytosis of 
S. suis strains (1x 10
6
) by murine microglia after 15, 30 and 60 min infection times. *P 
<0.05 compared to phagocytosis levels obtained with the wild-type strain. (B) Effect of 
opsonization on phagocytosis at 30 min post-infection. Bacteria were non-opsonized 
(no serum) or pre-opsonized with 20% of either normal or inactivated mouse serum. *P 
<0.05 compared to phagocytosis levels obtained with the wild-type strain and # P < 
0.05, indicates statistically significant differences between non-opsonized strains and 
their respective normal serum- or inactivated serum-opsonized counterparts. Numbers 
of internalized bacteria were determined by quantitative plating after 1 h of antibiotic 
treatment, and results are expressed as CFU recovered bacteria per ml (means ± SEM 
obtained from three independent experiments). WT, wild-type strain. CPS-, non-
encapsulated mutant. SLY-, suilysin-negative mutant.  
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FIG. 2. Interaction of murine microglial cells with S. suis. Microglia were infected with 
either S. suis wild-type (WT) strain (A) or the non-encapsulated (CPS-) mutant (B) for a 2 
h period. Cells were then washed, and bacteria were visualized with rabbit anti-S. suis 
serum and Alexa Fluor 488-conjugated goat anti-rabbit IgG (green), while 
phagolysosomes from BV-2 cells were evidenced with rat anti-LAMP1 antibody and 
Alexa Fluor 568-conjugated goat anti-rat IgG (red). The nuclei was stained with DAPI 
(blue). Images were examined with a confocal laser scanning microscope.  
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FIG. 3. Comparative study of cytokine production. (A) TNF- α, (B) IL-1β, (C) IL-6, (D) 
MCP-1, (E) IP-10. Murine microglial cells were incubated with the different S. suis 
strains (1 x 10
6
). Culture supernatant were harvested at 12 h post-stimulation and 
analyzed for cytokine production by ELISA. Data are expressed as mean ± s.d. (in pg/ml) 
from at least three independent experiments. n.i., non-infected cells. WT, wild-type 
strain. CPS-, non-encapsulated mutant. SLY-, suilysin-negative mutant. * P < 0.05, 
denotes significant differences with n.i. cells; # P < 0.05, denotes significant differences 
with WT S. suis strain.  
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FIG. 4. Increase of TLR2 mRNA expression in the murine microglia cell line BV-2 
following S. suis exposure. Microglia was stimulated for 1, 2, 4 and 8 h with 1× 10
6
 S. 
suis. Total RNA was isolated from microglia at the indicated time points and analyzed 
for TLR2 mRNA expression by real-time quantitative PCR as described in materials and 
methods. The levels of TLR2 gene expression following S. suis was calculated after 
normalizing cycle thresholds against the ‘housekeeping’ genes β-Actin and β2 
microglobulin (β2m) using the 2
–ΔΔCt
 method. The results are presented as fold-
induction value relative to non-infected microglia (mean ± SEM). *  P < 0.05 indicates 
significant differences between infected and non-infected cells. ** P < 0.001 indicates 
significant differences between microglia stimulated with S. suis wild-type (WT) versus 
cells infected with S. suis non-encapsulated (CPS-) mutant. Results are mean (± SEM) of 
three independent experiments. 
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FIG. 5. Time-course increase of nitric oxide production (A) and nitric oxide synthase 
(iNOS) expression (B) by murine microglial cells treated with S. suis. Heat killed S. suis 
wild-type (WT) or non-encapsulated (CPS-) strains (1 ×10
9
) were incubated with 
microglia for 6, 12, 24 and 48 h.  (A) Microglia supernatants were collected to measure 
nitric oxide production by Griess reaction method. Data are expressed as the mean ± 
SEM (in µM/ml) of three independent experiments. *P <0.05 denotes significant 
differences versus WT S. suis.  n. i., non-infected cells. (B) Representative western blot 
analysis of murine microglia extracts using an iNOS-specific antibody. Blotting with anti-
α-actin antibody was used as loading control. 
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FIG. 6. S. suis induced levels of (A) tyrosine (p-Tyr) and (B) serine phosphorylation (p-
PKC). Murine microglia BV-2 was infected for 15, 30 min, 1, 2 or 4 h with either the 
wild-type (WT) strain or its non-encapsulated (CPS-) mutant (1 x 10
6
). Cell lysates (total 
proteins) from non-infected (n.i.) cells  and infected cells were subjected to Western 
blot. p-Tyr and p-PKC protein levels were revealed by using anti-p-Tyr (clone 4G10) or 
anti-p-PKC monoclonal antibodies, respectively. The results are representative of three 
individual experiments. 
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FIG. 7. Time course phosphorylation of MAPKs in BV-2 microglia. Cells were infected 
with either S. suis wild-type (WT) strain or its non-encapsulated (CPS-) mutant (1 x 10
6
). 
Cell extracts were recovered at 15, 30 min, 1, 2 and 4 h post-incubation and were 
subjected to western blot analysis by using antibodies specific for phospho-MAPKs (p-
ERK, p-JNK and p-p38). Following analysis, blots were stripped and reprobed with an 
antibody specific for ERK, JNK or p38 to verify uniformity in gel loading. Results are 
representative of three independent experiments. n. i., non-infected cells.  
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FIG. 8. Pharmacologic inhibition of MAPKs. Murine microglial cells were treated with 
various inhibitors 1 h prior to infection with S. suis wild-type (WT) strain or its non-
encapsulated (CPS-) mutant (1 × 10
6
).  Apigenin (50 µM), SP600125 (50 µM) and 
SB203580 (75 µM) inhibit ERK 1/2, JNK and p38, respectively. Inhibitors were all used at 
maximal subcytotoxic dosis for a total of 13 h. (A) To confirm inhibition of MAPK 
phosphorylation, cells extracts were recovered after 2 h (p-ERK, p-JNK) or 4 h (p-p38) of 
bacteria-cell contact, and then analyzed by western blot using specific antibodies for 
each one of the proteins tested. Results are representative of three independent 
experiments. To evidence inhibition in cytokine production, cells were infected for 12 h 
and supernatant recovered for detection of (B) TNF-α and (C) MCP-1 production by 
ELISA.  Data are expressed as mean ± SEM (in pg/ml) from three independent 
experiments. n.i., non-infected cells. * P <0.05, denotes significant differences with 
cells treated with MAPK inhibitors.  
 
 
 
FIG. 9. S. suis activates nuclear factor NF-κB in BV-2 microglia cells.  Cells were infected 
with either S. suis wild-type (WT) strain or its non-encapsulated (CPS-) mutant (1 x 
10
6
).for 0.5 to 12 h. Non-infected (n.i.) cells were used as negative controls. LPS (1 
µg/ml) served as positive control. Cells were lysed and nuclear extracts were submitted 
to an electrophoretic mobility shift assay (EMSA). The presence of NF-κB-activated 
proteins in the cell nuclei was demonstrated by binding to oligonucleotide probes 
containing a single copy of the NF-κB-motif 5'-AGT-TGA-GGG-GAC-TTT-CCC-AGG-C-3' 
end labelled with γ-
32
P ATP. Binding reactions were electrophorezed on native 4% 
polyacrylamide gels to separate bound and unbound DNA probe. sp, specific probe. 
nsp, non-specific probe. 
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ABSTRACT 
Streptococcus suis is an important swine and human pathogen. Assessment of 
susceptibility to S .suis using animal models has been limited to monitoring mortality 
rates. We recently developed a hematogenous model of S. suis infection in adult CD1 
outbred mice to study the in vivo development of an early septic shock-like syndrome 
that leads to death and a late phase that clearly induces CNS damage, including 
meningitis. In the present study, we compared the severity of septic shock-like 
syndrome caused by S. suis between adult C57BL/6 (B6) and A/J inbred mice. Clinical 
parameters, pro-inflammatory mediators and bacterial clearance were measured to 
dissect potential immune factors associated with genetic susceptibility to S. suis 
infection. Results showed that A/J mice were significantly more susceptible than B6 
mice to S. suis infection, especially during the acute septic phase of infection (100% of 
A/J and 16% of B6 mice died before 24 h post-infection). The greater susceptibility of 
A/J mice was associated with an exaggerated inflammatory response, as indicated by 
their higher production of TNF-α, IL-12 p40/p70, IFN-γ and IL-1β, but not with different 
bacterial loads in the blood. In addition, IL-10 was shown to be responsible, at least in 
part, for the higher survival in B6 mice. Our findings demonstrate that A/J mice are very 
susceptible to S. suis infection and provide evidence that the balance between pro and 
anti-inflammatory mediators is crucial for host survival during the septic phase. 
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INTRODUCTION 
Streptococcus suis is one of the most important pathogens affecting the swine 
industry. This pathogen not only causes septicemia but also affects the central nervous 
system (CNS) and other tissues, leading to meningitis, endocarditis, pneumonia and 
arthritis. Although 35 serotypes have been described so far, serotype 2 is still the most 
frequently isolated from diseased animals (20). The ability of S. suis to cause disease is 
not limited to pigs. In humans, the organism is responsible for cases of septicemia with 
septic shock, meningitis, endocarditis and other pathologies (2). Human S. suis 
infections are reported mainly in people with occupational exposure to infected pigs or 
raw pork products, and latest serious outbreaks in Asia have led to critical recognition 
of S. suis as an emerging agent of zoonosis. The most recent outbreak in China resulted 
in more than 200 human cases which were characterized by an unusual clinical 
presentation of toxic shock-like syndrome with an increased death rate as high as 20% 
(50). In Vietnam, S. suis is by far the most common cause of adult meningitis (31). 
The pathogenesis of infection is poorly understood. To induce clinical disease in 
swine, it is believed that S. suis enters through the respiratory route to colonize the 
tonsils. In humans, however, the entrance is mainly through skin abrasions, although 
other routes of infections have also been proposed (3, 16). Thereafter, by mechanisms 
presently not well understood, it reaches the bloodstream, where it disseminates freely 
or as cell-bound bacteria attached to phagocytes (15) and causes bacteremia that can, 
in some cases, lead to fatal septicemia. If the host survives this critical phase of 
infection, S. suis may colonize the CNS and cause meningitis. Our knowledge of the 
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bacterial components involved in the pathogenesis of S. suis infection is also limited. 
These components include the antiphagocytic polysaccharide capsule, a hemolysin 
known as suilysin, different cell-wall associated and extracellular proteins, including 
enzymes (15, 20, 38). The wide distribution of these factors among strains isolated 
either from asymptomatic or clinically ill animals suggests that pathogenesis of S. suis is 
multi-factorial. 
 Clinical septicemia with septic shock and meningitis may be related to an 
exacerbated or uncontrolled inflammatory response that is also, in the case of 
meningtis, accompanied by an increase in the permeability of the blood-brain barrier 
(BBB) (15). For example, S. suis is able to up-regulate different adhesion molecules 
expressed by monocytes, thereby increasing leukocyte recruitment to sites of infection 
and providing a boost to the inflammatory response (1). In addition, it induces the 
production of different pro-inflammatory cytokines and chemokines by human, mouse 
and swine leukocytes and by human and swine brain microvascular endothelial cells 
(BMECs) (39-41, 46). It was reported only recently that human and murine 
monocytes/macrophages recognize whole S. suis or its purified cell wall components 
mainly through a Toll-like receptor (TLR)-2-dependent pathway, with the possible 
participation of CD14. This recognition was associated with a triggering of the 
inflammatory response via a MyD88-dependent downstream signaling pathway and 
subsequent production of pro-inflammatory cytokines and chemokines (17, 40).   
Assessment of the susceptibility to S. suis infection in experimental animal 
models has been limited to the evaluation of overall mortality (4, 23, 49). Recently, our 
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laboratory developed a hematogenous model of S. suis infection in adult CD1 outbred 
mice to study the in vivo development of an early septic shock-like syndrome that 
causes high mortality and a late phase that clearly induces CNS damage, including 
meningitis (11). We observed that during the septic phase of infection, S. suis induces a 
Th1 response that is characterized by an up-regulation of key pro-inflammatory 
cytokines, such as TNF-α, IL-1β, IL-12 (p40/p70), IL-6, IFN-γ, as well as chemokines 
including CCL2 (MCP-1), CXCL1 (KC) and CCL5 (RANTES). We postulate that these 
inflammatory mediators are responsible for exacerbating the inflammation and for high 
host mortality occuring during the septic phase of infection. In mice that develop 
clinical meningitis, S. suis is also able to trigger the expression of pro-inflammatory 
genes in the brain, including TLR2, TLR3, CD14, IκBα  (an index of NFκB expression), IL-
1β, TNF-α, and MCP-1 (11).  
Development of a suitable animal model enabling researches not only to assess 
mortality caused by S. suis infection, but also to gain new insights into host immune 
responses to infection with Gram positive bacteria might allow to delineate factors 
modulating host susceptibility to disease.  The aim of this study was to compare the 
severity of septic shock-like syndrome in adult C57BL/6 versus A/J inbred mice. We 
measured sepsis-related clinical parameters, pro and anti-inflammatory mediators and 
bacterial clearance to dissect potential immune factors associated with genetic 
susceptibility to S. suis infection. 
MATERIALS AND METHODS  
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Bacterial strain and growth conditions. S. suis serotype 2 strain 31533 was used 
for all experimental infections. This encapsulated, suilysin-positive virulent strain has 
been used largely in cell stimulation studies (39-41) as well as for experimental 
infections in mice and swine (11, 26). Bacteria were grown overnight on sheep blood 
agar plates at 37°C and isolated colonies were inoculated into 5 ml of Todd-Hewitt 
broth (THB) (Difco laboratories, Detroit, MI, USA), which was incubated for 8 h at 37°C 
with agitation. Working cultures were prepared by transferring 10 μl of 1/1000 
dilutions of 8 h-cultures into 30 ml of THB which was incubated for 16 h at 37°C with 
agitation. Stationary-phase bacteria were washed twice in PBS (pH 7.3). The bacterial 
pellet was then resuspended and adjusted to a concentration of 5 × 10
8
 CFU/ml. The 
inoculum for experimental infection was diluted in THB to obtain a final concentration 
of 1 × 10
7
 CFU/ml. This final suspension was plated onto blood agar to accurately 
determine the CFU/ml.  
 
Mice and experimental infections. Female 6 to 8-week-old C57BL/6J (B6) or A/J 
mice (Jackson Laboratory, Bar Harbor, ME, USA) were acclimatized to standard 
laboratory conditions of 12-h light/12-h dark cycle with free access to rodent chow and 
water. All experiments involving mice were conducted in accordance with the 
guidelines and policies of the Canadian Council on Animal Care and the principles set 
forth in the Guide for the Care and Use of Laboratory Animals, and approved by the 
Animal Welfare Committee of the Université de Montréal. On the day of the 
experiment, a 1 ml volume of either the bacterial suspension (1 × 10
7
 CFU/ml) or the 
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vehicle solution (sterile THB) was administrated by intraperitoneal injection (i.p.). Two 
independent preliminary trials were performed to establish the optimal bacterial dose 
and time points (data not shown). 
 
Study of mortality and clinical signs. A total of 19 mice per mouse strain were 
closely monitored daily to record mortality and clinical signs of disease, such as 
depression, rough appearance of hair coat and swollen eyes (11). Weight loss 
associated with infection was also recorded daily. Mice exhibiting extreme lethargy 
were considered moribund and were humanely euthanized.  
 
Histopathology studies. For histopathological examination, samples of the 
brain, heart, liver and spleen were fixed in 10% buffered formalin. After paraffin 
embedding, 4 μm wide tissue sections were stained with hematoxylin-eosin according 
to standard protocol and examined under light microscopy. 
 
Study of the systemic inflammatory response. A total of 38 B6 and 36 A/J mice 
were assessed for bacteriology and systemic levels of inflammatory mediators. Samples 
were taken at 3, 6, 12, 24, 36, 48 and 72 h post infection (p.i.) and analyzed as 
described below. 
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Determination of viable bacteria in organs. At each time point, at least 3 
infected and 2 non-infected mice per mouse strain were euthanized with CO2 and 
sampled. Blood was collected by cardiac puncture, and the brain, liver and spleen were 
obtained aseptically. The organs (0.05 g/organ) were trimmed, placed in 500 μl of PBS 
(pH 7.3), and homogenized with a vortex. Then, 50 μl of serial dilutions of the 
homogenate in PBS was plated onto blood agar plates. Blood samples (50 μl) were also 
processed. All samples were plated using an Autoplate 4000 Automated Spiral Plater 
(Spiral Biotech, Inc., Norwood, MA). Blood agar plates were incubated overnight at 
37°C. Colonies were counted and expressed as CFU/0.05g for organ samples or CFU/ml 
for blood samples.  
 
Plasma collection and measurement of cytokines and chemokines. Blood from 
CO2-anesthetized mice was collected by cardiac puncture into heparinized tubes and 
centrifuged at 10,000 × g for 10 min to obtain plasma. Samples were preserved at -80°C 
until analysis. Levels of IL-1β, IL-6, IL-10, IL-12 (p40/p70), TNF-α, IFN-γ, CCL2 (MCP-1), 
CXCL1 (KC) and CCL5 (RANTES) in plasma were determined using a liquid multiarray 
system (Luminex Co., Austin, TX, USA). Commercial Multiplex-coated beads, 
biotinylated antibodies and 96-well filter plates were obtained from Upstate Group, 
Inc. (Lake Placid, NY, USA). Each multiplex assay was performed in duplicate following 
the manufacturer’s specifications. Data were collected using the Luminex-100 system 
Version IS 2.2 and analyzed by MasterPlex Quantitation Software (MiraiBio, Inc., 
Alamada, CA, USA). Standard curves for each cytokine and chemokine were obtained 
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using the reference cytokine and chemokine concentrations supplied by the 
manufacturer.  
Treatment of mice with antibodies or recombinant proteins. The importance 
of IL-10 for the survival of mice to S. suis infection was determined using two separate 
approaches. In the first approach, neutralization of IL-10 in B6 mice was performed via 
a single i.p. injection of 1 mg/ml of rat anti-murine IL-10 receptor (IL-10R) monoclonal 
antibody (mAb) 1B1.3a. The anti-IL-10R mAb was administrated into 10 B6 mice 1 h 
before infection with S. suis. The control group, which consisted of 6 B6 mice, received 
1 ml of pyrogen-free saline containing an equivalent quantity of normal rat serum IgG 
(Jackson ImmunoResearch, West Grove, PA, USA). In the second approach, the role of 
IL-10 in modulating the survival of A/J mice to S. suis infection was tested by i.p. 
administration of recombinant mouse (rm) IL-10 (R&D Systems, Minneapolis, MN) in 10 
A/J mice. At different times relative to the infection, each mouse received a cumulative 
dose of 2.6 μg rmIL-10 diluted in 300 μl of pyrogen- free saline. The control group of 10 
A/J mice received vehicle alone. Injection doses of rmIL-10 or mAb 1B1.3a were 
selected based on previous publications (5, 7, 8, 21, 25).  
Statistical analyses. Overall survival for the different treatment groups were 
described using Kaplan-Meier plots. Survival curves were compared using the log-rank 
test. Values for bacterial loads in different tissues as well as serum cytokine levels 
between A/J and B6 mice were compared using the Mann-Whitney test. A P < 0.05 was 
considered as statistically significant. All analyses were performed using the Sigma Plot 
System (v.9; Systat Software, San Jose, CA). 
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RESULTS 
C57BL/6 and A/J mouse strains show important differences in their clinical 
susceptibility to S. suis infection. The inbred mouse strains A/J and B6 showed 
significant differences in clinical behavior and mortality after i.p. infection with S. suis. 
In A/J mice, clinical signs related to infection were observed at 2 h p.i., which quickly 
worsened and resulted in a mortality rate of 84% at 12 h p.i. and then 100% at 20 h p.i. 
(Fig. 1). Based on the clinical profile and progression, all deaths were considered 
related to septicemia. This was confirmed by bacteriological isolation of S. suis in 
different tissues (see below). S. suis infection in B6 mice had a slower and different 
pattern of progression, with subtle clinical signs of acute disease appearing at 8 h p.i. 
B6 mice showed higher survival compared with A/J mice; at 24 h p.i., only 16% of B6 
mice died due to septicemia (Fig. 1). Interestingly, from day 3 p.i. onward, 44% of 
surviving B6 mice developed sudden neurological signs, such as recumbence, difficult 
mobility and rear limbs weakness. Furthermore, 57% of B6 mice which showed 
neurological signs also presented unexpected clinical signs suggestive of cardiac 
distress. S. suis was isolated from different organs of all mice that died from the 
infection. Weight loss was another clinical characteristic observed in B6 mice infected 
with S. suis. At day 3 p.i., 69% of surviving B6 mice had suffered important weight loss 
of between 21 and 40% of their initial body weight. However, at day 15 p.i., the 
remainder of the surviving mice had recovered their initial body weight. 
No histopathological lesions were observed in the different tissues isolated from 
A/J and B6 mice that died during the first 48 h p.i. However, in B6 mice which died at 
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day 3 p.i. or later, histopathological studies confirmed that the neurological signs were 
consistent with encephalitis and meningitis, while clinical signs of cardiac distress 
suggested endocarditis. The main histopathological findings in the brain of mice with 
clinical signs of neurological disease were the presence of foci of malacia, hemorrhages 
and gliosis (Fig. 2A). S. suis was observed as bacterial emboli contained inside blood 
vessels with thickened walls due to neutrophil infiltration (Fig. 2B). A severe infiltration 
of the meninges mainly with macrophages and lymphocytes, as well as fibrin, was also 
observed (Fig. 2C). Endocarditis was diagnosed on the basis of partial occlusion of the 
atrio-ventricular right valves by thrombi formed by fibrin, a mix of inflammatory cells, 
cellular debris and bacteria (Fig. 2D).  
 
S. suis is present in different tissues. Intraperitoneal infection with S. suis in 
both A/J and B6 induced sustained bacteremia, as demonstrated by the recovery of 
bacteria from infected mice at different p.i. time points. A/J mice had high and 
sustained bacterial loads in the blood, liver and spleen, with more than 1 × 10
8
 CFU per 
ml or organ at 3 to 12 h p.i. (Fig. 3A-C). Interestingly, the number of S. suis recovered 
from the brain was lower compared with other organs although it increased with time 
from 5 × 10
4
 CFU/organ at 3 h p.i. to 8 × 10
5 
CFU/organ at 12 h p.i. (Fig. 3D). No data 
could be obtained at later times in this mouse strain because 100% of A/J mice died 
within 20 h p.i. Similar to A/J mice, B6 mice showed bacterial loads in the blood of 
above 1 × 10
8
 CFU/ml and these loads remained constant up to 48 h p.i. Bacterial loads 
remained elevated at 72 h p.i. (~1 × 10
5 
CFU/ml), demonstrating the ability of virulent S. 
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suis to survive successfully in the bloodstream (Fig. 3A). Likewise, bacterial loads were 
high in the liver and spleen of infected B6 mice, with more than 1 × 10
7
 CFU/organ 
during the first 36 h p.i. (Fig. 3B and 3C).  Similar to A/J mice, S. suis was found in lower 
numbers in the brain; however, in these mice, the presence of the pathogen was 
sustained throughout the experiment, with 1 × 10
4
 to ~1 ×
 
10
5
 CFU/organ at 72 h p.i. 
(Fig. 3D). There were no statistical differences in site-specific bacterial loads between 
the A/J and B6 mouse strains at any of the time points tested  throughout the 
experiment (P > 0.05). 
 
Profile of the inflammatory response induced by S. suis differs remarkably 
between A/J and C57BL/6 mice. There were important differences in the kinetics of 
cytokine and chemokine production between the two mouse strains in response to 
infection with S. suis. The inflammatory response in A/J mice could be determined only 
during the first 12 h p.i. given that, as discussed earlier, all A/J mice died within 20 h 
after S. suis infection. Indeed, in A/J compared with B6 mice, S. suis infection induced a 
rapid systemic production of diverse pro-inflammatory cytokines. There were notable 
differences in the kinetics of cytokine production, namely for TNF-α, IL-12 (p40/p70), 
IFN-γ and IL-1β, between the two mouse strains. A significant difference in TNF-α 
secretion between the mouse strains were found at 6 h p.i. (P = 0.018). In A/J mice, 
TNF-α, one of the most important mediators of septic shock, increased rapidly, peaked 
at 6 h and was still elevated at 12 h p.i. (Fig. 4A). In B/6 mice, TNF-α increased more 
slowly, peaking at 12 h p.i. and then declining to basal levels at 24 h p.i. (Fig. 4A). This 
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rapid and important upregulation of TNF-α in plasma of S. suis-infected A/J mice may 
be related to the early development of clinical signs resembling septic shock and 
associated death in these mice. A/J mice also presented a rapid and high increase in IL-
12p40 production compared to the modest induction of IL-12p40 observed in B6 mice 
(P = 0.024 at 6 h p.i.) (Fig. 4B). Levels of bioactive IL-12p70, a key cytokine bridging 
innate and adaptive immunity and IFN-γ, a critical marker of sepsis, were significantly 
higher in A/J mice than in B6 mice  (Fig. 4C and 4D). Production of IL-1β was lower than 
that of other cytokines, although a significant and sustained expression was observed 
in A/J compared with B6 mice at 6 h and 12 h p.i. (P = 0.002 and 0.023, respectively) 
(Fig. 4E). Interestingly, the expression of IL-6, another classical indicator of sepsis, was 
elevated and sustained in both mouse strains, without any significant difference. (P > 
0.05) (Fig. 4F).   
Concerning the chemokines, expression of KC, an important neutrophil 
chemoattractant, was rapidly induced, appearing as early as 3 h p.i., similarly in both 
mouse strains (P > 0.05) (Fig. 5A). Very little or no KC expression was detected in A/J 
mice after 12 h p.i, whereas in B6 mice S. suis-induced KC production started to 
decrease only at 36 h p.i. (Fig. 5A). High levels of MCP-1, a molecule with monocyte 
chemoattractant properties, were observed in both infected mouse strains which 
showed no significant differences (P > 0.05) (Fig. 5B). Similar to KC and MCP-1, the 
kinetics of RANTES expression were comparable between the two mouse strains 
although the levels detected were relatively modest (P > 0.05).  
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IL-10 plays an important role in controlling the severity of S. suis-induced 
septic infection. As described above, A/J mice showed an exacerbated inflammatory 
systemic response to S. suis infection and, to some extent, were also unable to mount 
an appropriate anti-inflammatory response. As shown in Fig. 6A, A/J mice secreted 
relatively low amounts of IL-10, with a highest mean level of 620 pg/ml detected at 12 
h p.i. In contrast, B6 mice were able to secrete significantly higher and more sustained 
levels of IL-10 from 12 h to 36 h p.i., with a mean production peak of 2,610 pg/ml at 12 
h p.i. (P = 0.014 vs. A/J mice) (Fig. 6A). We used two different approaches to elucidate 
the potential role of IL-10 in mediating host protection against lethal S. suis infection. 
First, systemic IL-10R was blocked in B6 mice to assess whether interference with the 
IL-10 pathway would increase susceptibility to infection and exacerbate mortality. 
During the first 12 h p.i., B6 mice treated with an anti-IL-10R mAb or vehicle control 
both showed similar clinical signs such as rough hair coat, depression and recumbence. 
However, the severity of disease increased with time only in the group which received 
the anti-IL-10R mAb. Indeed, during the course of the septic phase of disease, B6 mice 
treated with the anti-IL-10 mAb had significantly higher mortality than the control mice 
(P = 0.012). Of the B6 mice treated with anti-IL-10 mAb, 50% died at 20 h p.i. and 90% 
at 24 h p.i. (Fig. 6B). In contrast, only 17% of control mice died at 30 h p.i. and 50% at 
72 h p.i. (Fig. 6B). Overall, the survival curves during the first 24 h p.i. were comparable 
between A/J mice (Fig. 1) and B6 mice treated with anti- IL-10R mAb (Fig. 6B). 
Confirming the protective role of IL-10, Fig. 7 shows that anti-IL-10R mAb-treated B6 
mice produced significantly higher levels of TNF-α 24 h p.i. compared to non-treated B6 
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mice. Interestingly, levels of TNF-α in treated B6 mice were similar to those observed in 
A/J mice (Fig. 4A). 
In the second approach, we investigated whether administration of rmIL-10 to 
A/J mice would enhance their survival after S. suis infection. To this end, A/J mice 
received 1 μg of rmIL-10 1 h before and 3 h after i.p. infection with S. suis and a final 
dose of 0.6 μg at 24 h p.i. We observed striking differences in mortality between A/J 
mice treated with rmIL-10 and non-treated controls; at 20 h p.i., only 10% of the 
treated mice died compared with 80% of the non-treated controls (P < 0.001). At 36 h 
p.i., 100% of the non-treated controls succumbed to their infection (Fig. 6C), as 
reported above (Fig. 1), compared with 40% of the treated mice. Although the 
administration of rmIL-10 significantly prolonged the survival of infected A/J mice, it did 
not confer complete protection against S. suis, as 70% of rmIL-10-treated A/J mice died 
at 48 h p.i.  
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DISCUSSION 
S. suis is one of the most important causative agents of septicemia, septic shock 
and meningitis in pigs as well as in humans (20, 33). Most of past research on the 
activation of the innate immune response by S. suis has been conducted using in vitro 
models of infection. However, animal models are essential to achieve a better 
understanding of the activation and development of host immune responses to this 
important pathogen. Although in some diseases mouse models do not reflect the 
disease outcome in the natural host, we have recently shown for the first time that an 
adult mouse model for S. suis using i.p. route of infection in CD1 mice clearly reproduce 
clinical signs and lesions observed in swine (11). Kataoka et al, also showed that clinical 
signs, disease outcome and lesions in mouse models were similar to those in 
experimentally infected pigs using the same virulent and avirulent bacterial strains. In 
that study, authors observed differences in susceptibility among several mouse strains 
and suggested that differences in genetic background or immune responses might 
explain these discrepancies. However, no further analyses were carried out (23). In this 
study, we compared the susceptibility of two genetically different inbred mouse 
strains, A/J and B6, to S. suis infection. These mouse strains have been used frequently 
to investigate the genetic control of host immunity to infectious pathogens. Previous 
studies using these mouse strains have focused mainly on sepsis induced by endotoxin 
(LPS) challenge, cecal ligation and puncture (CLP) and systemic candidiasis (28, 30, 34, 
42, 44, 45). Study of genetic factors underlying susceptibility to systemic streptococcal 
infection has been limited mainly to Streptococcus pneumoniae and Group A 
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Streptococci (GAS, Streptococcus pyogenes) (13, 14, 22, 24, 28), and most of these 
studies evaluated only mortality and bacterial load in different tissues. To our 
knowledge, no studies describing host susceptibility and inflammatory response to S. 
suis infection have been published to date. 
In a previous study from our laboratory, S. suis showed intermediate virulence 
in outbred CD1 mice (11). Based on clinical behavior and mortality, the present study 
clearly demonstrated that A/J mice are significantly more susceptible to S. suis 
infection than B6 mice, especially during the acute septic phase of infection. Indeed, 
the susceptibility of B6 mice to S. suis infection shown in this study, is comparable to 
that previously observed in CD1 mice. These results are in agreement with studies of C. 
albicans or GAS infection (14, 30) to which A/J mice are highly susceptible while B6 
mice show intermediate susceptibility. Nevertheless, overall mortality to GAS infection 
is similar between B6 and A/J mice, although it is delayed for 48 h in B6 mice (28).  
Interestingly, these results differ from studies of LPS and cecal ligation and single 
puncture (CLP) in which A/J mice were considerably more tolerant than B6 mice (42). 
B6 mice show either high or intermediate susceptibility to infection with S pneumoniae, 
depending on the serotype used (29). Therefore, the genetic susceptibility of the 
mouse strain may vary depending on the pathogen encountered or injury received.  
Consistent with previous studies, mortality in both A/J and B6 mice during the 
first 48 h after S. suis infection can be attributed to a septic shock-like condition in 
which there is uncontrolled bacteremia and/or an exacerbated production of pro-
inflammatory cytokines and chemokines (30, 45). In the present study, the number of 
199 
 
 
CFUs in the blood, liver, spleen and brain were not significantly different between the 
mouse strains, arguing against the possibility that the higher mortality in S. suis-
infected A/J mice was due to uncontrolled bacteremia. Compared with B6 mice, A/J 
mice are known to carry a loss-of-function mutation in the structural gene of the C5 
component of the complement pathway (32, 35). In a model of C. albicans infection, 
there was no conclusive evidence that this deficiency is responsible for the higher 
fungal replication in the kidney of A/J versus B6 mice (30, 45) and direct fungicidal 
activity by complement could not be demonstrated (30). Similarly, complement alone, 
in the absence of specific antibodies, does not contribute to phagocytosis and killing of 
S. suis by monocytes and neutrophils (6). If the complement were essential for 
bactericidal activity against  S. suis, higher bacterial load would have been expected in 
A/J than B6 mice, whereas this study demonstrated no significant differences in the 
bacteria load between the two strains.  
Although a deficiency of complement might not modulate bacterial clearance, 
some studies suggests that it may play a role in the dysregulated cytokine response 
observed in A/J mice (30). Accordingly, the high mortality of A/J mice after S. suis 
infection might be caused by an uncontrolled release of pro-inflammatory cytokines. 
This hypothesis is supported by the lack of specific histopathological findings in A/J (as 
well as B6) mice which had succumbed to infection within the first 48 h p.i. Different 
cytokines released early after infection are thought to play opposing roles: pro-
inflammatory cytokines are necessary to control infection, although excessive or 
uncontrolled responses may disturb homeostasis and lead to increased disease severity 
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and mortality (47). In the present study, we observed that A/J mice had significantly 
higher production of TNF-α, IL-12p40, IL-12p70, IFN-γ and IL-1β compared with B6 
mice, particularly during the first 6 to 12 h p.i. Production of TNF-α, one of the most 
important acute phase cytokines and a reliable indicator of septic shock in both Gram 
positive and negative bacterial infections (9, 43), was comparable between B6 (this 
study) and CD1 mice (11). On the other hand, A/J mice produced twice as much TNF-α 
as B6 or CD1 mice did. Likewise, A/J mice produced 3 to 19-fold higher levels of IL-
12p40, IL-12p70 and IFN-γ than did B6 (this study) or CD1 mice (11). As previously 
observed in CD1 mice, the release of IL-12p40 preceded that of IL-12p70 following S. 
suis infection (11). In A/J mice, increased IL-12 expression may have been associated 
with induction of high levels of IFN-γ, a cytokine known for its potent ability to activate 
macrophages and enhance TNF-α synthesis, thereby exacerbating mortality as 
previously reported (18, 19). A/J mice had relatively low levels of IL-1 β, as previously 
reported in CD1 mice (11), but these levels were consistently higher than those in B6 
mice and might be sufficient to exert a biological effect. Both A/J and B6 mice produced 
high levels of IL-6 but to a lesser extent than did CD1 mice (11). Interestingly, there 
were no significant differences in any of the three chemokines measured, KC, MCP-1 
and RANTES, between both mouse strains at all time points. The levels of chemokines 
observed here were nearly identical to those reported in CD1 mice (11). Since both A/J 
an B6 mice infected with S. suis had secreted similar levels of these chemokines, the 
difference in mortality observed between the two strains makes these chemokines to 
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be unlikely candidates contributing to the difference in the development of septic 
shock-like syndrome after S. suis infection between the two mouse strains. 
In previous studies of sepsis in mice, a massive secretion of inflammatory 
mediators was postulated as a likely cause of severe disease and mortality (37). 
Available data with S. suis also suggest that this may be the case in both, swine and 
humans. We have demonstrated that S. suis stimulated swine cells in a whole cell blood 
system to induce high levels of pro-inflammatory cytokines (41). In addition, we have 
recently shown that pigs experimentally infected with virulent S. suis show high levels 
of IL-6 and IL-8 (G. Vanier, et al, presented at the First Symposium of the Centre de 
recherché en infectiologie porcine, Saint-Hyacinthe, QC, Canada, 28-29 May 2007). In 
humans, S. suis is able to induce the release of pro-inflammatory cytokines from brain 
microvascular endothelial cells (46), and cytokine levels in humans with streptococcal 
toxic shock-like syndrome due to S. suis infection were extremely high and shown to be 
identical to those observed in  C57BL/6 mice experimentally infected with the same 
strain that cause the Chinese outbreak (C. Ye, H. Zheng, J. Zhang, H. Jing, L. Wang, Y. 
Xiong, W. Wang, Q. Sun, X. Luo, H. Du , M. Gottschalk, and J. Xu, submitted for 
publication). Thus, levels of cytokines are a prognosis of human disease severity too.  
Differential survival of genetically different mouse strains after infection with 
invading pathogens has been linked to the ability to control this exacerbated pro-
inflammatory cytokine production. As such, Råberg et al. defined “resistance” as the 
manner in which a host can limit pathogen burden, whereas “tolerance” is defined by 
the manner in which the host can limit the damage done by a given pathogen burden 
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(36). The data presented here indicate that the two mice strains have similar loads 
throughout the first 12 hours after which all A/J mice succumb to infection. This 
indicates that at least over the first 12 hours, while both mice strains experience the 
same pathogen load, B6 mice are able to limit the induced damage and thus seem 
more tolerant. Indeed, the higher survival of B6 mice during the septic phase might be 
related to their ability to mount a competent anti-inflammatory response, as 
demonstrated by the high and sustained production of IL-10 from 12 h to 36 p.i. Similar 
results in CD1 mice were previously reported (11). Other studies have also 
demonstrated the importance of IL-10 for controlling cytokine production (10, 12) and 
for survival of mice to septic shock (48). Indeed, high mortality in IL-10 gene knock-out 
mice is associated with elevated circulating TNF-α levels, and more importantly, early 
treatment with rIL-10 delays the onset of irreversible shock (27). In the present study, 
we demonstrated that early systemic blocking of the IL-10R in B6 mice is detrimental 
for host survival to the septic phase of S. suis infection as anti-IL-10R mAb treatment 
before S. suis infection resulted in 90% mortality in B6 mice as early as 24 h p.i. with 
concomitant and dramatic increase in TNF- levels. S. suis-infected A/J mice, on the 
other hand, showed low and nearly undetectable IL-10 production. We hypothesized 
that the low IL-10 production might be partially responsible for the elevated levels of 
pro-inflammatory cytokines and the septic shock observed in these mice. In support of 
this concept, A/J mice treated with rmIL-10 showed 90% survival compared with 20% 
survival in non-treated mice.  
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Together these findings suggest that, in S. suis-infected mice, IL-10 plays an 
important role in the early control of sepsis-related inflammatory responses and 
consequently can improve host survival. Similar protection conferred by rIL-10 
treatment has been reported in mice after challenge with CPL, LPS, or GBS infection (8, 
21, 25). Interestingly, in agreement with these studies, rmIL-10 treatment delayed but 
did not abolish mortality due to S. suis in A/J mice, indicating that other 
immunoregulatory factors are also involved in controlling the inflammatory response 
and influencing long-term survival.   
Although B6 mice were more tolerant than A/J mice to the acute phase of 
infection, surviving B6 mice remained susceptible to developing S. suis-induced 
meningitis and endocarditis. These pathologies are similar to those described in S. suis-
infected swine, humans, as well as CD1 mice (2, 11, 20). The clinical neurological signs 
in S. suis-infected B6 mice were not as marked as those observed in CD1 mice (11). 
Nevertheless, our histopathological analysis confirmed neurological disease in the 
infected B6 mice. These findings raise the possibility that B6 mice are a potentially 
useful model for future studies of the pathogenesis of S. suis infection.  
Our findings show a clear susceptibility of A/J mice to S. suis infection and 
provide evidence that the balance between pro and anti-inflammatory mediators is 
crucial for survival during the septic phase. The different responses elicited in A/J 
versus B6 mice following systemic infection with S. suis warrant future studies using a 
genome-wide scan with F2 populations derived from both mouse strains.  
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ARTICLE II. FIGURES 
 
 
Fig.. 2. Relevant histopathological findings in C57BL/6 mice presenting clinical signs of 
neurological disease or sudden death (day 9 p.i.) after infection i.p. with S. suis. Hematoxilin-
eosin staining of brain and heart tissue samples was performed. (A) Micrograph of the brain 
parenchyma showing an area of malacia and hemorrhages (black arrows); magnification, ×100. 
Fig. 1. Survival curves of A/J 
and C57BL/6 (B6) mice after S. 
suis infection. Mice were 
injected i.p. with S. suis 
serotype 2 (1 × 10
7
 CFU/ml) 
and mortality recorded daily 
for 15 days. S. suis-infected A/J 
mice showed significantly 
greater mortality during the 
first 20 h p.i. compared with B6 
mice (P < 0.001). 
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(B) Micrograph of the brain cortex in which is evident the presence of a bacterial embolus (*) 
surrounded by neutrophils; magnification, ×400. (C) Micrograph of the meninges, which are 
severely and diffusely infiltrated by macrophages and other non-suppurative inflammatory cells 
(black arrows); magnification, ×100. (D) Micrograph of the heart at the atrioventricular valves 
with a thrombus occluding most of the valvular lumen (black arrows). The thrombus comprises 
fibrin, inflammatory cells and bacteria; magnification, ×200. 
 
 
Fig. 3. Bacterial loads in different organs from A/J and C57BL/6 mice infected i.p. with S. suis. 
Bacterial loads are expressed as CFU/ml for blood (A), and as CFU/0.05 g of tissue for the liver 
(B), spleen (C) and brain (D). Results are expressed as mean ± SEM of at least 3 infected mice 
per p.i. time point. No significant differences were found between the two mouse strains 
throughout the experiment (P > 0.05). 
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Fig. 4. Kinetics of the expression of inflammatory mediators in A/J and C57BL/6 mice infected 
i.p. with S. suis. (A) TNF-α, (B) IL-12p40, (C) IL-12p70, (D) IFN-γ, (E) IL-1β, and (F) IL-6. Cytokine 
concentration in sera was assayed by a liquid multiarray system (Luminex), as explained in the 
Materials and Methods. Data are expressed as mean ± SEM pg/ml. Values of uninfected 
controls did not show statistically significant changes from 3 h to 72 h. As such, time 0 h 
represents the mean (± SEM) results of non-infected mice through out the experiment. The 
asterisk (*) represents significant differences between mouse strains (P < 0.05).
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Fig. 5. Kinetics of serum chemokine expression in A/J and C57BL/6 mice infected i.p. with S. 
suis. (A) KC, (B) MCP-1, and (C) RANTES. Chemokine concentration was assayed by a liquid 
multiarray system (Luminex), as explained in the Materials and Methods. Data are expressed as 
mean ± SEM pg/ml. Time 0 h represents the mean (± SEM) results of non-infected mice through 
out the experiment.  
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Fig. 6. Role of IL-10 in the survival of 
A/J and B6 mice after S. suis infection. 
A) Kinetics of serum IL-10 production in 
A/J and C57BL/6 mice infected i.p. with 
S. suis. IL-10 concentration was assayed 
by a liquid multiarray system (Luminex), 
as explained in the Materials and 
Methods. Data are expressed as mean ± 
SEM pg/ml. Time 0 h represents the 
mean (± SEM) results of non-infected 
mice through out the experiment. The 
asterisk (*) represents significant 
differences between mouse strains (P 
<0.05). B) Survival of C57BL/6 mice 
treated with anti-IL-10R mAb (1 mg/ml) 
prior to challenge with S. suis. Blockage 
of IL-10R impedes the protective role of 
IL-10 and thus renders animals 
significantly more susceptible to S. suis 
infection. This is evidenced by a more 
rapid course of mortality in treated 
C57BL/6 mice compared with non-
treated controls (P = 0.012). C) Survival 
of A/J mice treated with rmIL-10 prior 
to challenge with S. suis. A/J mice were 
treated with rmIL-10 at different final 
concentrations and times relative to the 
infection. It is notable that rmIL-10 
treatment has a protective effect, 
significantly delaying mortality 
compared with that observed in the 
non-treated group (P < 0.001). 
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FIG. 7. Effect of blockage of IL-10R on cytokine production. C57BL/6 mice were treated with 
anti-IL-10R mAb (1 mg/ml) before i.p. infection with S. suis serotype 2 (1 × 107 CFU/ml). 
Serum samples were taken at 24 h p.i., and TNF-α levels measured by ELISA kit (R & D System). 
The asterisk (*) indicates significant differences between treated and non treated groups (P 
<0.001). Symbols represent values from individual mice while the horizontal lines indicate the 
median for each group.  
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IV. DISCUSSION 
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1. Validation of a mouse model of infection for the study of the pathogenesis of S. 
suis infection  
 As previously mentioned, the pig is the natural host of S. suis infection, and 
logically, it should be the best animal model. However, there are many obstacles at this 
respect. First, there is a lack of uniformity in experimental animals, as research has been 
carried out using pigs of different ages and with diverse genetic backgrounds, testing 
different inoculation routes or dose of inoculum, and considering different parameters to 
determine virulence. Second, many of the techniques and reagents necessary to identify 
host factors associated with the development of the infection and subsequent 
inflammation are not standardized for pig samples. Third, the use of the pig as animal 
model is limited due to handling of the animals, and the availability of facilities to carry out 
such experiments. To date, there is only one standardized pig model of S. suis infection, 
which requires the use of specific-pathogen-free (SPF) piglets, inoculated by the 
intravenous route, and kept in separated units, with filtered air-flow [133]. This model has 
been useful to determine virulence of field S. suis strains, and to measure different clinical 
signs, zootechnical performances, lesions, and bacteriological findings [133].  
 Mice may be an excellent alternative to carry out research on the pathogenesis of 
S. suis infection and to understand the mechanisms this pathogen uses to cause disease in 
pigs and humans. On one hand, as previously mentioned, the pig should be the first choice 
to develop an animal model for S. suis research, but unfortunately the lack of standardized 
models and availability of reagents limit its use. However, the mouse has been used to 
study the pathogenesis of some pig pathogens, including Pasteurella multocida 
(Progressive atrophic rhinitis) [468], Actinobacillus suis [469] and  Pseudorabies virus [470]. 
It is also widely accepted that mice are an excellent organism to understand human 
infectious diseases. Despite some differences, the immune systems of mice and humans 
are similar [427]. In addition, their physiological responses can be studied in an 
environment in which pathogen associated variables such as strain, virulence, dose, and 
route of infection can be carefully controlled. In addition, a wide variety of immunological 
and biochemical reagents in the form of assays, markers, and antibodies are available to 
characterize innate and adaptive immune responses in these infection models [471]. The 
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mouse has been widely used in the study of the pathogenesis of infections due to many 
meningitis- and sepsis-causing bacteria, including S. pneumoniae [432], L. monocytogenes 
[435], H. influenzae [443], N. meningitidis [444], and Group B Streptococcus (GBS) [472], 
among others.  
  In meningitis models of infection using adult mice, they are typically infected with 
live microorganisms by the intracisternal, intracerabral or intracranial routes of infection 
[296, 432, 440], which are traumatic, require anesthesia and special handling of the animal. 
In addition, these models bypass several steps, such as bacterial dissemination
 
and 
increased permeability of the blood-brain barrier (BBB), which is the natural
 
portal of entry 
into the CNS for most meningeal pathogens. In contrast,
 
challenge of adult animals using 
the intravenous or intraperitoneal routes, usually results in bacteremia and septicemia, 
leading sometimes to rapid
 
death of infected animals with modest, if any, brain pathology 
[432, 445]. In the case of infant animals are used, results are highly influenced by the route 
of infection chosen and mice strain selected [447, 448].  
 Although many researchers have used the mouse as model of infection to study S. 
suis infections, they have mainly evaluated overall mortality [473, 474]. In
 
the present 
research, we successfully developed a mouse model of S. suis infection
 
using the 
intraperitoneal route of infection, which better represents the natural course of infection 
(Articles I and III). With this model, we were able to study the two phases of S. suis 
infection, characterized by an early septic shock-like
 
syndrome leading to death and a 
second late phase that induces
 
evident CNS damage and clear clinical signs of neurologic 
disease. The use of this model allowed us to have a more detailed picture of the 
development of events leading to inflammation (systemic and the CNS), we were able to 
analyze the expression (at both mRNA and protein levels) of relevant pro-inflammatory 
mediators, and we studied the clinical progress of infection and development of sepsis and 
meningitis. It also served to study possible genetic host factors that may influence the 
progress of the disease (Article II). Furthermore, the CD1 model allowed us to compare the 
virulence of several strains deficient in putative S. suis virulence factors that may facilitate 
the development of inflammation and invasion of tissues  (Annex, articles V to VIII) [40, 
163, 272, 287]. In addition the capsule (CPS) and suilysin (SLY), components from the cell 
wall may help bacteria to develop a sustained bacteremia and colonize tissues. In this 
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regard, the CD1 model has been used to evaluate the role of some of these cell wall 
components. Indeed, the ᴅ-alanylation of lipoteichoic acid (LTA), has been postulated as a 
crucial virulence factor of S. suis. In vitro studies using a S. suis strain deficient in ᴅ-
alanylation of LTA (dltA-), provided evidence that this virulence factor helps bacteria resist 
the action of cationic antimicrobial peptides and killing by neutrophils. Challenge studies in 
CD1 mice demonstrated that in vivo, the ᴅ-alanylation of LTA helps results in sustained 
bacteremia and therefore, facilitates invasion of tissues. When mice were infected with a 
high dose of either a wild type strain (WT)or its the dltA- mutant, severe clinical signs 
associated with septicemia, and similar bacterial concentrations in blood and different 
organs were observed. This phase of the disease culminated in the death of several mice 
from both groups during the first 72 h post-infection. However, when mice were infected 
with an intermediate bacterial dose, no deaths associated with septicemia in any group. 
The findings obtained in mice were validated in a pig S. suis model of infection, in which the 
absence of ᴅ-alanylation of LTA also impaired the virulence of the dltA- mutant  (Annex, 
Article V) [163]. Other components of the cell wall possibly involved in the development of 
S. suis disease include the N-acetylation of peptidoglycan (PG), that may help bacteria to 
avoid recognition by phagocytic cells and to resist the effect of lysozyme. Indeed, the 
absence of N-acetylation of S. suis PG severely impaired the ability of the bacteria to cause 
sustained bacteremia and colonize different tissues in the mouse S. suis model. No major 
clinical signs associated with S. suis infection, no deaths were recorded and bacteria was 
cleared from circulation during the first three days of infection, mice inoculated with a S. 
suis mutant deficient in PG N-acetylation (pgdA-). In contrast, sustained levels of S. suis for 
several days in blood and different organs in  mice inoculated with the WT strain. 
Moreover, sustained bacteremia in mice infected with the WT strain was accompanied by a 
strong production of pro-inflammatory cytokines. Similar findings were observed when 
virulence of the pgdA- mutant was assessed in a pig model of S. suis infection, validating 
the results obtained with mice (Annex, Article VI) [40].   
 The repeatability of the bacteremia and mortality results in CD1 mice infected with 
different WT strains of S. suis, allowed us to use this model of infection to also investigate 
the importance of many putative virulence factors in the development of septicemia. 
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Different S. suis cell surfaces proteins possess a Leu-Pro-X-Thr-Gly (LPXTG) motif that may 
serve to mediate bacterial interactions with host cells, namely those from the extracellular 
matrix. These LPXTG cell surface proteins are anchored to the S. suis cell wall by a Sortase A 
(srtA), whose role in disease was evaluated by constructing a S. suis strain deficient in 
sortase A (srtA-) and comparing its virulence against its WT parental strain. The in vivo trials 
in the CD1 S. suis model, revealed no difference in virulence between the WT strain and the 
srtA- mutant, as the two strains caused sustained bacteremia and similar mortality, 
indicating that anchorage of LPXTG proteins alone is not sufficient for virulence in mice 
(Annex, Article VII) [287]. Another example of the importance of bacteremia for the 
development of the disease and further mortality in the CD1 model is the evaluation of S. 
suis mutants deficient in cell surface subtilisin-like proteinase. Proteases are hydrolytic 
enzymes that catalyze the cleavage of peptide bonds and are critical virulence factors for 
numerous microbial pathogens. These enzymes hydrolyze a variety of host proteins, 
including serum and tissue components, thus helping to neutralize the host immune 
defense system and causing tissue destruction and invasion. The subtilisine-like protease of 
S. suis contains a cell wall sorting signal LPXTG that is responsible for covalently anchoring 
proteins to cell wall PG. CD1 mice infected with two S. suis mutants deficient in subtilisine-
like proteinase presented a significantly higher survival rate in comparison to those mice 
infected with the parental WT strain. Survival was associated to the impairment of  these 
two subtilisine-like protease deficient mutants in their ability to cause sustained 
bacteremia and septicemia [475].  
In addition, this mouse model of infection was used to screen the virulence of five 
S. suis mutants that have a reduced invasion to porcine brain microvascular endothelial 
cells (PBMEC).  The in vivo experiments confirmed that sustained bacteremia is crucial for 
the development of the disease, and that although some putative virulence factors may 
have a more  active role when performing in vitro experiments, they are not critical for the 
development of the infection. Indeed, only two of the five mutants tested presented a 
significant diminution in virulence in comparison to their WT parental strain, causing less 
mortality and less severe clinical signs in mice. In fact, these two less aggressive mutants 
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rapidly disappeared from blood and were less invasive in different tissues (Annex, Article 
VIII) [272].  
 Finally, the CD1 model was used to evaluate potential vaccine candidates. S. suis 
possesses a alpha-enolase (SsEno) that binds specifically to fibronectin and plasminogen 
and that has a role in the bacterial adhesion and invasion of PBMEC [210]. It was 
postulated that similarly to other bacterial fibronectin-binding proteins, SsEno may 
contribute to the virulence of S. suis [210]. In addition, as purified SsEno is highly 
immunogenic in mice, it was hypothesized that it could be useful as a vaccine candidate. 
However, vaccination trials demonstrated that although vaccination with SsEno elicits a 
strong humoral response, it is not protective as, immunized and non immunized mice 
challenged with a virulent WT S. suis strain, presented similar clinical signs and mortality 
rates (Annex, Article IV)  [125].  
 
 
2. Development of the acute phase of S. suis infection 
 
2.1 Septicemia with high mortality is a first phase of S. suis infection: the role of the 
exaggerated inflammatory response   
 In CD1 mice, virulent S. suis induced a high and constant bacteremia for several 
days, and number of CFU in blood, liver and spleen were routinely high in all mice. This 
sustained bacteremia is likely to be attributed to the resistance of S. suis to phagocytosis by 
neutrophils and macrophages in the absence of specific IgG [142, 264]. Bacteria-released 
components, such as SLY may enhance bacterial dissemination due to their cytotoxic effect 
on phagocytic, endothelial and epithelial cells [4, 149, 282, 476]. Moreover, SLY may 
prevent complement deposition on S. suis. The toxin might reduce the amount of 
complement available for the opsonization of the bacteria, as has been observed with 
swine neutrophils and, more recently, with mouse dendritic cells [264, 477]. However, 
bacteremia was not always fatal, as in CD1 mice it caused only 20% mortality within 48 h 
post-infection (p.i.). In contrast to our findings, in other streptococcal diseases, the ability 
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of the host to decrease the bacterial loads seems to be critical for survival. For example,  in 
mouse models of septicemia with S. pneumoniae, blood bacterial titers are not sustained, 
as they decrease during the first 36 h p.i. with a new increase to the original inoculation 
dose at 48 h p.i. although no mortality is recorded during this second  period [478].   
 Different studies have demonstrated that the outcome of the immune response to 
infection is determined, in part, by the degree of inflammation it generates. Inflammatory 
cytokines, produced by cells including macrophages and neutrophils, are fundamental in 
generating an effective primary immune response and in clearing infection. However, 
excessive production of pro-inflammatory cytokines not only enhances immune responses 
to fight the invading pathogen, but also has deleterious effects that perturb regular 
hemodynamic and metabolic balances. In humans with severe sepsis, the production of 
pro-inflammatory cytokines, such as TNF-α, IL-1, and IL-6, among others, causes septic 
shock which has a mortality of >50% even when appropriate antimicrobial therapy is 
administered [479, 480].  
 Few studies have measured the kinetics of production of pro-inflammatory 
cytokines at the protein level in vivo after an experimental infection with Gram-positive 
bacteria [481-484]; most of these studies measured a limited number of mediators. The 
use of a multiplex system in this study allowed us to quantitatively measure the kinetics of 
production of several cytokines simultaneously in a small volume of plasma in vivo [485]. 
We took advantage of this system to compare the levels of cytokine between infected and 
non infected mice and to ascertain which particular cytokines were involved in the 
development of septic shock. Although it is not possible to make a direct comparison 
between in vitro and in vivo studies, kinetics of systemic cytokine and chemokine 
production found in the CD1 mouse model share some similarities with previous in vitro 
reports using the same strain of S. suis. These reports showed that high levels of TNF-α, 
and significant levels of IL-1β, IL-6, IL-8 and MCP-1, were released by activated mouse and 
human monocytic cells as well as by total swine whole blood leukocytes [486-488]. 
Moreover, in a pig model of S. suis infection, a substantial production of IL-6 was observed, 
which correlated with a high fever index [272]. 
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 In the present in vivo studies, high levels of the pro-inflammatory cytokines TNF-α, 
IL-6, IL-12 and IFN-γ and the chemokines MCP-1, KC and RANTES were observed during the 
first 24 h p.i. and were probably, at least in part, responsible for the sudden death of 20% 
of CD1. A general examination of the cytokine production suggests that in infected CD1 
mice S. suis would develop a Th1 type immune response. We observed that the 
inflammatory systemic response began with the early secretion of TNF-α. This cytokine that 
is mainly secreted by monocytes in response to inflammatory stimuli has been associated 
in the pathogenesis of toxic shock-like syndrome (TSLS) caused by Gram-positive bacteria, 
especially when high bacterial doses are used. Rodents infected with GBS demonstrated a 
significant increase of TNF-α levels within 12 - 72 h after challenge, high levels of 
production correlating with mortality. TNF-α production is followed by high levels of IL-1 
and IL-6  [489, 490]. In humans with sepsis, TNF-α is thought to be a major factor 
contributing to multiple organ failure related to a high mortality rate [373].  High levels of 
systemic TNF-α may also contribute to increased permeability of the BBB [491], facilitating 
invasion of S. suis to the brain. Infected mice also showed high levels of IL-6. However, the 
impact of some cytokines in the outcome of sepsis remains controversial, as is the case 
with IL-6. This cytokine is considered to have pro-inflammatory and anti-inflammatory 
effects, one evident feature being the ability to induce production of acute phase proteins 
in the liver [492]. It is known that IL-6 is greatly up-regulated in the serum of patients with 
bacterial infection of sepsis, [361], and many studies have reported a positive correlation 
between IL-6 serum levels and outcomes in septic patients [493]. Production levels of  IL-1β 
were not as high as other cytokines, although they may be high enough to have biological 
consequences in our mouse model, and may synergize the effects of TNF-α and stimulate 
the secretion of other pro-inflammatory cytokines.  
   
 
2.2 The development of septic shock due to S. suis in mice is influenced by genetic host 
factors 
 Once the hallmark of the septic phase of S. suis infection was established in CD1 
mice, the objective of subsequent research was to confirm the role of inflammation in 
mortality observed during the septic phase and also to determine if the genetic 
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background of the host may influence the response towards this pathogen and further 
outcome of the disease. In fact, previous research had indicated that genetically 
determined variations in the immune system could result in greater susceptibility to 
infection, or development of different forms of disease in some individuals [494]. 
Understanding the genetic basis of differential susceptibility to bacterial infection in inbred 
mouse strains has proven extremely informative for understanding the interface of 
host:pathogen interaction and identifying normal defence mechanisms of phagocytes that 
may fail in permissive hosts [471]. In addition, understanding the mechanisms underlying 
disease resistance or susceptibility to S. suis may be useful for the development of effective 
drug therapy. For this, the mouse model of S. suis infection was used with two genetically 
different inbred mouse strains: A/J and C57BL/6 (B6) mice (Article III). Indeed, study of 
inbred strains of mice has resulted in the identification of several host
 
resistance loci that 
regulate natural and acquired immunity
 
in response to several pathogens. The genetically 
inbred mouse strains included in this study are considered as the prototype of resistant 
(B6) and susceptible (A/J) mice strains.  They have been used frequently to investigate the 
genetic control of host immunity to infectious pathogens such as L. monocytogenes, 
Candida albicans, S. aureus and in models of sepsis with lipopolysaccharide (LPS) or cecal 
ligation [494-498]. Moreover, A/J and B6 mice strains have been successfully used for the 
study of the influence of the genetic control of immune responses in the outcome of 
streptococcal infections [484, 494, 499]. Nevertheless, most of these studies evaluated 
only mortality and bacterial loads in different tissues.  
 Results obtained demonstrated a stricking susceptibility to S. suis infection in A/J 
mice in comparison to B6 mice, as the former reached 100% of mortality at 20 h p.i., 
whereas mortality in the latter mouse strain reached up to 16 % at 36 h p.i.  Very 
interestingly, and similarly to CD1 mice (Article I), bacteremia did not seem to be 
responsible for the death of mice.  In fact, bacterial loads in different tissues were 
comparable between the two mouse strains; with sustained bacteremia during the first 3 
days p. i. and kinetics resembling those observed in CD1 mice. We postulated then, that 
the higher mortality in S. suis-infected A/J mice was due to uncontrolled cytokine 
production leading to sepsis and deadly septic shock. A/J mice are known to carry a loss-of-
function mutation in the structural gene of the C5 component of the complement pathway  
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[500]. C5 plays
 
several critical roles in host response to infection, including
 
target lysis and 
phagocyte recruitment. However, if complement was essential for bactericidal activity 
against S. suis, bacterial loads should be higher in A/J than B6 mice, whereas no significant 
differences in the bacterial loads between the strains were recorded. In fact, A/J mice 
presented outstanding levels of TNF-α, IL-12p40/p70, IL-1β and IFN-γ, levels of which 
significantly exceeded those found in B6 mice. A similar and potentially autodestructive 
cytokine pattern is found in susceptible mice strains infected with GAS [484, 501]. The 
remarkable cytokine production in A/J mice would lead to a series of pathogenic events 
that may lead to multiple organ dysfunction and death. Remarkably, chemokine levels (KC, 
MCP-1 and RANTES) were similar between strains, suggesting that they might have a 
limited participation in the development of septic shock due to S. suis.  
 Conversely, compared to A/J mice, better survival of B6 mice was partially related 
to a better regulation of the pro-inflammatory cytokine cascade. Indeed, B6 mice not only 
presented lower levels of several pro-inflammatory cytokines, but also showed a higher 
production of the anti-inflammatory cytokine IL-10 (discussed below). In addition, it 
seemed that following to S. suis infection, B6 mice present a Th1 type immune response. 
This would agree with previous findings stating that B6 mice portray a Th1-response in 
response to different pathogens, with a well controlled pro-inflammatory response that 
appears to be beneficial during sepsis [502, 503]. However, some other reports of mortality 
and severity of sepsis in B6 mice, concluded that a massive secretion of pro-inflammatory 
mediators was likely the cause of death [504]. This clearly exemplifies that the type of 
immune response is influenced by both pathogen and host factors. Very recently, 
independent research groups have also found that B6 mice inoculated with S. suis ST7 
(involved in the Chinese human outbreak), develop a strong inflammatory response with 
high levels of TNF-α, IL-1β, IL-6, KC and MCP-1 [97]. The cytokine levels they observed are 
indeed higher than those obtained when mice were infected with an European virulent 
strain (the same strain that we used in our studies).  
 Interestingly, the 2005 Chinese S. suis human outbreak was characterized by a very 
high prevalence of patients with TSLS that presented increased serum levels of TNF-α IL-1β, 
IL-6, IL-12p70, IFN-γ  and IL-8 [505]. The cytokine profile found in A/J mice resembles that 
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observed during the Chinese outbreak.  It has been assumed that  S. suis ST7 has acquired 
putative virulence factors responsible for the TSLS, although it will be interesting to study if 
the genetic background of the host plays a role, in addition to possible changes in the 
bacterial genome [97].  
 
2.3 Role of anti-inflammatory mediators in the survival of mice following septic shock 
dute to S. suis 
 The better survival of B6 mice could be due to the fact that they better controlled 
the release of pro-inflammatory cytokines and mounted a higher anti-inflammatory 
response, in comparison to A/J mice. IL-10 is a crucial down regulation-mechanism of 
inflammation which efficiently blocks the production of different pro-inflammatory 
cytokines, including TNF-α, IFN-γ, IL-1β and IL-6 from human/mouse monocytes and human 
neutrophils stimulated with LPS or lipoproteins from pathogens [506-509].  The results 
obtained in this study concerning the systemic production of IL-10, suggested that survival 
of B6 mice during the septic phase may be related to the capacity of their innate immune 
response to mount a competent anti-inflammatory response, whereas in the case of A/J 
mice, the production of IL-10 remained low and almost undetectable (Article III). 
Moreover, in mouse models of sepsis, IL-10 induces inhibition of TNF-α secretion and 
decreases mortality [510-512]. In humans, IL-10 seems to have a protective function in the 
progress to organ failure in sepsis. IL-10 suppresses TNF-α production and inhibits the 
expression of adhesion molecules and TNF-α receptors on neutrophils [513]. 
 We focused on IL-10 research using two approaches: the first, by blocking the cell 
receptor of IL-10 (IL-10R) with an anti-mouse IL-10R monoclonal antibody (Mab) in B6 mice 
and the second by providing recombinant mouse (rm)IL-10 (rmIL-10) to A/J mice. We 
expected in the first approach an increase in mortality in B6 mice caused by cytokine 
outburst whereas in the second we believed A/J mice would better control the 
development of sepsis. B6 mice that received the parental administration of IL-10R MAb 
before challenge with S. suis developed a clinical acute disease that resembled that 
observed in A/J mice, with an striking and fast increase in mortality and higher levels of 
TNF-α in comparison to infected mice that did not receive the treatment. Conversely, 
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treatment with rmIL-10 delayed the onset of septic shock in A/J mice infected with S. suis. 
These results show that survival to S. suis septic shock requires a tight regulation of pro- 
and anti-inflammatory mechanisms, and that the latter should be activated at the same 
time or soon after the onset of the pro-inflammatory response. The beneficial effect of 
parental administration of IL-10 has been documented in other streptococcal diseases. For 
example, when adult mice receive anti-IL-10 antibodies at the time of infection with GBS, 
they show an increase in mortality and in severity of lesions, accompanied by an early and 
sustained production of pro-inflammatory cytokines.  The opposite is observed if animals 
receive a treatment with rmIL-10 [514].  The administration of rmIL-10 has similar effect in 
infant models of GBS infection and in mouse models of septic shock with LPS [515-517]. We 
cannot conclude that resistance/susceptibility to S. suis infection in mice relies solely on 
the systemic production of IL-10, as with the rmIL-10 treatment in A/J, we observed a delay 
in the onset of septic shock, although mice finally succumbed to infection. There would be 
other regulators of the inflammatory response involved, which we have not yet identified. 
Possible candidates to study are the secretion of the endogenous IL-1Ra, which blocks the 
biological action of IL-1, polymorphisms in the promoter for the TNF-α  gene [518], 
secretion of sTNF-αR that antagonizes TNF-α  activity and participation of endogenous 
glucocorticoids (i.e. adrenocortical corticosterone (CS)), which among other biological 
effects, block the production of TNF-α [519]. 
 Currently, A/J mice are believed to be relatively deficient in the prophylactic 
activities of CS. In fact, B6 and A/J demonstrate relevant differences concerning the 
endogenous production of CS, as B6 adrenals exhibit abundant CS-producing cells, which 
have a cord-like array distribution, whereas A/J adrenals contain few, randomly arranged 
CS-producing cells [520]. Moreover, B6 mice have a significantly higher adrenal CS content 
than A/J mice [521]. Thus, we can argue that, once infected with S. suis, A/J mice will not 
have a sustained production of CS to help regulate the inflammatory response. The 
phenotype picture presented here is the
 
first step in the identification of host genes 
associated
 
with resistance against S. suis. Further steps should include studies with B6 IL-
10
-/-
 deficient mice,  as well as generation of recombinant inbred strains (B6 × A/J) to study 
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the phenotypic and genetic variations among them, and  cloning of possible host target 
genes. 
 
3) Development of Central Nervous System disease by S. suis: the role of an exaggerated 
inflammatory response   
 
 
3.1 A mouse model of S. suis infection with clear clinical signs and lesions of 
encephalitis/meningitis  
 One of the most remarkable achievements of the mouse model of infection 
described in this project is the development of clear clinical signs of neurological disease 
from 4 days p.i. (Article I). Interestingly, bacterial loads in the brains of the mice were lower 
in comparison to those in other sampled tissues, suggesting a particular mode of 
colonization for this organ that may be related to the degree of BBB dysruption. Moreover, 
S. suis may be present in the brain, without clinical signs of disease, as the bacteria were 
recovered from the brains of CD1 mice 6 days p.i. in the absence of clinical signs, indicating 
that a certain minimum number of invading bacteria might be needed to cause CNS 
disease. It is worth mentioning that assessment of bacterial concentrations from different 
organs (and determination of pro-inflammatory mediators in plasma) required sacrifice and 
sampling of animals at specific time points, and therefore it was not possible to determine 
if these mice with late positive cultures in brain would have developed nervous disease at 
later time. 
  The presence of clinical signs of CNS in mice infected by the intraperitoneal route 
with S. suis, represents a striking difference to mouse infection models of meningitis of 
Gram-positive cocci. As mentioned previously, in most of these experimental models, 
bacteria are inoculated directly into the CNS, inducing a rapid exacerbated inflammatory 
response in the brain and 100% of mortality of animals during the first 72 h p.i. unless 
antimicrobial treatment is included. In GBS infection of mice pups, clinical signs include 
apathy, anorexia, and pallor of the skin, whereas adult mice infected with S. pneumoniae 
are lethargic and unable to walk, opisthotonus and epileptic seizures being infrequently 
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observed [440, 522]. In the present model of S. suis meningitis, clear neurological signs 
were observed in CD1 mice who survived to the septic phase of infection. Neurological 
disease started with subtle changes in behaviour, and transformed quickly into 
disorientation, episthotonos, opisthotonus, walking in circles with the head towards one 
side, uncontrolled spinning (rolling) when in lateral recumbency, forelimb tilt, and in some 
cases, abnormal limb position at rest (crossed forelimbs), suggesting propioceptive deficits. 
All the aforementioned clinical signs closely resemble to those present in pigs infected with 
S. suis [6, 40, 133] (Annex, article V), and they represent CNS inflammation that is 
accompanied by vestibular syndrome.  
 CD1 animals with clinical signs of CNS disease showed inflammation
 
with 
suppurative and necrotizing lesions in the meninges and in different anatomical
 
sites of the 
brain parenchyma, such as the cortex,
 
hippocampus, corpus callosum, thalamus and 
hypothalamus (Article I). It is known the hippocampus is an area of the brain specialized in 
spatial learning and memory [523], and learning deficiencies are important sequelae in 
people that recover from bacterial meningitis [524]. In fact, spatial learning and memory 
deficits have been associated with lesions in the hippocampal formation, and inactivating 
synaptic transmission in the dorsal hippocampal formation reversibly impairs encoding and 
retrieval of spatial memory  [525, 526]. Moreover, mice with pneumococcal meningitis 
suffer neuronal damage at the hippocampus and develop long term spatial memory and 
learning deficits [527]. As we found severe damage to the hippocampus, it would be 
interesting to adapt this model to study if meningitis caused by this pathogen is also 
accompanied by long-term learning deficiencies and to evaluate the effect of treatment 
with anti-inflammatory drugs that seem to diminish the negative effect of these sequelae. 
We are not able to explain why S. suis seems to prefer these brain areas.  Currently, 
bacterial thrombi inside blood vessels and bacterial antigens in different structures of the 
brain of CD1 mice, including the hippocampus and corpus callosum are identified by means 
of immunohistochemistry using a primary polyclonal antibody against S. suis. Data 
obtained in our studies studies, as well as those of independent research groups [293], 
support the theory that S. suis can get access to the brain by traversing the BBB and the 
blood-cerebrospinal fluid barrier (BCSFB) (see discussion below). As the corpus callosum is 
located on the roof of the lateral ventricles (which are full of cerebrospinal fluid (CSF)), it is 
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possible that the relevant presence of S. suis antigens in these areas is by passage of 
bacteria contained in the CSF to this brain structure. Moreover, as in mice experimentally 
infected with pneumoccoccus, bacteremia plays a significant role in development  of 
apoptosis in the dentate gyrus of the hippocampus during meningitis [528].  We 
hypothesize that S. suis might also induce neuronal apoptosis in these structures. More 
research is needed to confirm this hypothesis.  
 A very interesting finding is the presence of bilateral areas of demyelination mostly 
restricted to the corpus callosum (Article I). Studies revealed that transcript expression of 
mouse proteolipid protein (PLP) - synthesized by oligodendrocytes - was diminished in 
these areas. The origin of such degenerative lesion may be associated to microglia [529], 
and will be discussed in the correspondent section. 
 The distribution pattern of these lesions shares some similarities with experimental 
S. pneumoniae infection in mice, in which there is inflammation of meninges, accompanied 
by inflammation and necrosis of the neocortex, dentate gyrus of the hippocampus and 
corpus striatum, although there also are brain abscesses due to the inoculation technique 
used [440].  In addition, some mice with S. suis meningitis develop a patent dilation of 
lateral ventricles that may cause an increase of intracranial pressure. This may be 
associated with the production TNF-α that can alter the permeability of the BCSFB [530]. 
Local production of nitric oxide by microglia (Article II) and astrocytes (unpublished 
publications) may also participate to increase the intracranial pressure and augmentation 
of meningeal inflammation. 
 
3.2 S. suis infection in mice is also associated with vestibular syndrome and other 
pathologies 
 As aforementioned, some of the clinical signs in infected CD1 suggested vestibular 
syndrome. The vestibular system maintains balance and body posture; it detects motion of 
the head. It is located in the labyrinth, at the inner ear [531]. In animals, dysfunction of the 
vestibular system is commonly recognized
 
by signs such as head tilt, recumbency, circling, 
and rolling.
 
Nystagmus (either horizontal, rotary, vertical, or positional)
 
can also be seen. It 
can result 
 
from lesions to the vestibular receptors in the membranous labyrinth
 
or the 
vestibulocochlear nerve (VIII cranial nerve) by inflammation, trauma, neoplasia, etc. [532, 
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533]. In humans suffering from meningitis due to S. suis, as there is cochlear and vestibular 
damage accompanied by hearing loss [131, 534], it is possible that CD1 mice with these 
particular clinical signs demonstrate the same pathology as humans infected with S. suis. In 
fact, as a complement of my work during my PhD, we recently demonstrated that CD1 mice 
with clinical signs of meningitis and vestibular syndrome present damage in inner ear 
structures, with severe inflammatory changes at the cochlea and suppurative labyrinthitis 
that is aggravated in perilymphatic spaces, with presence of high numbers of streptococci 
(ongoing studies, unpublished observations) (Fig. 1). These inflammatory changes are very 
similar to those observed in pigs and guinea pigs experimentally infected with S. suis, which 
develop otitis interna characterized by a mixed inflammatory exudate comprising 
neutrophils, lymphocytes, and less often macrophages in the perilymphatic ducts of the 
cochlea and perineuritis along the vestibulocochlear nerve [310, 535]. Rats experimentally 
infected with S. pneumoniae develop a similar pathology in inner ear structures, as there is 
disruption of the blood-labyrinth barrier that leads to extravasation of inflammatory cells in 
different structures of the cochlea, including the labyrinth spiral ligament, the stria 
vascularis and the spiral limbus. By means of Auditory Brainstem Response measurements, 
it has been determined that rats with such pathological changes in the inner ear manifest 
severe hear impairment [438]. All the clinical and histopathological data of inner ear 
damage by S. suis in CD1 mice provide additonal evidence of the accuracy of this 
experimental model studying the pathogenesis of S. suis infection and reinforce its 
usefulness in future research with the objective to determine if indeed S. suis causes 
deafness in mice. Our experimental model of infection may serve to study the participation 
of different pathways and reactive molecules from the host implicated and possible use of 
novel drugs that may help alleviate the negative consequences of such important sequelae 
of meningitis.  
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 Finally, around 2-3 days after infection some CD1 mice (with or without neurologic 
clinical signs) present a cloudy cornea (“white eye”), which is usually unilateral.  
Microscopic examination reveals severe acute endophthalmitis with presence of 
neutrophils and bacteria (data not shown). Interestingly, in humans, endophthalmitis may 
be associated with bacterial infections, including those due to S. suis [536, 537]. In 
addition, some infected mice may also manifest endocarditis, which is another pathology 
commonly found in pigs and humans affected by S. suis [538, 539]. 
 
3.3 Triggering of the inflammatory response at the Central Nervous System 
 The study of pro-inflammatory events at the CNS, similarly to the systemic studies, 
was carried out in mice sampled at specific time points and from those included in the 
mortality study that showed clear clinical signs of meningitis (Article I). We used the mouse 
model of S. suis infection to characterize the in vivo pro-inflammatory events that take 
place in the brain and identify the CNS cells that participate in the inflammatory response 
against this pathogen. For this, we used the in situ hybridization (ISH) technique. This 
unique technique localizes gene sequences in situ and visualizes the product of gene 
expression while preserving cell integrity within the heterogeneous tissue, permitting 
anatomically meaningful interpretations  [540].  
 Our results showed an early activation of TLR2 and CD14 genes first in cells lining 
the brain microvasculature, the meninges and choroid plexuses, supporting the hypothesis 
that S. suis traverses the BBB and the  BCSFB to gain access to the brain. In fact, previous in 
vitro studies had underlined the fact that S. suis can adhere and invade PBMEC, with the 
 
Fig. 1. Inner ear (cochlea) of CD1 mice with 
clinical signs of meningitis and vestibular 
syndrome. Presence of excessive inflammatory 
cells (white *) at the scala tympani, scala media 
and scala vestibuli (Domínguez-Punaro, et al, 
unpublished data).   
* 
* 
* 
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release of pro-inflammatory cytokines [4]. Trespassing of the BBB may be enhanced by the 
strong systemic secretion of TNF-α presented in mice. Moreover, S suis has the ability to 
compromise barrier function of porcine choroid plexus epithelial cells [541] that may be 
enhanced by SLY production that is cytotoxic for endothelial cells [4].  
 These findings also support previous in vitro studies finding  that recognition of this 
pathogen is through a TLR2-dependent pathway in collaboration with CD14. Indeed, 
studies with THP-1 human monocytes revealed that virulent
 
encapsulated S. suis or its 
purified cell wall components activate the expression of TLR2 [271] in association with 
CD14 [269, 271], events that are followed by the release of high amounts of pro-
inflammatory cytokines and chemokines (TNF-α, IL-1β, IL-6, IL-8 and MCP-1) [271]. In 
complementary studies, mouse macrophages deficient in TLR2 showed impaired (but still 
positive) cytokine
 
responses to encapsulated bacteria. As for CD14, it has been traditionally 
recognized as a molecule participating in LPS recognition [542]. In rats, the systemic 
injection of  LPS up-regulates the gene encoding CD14 early in brain areas devoid of BBB 
and later in the brain parenchyma [391]. However, CD14 also participates in the detection 
of bacterial components from Gram-positive bacteria, including brain pathogens. It has 
been shown that heat-killed S. aureus and S. pneumoniae induce activation of transcription 
of TLR2 in a CD14-dependent fashion [543]. Complementary studies demonstrated that the 
lipoteichoic acid from these two pathogens triggers innate immune recognition  via LPS-
binding protein-CD14-TLR2 [544].  
 In mice infected with S. suis, there is activation of IκBα (index of NF-κB activation). 
It has been postulated that IκBα expression in cells of the BBB is a general mechanism that 
takes place during systemic inflammation [388, 545]. Translocation of NF-κB leads to the 
expression of different pro-inflammatory genes. We could not determine if the increased 
mRNA expression
 
of inflammatory mediators observed in mice is directly related to TLR2-
NF-κB signaling
 
pathway, although previous studies with mouse macrophages infected with 
S. suis demonstrate that blocking of TLR2 significantly diminishes cytokine and chemokine 
production  [271]. 
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 The in vivo pro-inflammatory picture in the brain was completed by studying the 
expression of mRNA transcripts for several pro-inflammatory mediators, that is, IL-1β, TNF-
α, IL-6 and MCP-1. Interestingly, the transcripts for these mediators were always observed 
at different degrees of intensity in the choroid plexuses, cortex, corpus callosum and 
different areas of the brain, coinciding with those areas where inflammation, necrosis, 
demyelination and S. suis antigens were found. However, whereas MCP-1 was identified 
also in brain microvasculature, IL-1β and TNF-α were not. This agrees with previous studies 
with S. suis, which show an absence of TNF-α and IL-1β activation in brain microvascular 
endothelial cells (BMEC) [282]. Various studies highlight the production of similar panels of 
cytokines and chemokines in the brain inflammatory response towards different brain 
pathogens, such as H. influenzae, S. pneumoniae [546] and S. aureus [547]. Very 
interestingly, in S. suis mouse infection, it seems that participation of IL-6 is more relevant 
at the systemic level, but not at the CNS. Indeed, there was a low and inconstant IL-6 gene 
expression in the brain of infected CD1 mice, mostly restricted to blood vessels, choroid 
plexus and cortex. This was further confirmed in microglial cells (see below). 
 It is important to note a striking difference between our model and previous studies 
describing the development of the inflammatory response in the brain with respect to 
bacterial antigens. In several studies, it was found that the parental injection of LPS in 
rodents leads to cytokine gene expression in the circumventricular organs, which are 
devoid of BBB and further activation of microglia in the brain parenchyma [388, 390, 392, 
548]. Similarly, mice parentally infected with Salmonella enterica serovar Typhimurium, 
demonstrate increases in TLR2 mRNA levels in the circumventricular organs and brain 
parenchyma and infiltrating blood derived-myeloid cells [549]. In comparison, the 
intracisternal injection of live or killed
 
 S. pneumoniae, LTA or PG, triggers an immune 
reaction via
 
TLR2 [452]. However, mice with
 
S. pneumoniae-induced meningitis 
demonstrate increased TLR2, TLR4,
 
and TLR9 mRNA expression, whereas TLR2-deficient 
mice infected by the intracranial
 
route with S. pneumoniae express different pro-
inflammatory cytokines
 
in the CNS, indicating TLR2-independent recognition pathways 
[452, 550, 551]. 
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 Surprisingly, in the brains of S. suis infected mice, we observed a moderate 
induction of TLR3 mRNA expression that followed the same pattern of expression of TLR2 
(Article I). This receptor is known to recognize viral double-stranded RNA. Thus, the 
hypothesis that S. suis can activate other TLRs in adittion to TLR2 and possibly other 
components of the innate immune system in a non-specific manner cannot be ruled out. In 
fact, in vitro results showed that S. suis activates THP-1 monocytes in a TLR2-dependent 
and, to a certain extent, -independent (but MyD88-dependent) manner, indicating that 
other TLRs are also involved in S. suis recognition. Other bacterial agents can also induce an 
increase in TLR3 expression, as hippocampal cultures exposed
 
to S. pneumoniae showed 
up-regulation of both TLR2 and TLR3
 
mRNA expression [551]. Another example is the up-
regulation of TLR3 in human epithelial airways cells by H. influenzae [552, 553]. It is 
possible that the TLR3 up-regulation observed in the brain of S. suis-infected mice might 
leads to activation of the MyD88-independent pathway. Indeed, it has been demonstrated 
that in vitro, CPS from S. suis contributes to MCP-1 production in a MyD88-independent
 
manner [271]. The MyD88-independent pathway involves activation of the transcription 
factor IRF-3, and induction of IFN-β, which in turn, activates Stat1, leading to the induction 
of several IFN-inducible genes [321]. Viral infection or dsRNA, which are classical TLR3 
ligands,
 
also activate IRF-3 and thereby induce IFN-β in a MyD88-independent manner. 
Hence, TLR3 utilizes
 
the MyD88-independent component to induce IFN-β [5]. S. suis might 
use similar mechanisms. It is worth noting that MCP-1, along with RANTES and IP-10 are 
IFN-β-inducible genes [554]. 
 
 The pro-inflammatory signals in the mice brain increased quickly with time, 
reaching different areas of the brain and being much more evident in those animals with 
neurologic clinical signs. It is noteworthy  to mention that the presence of these signals had 
a positive correlation with the anatomical distribution of lesions. ISH in combination with 
immunohistochemistry identified cells resembling microglia or blood-derived monocytes, 
and to a lesser extent astrocytes, as those responsible for the pro-inflammatory gene 
activation. Therefore, in vitro studies were conducted to better understand the role of 
mouse microglia in the inflammatory response towards S. suis (Article II). Microglia are the 
first line of the brain and the main role of activated microglia is believed to be in brain 
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defense. However, if the activation of these cells is exacerbated, they may play a harmful 
role, significantly affecting the development of the inflammatory response and leading to a 
pathological state. Indeed, microglia produce a wide range of pro-inflammatory mediators, 
and a variety of biologically active molecules including cytotoxic and neurotrophic 
molecules that may harm the brain tissue.  
Studies with mouse microglia (Article II) initially evaluated their possible protective 
role in the development of S. suis meningitis. Activated microglia transform into 
phagocytes and may limit the multiplication of pathogens in the brain [398].  The use of 
mouse microglia cells allowed us to determine that in these cells, phagocytosis of S. suis is 
severely restricted by the presence of the CPS, similarly to findings in mouse and human 
macrophages [142, 148], pig neutrophils [264] and mouse dendritic cells [477]. These 
results were confirmed by confocal microscopy studies, which showed that only a few WT S 
suis were ingested by microglia, whereas the CPS- strain was found in high numbers inside 
phagolysosomes. The presence of serum significantly increased the rate of phagocytosis of 
capsulated bacteria, although again, phagocytosis of the CPS- mutant significantly 
exceeded those of its WT strain. The absence of the SLY has already been associated with a 
partial susceptibility of encapsulated S. suis to phagocytosis by neutrophils and dendritic cells in 
the presence of complement  [264, 477]. Since fragments from the complement cascade can be 
found in the brain [278], their possible effect of on phagocytosis of S. suis by microglia was 
evaluated. Results from the present study show that complement components do not seem to 
affect phagocytosis of the capsulated S. suis SLY- mutant by microglial cells, indicating a 
different behavior of phagocytes from different locations. The observed increased rate of 
phagocytosis in the presence of serum might be due to proteins other than complement 
fractions, such as albumin [555]. As murine microglia were not able to phagocyte virulent S. 
suis, it is likely that in vivo, this would facilitate multiplication of the pathogen thus creating 
a destructive environment that would attract more inflammatory cells to the site of 
infection and enhance the inflammatory response. Therefore, we foccused on the pro-
inflammatory activity of microglia in contact with S. suis, to try to understand how their 
activation may be necessary for the host, even though this may lead to negative 
consequences.  
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Microglia infected with S. suis are capable of producing different pro-inflammatory 
cytokines and chemokines, highlighting their relevance in the development of the 
inflammatory response towards this pathogen. The release of substantial quantities of TNF-
α and MCP-1 by microglia following contact with virulent S. suis was a significant finding, 
supporting the previous observations in infected mice, in which there was a strong up-
regulation of genes encoding TNF-α and MCP-1 in different areas of the brain and 
meninges (Article I). Microglia released low levels of IL-1β, still, which nevertheless may be 
enough to have a biological impact in the brain. It is likely that microglia are not the only 
glial cell implicated in the inflammatory response towards S. suis, as  in vivo experiments in 
mice suggested that astrocytes also play a pro-inflammatory role. In fact, recent 
experiments from our laboratory, complementing those of the present thesis, demonstrate 
that astrocytes infected with S. suis can release high levels of TNF-α and MCP-1, with a 
more modest production of IL-1β and similarly to microglia, the bacterial CPS is implicated 
in modulating cytokine production (data not shown). In contrast to observations in other 
phagocytic cells and S. suis [268, 269, 271] and with other streptococci and microglial cells 
[556], microglial cells activated with S. suis do not produce significant levels of IL-6. 
Nevertheless, this result agrees with findings in the brain of infected mice where there was 
no expression of IL-6 (Article I). It seems that SLY does not have a major role in cytokine 
release from microglia, as S. suis deficient in this putative virulence factor induced similar 
cytokine levels to its parental strain. This is in contrast to pneumolysin of S. pneumoniae, 
which presents a high homology with SLY and is known to play an active role in 
inflammation [306].  
The CPS seems to be critical for modulating the production of pro-inflammatory 
mediators, as the CPS- mutant induced, in most of the cases, the release of significant 
higher levels of pro-inflammatory mediators. This supports the assumption that several 
components of the cell wall (i. e. LTA, PG and lipoproteins), partially masked by the CPS, are 
potent pro-inflammatory activators. In fact, the importance of LTA and PG in the 
inflammatory response against S. suis has been recently assessed [477]. In addition, cell 
wall lipoproteins have recently been described as being responsible for cell activation 
[557]. Finally, as a low production of IP-10 for capsulated S. suis strains in comparison to 
238 
 
 
that for the CPS- mutant was also noted, we might hypothesize that the CPS might 
influence the onset of the adaptative inflammatory response, as recently shown for 
dendritic cells [477]. As a consequence, less lymphocytes T will be attracted to the site of 
infection.  
 Following demonstration that microglia can actively respond to the insult 
represented by S. suis by producing pro-inflammatory cytokines/chemokines, research was 
focused on studying mechanisms involved in pathogen recognition, as well intracellular 
pathways implicated in the development of the inflammatory response and production of 
cytotoxic effector molecules. As no differences were found between the SLY-deficient 
strain and its parental WT strain, signalization studies were conducted by comparing the 
WT strain and its CPS- mutant. 
 
 It has recently been demonstrated that TLRs, which are crucial pattern recognition 
receptors in innate immunity, are expressed in microglia [400]. TLR activation will set in 
motion a broad spectrum of intracellular events to initiate inflammatory response, 
including MAPK signaling pathways, activation of NF-κB and cytokine production [322]. 
Studies in mice had demonstrated up-regulation of TLR2 in different areas of the brain 
parenchyma following infection with virulent S. suis, and it was suggested that microglia or 
blood –derived macrophages were mainly responsible for recognition of the pathogen and 
further initiation of the inflammatory response (Article I). Interestingly, the present results 
demonstrate microglia in contact with S. suis, up-regulate the expression of TLR2 mRNA in 
a time-dependent manner. This is more pronounced in the case of a S. suis strain deficient 
in CPS, indicating an active role of cell wall components in TLR2-mediated recognition. 
Moreover, these findings agree with previous results obtained with human monocytes and 
S. suis [271]. It is likely that, during in vivo infections, local multiplication of
 
S. suis, 
stimulates the release of high amounts of LTA and PG that will activate
 
TLR2 up-regulation. 
It is worth noticing that under the in vitro conditions used, TLR1, TLR4, TLR6 and TLR9 gene 
expression was not modified. However, it is not possible to exclude their participation in S. 
suis recognition, as their basal expression may be high enough to trigger the inflammatory 
response. This differs from recent research, demonstrating that bacterial lipoproteins from 
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S. suis activate the TLR2/6 but not the TLR1/2 complex from epithelial cells [557]. It would 
be necessary to perform further studies with KO microglia (TLR2
-/-
, TLR1
-/-
, TLR6
-/-
) to verify 
the participation of these receptors. 
 The in vitro studies with mouse microglia also confirm the important participation 
of NF-κB as a key transcription factor involved in triggering the inflammatory response 
against S. suis, as results obtained in vivo in mice suggested (Article I). We determined that 
S. suis induces the translocation of NF-κB to the nucleus in microglia (Article II). Both S. suis 
WT and its CPS- mutant were able to increase the binding activity of NF-κB, it in a time-
dependent fashion. As the DNA binding activity of NF-κB was faster and more intense when 
cells were infected with non-capsulated S. suis, it is very probable that cell wall 
components, which are completely exposed in the CPS- mutant, influence the activation of 
NF-κB as observed by others [345, 558]. As aforementioned, in mice infected with S. suis, 
the IκBα transcript (index of  NF-κB activation) was observed in cells identified as astrocytes 
as well as in microglia. Our recent research with mouse astrocytes confirms this finding. 
We have demonstrated translocation of NF-κBp65 to the nucleus of these cells following 
infection with S. suis. Interestingly and similarly to microglia, this p65 translocation is 
influenced by the presence of CPS (unpublished observations). Moreover, TLR2 
participation and NF-κB translocation in astrocytes, with further induction of the 
inflammatory response has been recently documented for S. aureus [559]. 
 TLRs downstream signaling involves activation of PKC-family of proteins, Tyr protein 
and the Mitogen Activated Protien Kinases (MAPK) system [3], in addition to NF-κB. MAPK 
activation has gained recent attention as a crucial pathway for glia activation [338]. 
However, despite the relevant role these proteins may play, very little is known about their 
participation in S. suis inflammatory response (Article II). The lower and biphasic patterns 
of phosphorylation for PKC substrates and Tyr protein observed in mouse microglia 
infected with S. suis WT strain in comparison to those with the CPS- mutant may indicate 
that capsulated S. suis may modulate microglia signaling events most likely to avoid 
phagocytosis as it was previously documented  [148]. Our results obtained indicated that 
the CPS interferes with the MAPK-mediated response, as phosphorylation patterns (p-ERK, 
p-JNK, p-p38) found with the CPS- mutant were faster, stronger and more stable than 
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those obtained with the WT strain. Nevertheless, the partial exposition of cell wall 
components in the WT strain is enough to trigger MAPK signalization pathways. This 
supports recent studies, where purified cell wall preparations from S. suis triggered the 
activation of the MAPK pathway in human macrophages [560]. Similarly to the present 
research, following infection of pig macrophages with whole S. suis or a non-capsulated 
mutant, an increase in the transcriptional response involving different genes from the 
MAPK pathway was observed, in particular with a CPS deficient strain [270]. EstA protein, a 
recently described virulence factor of S. pneumoniae, present at the bacterial cell surface, 
induces MAPK phosphorylation and NF-κB translocation [561]. As the estA gene is also found in 
S. suis [562], it is probable that MAPK activation and other intracellular signaling pathways do 
not depend solely on a few S. suis constituents, but many of them participate at the same time 
to activate the pro-inflammatory machinery. The pharmacological inhibition of MAPK 
revealed an almost complete abrogation in the release of TNF-α and MCP-1 from microglia 
infected with either S. suis WT or CPS- strains, demonstrating the importance of MAPK in 
the inflammatory response against this pathogen. Similar findings have been observed 
when ERK, JNK or p38 are pharmacologically inhibited in microglia stimulated with LPS 
[396, 563, 564]. In the case of S. pneumoniae, LTA is capable of triggering the MAPK 
signalization pathway with cytokine production, iNOS induction and release of nitric oxide 
(NO). This latter is p-38 MAPK dependent [345]. It would be interesting to determine if in 
the case of S. suis, NO production by microglia is triggered by the same pathway or if it is 
mainly NF-κB-dependent. We cannot conclude that this MAPK induction is related to TLRs 
activation as it has been proved for other meningitis-causing bacteria, like S. aureus [565].  
To do so, we should either block TLRs (i.e. TLR2) with specific antibodies or preferably, use 
TLR KO microglia. In both cases, we would expect abrogation of MAPK phosphorylation 
followed by a decrease in cytokine production. Moreover, as ERK, JNK, and p38 pathways 
are all molecular targets for drug development, it would be interesting to test the efficacy 
of some of these MAPK-inhibitor drugs in our mouse model of S. suis meningitis. 
 As previously stated, mice infected with S. suis presented severe demyelinization, 
restricted mainly to the corpus callosum (Article I), leading to postulate that microglia may 
be involved in this process. In fact, parenteral LPS treatment in rabbits induces 
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oligodendrocyte damage but only in the presence of microglial cells [529]. There are 
several mechanisms by which activated microglia may induce white matter injury. When 
activated, microglial cells have been shown to release reactive nitrogen and reactive 
oxygen species (like NO) into the surrounding areas, causing damage to oligodendrocytes. 
Activated microglia also release excitotoxic metabolites, such as glutamate and quinolinic 
acid, which may cause glutamate receptor– or N-methyl-D-aspartic acid receptor–
mediated injury to oligodendrocytes [529]. In vitro studies with murine microglia (Article II) 
demonstrated that indeed these cells react to the insult represented by S. suis with the 
expression of iNOS and the release of NO in a time-dependent manner, events that are 
influenced by the presence of the capsule. We may theorize therefore that in vivo, NO 
release from microglia may damage oligodendrocytes and contribute to the loss of myelin 
or even cause direct neurotoxicity. Moreover, astrocytes may also enhance damage to 
oligodendrocytes as they also express iNOS following contact with S. suis, with kinetics 
similar to those of microglia (unpublished data). 
 
 
3.4 Possible future research on the development of S. suis meningitis using C57BL/6 mice 
 Interestingly, inbred mice of strain C57BL/6 develop clinical signs of CNS disease 
(Article III), although not as evident as in CD1 mice, and these include recumbency, 
problems in locomotion and rear limb weakness, sometimes accompanied by head tilt and 
their brain lesions have a close resemblance to those observed in CD1 mice (Article I).  
Preliminary studies with the C57BL/6 mouse model also show increase in the expression of 
TLR2 with a spatiotemporal pattern that mimics that found in CD1 mice (unpublished 
observations) (Fig. 2).  
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 These results encourage further research using different C57BL/6 knockout mice to 
pursue the study of signalization pathways involved sepsis, meningitis and inner ear 
damage by S. suis.  KO mice strains that should be tested include TLR2
-/-
, TLR1
-/-
, TLR6 
-/-
 
and MyD88
-/-
 mice. 
 In summary, this research project using a mouse model of infection enhanced the 
knowledge of the pathogenesis of S. suis infection. With this model, we studied the 
development of septic shock and evaluated a possible genetic role in the susceptibility of 
the disease. We also evaluatd the in vivo progress of the inflammatory response and 
associated lesions at the Central Nervous System. Moreover, the in vivo results obtained in 
the brain suggested the active participation of microglia in the local inflammatory 
response. Therefore, studies were conducted to understand some of the mechanisms 
implicated in the interactions of microglia and S. suis. The main observations found at the 
systemic level are summarized in Fig. 3, while those concerning the Central Nervous 
System are shown in Fig. 4. 
 
Fig. 2. TLR2 expression in brain of C57BL/6 mice infected with S. suis. In situ hybridization, 
brain coronal sections, from rostral (upper left) to caudal (down right). TLR2 expression is 
manifested as “black spots” (see black arrows) in different sections of the brain and in areas 
surrounding the choroid plexuses (Domínguez-Punaro, et al, unpublished observations). 
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Fig. 3. Proposed hypothesis for the development of S. suis infection. When bacteria reach 
the bloodstream, they will resist phagocytosis by phagocytic cells due to the presence of 
the CPS (1). Bacteria travel in the  blood either attached to these cells or free, resulting in 
bacteremia (2), which may lead to septicemia (3). Different virulence factors play istrategic 
roles for tissue colonization by S. suis (4). During the septic phase of disease, there will be 
an exaggerated systemic production of pro-inflammatory cytokines and chemokines (5) 
that may cause septic shock (6) and ultimately death (7). Activation of compensatory anti-
inflammatory mechanisms, such as production of IL-10 (8) are crucial for survival from 
sepsis in some cases (9) and recovery of disease (10). However, if the animal survives this 
acute phase of infection, S. suis may still get access to the CNS (11) through either the BBB 
(12) and/or the BCSFB (13). Traversing of the BBB may be enhanced by cytotoxic factors, 
such as SLY and production of pro-inflammatory mediators. Once in the CNS, the 
inflammatory response will be orchestrated mainly by microglia (see Figure 4), and to a 
lesser extent by astrocytes (14). This inflammatory response will include activation of 
receptors, such as CD14, TLR2, and TLR3 and production of pro-inflammatory cytokines and 
chemokines, such as IL-1β, TNF-α, MCP-1 (among others) in different areas of the brain 
(15), including the microvasculature, the corpus callosum (cc), the hippocampus (hp) and 
the thalamus (th). This will lead to the development high levels of inflammation with 
clinical signs of CNS and lesions of meningitis/encephalitis (16), accompanied by 
demyelination of specific brain structures.  
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Fig. 4.  
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Fig. 4. Proposed role of microglial cells in inflammation caused by S. suis at the CNS. 
Based on the results obtained in the present thesis, we can hypothesize that once in 
contact with microglia, the CPS of S. suis (1) will modulate different intracellular 
signalization pathways, including phagocytosis, in part by inhibition of the phosphorylation 
of PKC family of proteins (2). Nevertheless, once in contact with microglia, S. suis will be 
recognized through TLR2 in collaboration with CD14 (3) leading to the activation of the 
MyD88-downstream pathway (4), including up-regulation of IkBα (5) and translocation of 
NF-kB to the nucleus (6) to induce up-regulation of pro-inflammatory genes (7). Activation 
of MyD88 may also lead to TRAF6/MAPK/AP-1 signalization pathways (8-10), also with the 
up-regulation of pro-inflammatory genes (7). The signalization cascade (NF-kB and AP-1 
pathways) will cause the production of pro-inflammatory cytokines and chemokines (11) 
that will increase tissue inflammation (12). Furthermore, there will also be activation of the 
iNOS pathway and further release of NO (13), which may also have negative effects, 
including vasodilatation and demyelination, which lead to neurotoxicity (14).  All these 
inflammatory and degenerative events would lead to clinical signs of CNS disease (15). 
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V. GENERAL CONCLUSIONS AND PERSPECTIVES 
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General conclusions  
 
 Results from the present work demonstrate that: 
 
 The standardized mouse model of S. suis infection is useful for studying the 
mechanisms underlying sepsis and meningitis during bacterial infection. This model 
accurately reproduces the septic and clinical phases of infection, as well as mimicry 
CNS lesions found in natural infections in pigs and humans. 
 
 Death of mice during the acute phase of disease is associated with an exacerbated 
production of pro-inflammatory cytokines and weak participation of negative 
regulatory mechanisms.  
 
 Susceptibility to S. suis infection may be caused by a genetic predisposition of the 
host that will manifest a dysregulated inflammatory response.  
 
 Inflammation in the CNS of mice infected with S. suis starts at the brain 
microvessels, and extends quickly to different areas of the brain parenchyma and 
meninges. This inflammatory response initiates with the up-regulation of TLR2 with 
the participation of CD14 and NF-κB, followed by the expression of genes of several 
pro-inflammatory cytokines and chemokines in cells identified as microglia and to a 
lesser extent in astrocytes. 
 
 Microglia are active participants in the inflammatory response in S. suis infections, 
as once in contact with S. suis, they react by the up-regulation of  TLR2, following 
with translocation of  NF-κB to the nucleus and production of different cytokines, 
chemokines and reactive oxygen metabolites. In addition, the MAPK-signalization 
pathway is also actively involved in the inflammatory response towards S. suis in 
microglia. 
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Perspectives 
 
 Possible future steps for this research include: 
 
 Use of the mouse model of S. suis infection to: 
o Identify harmful and beneficial effects of the host immune response in different 
phases of the disease (septic shock/meningitis). 
o Test novel drugs (antimicrobial agents, anti-inflammatory drugs) that may help 
stop the progression of S. suis infection or the inflammatory consequences of 
the disease. 
o Study the molecular mechanisms underlying deafness present in cases of 
meningitis by S. suis and other Gram-positive pathogens (on going studies). 
o Study the virulence of S. suis strains lacking in putative virulence factors. 
o Develop novel effective vaccination strategies. 
 
 Development of F2 populations derived from resistant × susceptible mouse strains to 
perform genome-wide scan studies and delineate the genetic background associated to 
susceptibility to S. suis infection. 
 
 Delineate the in vivo relevance of the pro-inflammatory intracellular signalization 
pathways (MAPKs, iNOS) identified in microglia challenged with S. suis. 
 
 Determine the relevance of astrocytes in the inflammatory response against S. suis 
(manuscript in preparation). 
 
 Establishment of co-cultures of primary microglia or astrocytes with neurons to study 
the possible damage caused to the latter cells once glial cells have started the 
inflammatory response against S. suis. 
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SUMMARY 
 
In our ongoing efforts to develop a vaccine against Streptococcus suis infection, we 
tested the potential of Streptococcus suis enolase (SsEno), a recently described S. suis adhesin 
with fibronectin-binding activity, as a vaccine candidate in a mouse model of S. suis- induced 
septicemia and meningitis. Here, we show that SsEno is highly recognized by sera from 
convalescent pigs and is highly immunogenic in mice. Subcutaneous immunization of mice with 
SsEno elicited strong immunoglobulin G (IgG) antibody responses. All four IgG subclasses were 
induced, with IgG1, IgG2a and IgG2b representing the highest titers followed by IgG3. However, 
SsEno-vaccinated and non-vaccinated control groups showed similar mortality rates after 
challenge infection with the highly virulent S. suis strain 166’. Similar results were obtained 
upon passive immunization of mice with hyperimmunized rabbit IgG anti-SsEno. We also 
showed that anti-SsEno antibodies did not increase the ability of mouse phagocytes to kill S. 
suis in vitro. In conclusion, these data demonstrate that although recombinant SsEno 
formulated with Quil A triggers a strong antibody response, it does not confer effective 
protection against infection with S. suis serotype 2 in mice. 
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INTRODUCTION 
Despite increasing research in recent years, Streptococcus suis continues to cause a 
variety of diseases in pigs worldwide, including septicemia, meningitis, arthritis and 
endocarditis [1]. Among the 35 serotypes described, serotype 2 is considered the most virulent 
and is most frequently isolated from diseased pigs [1]. In addition, S. suis has also been 
described as an important zoonotic agent, especially in Europe and Asia [2]. Human infections 
with S. suis are most frequently manifested as purulent meningitis, but septic shock with 
multiple organ failure, endocarditis, pneumonia, arthritis, and peritonitis have also been 
reported [2].  
 
The pathogenesis of S. suis infection is not fully understood. In swine, the potential 
portals of entry for S. suis are the palatine and pharyngeal tonsils and thereafter bacteria can 
spread via the hematogenous or lymphogenous route [3]. Once in the bloodstream, S. suis has 
to resist phagocytosis and killing by phagocytic cells to cause acute septicemia that may lead to 
septic shock. Bacteria can reach different organs, including the central nervous system (CNS), 
via different mechanisms that are only partially elucidated to date [4].  
 
Several potential virulence factors have been implicated in the infection process. The 
most promising virulence factors to date are the capsule polysaccharide (CPS) and serum 
opacity factor (OFS) [5], as isogenic mutants lacking either of these factors are rapidly cleared 
and eliminated from circulation [5-7]. However, some non-virulent strains are also 
encapsulated or have allelic variations of OFS [8], indicating that virulence of S. suis likely 
involves multiple factors [4]. Other virulence candidates have been proposed, but most of them 
are not present in all virulent strains or are present in non-virulent strains [9]. So far, whole cell 
vaccines or bacterins (commercial and autogenous) have been used in the field to prevent S. 
suis disease, however, with disappointing results [10, 11]. Vaccination with these bacterins 
does not induce high levels of antibodies and causes, at most, serotype-specific responses [1]. 
We recently identified SsEno, a new S. suis surface fibronectin-binding protein [12] that might 
participate in the pathogenesis of S. suis infection by mediating bacterial attachment to and 
internalization into brain microvascular endothelial cells (BMEC) [12]. SsEno might be an 
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attractive vaccine candidate against S. suis infections as it possesses highly conserved epitopes 
[13] and is expressed at the surface of all S. suis serotypes described to date [12]. In addition, a 
recent study identified S. suis enolase as an important antigenic protein that contributes to the 
virulence of S. suis [14]. The objective of this study was to determine whether the immune 
response induced by immunization with purified SsEno can confer protection against challenge 
with the homologous strain of S. suis serotype 2 in a mouse model of infection. 
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METHODS 
 
Bacterial strains  
S. suis serotype 2 highly virulent strain 166’ [15] was kindly provided by Dr. M. Kobisch, 
AFSSA, Ploufragan, France. Working log-phase cultures were prepared in Todd Hewitt broth 
(THB) (BD, Sparks, MD) as previously described [16]. Growth was allowed until the suspension 
reached approximately 5 x 108 CFU ml-1. Final inoculum corresponded to 107 CFU ml-1 (for pigs) 
and 108 CFU ml-1 (for mice). Escherichia coli strain BL21DE3 (Novagen, Madison, WI) was used 
for expression experiments as described elsewhere [12].  
 
Cloning and expression of the α-enolase gene 
Cloning and purification of SsEno were performed as previously described [12]. Briefly, 
the coding sequence of SsEno (S. suis Enolase) was amplified by PCR using chromosomal DNA 
from S. suis SS166 as template and the complete gene was cloned into pET-32a vector 
(Novagen, Madison, WI). The plasmid pET-32a-SsEno was introduced into E. coli Bl21DE3 for an 
IPTG-inducible expression of recombinant S. suis enolase (rSsEno). The His-tagged fusion 
protein was purified by chromatography under native conditions on HisTrap according to the 
manufacturer's instructions (Amersham Biosciences AB, Uppsala, Sweden). Protein 
concentrations were determined by the Lowry method [17]. Prior to vaccination assay, the 
purity (>95%) of recombinant SsEno preparations was determined by scanning densitometry of 
the protein on an SDS-PAGE gel stained with Coomassie blue and with a silver-stained SDS-
PAGE gel (data not shown) as previously reported [12]. 
 
Presence of anti-SsEno antibodies in convalescent animals 
All animal experiments were conducted according to the guidelines and protocols set 
forth by the Canadian Council on Animal Care and approved by the Université de Montréal 
committee on animal care. Seven 4-week-old piglets from a herd free of S. suis serotype 2 
disease were infected intravenously with 107 CFU from a log-phase culture of S. suis strain 166’. 
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Animals were monitored for clinical signs and treated with antibiotics if needed to avoid death. 
Serum samples were taken befor and three weeks post-infection. Antibody titers against 
rSsEno from these convalescent pig sera were measured by direct ELISA. Maxisorp® flat-bottom 
microtiter 96-well plates (Nunc, VWR, Mississauga, ON, Canada) were coated overnight at 4°C 
with 5 µg ml-1 of purified recombinant SsEno. The plates were further incubated with 1/1000 
dilution of pig sera and bound antibodies were detected by incubation with peroxydase-
conjugated goat anti-swine IgG (Jackson Immunoresearch Laboratories West Grove, PA) for 1 h 
at room temperature. The plates were developed with TMB substrate (Zymed, S. San Francisco, 
CA, USA) and absorbance was measured at 450 nm. 
 
Active protection assay of mice with rSsEno 
Six-week-old female CD-1 mice (Charles River Laboratories, Wilmington, MA, USA) were 
immunized subcutaneously twice, one week apart, with either 20 µg of purified SsEno mixed 
with 20 µg of Quil-A adjuvant (Brenntag Biosector, Frederikssund, Denmark) or 20 µg of Quil-A 
only as a control in 100 µl of phosphate-buffered saline (PBS) per mouse. Ten days after the 
second vaccination, animals were challenged intraperitoneally with 108 CFU per mouse of log-
phase S. suis, strain 166’ in 1 ml of THB. Sera collected from each mouse before immunization, 
before the second dose and before challenge infection were assayed for anti-SsEno antibody 
titers by ELISA, as described below. Mice were monitored daily for clinical signs such as 
abnormal behavior (hyperexcitation, episthotonus, opisthotonus, bending of the head toward 
one side, walking in circles or strong locomotive problems), rough hair coat, ataxia and 
mortality until day 10 post-infection [16]. This mouse model of infection was recently used to 
reproduce septic shock and meningitis that might be consider to be similar to those induced by 
S. suis in pigs [1, 16]. 
 
Passive protection of mice with rabbit antibodies against rSsEno 
Groups of 12 female CD-1 mice (Charles River, 6 week old) were injected 
intraperitoneally with 0.5 ml of rabbit anti-rSsEno serum [12] or 0.5 ml of normal rabbit serum 
as a control. Hyperimmune sera against rSsEno was produced as previously described [18] and 
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the titer (<1/100 000) evaluated by ELISA [19]. Three hours later, 10 mice per group were 
injected intraperitoneally with 108 CFU per mouse of log-phase S. suis, strain 166’ in 1 ml of 
THB. Sera were collected 24 h after the serum administration to measure anti-SsEno antibodies 
by ELISA assay as described below. Mice were monitored daily for weight loss, clinical signs and 
mortality.  
 
Determination of active and passive antibody titers in mice by ELISA  
Titers of SsEno-specific total IgG in mice sera were determined by ELISA as previously 
described [18]. Briefly, Polysorb plates (Nunc-Immunoplates, Rochester, NY, USA) were coated 
overnight at 4°C with purified recombinant SsEno. Due to an extremely high antibody response 
(see below), and comparing to what was used to measure antibodies in swine,  a significant 
reduced concentration of SsEno (0.3 µg ml-1) was used to coat the plates. After incubation with 
serial dilutions of test, bound antibodies were detected by incubation with peroxidase-
conjugated goat anti-mouse IgG, IgG1, IgG2a, IgG2b or IgG3 antisera (Serotec, Kidlington, 
Oxford, UK) for 1 h at room temperature. For determination of antibodies titers in the passive 
protection assay, the same protocol was used but with peroxidase-conjugated anti-rabbit IgG 
(Jackson ImmunoResearch Laboratories, West Grove, PA) as a secondary antibody. Plates were 
then developed as described above. The antibody titer was considered as the serum dilution 
that resulted in an OD450 reading of 0.1 after subtracting background. 
 
Killing of S. suis serotype 2 strain 166’ by mouse phagocytes in the presence of anti-SsEno 
antibodies 
In vitro killing of S. suis serotype 2 strain 166’ by mouse phagocytes in the presence of 
polyclonal anti-SsEno antibodies was measured as described previously [20, 21] with some 
modifications. Briefly, 0.3 ml (from 5 different animals) of freshly heparinised blood was mixed 
with 0.5 ml of appropriately THB diluted bacteria (200-500 CFU ml-1) in the presence of 25 g 
ml-1 of protein G purified rabbit anti-SsEno antibodies [12]. Similar concentrations of purified 
normal rabbit antibodies were used as negative control and of purified hyperimmune rabbit 
anti-S. suis (whole cell) antibodies as a positive control, as previously described [22]. Mixtures 
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were incubated at 37ºC for 3 h with constant slow rotation [20, 21]. At the end of the 
incubation, an appropriately diluted aliquot was plated onto THB agar and incubated overnight 
at 37ºC to count surviving bacteria. Results are expressed as mean percentage ± standard 
deviation of bacterial survival, with survival of bacteria opsonised with normal rabbit antibodies 
considered as 100%. Data are representative of four independent experiments. An internal 
control for the growth of S. suis serotype 2 strain 166’ in the presence of the different 
conditions was also included. Briefly, the same concentration of diluted bacteria (200-500 CFU 
ml-1) were grown in THB in the presence of 25 g ml-1 of the different purified antibodies or no 
antibodies for 3 h in stationary conditions and the number of CFU in each condition were 
counted. 
 
Statistics 
Antibody titers and percentage of killed bacteria of experimental groups were 
compared using student’s t-test (*** p<0.0005,** p<0.005, * p<0.05). Survival curves were 
evaluated using the Kaplan-Meier method and the significance of the difference was tested 
using the Log-rank test.  
 
RESULTS 
Immunogenicity of SsEno in pigs 
None of the seven animals used in this study had SsEno-specific antibodies before the 
experimental infection (Fig. 1), as only background values were detected in these animals. In 
contrast, pigs infected with a log-phase culture of S. suis strain 166’ showed significant anti-
SsEno-IgG responses at 3 weeks post-infection (Fig. 1). 
 
 SsEno-specific IgG and IgG subclasses in active protection assay 
There were no SsEno-specific antibodies in sera from any of the animals before the first 
vaccination (Fig 2(a)). Immunization of mice with SsEno elicited a strong antigen-specific 
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response. At 14 days after the first vaccination, SsEno elicited a significant IgG response that 
was further increased after the second immunization (Fig. 2(a)). Analysis of sera demonstrated 
that although SsEno-immunized animals produced all IgG subclasses, IgG1, IgG2a and IgG2b 
responses were predominant followed by IgG3 (Fig. 2(b)). In contrast, animals vaccinated only 
with adjuvant did not show any antibody responses (Fig. 2(a) and 2(b)). 
 
Clinical signs and mortality in the active protection assay 
A few hours after challenge infection with S. suis serotype 2 strain 166’, all mice 
(control and SsEno immunized group) exhibited clinical signs, such as ruffled hair coat 
suggesting fever and slow response to stimuli. From day 0 to 3 post-infection, 25 % of 
immunized animals died from septicemia (Fig. 3(a)). After day 3 post-infection, 58 % of the 
immunized animals that survived to septicemia developed severe CNS signs such as running in 
circles and opisthotonos and died or met criteria for euthanasia due to the severity of their 
condition (Fig. 3(a)). Similar results were observed in the control group; although all the 
animals resisted the septicemic phase, 33 % of animals died after day 3 post-infection due to 
meningitis (Fig. 3(a)). In all dead animals, S. suis serotype 2 was isolated from different organs 
(data not shown). 
During the septicemic phase, the immunized group lost ~15 % of their body weight (Fig. 
3(b)). Similar results were seen in the control group (Fig. 3(b)). In both groups, animals that 
survived the septicemic phase were able to recover their initial body weight at the end of the 
experiment (Fig. 3(b)).  
 
Clinical signs and mortality in the passive protection assay 
A few hours after infection, passively immunized animals presented similar clinical signs as 
those vaccinated in the active protection assay. During the first 12 h, 30% of animals 
immunized with anti-SsEno antibody died from septicemia compared with 70% of the control 
group. However, all passively immunized animals as well as control mice died within the first 6 
days post-infection from either septicemia or meningitis (Fig. 4). Analysis of sera clearly 
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indicated that there was a high titer of rabbit anti-SsEno only in the passive immunized group 
(data not shown). 
 
Killing of S. suis serotype 2 strain 166’ by mouse phagocytes 
To further evaluate the bactericidal/opsonic capacity of anti-rSsEno antibodies, a killing 
assay was performed using mouse whole blood. As shown in Fig. 5, S. suis treated with normal 
rabbit IgGs grew well in mouse blood (negative control). In contrast, S. suis treated with rabbit 
anti-whole S. suis IgGs was rapidly killed as expected (positive control). Incubation of S. suis 
with affinity purified anti-SsEno IgG antibodies did not enhance bacterial killing, confirming 
results obtained in the passive protection assay. 
 
DISCUSSION 
 
Several approaches have been used to develop vaccines for S. suis. However, little 
success has been achieved thus far because the protection elicited was either serotype or 
strain dependent, and results in most instances have been equivocal [23]. For example, killed 
whole cells or live avirulent vaccines can provide partial protection but only with repeated 
immunization [24, 25].  Subunits protein-based vaccines have also been tested. using virulence 
markers such the hemolysin [26], the muramidase-released protein and extracellular protein 
factor [25] that have been shown to protect pigs from homologous and heterologous serotype 
2 strains. However,  their use is hindered by the fact that a substantial number of virulent 
strains in some geographical regions do not express these proteins [4]. More recently, a surface 
expressed protein (SAO) has been observed to confer protection against experimental infection 
in mice and pigs [27]. However, as this protection is not complete, other proteins could be 
combined with SAO to optimize protection. 
 
Fibronectin-binding proteins have been suggested as potential vaccine targets for 
preventing bacterial infections because antibodies directed against such adhesins may prevent 
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bacterial attachment and also enhance opsonization and killing by leukocytes [28, 29]. In this 
study, we tested the potential of the recently described fibronectin-binding protein, SsEno, as a 
vaccine candidate in a mouse model of S. suis-induced septicemia and meningitis [16]. SsEno is 
a good vaccine candidate based on the following characteristics: i) it is present at the surface of 
all 35 different S. suis serotypes [12]; ii) it contributes to S. suis adhesion to and invasion of host 
cells [12]; and iii) it is a highly conserved protein [13]. In addition, we further showed that sera 
from convalescent animals strongly recognize this protein, suggesting expression of SsEno in 
vivo. Very recently, another study also suggested an important role of enolase in the virulence 
of S. suis [14].  However, the potential of this protein to confer protection against other 
pathogens is controversial. Mice immunized with antibodies against Plasmodium falciparum 
enolase are protected from challenge infection with a lethal mouse malaria strain [30]. In 
contrast, recombinant enolase from Candida albicans induces only modest protection against 
disseminated candidiasis [31]. To our knowledge, a protection test against streptococci using 
enolase as an antigen to elicit an immune response has not been reported yet. 
To evaluate SsEno as a vaccine candidate against S. suis infection, we used a highly 
virulent strain for swine in a well standardized mouse model, which presents two different 
phases: a) a septicemic phase, (24-48h post-infection) and, b) a meningitis/encephalitis phase, 
where animals that survive septicemia will subsequently die from a serious infection of the CNS 
[16]. Our results indicated that the antibodies actively elicited by SsEno at the concentration 
used in combination with Quil-A adjuvant was not protective from either phase of challenge 
infection with S. suis. The Th1-type responses and IgG subclasses induced by the SAO protein 
are two main components of host immunity against S. suis infection [27]. In this study, all 
SsEno-specific IgG subclasses (IgG1, IgG2a, IgG2b and IgG3) were induced, with IgG1 and the 
Th1-type antibodies, IgG2a and IgG2b, as the predominant subclasses. Therefore, other 
components of the host immune response besides non-opsonic antibodies may be necessary 
for effective protection against S. suis infection. We attributed the fact that the vaccinated 
group presented a higher level of mortality than the control group to a simple variation in an 
animal assay. Although it would have been tempting to interpret the results as a possible role 
of antibodies against enolase playing a certain role in autoimmunity as described [32], animals 
from both groups were perfectly healthy at the moment of challenge. 
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To confirm these results, we tested whether rabbit anti-SsEno serum provides passive 
protection against challenge infection with the same strain of S. suis in mice. As expected, and 
although a slight delay in the appearance of severe clinical signs, passive immunization with 
anti-SsEno serum did not confer significant protection against S. suis infection. As it has been 
shown that antibodies derived from hyperimmune sera against whole bacteria (including 
antibodies against the capsule) can protect mice against infection [33] and induce bacteria 
killing [22], it is possible that anti-SsEno antibodies are not opsonic, allowing bacteria to 
reproduce in high numbers to cause disease. On the other hand, antibodies against other 
fibronectin-binding proteins have already been described to enhance phagocyte killing in other 
bacterial species [28]. To test this, we evaluated the capacity of the purified anti-SsEno IgGs to 
opsonize bacteria and promote their killing by murine phagocytes. Although most of the 
produced antibodies were of the Th1 type, results obtained in this study showed that the anti-
SsEno IgG subclasses were not able to induce S. suis killing by mouse phagocytes. 
 Since anti-SsEno has been shown to reduce bacterial adhesion and invasion to BMEC in 
vitro [12], we had expected a certain degree of protection against the CNS phase of infection. 
However, SsEno is not the only receptor involved in such process [34]. It is possible that the 
high concentration of S. suis in blood, as a consequence of a lack of bacterial killing by 
leukocytes, may overcome the partial inhibition of bacterial-BMEC interactions mediated by 
anti-SsEno antibodies.  
 
In summary, although we demonstrated that SsEno elicits an important antibody 
response in convalescent pigs and immunized mice, this response as evaluated in the present 
study is inadequate for effective protection against S. suis infection.  
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Fig. 1. ELISA detection of 
antibodies against SsEno in sera 
from pigs before and after 
challenge with S. suis serotype 
2. Plates were coated with 
rSsEno and then incubated for 
1.5 h with a dilution of 1/1000 of 
swine sera (before and after 
challenge). Mean values (line) 
comparing sera from non-
infected (n = 7) and infected pigs 
(n = 7) are shown. **, P<0.005. 
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Fig. 2. Serum antibody 
responses in mice immunized 
with Quil A (open cycles) alone 
or Quil A plus recombinant 
SsEno (solid cycles). (a) Total 
SsEno-specific serum IgG. (b) IgG 
subclasses in sera at 14 days 
after the second immunization 
(before challenge). Antibody 
titers of individual mice are 
shown, with the average titer 
represented as a bar. (n=16 for 
SsEno-immunized animals; n=15 
for control animals). ***, 
P<0.0005 
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Fig. 3. Survival (a) and weight lost (b) of mice in the active protection assay. Mice 
were first immunized with Quil A (n=14, white) or Quil A-rSsEno (n=15, black) and then 
challenged with 108 CFU ml-1 of S. suis 166’. Survival rate (a) and % of initial body 
weight (b) were monitored for 10 days. Body weight of each mouse was measured 
every day.  
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Fig. 4. Survival of mice in the passive protection assay. Mice were immunized with 
rabbit anti-SsEno antibodies (n=12) or control rabbit antibodies (n=12). Mice were 
then challenged intraperitoneally with 108 CFU ml-1 of S. suis serotype 2 strain 166’ 
and survival was monitored for 10 days. 
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Fig. 5. Effect of antibodies on opsonophagocytic killing of S. suis strain 166’ by mouse 
phagocytes. Antibodies were purified from sera of a rabbit immunized with SsEno. 
Antibodies from a normal rabbit and from a rabbit hyperimmunized with whole S. suis 
serotype 2 were used as negative and positive controls, respectively. Data are 
expressed as mean percentage ± standard deviation of bacterial survival, with survival 
of bacteria opsonised with normal rabbit antibodies considered as 100%. Data are 
representative of four independent experiments. ***, P<0.0005. 
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Abstract 
We generated by allelic replacement a ΔdltA mutant in a virulent Streptococcus suis 
serotype 2 field strain and evaluated the contribution of lipoteichoic acid (LTA) D-alanylation to 
the virulence traits of this swine pathogen and zoonotic agent. Absence of LTA D-alanylation 
resulted in increased susceptibility to the action of cationic antimicrobial peptides. In addition, 
and in contrast to the wild type strain, the ΔdltA mutant was efficiently killed by porcine 
neutrophils and showed diminished adherence to and invasion of porcine brain microvascular 
endothelial cells. Finally, the ΔdltA mutant was attenuated in both the CD1 mouse and porcine 
models of infection, probably reflecting decreased ability to escape immune clearance 
mechanisms and impaired capacity to traverse across host barriers. The results of this study 
suggest that LTA D-alanylation is an important factor in S. suis virulence. 
Introduction 
Streptococcus suis is a major swine pathogen and a zoonotic agent responsible for, 
among other diseases, meningitis and septicemia (15). In swine, S. suis causes severe losses to 
the industry (15) while human S. suis infection is emerging as an important public health issue 
(13). Very recently, more than 200 cases of human S. suis infection were reported during an 
outbreak in China, 38 of which resulted in death (39). S. suis is considered the primary cause of 
adult meningitis in Vietnam (20) and human S. suis infection resulting in death or in severe 
post-infection sequelae has already been reported in different Asian and European countries as 
well as in New Zealand, Australia, Argentina, Canada and the United States (13). Among S. suis 
serotypes, serotype 2 is responsible for most cases of disease in both swine and humans, and 
almost all studies on virulence factors and pathogenesis of the infection have been carried out 
with this serotype (13, 15). Despite the increasing number of studies, our understanding of the 
pathogenesis of S. suis infection remains limited. The polysaccharide capsule is known to play a 
critical role in the pathogenesis of S. suis infection (15). It has been shown that unencapsulation 
of S. suis correlated with increased phagocytosis by porcine macrophages and killing by porcine 
neutrophils (4, 6, 29) and that it severely impaired virulence in a porcine model of infection 
(29). Recently, an isogenic mutant for a serum opacity-like factor was found to be highly 
attenuated in pigs (2). Other proposed putative virulence factors such as the suilysin, the 
extracellular protein factor, the muramidase-released protein and a fibronectin/fibrinogen-
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binding protein were found to be associated with and/or partially involved in, but not essential 
for, virulence (7, 15). 
S. suis can affect the viability of porcine blood brain barrier (BBB)-forming cells such as 
porcine choroid plexus epithelial cells (CPEC) through necrotic and apoptotic mechanisms (34). 
It also can adhere to and invade in vitro-cultured porcine brain microvascular endothelial cells 
(porcine BMEC), another type of BBB-forming cells (35). The ability of S. suis to interact with 
these cells is thought to be important for attaining the central nervous system (CNS) and 
causing meningitis in swine (13). In a recent study (11), the selective capture of transcribed 
sequences (SCOTS) approach was used to elucidate genes that this pathogen preferentially 
upregulates upon its interactions with porcine BMEC. Among other genes, the study identified 
a gene member of a putative S. suis dlt operon (11). In all bacteria where this operon has been 
studied, it has been found to be responsible for the incorporation of D-alanine residues into 
lipoteichoic acids (LTA), surface-associated amphiphilic molecules found in most Gram positive 
bacteria (23). 
The cell wall of S. suis has been proposed as an important virulence factor. Several 
studies have shown that the cell wall or its purified components such as the LTA contribute to 
exacerbate the host inflammatory response to infection (13, 15). However, the structure and 
composition of S. suis LTA are poorly known.  It has been proposed that LTA from S. suis may 
have a backbone structure similar to that of Group A streptococcal teichoic acid, but with 
differences in the attachment of glucosyl substituents (9). Besides its involvement in 
inflammation, LTA may also play a direct role in S. suis virulence. Indeed, a recent study has 
shown that inhibition of the adherence of S. suis to porcine BMEC can be obtained by pre-
incubation of the cells with purified LTA (36). In addition, it has been proposed that S. suis may 
D-alanylate its LTA and that a high ratio of D-alanine to glycerol phosphate in this molecule may 
be important for the interaction of this pathogen with host cells (11). It is known from previous 
reports that D-alanylated LTA is important for the virulence of Gram-positive pathogens based 
on findings that it enables these organisms to modulate their surface charge, to regulate ligand 
binding and to control the electromechanical properties of the cell wall (23). In addition, 
formation of D-alanyl-LTA is required to resist the action of cationic antimicrobial peptides 
(CAMPs) (1, 17, 18, 26). The D-alanylation of S. suis LTA and its contribution to the pathogenesis 
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of infection have yet to be documented. In this study, we demonstrate that S. suis D-alanylates 
its LTA and that this modification is important for the virulence traits of this pathogen. 
Materials and methods 
Bacterial strains, plasmids, media, culture conditions and chemicals.  
Bacterial strains and plasmids used in this study are listed in Table 1. Unless otherwise 
indicated, S. suis strains were grown in Todd-Hewitt (Becton Dickinson, Sparks, MD) broth 
(THB) or agar (THA) at 37°C under 5% CO2. Escherichia coli strains were cultured in Luria-Bertani 
(LB) broth or agar medium (Becton Dickinson) at 37°C. When needed, antibiotics (Sigma, 
Oakville, Ontario, Canada) were added to the culture media at the following concentrations: for 
S. suis, chloramphenicol (Cm) at 5 µg/ml and spectinomycin (Sp) at 100 µg/ml; for E. coli, 
kanamycin (Km) and Sp at 50 µg/ml; Cm at 10 µg/ml. Unless otherwise indicated, all chemicals 
were purchased from Sigma. 
DNA manipulations.  
Restriction enzymes, DNA-modifying enzymes and Taq and Pwo DNA polymerases were 
purchased from GE Healthcare (Piscataway, NJ, USA) or Takara Bio (Otsu, Shiga, Japan) and 
used according to the manufacturers’ recommendations. S. suis genomic DNA was prepared by 
the guanidium thiocyanate method (24). Mini-preparations of recombinant plasmids from E. 
coli and transformation of E. coli were performed by standard procedures (27). Southern 
hybridizations were performed by the procedures described previously (28), except that 
hybridization was carried out at 68°C. For preparation of probes, DNA fragments were labelled 
with digoxigenin (DIG) using the DIG-PCR labeling mixture (Roche Diagnostics, Laval, Qc, 
Canada) according to the manufacturer's instructions. Oligonucleotide primers were from 
Invitrogen (Burlington, Ontario, Canada).  
Allelic replacement.  
(i) Construction of the knockout vector. DNA fragments corresponding to regions 
upstream and downstream the dltA gene (Fig. 1A) were amplified from genomic DNA of S. suis 
strain 31533 by PCR using the primer sets 2872F plus 3765R (left arm) and 5250F plus 5809R 
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(right arm). A Sp resistance cassette (gene aad9) was amplified from plasmid pSmall with 
primers specF3 and specR. All three primers sets introduce unique restriction sites (Table 2). 
PCR amplicons were digested using the appropriate restriction enzymes, and sequentially 
ligated in the order left arm-Sp cassette-right arm using T4 DNA ligase. The resulting fragment 
was amplified by PCR using primers 2872F and 5809R, cloned into vector pCR4 (TOPO TA PCR 
cloning kit; Invitrogen), excised with HindIII and BamHI and recloned into the HindIII and BamHI 
sites of the temperature sensitive S. suis-E. coli shuttle vector pSET5s, which carries the gene 
cat conferring Cm resistance (32), giving rise to knockout vector p5ΔdltA (Fig. 1B). (ii) 
Generation of S. suis ΔdltA. Procedures for selection of mutants by allelic exchange via double 
crossover have been described previously (32). Briefly, S. suis strain 31533 was transformed 
with p5ΔdltA by electroporation as previously described (31). The cells were grown at 28°C in 
the presence of Cm and Sp selection. Bacteria at mid-logarithmic growth phase were diluted 
with THB containing Sp and grown at 28°C to early logarithmic phase. The cultures were then 
shifted to 37°C and incubated for 4 h. Subsequently, the cells were spread onto THA agar 
containing Sp and incubated at 28°C. Temperature-resistant, Sp-resistant colonies were 
screened for loss of vector-mediated Cm resistance to detect putative mutants which had 
exchanged their wild-type allele for a genetic segment containing the aad9 gene as a 
consequence of homologous recombination via a double crossover. Allelic replacement in 
candidate clones was verified by PCR and Southern hybridization, which confirmed the 
expected genotype (data not shown). 
Transmission electron microscopy.  
Transmission electron microscopy was performed as previously described (12). Briefly, 
overnight (ON) cultures of S. suis wild type (WT) or mutant ΔdltA strains were mixed with rabbit 
anti-S. suis serotype 2 polyclonal serum and incubated at room temperature for 1 h. Cells were 
then fixed in cacodylate buffer (0.1M cacodylate, 5% glutaraldehyde, 0.15% ruthenium red, pH 
7.2) for 2 h. After fixation, cells were immobilized in 4% agar, washed in cacodylate buffer and 
post-fixed ON at 4°C in 2% osmium tetraoxyde. Samples were dehydrated in graded series of 
ethanol and embedded in Spurr low-viscosity resin. Thin sections were post-stained with uranyl 
acetate and lead citrate and examined with a transmission electron microscope (Model 420, 
Philips Electronics, The Netherlands). 
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Determination of LTA D-alanine content.  
S. suis WT and ΔdltA mutant strains were cultured in tryptic soy broth (Becton 
Dickinson) containing beef extract (5 g/l) and glucose (8 g/l) at 37°C for 18 h with shaking. After 
incubation, bacteria were harvested by centrifugation at 4225 x g for 20 min. Integrity of 
bacteria and potential contamination by Gram-negative species were checked by Gram staining 
and microscopy. LTA were prepared by butanol extraction (which preserves the integrity of the 
D-alanine substitutions) and hydrophobic interaction chromatography as previously described 
(22). Nuclear magnetic resonance (NMR) spectra from LTA were recorded on a Bruker Avance 
DRX 600 spectrometer (Bruker BioSpin, Ettlingen, Germany) equipped with an inverse TXI-
H/C/N triple resonance probe at 300 K using 3 mm Bruker Match sample tubes. Spectra were 
measured in D2O using sodium 3-trimethylsilyl- 3,3,2,2-tetradeutero-propanoate as an internal 
standard for 1H NMR (δH 0.00 ppm). 
Antimicrobial peptides sensitivity.  
Assays were carried out in sterile 96-well microtiter plates. Logarithmic-phase S. suis 
cells were adjusted to approximately 104 CFU/ml in 100 µl THB containing one of the following 
antimicrobial compounds in serial dilutions: Colistin (0 to 200 µg/ml), polymyxin B (0 to 300 
µg/ml) and magainin II (0 to 45 µg/ml). Plates were incubated for 24 h at 37°C. The MIC was 
defined as the lowest antimicrobial concentration yielding no detectable bacterial growth by 
OD600 nm measurement. 
Killing by porcine neutrophils.  
Experiments were carried out as described previously (4). Briefly, blood samples were 
collected by venous puncture from high health status pigs which tested negative by ELISA (19) 
for S. suis serotype 2. Cell populations were separated by Ficoll-Hypaque (GE Healthcare) 
density gradient centrifugation and neutrophils isolated by sedimentation in 6% dextran. 
Contaminating erythrocytes were removed by lysis with 0.83% ammonium chloride. 
Neutrophils were resuspended at a final concentration of 5×106 cells/ml in RPMI 1640 medium 
(Invitrogen) supplemented with 10% heat-inactivated porcine serum. Bacteria (WT or ΔdltA 
mutant strains at approx. 1×104 CFU/ml) were opsonized with complete normal porcine serum 
for 30 min at 37°C and then mixed in microtubes with neutrophils at 5×106 cells/ml. The 
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mixture was incubated for 90 min at 37°C under 5% CO2. Under these conditions bacteria are 
not toxic to neutrophils (4). After incubation cells were lysed with sterile water and viable 
bacterial counts on THA were performed. 
Experimental infections.  
All experiments involving animals were conducted in accordance with the guidelines 
and policies of the Canadian Council on Animal Care. (i) Pigs: A total of 20, 4-week-old, second-
generation of caesarean-derived pigs were used in this study. Strict biosecurity measures were 
implemented to avoid undesirable contamination of the pigs; these included an air filtration 
system and airlocks for each unit. Pigs were divided in 3 groups. Six out of 7 animals in groups 1 
and 2 were inoculated by intravenous injection of 108 CFU of the S. suis WT 31533 or mutant 
ΔdltA strains, respectively. The remaining animal in both the WT and ΔdltA mutant groups was 
not inoculated although it was housed with inoculated animals and served as sentinel. Group 3 
(N=6) were sham-inoculated animals. Clinical signs and presence of S. suis in blood were 
monitored during the trial. Surviving animals in all 3 groups were sacrificed 7 days pi and 
examined for pathological lesions. Bacteriological isolation from different organs (liver, spleen, 
lungs, heart and articulations) was performed as described below for mice.  (ii) CD1 mice: A 
recently described murine model for S. suis infection was used (8). A total of 60 female CD1 
mice aged 6 weeks (Charles River laboratories, Wilmington, MA) were used for virulence 
assessment. At day 0, animals were divided in 4 groups of 15 mice. Group 1 was inoculated by 
intraperitoneal injection of 1 ml of S. suis strain 31533 suspension at 5 x 107 CFU/ml, while 
group 2 received the same dose of mutant strain ΔdltA. Groups 3 and 4 received 1 ml of a 5 x 
106 CFU/ml suspension of the WT and the mutant strains, respectively, using the same route of 
inoculation. Mice were monitored 3 times/day for 10 days for clinical signs and assigned clinical 
scores as previously described (8). Blood samples (5 μl) were collected daily (from the tail vein) 
and at euthanasia (by cardiac puncture) and used to evaluate bacterial load by plating onto 
sheep blood agar plates. Isolated tiny α-hemolytic colonies were counted and assigned to S. 
suis by serotyping as previously described (16). Surviving animals in both groups were sacrificed 
at day 10 and macroscopic examination was performed. Bacterial colonization of the liver, 
spleen and brain of infected animals was also evaluated. Briefly, small pieces of these organs 
weighing 0.5 g were trimmed, placed in 500 μl of PBS and homogenized. Thereafter, 50 μl of 
the suspensions were plated as described above. In addition, an enrichment of the samples was 
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carried out by inoculation of 300 μl of homogenized organ samples or 100 μl of blood into THB, 
followed by ON incubation at 37°C and subsequent dilution and plating onto sheep blood agar 
plates as described above. 
Adherence to and invasion of porcine BMEC.  
The porcine BMEC cell line PBMEC/C1-2 (33) was grown in Primaria 24-well tissue 
culture plates (Becton Dickinson, Franklin Lakes, NJ) using IF culture medium (a mixture of 1:1 
Iscove’s modified Dulbecco’s and Ham’s F-12 media, Invitrogen) supplemented as previously 
described (35). S. suis was grown in THB for 16 h at 37°C, harvested by centrifugation, washed 
twice in phosphate-buffered saline (PBS), pH 7.3, and resuspended in fresh IF culture medium. 
The invasion assays were performed as described previously (35). Briefly, confluent monolayers 
of porcine BMEC at 105 cells/well were infected with 1-ml aliquots of bacterial suspensions at 
105 CFU/ml (multiplicity of infection (MOI) of 1). The plates were centrifuged at 800 x g for 10 
min and incubated for 2 h at 37°C with 5% CO2. The monolayers were then washed twice with
 
PBS. A 1 ml volume of cell culture medium containing 100 µg/ml of gentamicin and 5 µg/ml of 
penicillin G was added to each well, and incubation continued for 1 h. After incubation, 
monolayers were washed 3 times with PBS, trypsinized and disrupted by repeated pipetting. 
Serial dilutions of the cell lysates were plated onto THA and incubated ON at 37°C. To confirm 
that 100% of the extracellular bacteria were killed after the antibiotic treatment, a 100-µl 
sample of the last PBS wash was plated onto THA (results not shown).  Adherence assays were 
performed essentially as described for invasion, but neither antibiotic treatment nor extended 
incubation was performed. After 2 h incubation, cells were vigorously washed 5 times with PBS, 
trypsinized, disrupted, and serial dilutions of the cell lysates were plated as described above.  
Results and Discussion 
The dlt operon is responsible for LTA D-alanylation in S. suis.  
The genetic organization of the S. suis dlt operon is depicted in Fig. 1A. Sequence 
comparison at The National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/BLAST/), as well as previous reports (17, 18, 25), showed that 
the S. suis dlt operon is organized in a fashion similar to that of all dlt operons reported in 
pathogenic streptococci so far, with the exception of S. agalactiae, which also includes 2 
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regulatory genes upstream of the dltA gene (25). Accordingly, the deduced proteins showed a 
high degree of similarity to streptococcal Dlt proteins (data not shown). To assess the 
contribution of the dlt operon to LTA D-alanylation, we constructed by allelic replacement a 
ΔdltA mutant strain and analyzed the content of D-alanine in purified LTA of the WT and ΔdltA 
mutant strains by NMR. Fig. 2 shows the NMR spectra for LTA of the two strains. Both LTA 
showed the expected peaks for fatty acids (0.85 and 1.3 ppm) and sugars (3.5 to 4.5 ppm). 
However, peaks for D-alanine (1.65, 4.3 and 5.4 ppm) were absent in the ΔdltA mutant 
spectrum, suggesting that the LTA of the mutant is devoid of this amino acid substitution. In 
vitro growth of the ΔdltA mutant was comparable to that of the WT strain (Fig. 3A) and no 
other major phenotypic changes were observed. In contrast to previous reports on S. 
agalactiae and Streptococcus pyogenes ΔdltA mutants, which were either poorly separated or 
multiseptated in the stationary phase of growth (18, 26), the S. suis ΔdltA mutant was 
encapsulated, well separated and presented normal septation (Fig. 3B). 
S. suis LTA D-alanylation contributes to antimicrobial peptide resistance and decreases 
susceptibility to neutrophil killing.  
CAMPs kill bacteria by forming pores in the cytoplasmic membrane (30). Introduction 
of positively charged D-alanine residues into the LTA would reduce the global negative charge 
of the S. suis envelope, thus providing the bacterium with a physical mechanism of resistance 
against the action of CAMPs (23). To assess this hypothesis, we performed an evaluation of the 
sensitivity of the WT and ΔdltA mutant to selected CAMPs. The S. suis ΔdltA mutant was more 
sensitive than the WT strain against the bacteria-derived cationic peptide polymyxin B and 
colistin and the frog-derived peptide magainin II (Table 3). These results were in agreement 
with previous reports of inactivation of the dltA gene in streptococcal species (17, 18, 26) and 
indicate that D-alanylation of LTA is an important component of the intrinsic resistance of S. 
suis to CAMPs killing. On the other hand, the WT and dltA mutant strains were equivalent in 
their susceptibility to the antibiotics gentamicin and penicillin G and to lysozyme (data not 
shown). Functional homologues of the CAMPs tested in this study are secreted by neutrophils 
both into the phagosome as well as extracellularly. (21). When we compared killing of WT and 
ΔdltA mutant strains by purified porcine neutrophils, in agreement with a previous study (4), 
the WT strain avoided killing by neutrophils when opsonized with normal complete porcine 
sera. On the other hand, 20% of the ΔdltA mutant bacteria were killed by neutrophils (Fig. 4). 
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This level of killing was similar to that of the unencapsulated mutant strain BD102, despite the 
fact that the ΔdltA mutant does not have altered capsule expression (Fig. 4). This was 
surprising, since encapsulated WT S. suis has been shown to prevent phagocytosis by porcine 
neutrophils (unless opsonized by specific antibodies) (4).  However, it is known that neutrophils 
are also able to destroy infecting microorganisms in the absence of phagocytosis in the so-
called neutrophil extracellular traps (NETs) (3). Interestingly, it has recently been shown in 
Streptococcus pneumoniae that absence of LTA D-alanylation results in enhanced extracellular 
killing in NETs by neutrophils but not in an increased phagocytosis of this organism by these 
polymorphonuclear cells (37). Although our killing assay is not able to discriminate between 
intra and extracellular killing, taking all these findings together, it might be proposed that the 
encapsulated S. suis ΔdltA mutant is killed by porcine neutrophils extracellularly, perhaps after 
being trapped in NETs. In addition, we speculate that the enhanced killing of the S. suis ΔdltA 
mutant might be the consequence of the absence of LTA D-alanylation, which results in an 
increased susceptibility to CAMPs released by neutrophils. Further experiments are needed to 
evaluate this hypothesis. 
Virulence of the ΔdltA mutant is attenuated in pigs.  
Several ΔdltA mutants in different Gram positive pathogens have been reported and 
almost all of these mutants were highly susceptible to CAMPs and killing by neutrophils and/or 
macrophages (1, 5, 10, 14, 17, 18, 26, 37, 38). However, only a limited number of studies have 
analyzed in vivo the contribution of LTA D-alanylation to the virulence of these pathogens. In 
these cases, virulence of the tested ΔdltA mutants greatly varied between bacterial species 
preventing the drawing of conclusions regarding the contribution of LTA D-alanylation to 
virulence traits of pathogens from previous studies (1, 26, 37, 38). Finally, for various valid 
reasons, previous studies on the virulence of ΔdltA mutants in Gram positive species have used 
surrogated models of infection instead of the natural hosts (1, 26, 37, 38). S. suis shares certain 
characteristics with pathogens for which ΔdltA mutants have been described. However, its 
pathogenesis of infection is essentially different (15). In this study, we have for the first time 
evaluated the virulence of a Gram positive ΔdltA mutant in the context of its natural host by 
intravenous inoculation of pigs. Animals in the sham-inoculated group did not present any 
clinical signs during the entire duration of the trial. In contrast, severe clinical signs were 
recorded in 5 out of the 6 animals inoculated with the WT strain during the first 4 days of the 
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trial. These 5 pigs died or were sacrificed for ethical reasons at day 2 pi (3 animals) and at day 4 
pi (2 pigs). The remaining inoculated animal and the sentinel pig in this group survived until the 
end of the trial (Fig. 5). Animals infected with the ΔdltA mutant presented, on average, less 
severe clinical signs during the 4 first days pi. However, 2 animals died and an additional was 
euthanized by ethical reasons in this group (Fig. 5). Nevertheless, the remaining inoculated 
animals noticeably recovered starting at day 4 pi, and, along with the sentinel pig in the ΔdltA 
group, survived until the end of the trial. Hyperthermia (> 40.5°C) was observed in all pigs 
infected with either WT or ΔdltA strain at 24 h pi. Temperatures returned to normal values 
after day 4 in both groups. However, in the WT group, the sentinel pig developed hyperthermia 
from day 6 pi. S. suis serotype 2 could be isolated from the blood of all inoculated pigs in both 
groups and the sentinel animal in the WT group. Pigs in the latter group had higher bacterial 
counts (as high as 1 x 1010 CFU/ml in some cases) than those infected with the ΔdltA mutant 
(average of 1 x 108 CFU/ml) during the first 4 days pi.  Similar to the blood, bacterial titers in 
organs were slightly lower in pigs inoculated with the ΔdltA mutant compared with animals 
inoculated with the WT strain. However, examination at necropsy did not find major 
differences between the WT and ΔdltA mutant groups regarding damage to tissues or organs. 
At euthanasia, macroscopic lesions typical of S. suis infection were found in most animals 
infected with the WT or ΔdltA strains, especially at the pleura, pericardium and peritoneum. 
Fibrin deposits were observed in the liver and spleen of most animals in both groups. 
Pneumonia and fibrinal pleurisy were also observed in some animals. Additionally, the 
meninges showed inflammation consistent with meningitis. Lameness was observed in all pigs 
infected with the WT or ΔdltA strain. At necropsy, articulations showed inflammation, with 
fibrin deposits and excess of synovial liquid.  Results from the experimental infection showed 
that the ΔdltA mutant is attenuated in the pig and suggest that LTA D-alanylation provides an 
advantage to the WT strain. However, this conclusion is mitigated by the facts that 
dissemination of the bacterium was not prevented and mortality was observed among animals 
inoculated with the ΔdltA mutant. Since clearance of the mutant from circulation might 
primarily rely on neutrophil activity, the high dose used to inoculate the animals may explain, 
at least in part, the mortality observed. Indeed, it has been proposed that suilysin may affect 
complement activity and suilysin-producing S. suis strains, such as the WT and mutant strains 
used in this study, have been shown to be toxic to neutrophils at high titers (4). In addition, 
since CAMPs activity primarily occurs at mucosal surfaces, the extremely aggressive 
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intravenous route of administration may have also influenced the clinical onset observed in 
pigs.  
Absence of LTA D-alanylation impairs S. suis virulence in mice.  
To better evaluate the attenuation of the S. suis ΔdltA mutant observed in the pig we 
performed additional in vivo trials using the CD1 mouse model of infection that uses the 
intraperitoneal route of inoculation (8). We performed two different trials at high and 
intermediate doses of infection. At the high dose (5 x 107 CFU per animal) most mice in both 
the WT and ΔdltA mutant groups presented severe clinical signs associated with septicemia, 
such as depression, swollen eyes, weakness and prostration during the first 72 h pi. At this dose 
we did not find a clear reduction in the ability of the ΔdltA mutant to successfully initiate 
infection and induce septicemia in mice. In fact, several mice died from septicemia in both 
groups during the first 3 days of the trial (Fig. 6A). S. suis was isolated at high titers (> 1 x 107 
CFU/ml) from blood samples and organs such as the liver and spleen of septicemic animals (> 1 
x 107 CFU/0.5 g of tissue in some animals). From day 5 pi, some mice in both WT and ΔdltA 
groups developed clinical signs associated with S. suis meningitis in the mouse (8), such as 
hyperexcitation, episthotonus, opisthotonus, bending of the head and walking in circles. It has 
been proposed that maintaining a high level of bacteremia is essential for CNS disease to 
appear at later stages of the infection (13). Interestingly, the number of meningitis-presenting 
mice was lower in the ΔdltA group (N=1) than in the WT group (N=6), and this observation was 
consistent with the reduction in the bacterial load in blood among animals inoculated with the 
ΔdltA mutant compared to those having received the WT strain (data not shown). Therefore, 
we performed a second trial in the mouse using an intermediate dose of infection (5 x 106 CFU 
per animal) in order to avoid development of septicemia. Mice in both groups presented 
moderate clinical signs during the first 72 h pi, but no animals died from septicemia in either 
group. However, from day 7 pi, several mice in the WT group developed clinical signs 
associated with meningitis. S. suis was isolated from the brain of these animals at high titers (>1 
x 106 CFU/0.5 g of tissue). In strong contrast, no clinical signs of meningitis were observed in 
the ΔdltA group nor was S. suis isolated from the brain of any animal infected with the ΔdltA 
mutant. Significant differences in the mortality rate were noted between mice inoculated with 
the WT and those with the ΔdltA mutant strain (Kaplan-Meyer, P < 0.05) at the intermediate 
dose of infection (Fig. 6B).  
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S. suis LTA D-alanylation promotes adherence to and invasion of porcine BMEC.  
Experimental infection of mice at the intermediate dose of infection clearly 
demonstrated that the ΔdltA mutant is less fit to induce CNS disease. A recent study of S. suis 
meningitis in the mouse showed that cells lining the choroid plexus and the brain endothelium 
are potential entry sites for this pathogen into the CNS (8). In addition, previous studies 
demonstrated the ability of S. suis to adhere to and invade immortalized porcine BMEC (35, 
36). Recently, it has been shown that expression of the dlt operon is upregulated upon 
interaction of S. suis with porcine BMEC (11). Therefore, to assess the contribution of the LTA 
D-alanyl modification to adherence to and invasion of porcine BMEC, we compared the 
interactions of WT and ΔdltA mutant strains with cultured monolayers of these cells. After 2 h-
incubation of S. suis with porcine BMEC at a MOI of 1, followed by vigorous washing, we found 
a marked decrease in the total number of cell-associated ΔdltA mutant bacteria compared with 
the WT parent strain (Fig. 7). Using antibiotic protection to quantify bacteria which had invaded 
the intracellular compartment, a similar reduction in internalization of the ΔdltA mutant was 
observed (Fig. 7). Therefore, LTA D-alanylation itself plays a role in facilitating S. suis adherence 
to and invasion of porcine BMEC and we speculate that this occurs, mainly, through cell 
envelope charge stabilization that allows efficient display of proteinaceous adhesins and/or 
invasins (23). Porcine BMEC are one of the main cellular types forming the porcine BBB, a 
structure that successful meningitis-causing pathogens must cross in order to develop 
meningitis. Interestingly, a previous report proposed that the diminished resistance to killing by 
leucocytes was responsible for the impairment in its ability to induce meningitis in the mouse 
of a S. agalactiae ΔdltA mutant (26). Taking together our results with porcine BMEC and the 
observed outcome of the experimental infections in both the murine and porcine models of 
infection, we speculate that in addition to failure of the ΔdltA mutant to maintain a high level 
of bacteremia, impaired interaction with BMEC are also responsible for the reduced ability of 
the ΔdltA mutant to induce meningitis.  
In summary, S. suis LTA D-alanylation mediated by the dlt operon contributes 
phenotypically to resistance to CAMPs, likely through an increased net positive surface charge. 
It also enhances the resistance of S. suis to neutrophil killing as well as its capacity for 
adherence to and invasion of porcine BMEC. In addition, LTA D-alanylation contributes to S. suis 
virulence in both the murine and the porcine models of infection, probably through 
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interference with innate immune clearance mechanisms and by facilitating penetration of host 
barriers. The results of this study strongly suggest that LTA D-alanylation is an important 
virulence factor of this swine pathogen and zoonotic agent. 
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ANNEX 2. ARTICLE V. TABLES 
Table 1. Bacterial strains and plasmids used in this study. 
 Relevant characteristics Source 
Bacterial 
strains 
  
E. coli Top 
10 
General strain for cloning. F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara-leu) 7697 galU 
galK rpsL (StrR) endA1 nupG 
Invitrogen 
S. suis 
31533 
Serotype 2 field strain. Highly virulent (35) 
S. suis 
ΔdltA 
∆dltA mutant strain derived from strain 31533 This work 
S. suis 
BD102 
Unencapsulated mutant strain derived from strain 31533 (12) 
Plasmids   
pCR4 E. coli vector for cloning of PCR fragments Invitrogen 
pSmall E. coli-S. suis shuttle vector. SpR. Source of aad9 Willson, P 
(unpublished 
results) 
pSET5s Temperature sensitive suicide vector for S. suis 
mutagenesis. CmR (cat) 
(32) 
p5ΔpgdA pSET5s carrying the construction for allelic exchange This work 
 
 
Table 2. Oligonucleotide primers used in this study. Restriction sites are in bold 
Primer name Sequence (5’ – 3’) Restriction site 
2872F GCAGTTACCTCTAAGCTTGCGACAACGG HindIII 
3765R CTGCTAATCATTTGGATCCTCTCCTC BamHI 
5250F CTTCCTTTGACTGCAGATGGGAAGATT PstI 
5809R CGTCTATAAGGATCCATAGGG BamHI 
specF3 GCCAATGAGATCTATAAATAAAC BglII 
specR AAAGTGTTTCCTGCAGTTTTTCAA PstI 
 
 
Table 3. Sensitivity of the S. suis WT and ΔdltA mutant strains to the action of selected 
antimicrobial peptides. 
Peptide (origin) Net charge 
MICs (µg/ml) 
31533 (WT) ∆dltA 
Colistin (Bacillus colistinus) +5 50 25 
Polymyxin B (Bacillus polymyxa) +5 75 18.75 
Magainin II (claw frog skin) +4 45 5.6 
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 ANNEX 2. ARTICLE V. FIGURES 
 
Fig. 1. Genetic organization of the S. suis dlt operon and strategy for the construction of the 
∆dltA mutant. 
(A) Genetic organization of the S. suis dlt operon as determined by sequencing of the region 
in strain 31533 and comparison with data from sequenced strain P1/7 available at the Sanger 
Institute (http://www.sanger.ac.uk/Projects/S_suis/). The S. suis dlt operon comprises 4 genes, 
dltABCD, and extends for 4340 bp. A putative strong promoter (indicated by P) was predicted 
upstream of the dltA gene. The operon comprises 4 genes, dltA (1563 bp), dltB (1242 bp), dltC 
(240 bp) and dltD (1266 bp). A putative strong promoter was predicted 228 bp upstream of the 
start codon for dltA using the software package Softberry BProm 
(http://www.softberry.com/berry.phtml?topic=bprom&group=programs&subgroup=gfindb). 
(B). Strategy followed in this study to construct the knock-out vector used to generate the 
ΔdltA mutant. See Materials and Methods for details. 
 
lxiii 
 
 
 
 
 
Fig. 2. Nuclear magnetic 
resonance spectra of WT (upper 
panel) and ΔdltA mutant (bottom 
panel) LTA analysis.  
The arrows show the peaks for D-
alanine residues in the WT strain 
spectrum. These peaks are missing 
in the ΔdltA mutant spectra. No 
other differences between LTA of 
the two strains were found. 
Fig. 3. Growth curves and 
morphology of the WT and ∆dltA 
mutant strains. 
A) Growth curves of S. suis WT 
and ΔdltA mutant strains. The 
ΔdltA mutant grew similarly as the 
WT parent strain under normal 
laboratory conditions. B) 
Morphology of the ΔdltA mutant 
(left) and the WT (right) strains. 
Transmission electron microscopy 
showed that both strains were 
well separated, presented normal 
septation and were surrounded by 
a thick polysaccharide capsule. Bar 
= 0.5 µm. 
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Fig. 4. Percentage of bacteria 
killed after 90 min incubation 
with porcine neutrophils.  
The different strains were 
opsonized with complete porcine 
sera before incubation. The level 
of killing of the ΔdltA mutant was 
similar to that observed for the 
unencapsulated mutant BD102 
and significantly higher than that 
of the WT strain. Data are from at 
least 3 independent experiments. 
Error bars show standard 
deviation. Asterisks indicate 
significant differences, t-test, 
P<0.05. 
 
Fig. 5. Survival of pigs inoculated 
with the WT (dotted line) or the 
ΔdltA mutant (solid line) strains 
and pigs that were sham-
inoculated (dashed line). 
All the sham-inoculated animals 
survived the trial. The survival rate 
of pigs in the ΔdltA mutant group 
was 50%, while in the WT group 
most animals died from 
septicemia in the first days of the 
trial (survival rate of 17%). The 
sentinel animals were not 
considered in this analysis. See 
text for details. deviation. 
Asterisks indicate significant 
differences, t-test, P<0.05. 
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Fig. 6. Survival of mice inoculated with the WT (dotted line) or the ΔdltA mutant (solid line) 
strains.  
A)No significant differences in survival were observed between groups at the high dose of 
inoculation. However, fewer animals in the mutant group died from meningitis. (B) At the 
intermediate dose of inoculation all mice in the ΔdltA mutant group survived, while 35% of the 
WT group died from meningitis. Significant differences in survival, Kaplan-Meyer, P<0.05. 
 
 
 
 
Fig. 7. Interactions of the ΔdltA 
mutant and the WT strains with 
porcine BMEC.  
The ΔdltA mutant showed reduced 
levels of adherence to and 
invasion of porcine BMEC. Data for 
the WT strain has been normalized 
to 100%. Data are from at least 4 
independent experiments. Error 
bars show standard deviation. 
Asterisks indicate significant 
differences, t-test, P<0.05. 
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Summary 
Streptococcus suis is a major swine pathogen and emerging zoonotic agent. In this 
study we have determined the muropeptide composition of S. suis peptidoglycan (PG) and 
found, among other modifications, N-deacetylated compounds. Comparison with an isogenic 
mutant showed that the product of the pgdA gene is responsible for this specific modification 
which occurred in very low amounts. Low level of PG N-deacetylation correlated with absence 
of significant lysozyme resistance when wild type S. suis was grown in vitro. On the other hand, 
expression of the pgdA gene was increased upon interaction of the bacterium with neutrophils 
in vitro as well as in vivo in experimentally inoculated mice, suggesting that S. suis may enhance 
PG N-deacetylation under these conditions. Evaluation of the ΔpgdA mutant in both the CD1 
murine and the porcine models of infection revealed a significant contribution of the pgdA 
gene to the virulence traits of S. suis. Reflecting a severe impairment in its ability to persist in 
blood and decreased ability to escape immune clearance mechanisms mediated by neutrophils, 
the ΔpgdA mutant was severely attenuated in both models. The results of this study suggest 
that modification of PG by N-deacetylation is an important factor in S. suis virulence.
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Introduction 
Streptococcus suis is a major swine pathogen responsible for severe economic losses to 
the porcine industry (Higgins & Gottschalk, 2005). It is also the causative agent of serious 
infections in humans, especially in people in close contact with swine or pork by-products 
(Gottschalk et al., 2007). In both swine and humans the main clinical manifestations of S. suis 
are meningitis and septicaemia. While S. suis outbreaks in swine are common and sometimes 
devastating, most reports in humans describe sporadic cases resulting in either death or severe 
post-infection sequelae (Gottschalk et al., 2007). In recent times, however, S. suis has strongly 
emerged as an important public health issue in some Asian countries. For instance, it has very 
recently been shown that it is the primary cause of adult meningitis in Vietnam (Mai et al., 
2008). Moreover, during an episode in China, more than 200 human S. suis cases, 39 of which 
resulting in death, were reported in a single outbreak (Yu et al., 2006). Most cases of disease in 
both swine and humans are caused by S. suis serotype 2 and, therefore, almost all studies on 
virulence factors and pathogenesis of the infection have been carried out with this serotype 
(Higgins & Gottschalk, 2005). However, the current understanding of the S. suis pathogenesis of 
infection remains limited. It has been shown that the polysaccharide capsule is essential for the 
virulence of the bacterium (Chabot-Roy et al., 2006, Charland et al., 1998, Smith et al., 1999). 
Recently, an isogenic mutant for a serum opacity-like factor was found to be attenuated in pigs 
(Baums et al., 2006). Several other factors, such as a heamolysin (suilysin), the so-called 
extracellular protein factor and muramidase-released protein, as well as a 
fibronectin/fibrinogen-binding protein, have been shown to be linked to, but not essential for, 
the virulence of S. suis (de Greeff et al., 2002, Higgins & Gottschalk, 2005). 
Cell wall components of S. suis have also been proposed to be important virulence 
factors and several studies have shown that they contribute to exacerbate the host 
inflammatory response to infection (Gottschalk et al., 2007, Higgins & Gottschalk, 2005). The 
main cell wall component of Gram-positive bacteria is peptidoglycan (PG), which ensures the 
stability and rigidity of the cell wall. PG consists of glycan strands made of alternating β-1,4-
linked N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) which are cross-linked by 
short peptide chains (Vollmer et al., 2008a). This rather invariant structure is exploited by the 
host for both recognition of bacteria, through the nucleotide-binding oligomerisation domain 
(Nod)1 and Nod2 proteins, which recognise muropeptides released during cell wall turnover, as 
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well as for destruction of the microorganisms through the hydrolytic activity of lysozyme 
(Boneca, 2005, Chaput & Boneca, 2007). However, some Gram positive bacteria have 
developed efficient mechanisms to circumvent these host defences. For instance, 
Staphylococcus aureus, Enterococcus faecalis and Streptococcus pneumoniae modify their PG 
by O-acetylation of the C-6 atom of NAM through the action of the OatA protein (Crisostomo et 
al., 2006, Hebert et al., 2007, Herbert et al., 2007). Some pathogens, such as Streptococcus 
pneumoniae and Listeria monocytogenes, deacetylate the NAG (mostly) and NAM (to a lesser 
extent) residues into glucosamine or muramic acid through the action of the pgdA gene 
product (Boneca et al., 2007, Vollmer & Tomasz, 2000). These modifications have been shown 
to result in escaping Nod1 and Nod2 surveillance and/or increased resistance to lysozyme. 
The structure of S. suis PG has not yet been reported. However, a recent study 
identified a S. suis homolog of the S. pneumoniae pgdA gene which was highly upregulated 
during the interactions of S. suis with porcine brain microvascular endothelial cells, suggesting 
that this bacterium might be able to modify its PG by N-deacetylation (Fittipaldi et al., 2007a). 
In this study, we determined the S. suis PG composition and compared it to that of a ΔpgdA 
isogenic mutant. We demonstrate that S. suis N-deacetylates its PG through the action of the 
pgdA gene product and show that the deletion of this gene has a significant impact on the 
virulence traits of this pathogen. 
Results 
Fine structure of S. suis PG.  
The fine structure of S. suis PG has never been reported. To determine it, we used the 
classical method, i.e. isolation and purification of the SDS-insoluble cell wall, removal of 
teichoic acids by hydrofluoric acid, release of muropeptides by the muramidase cellosyl, 
separation of muropeptides by high-performance liquid chromatography (HPLC), and matrix 
assisted laser desorption-ionization-time of flight (MALDI-TOF) mass spectrometry (MS) of the 
collected muropeptide fractions. Based on previous reports on the amino acids present in the 
PG of streptococci (Schleifer & Kandler, 1972) the chromatographic behaviour of the 
muropeptides and their molecular masses, the structures of 13 muropeptides isolated from S. 
suis PG could be proposed with high confidence. The PG of S. suis had mainly D-isoglutamine in 
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position 2 and L-lysine in position 3 of the peptide. The cross-links did not contain an 
interpeptide bridge frequently found in streptococci. Thus, the muropeptide profile of S. suis 
appeared relatively simple (Fig. 1A), with three major compounds accounting for >75% of the 
total material, the monomer Tri (the disaccharide tripeptide, compound 1) (Fig. 1B), the dimer 
TetraTri (bis-disaccharide tetratripeptide, compound 7), and the trimer TetraTetraTri (tris-
disaccharide tetratetratripeptide, compound 15). Minor compounds identified had either non-
amidated D-glutamate at position 2 (compounds 2 and 8) or a free tetrapeptide or 
pentapeptide instead of the prevailing tripeptide at the acceptor site of the peptide 
(compounds 5, 6, 13, 14). Other minor muropeptides had lost a GlcNAc residue (compounds 3, 
10, 17), indicating the previous activitiy of a PG glucosaminidase, or a GlcNAcMurNAc moiety 
(compound 12) due to the activity of a PG amidase. These major and minor muropeptides 
accounted together for >93% of the total UV-absorbing material (Supplemental Table 1). 
Strikingly, the classical method for PG analysis failed to detect any deacetylated 
muropeptides in the PG of S. suis wild-type (WT) field strain 31533, despite the presence of an 
intact pgdA N-deacetylase gene in its genome (see below). Thus, if present at all, deacetylated 
muropeptides were expected in very small quantities. Therefore, we analysed the muropeptide 
mixture on a linear ion trap-Fourier transform (LTQ-FT) mass spectrometer which has superior 
sensitivity and mass accuracy. LTQ-FT-MS detected all 13 major and minor muropeptides from 
the previous HPLC-MALDI-TOF analysis (Table 1). In addition, 7 new muropeptides were 
identified including the trimer TetraTetraTetra (compound 19), the tetramer TetraTetraTetraTri 
(compound 20) and two additional muropeptides with losses of two GlcNAc residues 
(compounds 11 and 18). Interestingly, LTQ-FT-MS identified the deacetylated versions of all 
three major muropeptides (compounds 4, 9, 16, Fig. 1B and Table 1). Deacetylated 
muropeptides were identified in very low quantities, probably lower than 1% of the total 
muropeptides, preventing determination of the site of deacetylation (NAG or NAM). However, 
the observed mass intensities of these deacetylated muropeptides were well above the signal 
noise (Table 1).  
The pgdA gene product is responsible for N-deacetylation of S. suis PG.  
N-deacetylation of PG has been shown to occur through the action of the pgdA gene 
product in some Gram-positive species (Boneca et al., 2007, Meyrand et al., 2007, Vollmer & 
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Tomasz, 2000). A S. suis pgdA homolog has recently been identified (Fittipaldi et al., 2007a). 
Genomic searches at the 4 currently available S. suis sequenced genomes available at the NCBI 
(http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi), the Wellcome Trust Sanger Institute 
(http://www.sanger.ac.uk/Projects/S_suis/ ), and the DOE Joint Genome Institute 
(http://genome.jgi-psf.org/draft_microbes/strsu/strsu.home.html) databases, as well as 
Southern hybridizations using specific probes revealed that pgdA is the only putative PG N-
deacetylase encoded by S. suis (data not shown). The S. suis pgdA gene comprises 1398 bp and 
seems to be transcribed from a putative promoter located 30 bp upstream of the beginning of 
the coding sequence (identified using the Bprom software at 
http://www.softberry.com/berry.phtml?topic=bprom&group=programs&subgroup=gfindb) 
(Fig. 2A). A region of dyad symmetry that might function as a Rho-independent transcription 
terminator was detected 11 bp downstream the stop codon using the Findterm program 
(http://www.softberry.ru/berry.phtml?group=programs&subgroup=gfindb&topic=findterm). 
The predicted translated sequence of the S. suis pgdA gene showed strong homology to 
previously reported PgdA proteins, including the presence of all the conserved catalytic 
residues and metal ligand amino acids previously reported for S. pneumoniae PgdA (Blair et al., 
2005) (Fig. 2B). In order to investigate the involvement of S. suis pgdA in PG N-deacetylation we 
inactivated the gene via a double crossover event, generating a mutant strain in which the 
pgdA gene was replaced by a spectinomycin (Sp) resistance cassette (aad9 gene). Inactivation 
of pgdA had no major consequences on growth either in normal laboratory medium (Fig. 3A) or 
in the presence of 10 % porcine or foetal bovine sera (data not shown). In addition, the ΔpgdA 
mutant strain presented a normal morphology and was as encapsulated as the WT strain (Fig 
3B). However, when we prepared PG from the ΔpgdA mutant and analysed it as described 
above for the parent strain, no N-deacetylated muropeptides were found (Table 1), showing 
that N-deacetylation of S. suis PG is achieved through the action of the pgdA gene product. 
S. suis is susceptible to lysozyme in vitro and inactivation of the pgdA gene does not result in 
an increased susceptibility. 
In some Gram positive species N-deacetylation of NAG and/or NAM residues has been 
shown to confer resistance to lysozyme (Boneca et al., 2007, Meyrand et al., 2007, Vollmer & 
Tomasz, 2000). Since S. suis modifies its PG by N-deacetylation, we sought to evaluate whether 
this modification results in resistance against this hydrolytic enzyme. We therefore performed 
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a comparison of the sensitivity to lysozyme of both the S. suis WT and ΔpgdA mutant strains. 
Growth of WT S. suis was found to be inhibited by lysozyme in a dose-dependent manner. This 
behaviour was observed both when lysozyme was added at the beginning of the stationary 
phase of growth (Fig. 4) or at the mid-log phase (data not shown). Growth of S. suis was 
inhibited at concentrations (5 μg/ml) which were much lower than those not affecting growth 
of several other Gram-positive species such as S. pneumoniae (80 μg/ml) and L. monocytogenes 
(10 μg/ml), probably reflecting the low percentage of N-deacetylated muropeptides in its PG. 
Although recorded values of OD600 nm were slightly lower than those of the WT strain, the 
ΔpgdA mutant behaved essentially as the WT strain at all the concentrations tested. Since the 
OD600 nm assay does not prove lysozyme-mediated killing, we performed plating and colony 
counts for every condition and time tested. Results showed a strong correlation between the 
reported decrease in OD600 nm and loss of viability of S. suis (data not shown). 
The virulence of the ΔpgdA mutant is severely impaired in the murine model of infection. 
Components of the S. suis cell wall have been proposed to play an important role in the 
pathogenesis of infection of this pathogen (Higgins & Gottschalk, 2005). In order to evaluate if 
PG N-deacetylation contributes to the virulence of S. suis we performed an experimental 
infection of CD1 mice using a recently described model of infection (Dominguez-Punaro et al., 
2007). Results of the trial showed that most animals in the WT group presented severe clinical 
signs associated with septicaemia and septic shock, such as depression, swollen eyes, weakness 
and prostration during the first 72 h post-inoculation (pi). Several mice died from septicaemia 
in this group. From day 5 pi, some animals in the WT group developed clinical signs associated 
with S. suis meningitis in the mouse (Dominguez-Punaro et al., 2007), such as hyperexcitation, 
episthotonus, opisthotonus, bending of the head and walking in circles. In strong contrast, mice 
in the ΔpgdA group did not present any major clinical sign associated with S. suis infection 
during the trial, with the exception of slight depression following inoculation which subsided 48 
h pi (24 h pi in some cases). No mouse died in this group and significant differences in the 
mortality rate were noted between the WT and ΔpgdA groups (LogRank test, P < 0.05) (Fig. 5A). 
S. suis was isolated at high titres for several days (> 1 x 107 CFU/ml in some cases) from blood 
samples (Fig. 5B) and, at euthanasia, from organs such as the liver and spleen of septicaemic 
animals in the WT group (data not shown). In addition, isolation from the brain and 
cerebrospinal fluid of animals showing clinical signs of meningitis demonstrated the presence 
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of S. suis at high titres in both samples (data not shown). In strong contrast, titres in blood 
following inoculation were lower on average in the ΔpgdA mutant group and decreased rapidly. 
After day 3 pi S. suis could was not isolated from this tissue, even if an enrichment of the 
sample was performed, suggesting that the bacterium had been cleared from circulation (Fig. 
5B). In addition, at euthanasia, the ΔpgdA mutant could not be isolated from the liver, spleen 
or brain of any animal in the mutant group (data not shown). No macroscopic lesions 
associated with S. suis were observed in this group at post-mortem examination.  
Induction of key cytokines involved in septic shock is abolished in mice inoculated with the 
ΔpgdA mutant.  
Differences in PG composition between the WT and ΔpgdA mutant strains might result 
in a dissimilar ability to induce production of several cytokines, as demonstrated for L. 
monocytogenes (Boneca et al., 2007). On the other hand, it has been suggested that an 
exacerbated inflammatory response leading to septic shock is responsible for death at early 
stages of the infection of most mice infected with S. suis (Dominguez-Punaro et al., 2007). Since 
we did not observe clinical signs associated with septic shock in mice inoculated with the 
ΔpgdA mutant, we studied kinetically the ability of this strain to induce cytokine production in 
the mouse. Analysis of the response showed that production of both interferon-γ (IFN-γ) and 
interleukin (IL)-6 was severely impaired in animals which received the ΔpgdA mutant in 
comparison to those inoculated with the WT strain. In fact, mice that received the WT strain 
presented an important peak of both IFN-γ and IL-6 at 6 h pi followed by a gradual return to 
basal levels at 48 h pi. In contrast, animals in the mutant group did not show production of 
these cytokines above basal levels (Fig. 6A and 6B). Animals in the WT group also showed 
augmented production of IL-1β up to 48 h pi, whereas the ΔpgdA mutant induced very low 
amounts of this cytokine (Fig. 6C). On the other hand, production of tumour necrosis factor-α 
(TNF-α) was essentially similar in mice inoculated either with the WT or ΔpgdA mutant strains 
(data not shown). We also studied the chemokine response. Induction of both KC RANTES 
chemokines was abolished in the ΔpgdA mutant group while in the the WT group animals 
reached peak production between 6 and 12 h pi to return to baseline at 48 pi (Fig. 6D and 6E).  
Levels of monocyte chemotactic protein-1 (MCP-1) were similar in both groups during the 12 
first hours pi, but, thereafter, this chemokine abruptly dropped in the mutant group while it 
persisted in the WT group up to 36 h pi (Fig. 6F). Overall, with the exception of TNF-α, the 
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ΔpgdA mutant failed to stimulate the production of pro-inflammatory cytokines and 
chemokines at all the time points tested. On the other hand, the observed production of these 
inflammatory mediators in the WT group was in perfect agreement with a previous report 
(Dominguez-Punaro et al., 2007). 
The ΔpgdA mutant is killed by porcine neutrophils. 
It has been shown that in the absence of a specific humoral response, well 
encapsulated S. suis can avoid killing by phagocytes and persist in blood (Chabot-Roy et al., 
2006, Charland et al., 1998, Smith et al., 1999). However, our in vivo results suggested that the 
impaired virulence of the ΔpgdA mutant may result from its reduced ability to survive in this 
tissue. Based on previous results in L. monocytogenes that showed diminished ability of a 
ΔpgdA mutant to resist killing by phagocytic cells (Boneca et al., 2007), and taking into account 
that S. suis rapidly disappeared from blood, we postulated that clearance of the organism was 
primarily driven by neutrophils. Indeed, neutrophils are significantly increased in pigs infected 
with S. suis virulent strains and are usually predominant in lesions caused by this pathogen 
(Salles et al., 2002, Sanford, 1987). When we compared in vitro killing of the WT and ΔpgdA 
mutant strains by porcine neutrophils, under our conditions, in the absence of opsonising 
antibodies but in the presence of normal complete porcine sera, the WT strain resisted the 
bactericidal effect of porcine neutrophils. On the other hand, suggesting a potential 
contribution of PG N-deacetylation to this resistance, the ΔpgdA mutant strain was efficiently 
eliminated at rates similar to those observed for an unencapsulated mutant. At the end of the 
assay, more than 20% of the ΔpgdA mutant bacteria were killed by neutrophils compared to 
less than 5% of the WT strain (Fig. 7).  
The ΔpgdA mutant is attenuated in the porcine model of infection.  
To confirm the observed impaired virulence of the ΔpgdA mutant, we conducted a trial 
in the pig, which is the natural host of S. suis. To this end, we used a well-standardised infection 
model that utilises the aggressive intravenous route of inoculation but provides repeatability 
(Berthelot-Herault et al., 2001). Animals in the sham-inoculated group did not present any 
clinical signs during the entire extent of the trial. On the other hand, severe clinical signs such 
as depression, prostration, lameness and shaking were observed in all 10 animals inoculated 
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with the WT strain. Four pigs died or were sacrificed for ethical reasons within 24 h pi and 4 
others at day 2 pi (Fig. 8). One of these pigs developed clinical signs of meningitis, including 
convulsions, episthotonus, opisthotonus and bending of the head. At euthanasia, macroscopic 
lesions typical of S. suis infection were found in most animals infected with the WT strain. 
Fibrin deposits were observed at the pleura and the pericardium of most animals in this group. 
In addition, all pigs inoculated with the WT group presented at least one swollen articulation 
with fibrin deposits and excess of synovial liquid. Additionally, some animals in the WT showed 
damage at the meninges consistent with meningitis. In comparison, animals inoculated with 
the ΔpgdA mutant strain showed less severe clinical signs during the trial. No animal presented 
shaking or convulsions in this group and no cases of meningitis were recorded. However, 
depression, prostration and lameness were common during the first 24 h pi. Mortality was also 
observed in this group, as 4 pigs were sacrificed for strict ethical reasons within the first 3 days 
pi (Fig. 8). Differences between groups regarding mortality were nonetheless significant 
(LogRank test, p<0.05). The remaining animals in the mutant group recovered starting from day 
3 pi (day 2 pi in some cases) and survived until the end of the trial. Examination at necropsy did 
not reveal major damages to tissues or organs in this group, with the exception of swollen 
articulations in some animals. Hyperthermia was observed in all pigs infected with either the 
WT or ΔpgdA strains at 24 h pi and no major differences were observed between groups. 
Temperatures returned to normal values in surviving animals after day 3 in the ΔpgdA group 
and the 2 surviving inoculated animals in the WT group. S. suis could be isolated from the blood 
of all surviving pigs in both groups 48 h pi. However, pigs infected with the WT strain showed 
higher bacterial counts (1 x 109 CFU/ml in some cases) than those infected with the ΔpgdA 
mutant (average of 5 x 106 CFU/ml). Bacterial isolation from different organs revealed a high 
bacterial colonization of the liver, the spleen and (in some cases) the brain of pigs in the WT 
group. In contrast, isolation from the brain was negative in the ΔpgdA group, although the 
bacterium was found in the liver and spleen of most animals in this group. Similar to the blood, 
bacterial load in organs was lower in pigs inoculated with the ΔpgdA mutant compared with 
animals inoculated with the WT strain. 
The pgdA gene is upregulated upon interaction with porcine neutrophils and within the host. 
In vitro results obtained in this study showing a high sensitivity of the WT strain to 
lysozyme seem incompatible with the observed outcomes of the experimental infections of 
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both mice and swine as well as with the reported ability of S. suis to initiate and establish 
infections in other hosts (Gottschalk et al., 2007). However, absence of lysozyme resistance in 
vitro might be explained by a rather inactive pgdA gene and a subsequent low extent of PG 
deacetylation when S. suis grows in Todd-Hewitt broth (THB). We therefore hypothesised that 
S. suis might express the pgdA weakly in THB and upregulate its expression upon interaction 
with the host or host cells in order to resist the deleterious effects of lysozyme. To assess this 
hypothesis, we compared the relative expression levels of the S. suis pgdA gene under standard 
laboratory conditions to that observed upon interaction (as described above) with porcine 
neutrophils. After reverse transcription, the quantitative PCR (Q-PCR) assays showed that while 
the expression of the pgdA gene by S. suis remained essentially unchanged in the mock-
infection sample (without neutrophils), it was highly upregulated (mean fold change of 6.7) 
after 90 min incubation with neutrophils (Fig. 9). We also performed the same analysis from in 
vivo samples (liver and spleen) collected after experimental infection of CD1 mice. Data 
obtained showed that S. suis consistently upregulated the expression of the pgdA gene in all 
the mice tested, with fold changes ranging from 3 to 13, depending on the animal and organ 
tested (Fig. 9). 
Discussion 
Even though it has been proposed as an important factor for S. suis virulence (Higgins & 
Gottschalk, 2005), knowledge on the cell wall composition of this pathogen is very limited. A 
partial structure of S. suis (lipo)teichoic acids (LTA) has been reported (Elliott et al., 1977), and 
very recently it has been shown that S. suis modifies LTA by D-alanylation (Fittipaldi et al., 
2008). However, PG composition of this bacterium has largely remained elusive. In this study 
we provide for the first time evidence regarding the composition of this essential polymer in S. 
suis, which was found to be, in several aspects, typical of species within the low GC-content 
Gram-positive phylum Lactobacillales. Like in other streptococci, in S. suis mostly D-Gln is found 
at position 2 of the stem peptide, and an L-Lys residue is present at position 3, which can 
participate in 4-3 cross-links with neighbouring peptides (Schleifer and Kandler, 1972). 
However, unlike other streptococci, the PG of S. suis lacks an interpeptide bridge but contains 
direct L-Lys-D-Ala cross-links. Consistently, database searches revealed the absence in S. suis of 
homologues of genes encoding for known peptide branching enzymes of the Fem transferase 
or ATP-grasp families (Bellais et al., 2006, Filipe & Tomasz, 2000) (data not shown). About 67% 
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of the peptides are present in dimeric or trimeric cross-links (Supplemental Table 1). S. suis PG 
has a low proportion of pentapeptides and tetrapeptides indicating high activities of DD- and 
LD-carboxypeptidases in this species. Some of the minor muropeptides correspond to 
modifications of canonical structures, suggesting the presence of glucosaminidase, amidase 
and N-deacetylase activities. While the enzymes responsible for the two former activities 
remain to be identified, N-deacetylation could be linked to the S. suis pgdA gene product. To 
fully ascribe this link, we tried to restore the WT phenotype by complementation of the ΔpgdA 
mutant strain with several different constructions and E. coli-S. suis shuttle vectors but, 
perhaps because it has deleterious effects in E. coli, we failed to obtain recombinant plasmids 
carrying the S. suis pgdA gene (data not shown). However, repeated generation of ΔpgdA 
mutants (3 additional independent mutants, ΔpgdA 2, 3 and 4, Supplemental Table 3) and 
consistent verification of a key phenotype such as neutrophil killing for each of them 
(Supplemental Figure 1) suggest that the occurrence of genetic events elsewhere in the 
genome other than inactivation of pgdA during the procedures for mutant isolation are 
unlikely. In addition, the genetic organization of the region (Fig. 2A) suggests that polar effects 
are highly improbable. 
S. suis is an important swine pathogen and a zoonotic agent causing septicaemia and 
meningitis in both pigs and humans (Gottschalk et al., 2007). In order to establish an infection 
S. suis must first overcome the innate immune response of the host. One important mediator of 
this response is lysozyme. However, some bacterial species resist lysozyme activity by means of 
PG N-deacetylation and it has been proposed that the level of this modification may correlate 
with the level of resistance (Hebert et al., 2007, Vollmer et al., 2008b). Consistently with this 
suggestion, the S. suis WT strain, which N-deacetylates PG during growth in normal laboratory 
culture medium to a very little extent, was sensitive to lysozyme at concentrations much lower 
than those allowing growth of S. pneumoniae and L. monocytogenes (Boneca et al., 2007, 
Vollmer & Tomasz, 2000). Furthermore, we did not observe any major differences between S. 
suis WT and ΔpgdA mutant strains regarding resistance to the action of this enzyme in vitro. In 
fact, these results may be explained by an already low degree (probably < 1 % of total 
muropeptide) of PG N-deacetylation of the WT strain. By comparison, resistance to lysozyme in 
S. pneumoniae correlated with over 80% of N-deacetylated glucosamine residues (Vollmer & 
Tomasz, 2000). In L. monocytogenes the extent of N-deacetylation was lower, but still very 
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important, with up to 50 % of N-deacetylated muropeptides (Boneca et al., 2007). In this 
regard, the demonstration that S. suis upregulates the expression of the pgdA gene upon 
interaction with neutrophils as well as during growth in vivo constitutes an interesting and 
unprecedented finding of this work. Since it is apparent that the S. suis pgdA gene product is 
responsible for PG N-deacetylation, it is tempting to speculate that this increased expression of 
the pgdA gene correlates with a higher degree of PG N-deacetylation under these conditions 
that, in turn, results in enhanced resistance to lysozyme produced by neutrophils. However, in 
view of the fact that it is technically impossible to prepare PG from these samples in amounts 
and purity suitable to perform HPLC and LTQ-FT mass spectrometry, we are unable to provide 
conclusive evidence for this hypothesis. 
Results of the experimental infections carried out in this study using the ΔpgdA mutant 
suggest that PG N-deacetylation is a major factor in the virulence of S. suis. Overall, the 
infection outcome in the mouse clearly indicates that the ΔpgdA mutant is severely hampered 
in its ability to inflict damage to the host. The most important consequences of PG N-
deacetylation are increased survival of S. suis at early stages of the infectious process and an 
increased ability of the pathogen to survive in blood. Interestingly, there was a complete 
absence of septic shock signs in mice inoculated with the ΔpgdA mutant and the production of 
inflammatory mediators was completely abrogated in mice inoculated with the ΔpgdA mutant, 
while, in perfect agreement with a previous study (Dominguez-Punaro et al., 2007), an 
exacerbated T helper-1 inflammatory response in mice inoculated with the WT strain was 
observed. Different results were obtained in a previous study with L. monocytogenes showing 
that the absence of PG N-deacetylation does not result in muropeptides unable to activate the 
NF-κB pathway, but, instead, in enhanced activation of that pathway in a Nod1- and Nod2-
dependent manner (Boneca et al., 2007). With the results obtained in our study we thus 
propose that, rather than an impaired ability of the unmodified PG to induce exaggerated 
inflammation, the observed basal levels of pro-inflammatory cytokines in mice inoculated with 
the ΔpgdA mutant might result from the rapid clearance of the mutant by neutrophils (low 
levels of bacteraemia) along with an irrelevant activation of macrophages, lymphocytes and NK 
cells in this process.  
In spite of the fact that the ΔpgdA mutant was able to induce clinical signs in some pigs, 
conclusions obtained for the mouse may be extended to the pig. Indeed, mortality observed in 
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the ΔpgdA mutant group may be explained, at least in part, by the fact that we have prioritised 
the use of the highly aggressive intravenous route of administration and a high dose of inocula 
in order to use a validated model of infection (Berthelot-Herault et al., 2001). Nevertheless, in 
contrast to the WT group, pigs that survived septic shock in the ΔpgdA mutant group noticeably 
recovered and it was apparent that the ΔpgdA mutant was less fit to survive in blood. This 
inability to persist in blood might also be important for later stages of the infection. Firstly, 
colonisation of organs was hampered in the mutant group in both the mouse and pig. In 
addition, it has been shown that if S. suis fails to induce acute fatal septicaemia but the level of 
bacteraemia remains high, CNS disease may appear afterwards (Dominguez-Punaro et al., 
2007, Segura et al., 2006). Interestingly, and in agreement with its observed rapid clearance 
from blood, we did not record any case of meningitis in neither model with the ΔpgdA mutant. 
On the other hand, meningitis was responsible for the death of 35 % of mice and 10 % of pigs in 
the respective WT groups. 
Enhanced clearance of the ΔpgdA mutant strain from blood might be attributed to an 
increased susceptibility of the mutant to killing by neutrophils, as shown in this study. 
Interestingly, neither the WT or ΔpgdA mutant strains showed differences in resistance to the 
action of cationic antimicrobial peptides such as polymixin B, magainin II, colistin, human 
neutrophil peptide (HNP)-1 and HNP-2 (Supplemental Table 2), functional homologues of which 
are secreted by porcine neutrophils. We speculate that differences observed in killing by 
neutrophils between strains might primarily be explained by the enhanced resistance of the WT 
strain to lysozyme secreted by neutrophils, due to increased PG N-deacetylation after induction 
of the pgdA gene. On the other hand, since our killing assay does not differentiate between 
intra and extracellular killing it is difficult to estimate if increased killing of the ΔpgdA mutant 
correlate with increased phagocytosis. However, since the ΔpgdA mutant is as encapsulated as 
the WT strain and, on the other hand, it has been shown that capsular material interferes with 
the uptake of S. suis by phagocytes (Chabot-Roy et al., 2006, Charland et al., 1998, Segura et 
al., 2004, Smith et al., 1999), enhanced phagocytosis of the mutant might be unlikely. 
Interestingly, it has been suggested, although not proved, that an encapsulated S. suis ΔdltA 
mutant might be killed by porcine neutrophils extracellularly in the so called neutrophil 
extracellular traps (NETs) (Fittipaldi et al., 2008). Since neutrophils, in addition to delivering 
their complex antibiotic arsenal into the phagosome, also discharge their lysozyme-rich specific 
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granules extracellularly in the NETs (Cho et al., 2005, Mollinedo et al., 2006) it might be 
postulated that the ΔpgdA mutant may also be killed through the action of this enzyme after 
being trapped in these extracellular structures. Further experiments are needed to confirm this 
hypothesis. 
In conclusion, we have determined the muropeptide composition of S. suis and showed 
that this bacterium, through the action of the pgdA gene product, modifies its PG by means of 
N-deacetylation. We showed that this PG modification, which is probably enhanced in vivo, 
greatly contributes to the virulence of S. suis in both the murine and porcine models of 
infection. The results of this study strongly suggest that PG N-deacetylation is a major virulence 
factor of this swine pathogen and zoonotic agent. 
Experimental procedures 
Bacterial strains, plasmids, and culture conditions.  
Bacterial strains and plasmids used in this study are listed in Supplemental Table 3. S. 
suis strains were grown in THB or in Todd-Hewitt agar (THA) (Becton Dickinson, Sparks, MD, 
USA) at 37°C under 5% CO2. Escherichia coli strains were cultured in Luria-Bertani broth or agar 
medium (Becton Dickinson) at 37°C for 18 h. When necessary, antibiotics (purchased from 
Sigma-Aldrich, Oakville, On, Canada) were added to culture media at the following 
concentrations: for E. coli, kanamycin, 50 µg/ml; chloramphenicol (Cm), 10 µg/ml and Sp, 50 
µg/ml; for S. suis, Cm, 5 µg/ml and Sp, 100 µg/ml. 
Purification of PG.  
S. suis cell wall was prepared from cultures in the exponential growth phase as 
described for S. pneumoniae (Garcia-Bustos & Tomasz, 1987, Severin et al., 1997) Wall teichoic 
acid and acid-labile modifications (such as O-acetylation) were removed by treatment with 
hydrofluoric acid to obtain PG (Severin et al., 1997). 
Preparation and HPLC-analysis of muropeptides.  
PG (ca. 1.25 mg/ml) was stirred with 25 μg/ml cellosyl (kindly provided by Hoechst, 
Frankfurt, Germany) in 20 mM sodium phosphate pH 4.8 for 24 h at 37°C. Then, a second 25 
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μg/ml-aliquot of cellosyl was added and the incubation continued for another 24 h. The sample 
was boiled for 10 min and centrifuged at room temperature for 15 min at 16000 × g. The 
supernatant was recovered and reduced with sodium borohydride as described (Glauner, 
1988). The reduced muropeptides were separated on a 250×4.6 mm, 3 μm Prontosil 120-3-C18 
AQ reversed-phase column (Bischoff, Leonberg, Germany) as described (Glauner, 1988), with 
the exception of the running buffers. Buffer A was 10 mM sodium phosphate pH 6.0 
supplemented with 13 μl/l of 10% sodium azide; buffer B was 10 mM sodium phosphate pH 6.0 
with 30% methanol. The eluted muropeptides were detected at 205 nm.  
MALDI-TOF analysis of muropeptides.  
Muropeptides eluted from the C18 column were collected, concentrated in a SpeedVac 
to 10-20 μl, and acidified with 0.1% trifluor acetic acid (TFA). The sample was then zip-tipped 
(C-18 material, Millipore, UK) according to the manufacturer's standard protocol, eluted from 
the zip-tip with 3 μl of 50% acetonitrile, 0.1% TFA and mixed with α-cyano-4-hydroxycinnamic 
acid matrix prior to spotting on a target plate. MALDI-TOF analysis was done on a Voyager-DE 
STR mass spectrometer (Applied Biosystems, Warrington, UK) operating in positive ion 
reflectron mode over the mass range (m/z) of 500 to 3000.  
Preparation of muropeptides and LTQ-FT-MS analysis.  
Different conditions for muropeptide preparation were used for samples subjected to 
LTQ-FT-MS analysis. PG (ca. 0.8 mg/ml) was digested with 13 μg/ml cellosyl in 20 mM 
ammonium acetate buffer, pH 4.8, for 16 h at 37°C. The sample was boiled for 10 min and 
centrifuged at room temperature for 15 min at 16.000×g. The sample (1 μl) was applied on a 
C18-reversed phase self-packed 100×0.5 mm column and eluted with a linear gradient of 
acetonitrile in water, 0.1% formic acid. The eluted fractions were sprayed directly into an LTQ-
FT mass spectrometer (Thermo, Bremen, Germany) operating in the positive ion mode. The 
details of the method will be published elsewhere (Bui et al., manuscript in preparation).  
DNA manipulations.  
Restriction enzymes, DNA-modifying enzymes and DNA polymerase were purchased 
from GE Healthcare (Piscataway, NJ, USA) or Takara Bio (Otsu, Shiga, Japan) and used 
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accordingly to the manufacturer's recommendations. Minipreparations of recombinant 
plasmids from, and transformation of E. coli were performed by standard procedures 
(Sambrook et al., 1989). Transformation of S. suis was carried out as previously described 
(Takamatsu et al., 2001a). S. suis genomic DNA was isolated by the guanidium thiocyanate 
method (Pitcher et al., 1989). Southern hybridizations were performed by the procedures 
described previously (Sekizaki et al., 2001). For preparation of probes, DNA fragments were 
labelled with digoxigenin (DIG) using the DIG-PCR labeling mixture (Roche Diagnostics, Laval, 
QC, Canada) according to the manufacturer's instructions. Oligonucleotide primers (Invitrogen, 
Burlington, ON, Canada) are listed in Supplemental Table 4. 
Construction of the knockout vector for gene replacement.  
DNA fragments were amplified from genomic DNA of S. suis strain 31533 by PCR using 
the primer sets 4197F-PG plus 4985R-PG (left arm) or 6276F-PG plus 6838R-PG (right arm) 
(Supplemental Table 4). A Sp resistance cassette (aad9 gene) was amplified from pSmall with 
primers specF3 and specR. All three primer sets introduce unique restriction sites. PCR 
amplicons were digested using the appropriate restriction enzymes, and sequentially ligated in 
the order left arm-Sp cassette-right arm using T4 DNA ligase. The resulting fragment was 
amplified by PCR using primers 4197F-PG and 6838R-PG, cloned into pCR4 using the TOPO TA 
PCR cloning kit (Invitrogen) following the manufacturer’s instructions and propagated in E. coli. 
The insert was then cut out with HindIII and BamHI and recloned into the HindIII and BamHI 
sites of the thermosensitive vector pSET-5s, which carries the Cm resistance gene cat 
(Takamatsu et al., 2001b), generating knockout vector p5ΔpgdA. 
Generation of S. suis ΔpgdA.  
Procedures for selection of mutants by allelic exchange via double crossover were 
described previously (Takamatsu et al., 2001b). Briefly, S. suis strain 31533 was transformed 
with p5ΔpgdA, and the cells were grown at 28°C in the presence of Cm and Sp selection. 
Bacteria at the mid-logarithmic growth phase were diluted with THB containing Sp and grown 
at 28°C to early logarithmic phase. The cultures were then shifted to 37°C and incubated for 4 
h. Subsequently, the cells were spread on THA containing Sp and incubated at 28°C. 
Temperature-resistant Sp-resistant colonies were screened for loss of vector-mediated Cm 
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resistance to detect putative mutants which had exchanged their WT allele for a genetic 
segment containing the aad9 gene as a consequence of homologous recombination via a 
double crossover. Finally, the genetic organization of the resulting ΔpgdA mutant was verified 
by PCR and by Southern hybridisation (data not shown). Three additional independent ΔpgdA 
mutants (named ΔpgdA 2, 3, and 4 respectively, Supplemental Table 3) were generated using 
the same strategy. 
Transmission electron microscopy.  
ON cultures of S. suis WT strain 31533 or mutant strain ΔpgdA were mixed with specific 
polyclonal serum anti-S. suis serotype 2 and incubated at room temperature for 1 h, followed 
by fixation in cacodylate buffer (0.1M cacodylate, 5%, v/v, glutaraldehyde 0.15%, w/v, 
ruthenium red, pH 7.2) for 2 h. Cells were then immobilised in 4% (w/v) agar and post-fixed ON 
at 4°C in 2% (v/v) osmium tetraoxyde. Samples were dehydrated in graded series of ethanol 
and embedded in Spurr low-viscosity resin. Thin sections were post-stained with uranyl acetate 
and lead citrate and examined with a transmission electron microscope (Model 420, Philips 
Electronics, The Netherlands). 
Lysozyme and cationic antimicrobial peptide sensitivity.  
S. suis WT and ΔpgdA mutant were grown in THB to which was added hen egg 
lysozyme (final concentrations ranging from 2 to 50 μg/ml; Sigma-Aldrich). Growth was 
monitored by following the optical density at 600 nm and by plating serials dilutions onto THA 
followed by CFU enumeration after ON incubation. Assays for sensitivity to cationic 
antimicrobial peptides were carried out in sterile 96-well microtiter plates. Logarithmic-phase 
S. suis
 cells were adjusted to approximately 104 CFU/ml in 100 µl THB containing one of the 
following antimicrobial compounds (purchased from Sigma-Aldrich) in serial dilutions: Colistin 
(0 to 200 µg/ml), polymyxin B (0 to 300 µg/ml), magainin II (0 to 45 µg/ml), HNP-1 (0 to 15 
µg/ml) and HNP-2 (0 to 15 µg/ml). Plates were incubated for 24 h at 37°C. The MIC was defined 
as the lowest antimicrobial concentration yielding no detectable bacterial growth by OD600 nm 
measurement. 
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Killing by porcine neutrophils.  
Blood samples were collected by venous puncture from high health status pigs which 
tested negative by ELISA (Lapointe et al., 2002) for S. suis serotype 2. Cell populations were 
separated by Ficoll-Hypaque (GE Healthcare) density gradient centrifugation and neutrophils 
isolated by sedimentation in 6% dextran, as decribed (Chabot-Roy et al., 2006). Contaminating 
erythrocytes were removed by lysis with 0.83% ammonium chloride. Neutrophils were 
resuspended in RPMI 1640 medium (Invitrogen) supplemented with 10% of heat-inactivated 
porcine serum at a final concentration of 5×106 cells/ml. Bacteria (WT or ΔpgdA mutant strains 
at approx. 1×104 CFU/ml) were opsonised with complete normal porcine serum for 30 min at 
37°C and then mixed in microtubes with neutrophils at 5×106 cells/ml. The mixture was 
incubated for 90 min at 37°C under 5% CO2. Under these conditions bacteria are not toxic to 
neutrophils (Chabot-Roy et al., 2006). After incubation cells were lysed with sterile water and 
viable bacterial counts on THA were performed. 
Experimental infection of mice.  
All experiments involving animals were conducted in accordance with the guidelines 
and policies of the Canadian Council on Animal Care. For virulence studies a total of 30 female 
CD1 mice aged 6 weeks old (Charles River laboratories, Wilmington, MA, USA) were used. At 
day 0, animals were divided in two groups. Group 1 was inoculated by intraperitoneal injection 
of 1 ml of a S. suis strain 31533 suspension at 5 x 107 CFU/ml, while group 2 received the same 
dose of the mutant strain ΔpgdA using the same route of administration. Mice were monitored 
3 times a day during 10 days for clinical signs and assigned clinical scores as previously 
described (Dominguez-Punaro et al., 2007). Surviving animals in both groups were sacrificed at 
day 10 pi. Blood was collected daily from the tail vein and at euthanasia by cardiac puncture 
and used to evaluate bacterial load in this tissue by plating onto sheep blood agar plates and 
enumeration after ON incubation. Bacterial colonisation of the liver, the spleen and the brain of 
infected animals was also evaluated. Briefly, small pieces of these organs weighing 0.5 g were 
trimmed, placed in 500 μl of phosphate buffered saline (PBS), pH 7.3, and homogenised. 
Thereafter, 50 μl of the suspensions were plated as described above. In addition, an 
enrichment of the samples was carried out by inoculation of 300 μl of homogenised organ 
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samples or 100 μl of blood into THB, followed by ON incubation at 37°C and subsequent 
dilution and plating onto sheep blood agar plates as described above.  
Analysis of the systemic immune response in mice.  
A total of 42 female CD1 mice aged 6weeks old (Charles River) were used to study the 
systemic immune response. The WT strain (1 ml of a 5 x 107 CFU/ml suspension) was inoculated 
as described above to 18 mice. The same number of mice received the ΔpgdA mutant (1 ml of a 
5 x 107 CFU/ml suspension). Finally, 6 mice were sham-inoculated. At defined intervals (3h, 6h, 
12 h, 24 h, 36 h and 48 h) pi infected mice were sacrificed (3 animals per time for those 
inoculated with the WT or mutant strains, and 1 mouse per time for those sham-inoculated), 
and blood was collected by cardiac puncture. The bacterial dose and time points used were 
those reported in a previous study (Dominguez-Punaro et al., 2007). For validation of the 
conditions, we previously performed an additional independent study with a limited number of 
animals and time points which showed results consistent with those obtained in the major 
experiments described in the manuscript (data not shown). Plasma was recovered from blood 
samples by centrifugation and the levels of IFN-γ, IL-6, IL-1β, TNF-α, MCP-1, KC and RANTES 
were determined using a liquid multiarray system (Luminex Molecular Diagnostics, Toronto, 
ON, Canada). Commercial Multiplex coated beads and biotinylated antibodies, as well as the 
Beadlyte microtiter 96 well filter plates were obtained from Millipore, (Billerica, MA, USA). Each 
multiplex assay was performed in duplicate following the manufacturer’s specifications. Data 
were collected using the Luminex-100 system Version IS 2.2 and analysed by MasterPlex 
Quantitation Software (MiraiBio, San Francisco, CA, USA). Standard curves for immune 
response mediators were obtained using the standards supplied by the manufacturer.  
Analysis of the pgdA gene expression.  
Total RNA was prepared from 1 ml of an early stationary phase S. suis culture in THB 
(“untreated control”, approx 107 CFU/ml) using RNAwiz (Ambion, Austin, TX, USA) according to 
the manufacturer's instructions. To analyze expression of pgdA upon interaction of S. suis with 
neutrophils, the WT type strain was treated as described above in the killing section and 
allowed to interact with porcine neutrophils for 90 min. Five tubes of the mixture of 
neutrophils and bacteria were then pooled and total RNA was prepared as described above. In 
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addition, 5 tubes of a “killing mock-infection” (RPMI plus 10 % porcine serum without 
neutrophils, as described in the killing section) were pooled and total RNA prepared from using 
RNAwiz. For analysis of in vivo expression, 5 female CD1 mice aged 6weeks old were inoculated 
as described above with 1 ml of a S. suis strain 31533 suspension at 5 x 107 CFU/ml. Animals 
were sacrificed 24 h pi. Pieces of spleen and liver (weighing approx 0.2 g) were collected and 
disrupted with 0.1 mm glass beads using a mini bead beater (Biospec Products, Bartlesville, OK, 
USA) and total RNA prepared with RNAwiz, as described. All RNA samples were treated with 
TurboDNAse (Ambion), and absence of contaminating DNA was verified by PCR using primers 
AROA-F and BA9 (Supplemental Table 4), which target the aroA gene. RNAs were quantified by 
measurement of absorbance at 260 nm and their integrity verified by visualization on 1% 
denaturing agarose gels. Synthesis of cDNAs was performed in triplicate using SuperScript II 
(Invitrogen) with random hexamers (Roche, Laval, Qc, Canada). Q-PCR was carried out by using 
the QuantiTect SybrGreen PCR Kit (Qiagen, Mississauga, ON, Canada) according to the 
manufacturer’s instructions. For each sample, a no-reverse transcription reaction was run as a 
control. For each Q-PCR run, to normalize for the amount of sample cDNA added to each 
reaction, the Ct value of the pgdA gene was subtracted by the Ct value of the endogenous 
control rpoD gene (delta Ct = Ct pgdA –Ct rpoD), and then, for a comparison between the 
“untreated control” (bacteria grown in THB) group and the “treated” groups (upon interaction 
with neutrophils, “killing mock infection”, in vivo samples), the delta Ct values of the treated 
groups were subtracted by the delta Ct value of the untreated control (delta delta Ct = delta Ct 
treated group − delta Ct untreated control). The fold changes were calculated by the formula of 
2−delta delta Ct (Livak & Schmittgen, 2001). Primers were SSU1448-FQ and SSU1448-RQ for pgdA 
and RPDO-F and RPDO-R for rpoD (Supplemental Table 4). 
Experimental infection of pigs.  
A total of 24 high-health-status pigs (ages 4 to 5 weeks) which tested negative by ELISA 
(Lapointe et al., 2002) for S. suis serotype 2 were used. Strict biosecurity measures were 
implemented to avoid undesirable contamination of the pigs; these included an air filtration 
system and airlocks for each unit. Pigs were divided in 3 groups. Animals in groups 1 (N=10) and 
2 (N=10) were inoculated by intravenous injection of 1 ml of 1 x 108 CFU/ml of S. suis WT strain 
31533 or mutant ΔpgdA, respectively. Group 3 (N=4) were sham-inoculated animals. Clinical 
signs and presence of S. suis in blood were monitored during the trial. Surviving animals in all 3 
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groups were sacrificed 5 days pi and examined for pathological lesions. Bacteriological isolation 
from different organs (liver, spleen, lungs, heart and articulations) was performed essentially as 
described above for the mice. 
Statistics.  
Unless otherwise specified, all the data were expressed as means ± standard 
deviations. Unless otherwise specified, data were analysed by two-tailed, unpaired t test and all 
assays were repeated at least three times. For data analysis of the systemic immune response 
and bacteremia in mice the Mann-Whitney test was used. For in vivo virulence experiments, 
survival was analysed with the LogRank test. For all tests, a value of P < 0.05 was considered as 
the threshold for significance. 
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ANNEX 3. ARTICLE VI. TABLES 
Table 1. Muropeptides detected by LTQ-FT mass spectrometry. 
Muropeptide WT ΔpgdA 
No proposed structure 
theoretical 
neutral 
mass (Da) 
neutral 
mass (Da) 
signal 
intensity 
(A.U.)1 
neutral 
mass (Da) 
signal 
intensity 
(A.U.)1 
1 Tri 823.3811 823.3793 157,566 823.3795 124,676 
2 Tri (Glu) 824.3889 824.3644 n. q.2 824.3646 n. q. 
3 Tri (-G) 620.3017 620.3012 5,961 620.3012 4,212 
4 Tri (deAc) 781.3705 781.3708 450 n.d.3 n.d. 
5 Tetra 894.4182 894.4171 17,168 894.4173 15,822 
6 Penta 965.4553 965.4541 9,763 965.4549 4,835 
7 TetraTri 1699.7887 1699.7874 108,961 1699.7871 59,454 
8 TetraTri (Glu) 1700.7966 1700.7580 n.q. 1700.7598 n.q. 
9 TetraTri (deAc) 1657.7781 1657.7766 5,488 n.d. n.d. 
10 TetraTri (-G) 1496.7093 1496.7084 5,551 1496.7083 3,095 
11 TetraTri (-2G) 1293.6299 1293.6287 10,318 1293.6291 3,716 
12 TetraTri (-GM) 1221.6088 1221.6080 3,021 1221.6086 903 
13 TetraTetra 1770.8259 1770.8249 2,588 1770.8261 1,288 
14 TetraPenta 1841.8630 1841.8620 3,834 1841.8626 2,013 
15 TetraTetraTri 2576.1964 2576.1952 17,734 2576.1995 7,391 
16 TetraTetraTri (deAc) 2534.1858 2534.1944 139 n.d. n.d. 
17 TetraTetraTri (-G) 2373.1170 2373.1174 1,813 2373.1226 544 
18 TetraTetraTri (-2G) 2170.0376 2170.0369 2,191 2170.0407 780 
19 TetraTetraTetra 2647.2335 2647.2275 84 2647.2398 19 
20 TetraTetraTetraTri 3452.6040 3452.6084 1.972 3452.6113 708 
1 the noise of the signal is ≈10 A.U. 
2 not quantified because the signal partly overlaps with the isotope signal of the amidated 
compound 
3 n.d. not detected
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Supplemental Table 1. Quantification and MALDI-TOF-MS analysis of the muropeptides 
separated by HPLC. 
Muropeptide Area % 
Positive mass (Da) 
from collected peaks2 
reduced, Na+ form 
No proposed structure1 WT ΔpgdA measured calculated 
1 Tri 18.8 20.9 848.40 848.39 
2 Tri (Glu) 2.2 2.4 849.38 849.40 
3 Tri (-G) n.q.3 n.q. 623.334 623.334 
4 Tri (deAc) n.d. 5 n.d. n.d. 806.38 
5 Tetra 2.6 2.7 919.46 919.42 
6 Penta 1.5 1.7 990.51 990.46 
7 TetraTri 46.0 46.7 1726.86 1726.81 
8 TetraTri (Glu) 2.5 1.9 1727.88 1727.82 
9 TetraTri (deAc) n.d. n.d. n.d. 1684.80 
10 TetraTri (-G) 3.3 4.1 1523.77 1523.73 
11 TetraTri (-2G) n.d. n.d. n.d. 1320.65 
12 TetraTri (-GM) 1.1 0.3 1246.67 1246.61 
13 TetraTetra 1.7 1.3 1797.97 1797.85 
14 TetraPenta 1.9 2.0 1869.02 1868.88 
15 TetraTetraTri 11.7 10.2 2605.34 2605.23 
16 TetraTetraTri (deAc) n.d. n.d. n.d. 2563.22 
17 TetraTetraTri (-G) n.q.6 n.q.6 2402.27 2402.15 
18 TetraTetraTri (-2G) n.d. n.d. n.d. 2199.07 
19 TetraTetraTetra n.d. n.d. n.d. 2676.27 
20 TetraTetraTetraTri n.d. n.d. n.d. 3483.65 
1 see Fig. 1B 
2 peaks were collected from the WT sample 
3 not quantified, co-elutes with Tri 
4 mass of the H+ form 
5 n.d., not detected 
6
 n.q., not quantified, co-elutes with TetraTetraTri 
 Supplemental Table 2. Sensitivity of the S. suis WT and ΔpgdA mutant strains to the action of 
selected antimicrobial peptides. 
Peptide (origin) Net charge 
MICs (µg/ml) 
WT ΔpgdA 
Colistin (Bacillus colistinus) +5 50 50 
Polymyxin B (Bacillus polymyxa) +5 75 75 
Magainin II (claw frog skin) +4 45 45 
HNP-1 (human) +3 6 6 
HNP-2 (human) +3 5 5 
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Supplemental Table 3. Bacterial strains and plasmids used in this study. 
Bacterial strains Relevant characteristics Source 
E. coli Top ten General strain for cloning. F- mcrA Δ(mrr-hsdRMS-
mcrBC) φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara-leu) 
7697 galU galK rpsL (StrR) endA1 nupG 
Invitrogen 
S. suis 31533 Serotype 2 field strain. Highly virulent (Vanier, Segura 
et al. 2004) 
S. suis ΔpgdA Derived from strain 31533. Deletion of the pgdA gene This work 
S. suis ΔpgdA 2 Derived from strain 31533. Deletion of the pgdA gene This work 
S. suis ΔpgdA 3 Derived from strain 31533. Deletion of the pgdA gene This work 
S. suis ΔpgdA 4 Derived from strain 31533. Deletion of the pgdA gene This work 
S. suis BD102 Derived from strain 31533. Deletion of the promoter of 
the aro operon. Unencapsulated.  
(Fittipaldi, Harel 
et al. 2007) 
Plasmids   
pCR4 E. coli vector for cloning of PCR fragments Invitrogen 
pSmall E. coli-S. suis shuttle vector. SpecR. Source of aad9 P. Willson 
(unpublished) 
pSET5s Thermosensitive suicide vector for S. suis mutagenesis. 
CmR (cat) 
(Takamatsu, 
Osaki et al. 
2001) 
p5ΔpgdA pSET5s carrying the construction for allelic exchange This work 
 
Supplemental Table 4. Oligonucleotide primers used in this study. Restriction sites are in 
bold. 
Primer name Sequence (5’ – 3’) Restriction site 
4197F-PG GACGGGTGGTCAAGCTTTTGAATA HindIII 
4985R-PG CCATTATGCCGAGCAAGGAGATCTTG BglII 
6276F-PG GTAACAGACTTACTCTGCAGTCCTC PstI 
6838R-PG GTGAACGTTTGGATCCTCTACGTAA BamHI 
SPECF2 TTATCAGGATAGATCTTCGTTCGTGA BglII 
SPECR AAAGTGTTTCCTGCAGTTTTTCAA PstI 
COMPPGDA-F3 GGATTTAAGGGTACCCGTCGCAAGGA KpnI 
COMPPGDA-R ACCAGGGATCCTACTAACATGATTC BamHI 
AROA-F AACGTGACCTACCTCCGTTG  
AROA-R CGGTCATCGTAGAATTCGAGT  
SSU1448-FQ TTCTCTCTGTACTTGCTCCC  
SSU1448-RQ GGTCGCTCTAACCTTTGATG  
RPOD-F TCTTTCAAATACATGCGGACTG  
RPOD-R ATTCCATTTACGCTTGATGCTG  
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ANNEX 3. ARTICLE VI. FIGURES 
 
Fig. 1. S. suis muropeptide 
composition and proposed 
structures. 
A. Muropeptide composition of S. 
suis WT and ΔpgdA mutant. The 
numbers correspond to the 
structures shown in B. The profiles 
of both strains showed similar 
muropeptide composition. 
However, see Table 1 and the text 
for differences between the WT 
and ΔpgdA mutant. B. Proposed 
structures for S. suis 
muropeptides. G indicates N-
acetylglucosamine residue; M 
indicates N-acetylmuramic acid 
residue. Asterisks indicate 
deacetylation of G or M. In 
compounds marked with 1 it is not 
known which of the residues is 
modified. 
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Fig.2. Genetic organization of the pgdA region and Clustal alignment of the predicted S. suis 
PgdA.  
A. Genetic organization of the S. suis pgdA gene showing the predicted putative strong 
promoter (indicated by P) and the Rho-independent putative terminator. The region deleted in 
the ΔpgdA mutant (replaced by gene aad9) is also indicated. See the text for details B. 
Sequence alignment of S. suis (SsPgdA) and the described N-acetylglucosamine deacetylases 
from S. pneumoniae (SpPgdA) L. lactis (LlPgdA) and L. monocytogenes (LmPgdA). Sequences 
were aligned using the CLUSTALW software (http://www.ebi.ac.uk/Tools/clustalw/). Residues 
in grey and black boxes indicate the conserved catalytic residues and metal ligand amino acids 
characterised for S. pneumoniae PgdA (Blair et al., 2005), respectively. Asterisks below 
alignment indicate identical aminoacids, colons strongly conserved aminoacids and dots weakly 
conserved aminoacids. 
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Fig. 3. Growth curves and 
morphology of the WT and ∆pgdA 
mutant. (A) Growth curves of S. 
suis WT and Δpgda mutant 
strains. The ΔpgdA mutant (open 
triangles) grew similarly as the WT 
parent strain (closed circles) under 
normal laboratory conditions. (B) 
Morphology of the WT (left) and 
the ΔpgdA mutant (right) strains. 
Transmission electron microscopy 
showed that both strains were 
well separated and surrounded by 
a thick polysaccharide capsule. 
Original magnification : 30 000X. 
 
Fig. 4. Lysozyme sensitivity of S. 
suis WT and ΔpgdA mutant 
strains.  
The WT and the ΔpgdA mutant 
strains were grown at 37 C, until 
the beginning of stationary phase 
of growth was reached, at which 
point, indicated by the arrow, 
lysozyme was added at different 
concentrations. Growth was 
monitored by measuring 
absorbance at 600nm. Experiments 
were performed at least 3 times. 
Error bars are not shown for 
simplicity. 
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Fig. 5. Results of the WT and ∆pgdA mutant infection in mice.  
A. Survival of mice inoculated with the WT (solid line) or the ΔpgdA mutant (dotted line) 
strains. All the mice in the ΔpgdA mutant (N=15) group survived, while 80% of the WT group 
(N=15) died from septicaemia or meningitis. Significant difference in survival were noted 
(LogRank test, P<0.05). B. Kinetics of bacterial clearance from blood in the WT and ΔpgdA 
mutant. The ΔpgdA mutant was isolated at lower titers than the WT strain following 
inoculation and was undetectable in this tissue from day 3 pi. Squares and triangles represent 
values from individual mice. The horizontal lines indicate the median for each group (WT: solid 
line; ΔpgdA mutant: dashed line). Significant differences in isolation from blood were noted 
between groups from day 1 to day 4 pi (Mann-Whitney, P<0.05).  
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Fig. 6. Production of inflammatory mediators by mice inoculated with the WT strain (black 
bars, 3 animals per time), the ΔpgdA mutant (white bars, 3 animals per time) or sham-
inoculated mice (dashed bars, 1 animal per time).  
A. IFN-γ; B. IL-6; C. IL-1β; D. KC; E. RANTES; F. MCP-1. Significant differences (Mann-Whitney 
test P<0.05) were observed between the WT and the ΔpgdA mutant for all the inflammatory 
mediators at different time points (indicated by asterisks). Error bars indicate the standard 
errors of the median. See the text for further details.  
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Fig. 7 Percentage of bacteria 
killed after 90 min incubation 
with porcine neutrophils.  
The level of killing of the ΔpgdA 
mutant was similar to that 
observed for an unencapsulated 
mutant BD102 and significantly 
higher (t-test, P<0.05) than that of 
the WT strain. The different strains 
were opsonised with complete 
porcine sera before incubation. 
The experiment was repeated at 
least 5 times. Error bars indicate 
standard deviations calculated 
from biological repetitions.  
Fig. 8. Results of the WT and 
∆pgdA mutant infection in swine. 
Survival of pigs inoculated with the 
WT (solid line, N=10) or the ΔpgdA 
mutant (dotted line, N=10). Sham 
inoculated animals are not shown 
for simplicity. Significant 
differences in survival were noted, 
LogRank test, P<0.05. The survival 
rate of pigs in the ΔpgdA mutant 
group was 60%. In the WT group 
80 % of the animals did not survive 
the trial. See the text for further 
details. 
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Fig. 9. Q-PCR analysis of the level of expression of the S. suis pgdA gene upon 90 min 
interaction of the bacteria with porcine neutrophils, or in vivo in the liver and spleen of 
experimentally infected mice.  
The listed fold changes are relative to expression of pgdA when the bacteria were grown in THB 
(defined as 1 and shown by the dashed line). Fold changes were calculated using the delta-
delta Ct method (Livak & Schmittgen, 2001). Please see the materials and methods section for 
further details. For in vitro samples (neutrophils), bars show the mean ± standard deviation of 
at least three biological repetitions. For in vivo samples, bars represent individual animals 
(mean ± standard deviation of three technical repetitions). 
 
 
 
Fig. S1. Killing of the different 
∆pgdA mutants by porcine 
neutrophils. 
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ABSTRACT 
 
 Streptococcus suis, a major pathogen of swine, is an emerging zoonotic agent which 
causes meningitis and septic shock. In this study, we investigated the ability of S. suis mutant 
Strain (SRTΔA) lacking the sortase A gene (srtA) to interact with host cells and extracellular 
matrix (ECM) proteins, as well as its virulence in a mouse infection model. We demonstrated 
that mutant SRTΔA had reduced capacity to adhere to and invade porcine brain microvascular 
endothelial cells compared to the wild-type strain. In addition, mutant SRTΔA also showed 
significantly less adherence to plasma fibronectin, cellular fibronectin and collagen type I. 
However, disruption of srtA had little effect on the virulence of S. suis in a mouse 
intraperitoneal model of infection. These results indicate that surface proteins anchored by 
sortase A are required for a normal level of bacterial binding. However, other factors may also 
be important for S. suis virulence and interaction with host tissues. 
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INTRODUCTION 
Streptococcus suis serotype 2 is an important swine bacterial pathogen associated 
mainly with meningitis but also with other diseases such as endocarditis, arthritis, septicemia, 
and pneumonia [1]. Among 35 described serotypes, S. suis serotype 2 is the serotype most 
frequently recovered from diseased animals [1]. Recently, serotypes 32 and 34, unlike other 
serotypes, have been shown to be more related to Streptococcus orisratti [2]. As a zoonotic 
agent, S. suis has been isolated from human cases of meningitis, endocarditis, and toxic shock-
like syndrome [3, 4]. A recent, unprecedented outbreak in China resulted in >200 human cases 
that were directly linked to a concurrent outbreak of S. suis infection in pigs. Of these human 
cases, 20% were fatal [4]. 
 
Our understanding of S. suis virulence factors remains limited. While a few factors have 
been shown to be critical for virulence, others are considered as putative although their precise 
role in S. suis related pathogenesis has yet to be clearly defined [5]. In addition, the multistep 
pathogenesis of meningitis caused by S. suis is poorly understood [5]. Most bacterial infections 
are initiated when bacteria adhere to host tissues. Likewise, initial interactions between S. suis 
and host tissues are also thought to be important for infection. In particular, interactions 
between S. suis and porcine brain microvascular endothelial cells (PBMEC) from the blood-
brain barrier (BBB), which separates the central nervous system (CNS) from the bloodstream [6, 
7], are thought to comprise a key step in the pathogenesis of S. suis induced meningitis [8]. 
 
The extracellular matrix (ECM) is a complex structural network beneath epithelial and 
endothelial cells and surrounding connective tissue cells [9]. Recently, it has been established 
that S. suis binds to several immobilized serum and ECM proteins such as plasma and cellular 
fibronectins and collagen types I, III, and V. Moreover, the adhesin(s) responsible for these 
interactions are proteinaceous in nature [10]. However, the mechanisms underlying 
interactions between these proteins and S. suis have not been elucidated. In other Gram 
positive bacteria, many cell surface proteins possessing a Leu-Pro-X-Thr-Gly (LPXTG) motif have 
cix 
 
been reported to mediate bacterial interaction with host cells, namely ECM, and thus play an 
important role in virulence [11]. These specific proteins are covalently anchored to the cell wall 
by sortase A (SrtA), a membrane-bound thiol transpeptidase enzyme [11, 12]. Five sortases of 
S. suis have been described thus far: SrtA, SrtB, SrtC, SrtD and SrtE [13]. Of the five sortases, 
SrtA (recently classified as a class A sortase) has been shown to play a critical role in anchoring 
LPXTG proteins to S. suis cell wall [13, 14]. 
 
It is not clear whether SrtA and LPXTG proteins of S. suis are important for virulence 
and initial interactions between bacteria and host cells. In this study, we investigated the 
effects of a disruption of srtA gene on the capacity of S. suis to interact with PBMEC and ECM 
components and subsequently be virulent in an experimental mouse model of infection. 
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MATERIALS AND METHODS 
Bacterial strains and growth conditions 
 S. suis serotype 2 reference strain NCTC 10234 and its mutant SRTΔA, with targeted 
disruption of srtA as generated by allelic exchange via double crossover [13], were used in this 
study. Bacteria were grown overnight onto sheep blood agar plates at 37 °C and isolated 
colonies were incubated in Todd-Hewitt broth (THB; Difco Laboratories, Detroit, MI, USA) for 8 
h at 37 ºC with agitation. Working cultures were obtained by inoculating 10 l of a 10-3 dilution 
of these cultures in 30 ml of THB and incubating for 16 h at 37 °C with agitation. Bacteria were 
washed twice in phosphate buffered saline (PBS) pH 7.3, and were appropriately diluted in cell 
culture medium before infection. An accurate determination of the number of colony forming 
unit per ml (CFU/ml) in the final suspension was made by plating onto THB agar using 
Autoplate® 4000 (Spiral Biotech, Norwood, MA, USA). S. suis mutant SRTΔA was grown in the 
presence of 5 μg ml-1 of chloramphenicol (Sigma-Aldrich, Oakville, ON, Canada). Both strains 
showed similar growth rates (data not shown). 
 
Cell culture 
The PBMEC/C1-2 cell line [15]was cultivated as previously described (Vanier et al., 
2004). Briefly, cells were grown in a 1:1 mixture of Iscove’s modified Dulbecco’s medium and 
Ham’s F-12 (Invitrogen, Burlington, ON, Canada) supplemented with 7.5% (v/v) heat inactivated 
fetal bovine serum, penicillin-streptomycin (Invitrogen), sodium bicarbonate, L-glutamine, 
human transferrin (MP Biomedicals, Solon, OH, USA), N-acetyl-cysteine, hypoxanthine, porcine 
heparin, human recombinant fibroblast growth factor-basic (Sigma-Aldrich), and -
mercaptoethanol (BioRad Laboratories, Mississauga, ON, Canada). Flasks (BD FalconTM; BD 
Biosciences, Mississauga, ON, Canada) and 24-well tissue culture plates (Primaria, BD 
FalconTM) were precoated with 1% (w/v) type A gelatin from porcine skin (Sigma-Aldrich). Cells 
were maintained at 37 °C with 5% CO2 in a humid atmosphere. For assays, PBMEC were 
trypsinized by adding a trypsin-EDTA solution (Invitrogen) and diluted in culture medium at 8 x 
104 cells/ml. The cell suspension was distributed in tissue culture plates and incubated to 
confluence. Before the experiments, medium was removed from the plates and replaced by 
medium without antibiotics. 
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Adherence and invasion assays 
For adhesion assay, bacteria were pelleted, washed twice with PBS, and resuspended 
at 106 CFU/ml in fresh cell culture medium without antibiotics as previously described [8, 16]. 
Confluent cell monolayers were infected with 1 ml aliquots of bacterial suspension. Plates were 
centrifuged at 800 × g for 10 min and incubated for 2 h at 37 °C with 5% CO2. The monolayers 
were washed five times with PBS, and incubated with 200 l of 0.05% trypsin-0.03% EDTA for 
10 min at 37 °C. After the addition of 800 l of ice-cold deionised water, cells were detached 
and disrupted by scrapping the bottom of the well. Serial dilutions of this cell lysate were 
plated onto THB agars to enumerate viable bacteria. An invasion assay to quantify intracellular 
bacteria was performed in a similar manner as the adhesion assay, with one exception. 
Following the initial infection period, cells were washed twice with PBS and incubated with 1 ml 
of cell culture medium containing 100 g/ml of gentamicin and 5 g/ml of penicillin G (Sigma-
Aldrich) for 1 h at 37 °C with 5% CO2 (Vanier et al., 2004; Vanier et al., 2007). Levels of 
adhesion and invasion are expressed as the total number of CFU recovered per well. 
 
Binding of S. suis to ECM proteins 
Bacteria grown to a late exponential-phase were washed three times in PBS, 
resuspended at a concentration of 108 CFU/ml in 0.2% (v/v) formaldehyde, and incubated 
overnight at 4 °C. An enzyme linked immunosorbent assay (ELISA) was performed as previously 
described [10] using microtiter plates (Maxisorp, Nunc, VWR, Mississauga, ON, Canada) that 
had been coated overnight at 4 °C with 100 l of plasma fibronectin (1 to 10 g/ml) (Roche 
Diagnostics Corp., Indianapolis, IN, USA), cellular fibronectin (20 g/ml) (Sigma-Aldrich), or 
collagen type I (1 to 12.5 g/ml) (BD Biosciences) in 0.1 M carbonate coating buffer (pH 9.6). 
Wells were washed three times with PBS containing 0.05% (v/v) Tween 20 (PBST, pH 7.3), and 
blocked with 200 l of 3% (w/v) non-fat dry milk in PBST. After 1 h at 37 °C, wells were washed 
three times with PBST and formaldehyde-killed bacterial suspensions (100 l) were added. 
Plates were incubated for 2 h at 37 °C and washed three times. A 100 l volume of S. suis 
serotype 2-specific rabbit antiserum [17] (diluted 1/3000 in PBST) was then added to each well. 
Plates were incubated for 1 h at 37 °C and were washed three times. A volume of 100 l of 
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horseradish peroxidase-labelled anti-rabbit IgG (Jackson Immunoresearch Laboratories Inc., 
West Grove, PA, USA) (diluted 1/8000 in PBST) was added and plates were incubated for 1 h at 
37 °C. After washing three times with PBST, 3,3’,5,5’-TetraMethylBenzidine (Zymed, Invitrogen) 
was used according to the manufacturer’s instructions. Reactions were stopped by adding 25 l 
of H2SO4 (1 N) and then read at 450 nm using a microplate reader (UVmax; Molecular Devices, 
Sunnyvale, CA, USA). Uncoated and casein-coated wells served as background and non-specific 
adhesion of S. suis to protein coated control wells, respectively. In addition, controls were 
performed to ensure that S. suis serotype 2- specific rabbit antiserum recognized wild-type 
strain and SRTΔA equally. 
 
Intraperitoneal mouse virulence model 
A total of 40 female CD1 6-week-old mice (Charles River Laboratories, Wilmington, MA, 
USA, 10 animals per group) were infected intraperitoneally with either 1 ml of S. suis strain 
NCTC 10234 or 1 ml of mutant SRTΔA (approximately 108 CFU in PBS). The CD1 mouse model 
was recently shown to be an excellent model of S. suis infection causing septic shock and 
meningitis [18]. Body weight changes (due to an excessive production of pro-inflammatory 
cytokines) were recorded daily post-infection (p.i.) [18]. Survival and development of clinical 
signs of meningitis were recorded over a 10-day period. In addition, bacterial numbers in blood 
and homogenized brain samples were determined by plating on sheep blood agar plates using 
Autoplate®  4000 at different timepoints p.i . Experiments involving mice were repeated twice 
(total number of 20 animals per group) and were conducted in accordance with the guidelines 
and policies of the Canadian Council on Animal Care and the principles set forth in the Guide 
for the Care and Use of Laboratory Animals, Animal Welfare Committee of the Université de 
Montréal. 
 
Statistical analysis 
All data are expressed as means  standard deviations (error bars). Data were analyzed 
by twotailed, unpaired t test. Unless specified, all assays were repeated at least three times. 
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Statistical analysis of the survival data was performed with the LogRank test. A P value of ≤ 0.05 
was accepted as the minimal level of significance. 
 
RESULTS 
srtA gene contributes to the interactions between S. suis and endothelial cells 
As shown in Fig. 1, adhesion and invasion levels of mutant SRTΔA were strongly 
reduced to 16 ± 24% and 17 ± 12%, respectively, compared to those of the wild-type strain 
(considered as 100%) when 106 CFU ml-1 bacterial suspensions were used. Similar results were 
obtained with different concentrations of bacteria (data not shown). The complemented 
mutant SRTΔA (Osaki et al., 2002) showed adhesion and invasion values of 88 ± 17% (P = 0.008 
compared to the mutant SRTΔA) and 47 ± 4% (P = 0.004 compared to the mutant SRTΔA), 
respectively. These results confirm that sortase A is at least partially involved in S. suis-specific 
adhesion to and invasion of endothelial cells 
srtA gene contributes to adherence of S. suis to ECM proteins 
An ELISA binding assay was used to determine whether the mutant SRTΔA had altered 
capacity to bind plasma and cellular fibronectins and collagen type I. As shown in Fig. 2 (a), 
SRTΔA had reduced binding to plasma fibronectin by (P < 0.05) compared to the wild-type 
strain. A similar decrease in adhesion to cellular fibronectin was also observed (data not 
shown). Binding to collagen type I by mutant SRTΔA was also diminished (P < 0.05; Fig. 2 (b)). 
Adhesion to fibronectin and collagen type I by both strains was dependent on the protein 
concentration (Fig. 2). 
Effect of srtA gene disruption on virulence 
Animals from both groups showed only limited weight loss (0 to 10% of initial weight) 
between day (d) 0 and d 5, with maximum loss observed at d 2 p.i. (data not shown). In 
addition, weight gain from d 6 to the end of the experiment was not significantly different 
between groups (P > 0.05; data not shown). With respect to cumulative survival, CD1 mice 
infected with SRTΔA had slightly longer median survival (2 d), although this was not statistically 
significant (P > 0.05) compared to mice infected with the wild-type strain (1 d) (Fig. 3). Both 
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strains displayed a similar mortality rate, with 80% of all animals dying within 10 d. Morbidity 
also did not differ between the groups; one mouse in each group developed clinical signs of 
meningitis (i.e. spatial disorientation). Blood and brain samples collected from infected animals 
during the first 2 d p.i. showed no significant differences in bacterial load between the two 
groups (data not shown) 
 
DISCUSSION 
In this study, we demonstrated that the mutant SRTΔA strain of S. suis has markedly 
impaired interactions with PBMEC in vitro. These findings provide evidence that sortase A of S. 
suis is involved in adhesion to and invasion of host cells and are consistent with those reported 
for other Gram-positive pathogens, such as Streptococcus pneumoniae [19], Streptococcus 
sanguinis [20], and Streptococcus agalactiae [21]. Our results also showed mutant SRTΔA has 
reduced binding to ECM proteins, suggesting that SrtA of S. suis may anchor LPXTG-containing 
microbial surface components which recognize adhesive matrix molecules (MSCRAMM) that 
mediate binding to plasma and cellular fibronectins and to collagen type I. These findings are in 
agreement with previous studies on S. agalactiae [21] and S. gordonii [22], showing that SrtA-
expressing strains bind in significantly higher numbers to fibronectin compared to isogenic srtA 
mutant strains. Together these results suggest that LPXTG proteins anchored by SrtA are at 
least partially involved in the interactions between S. suis and host tissues.  
Few LPXTG proteins of S. suis have been identified. Among these, the opacity factor of 
S. suis (OFS) and surface antigen one (Sao) have been recently described [23, 24]. OFS is an 
opacity factor involved in virulence but not in colonization [23]. Sao is an immunogenic protein 
that is expressed on the bacterial surface and confers protection to immunized animals [24]. 
Moreover, surface expression of some LPXTG proteins is downregulated after disruption of the 
srtA gene [13]. Indeed, mutant SRTΔA of S. suis has reduced expression of more than 15 major 
protein spots as visualized with two-dimensional polyacrylamide gel electrophoresis. From 
these protein spots, a previously described protein, the muramidase-released protein (MRP), as 
well as other newly described proteins similar to 5’-nucleotidase, and encoded by the genes 
sntA, sntB, and sntC, were identified. In European S. suis strains, MRP is considered to be a 
virulence marker [5]. However, MRP alone is not necessary for virulence in swine and is absent 
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in most North American virulent strains [1]. Other putative S. suis LPXTG proteins and their role 
in virulence have yet to be identified. Moreover, the precise LPXTG protein(s) involved in S. 
suis-host interactions are unclear and warrant further investigation. 
 
 It should be noted that a deficiency of sortase A did not completely abolish 
interactions between S. suis and PBMEC or ECM proteins, suggesting that other factors may 
also contribute to S. suis mediated pathogenesis. This is in agreement with our previous 
observations [16] demonstrating that non-proteinaceous cell wall components, such as 
lipoteichoic acid (LTA), are also involved in interactions between S. suis and PBMEC. Other 
pathogens, such as S. pyogenes, have been shown to possess multiple types of adhesins (LTA 
and proteins) that mediate interactions with host cells [25]. Non-LPXTG proteins (non-
MSCRAMM) might also be involved in binding to ECM proteins. Notably, S. suis possesses non-
MSCRAMM ECM-binding proteins such as FBPS [26], a 52-kDa IgG-binding protein [27], and a 
recently described Enolase [28]. In a previous study, bacteria coated with plasma fibronectin 
showed high levels of adhesion to and invasion of PBMEC, suggesting that S. suis uses plasma 
fibronectin as a bridge between bacteria and the host cell surface [16]. Results obtained in the 
present study suggest that non-MSCRAMM as well as LPXTG-containing MSCRAMM ECM-
binding proteins may be involved in these host-pathogen interactions. 
 
Disruption of srtA gene had little effect on the virulence of S. suis in a mouse 
intraperitoneal model of infection. Our findings are consistent with those reported by Kharat 
and Tomasz (2003) showing that a srtA mutant of S. pneumoniae was as virulent as the wild-
type strain in mice. Paterson and Mitchell (2006) demonstrated using a competitive infection 
model that srtA is a factor required for fitness rather than virulence of S. pneumoniae. It is not 
known whether a similar function can be attributed to srtA in S. suis infection. Indeed, there 
were no significant differences in levels of bacteremia between the wild-type and mutant 
strains. Survival of bacteria in blood is a critical step that enables the bacteria to disseminate 
throughout the host and ultimately gain access to the CNS. There is much evidence that the 
capsule is an important virulence factor that promotes bacterial resistance to phagocytic 
clearance [5]. Recent results in our laboratory obtained using a coagglutination assay showed 
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that the mutant SRTΔA is encapsulated (unpublished observation), which may explain its 
normal bacterial loads in blood. A high-grade bacteraemia was shown to be required for S. suis 
to subsequently reach the CNS, thus suggesting a critical role of the capsule for bacterial 
survival and dissemination in blood during S. suis invasion of the BBB [29]. 
 
Lastly, other class C sortases genes (srtB, srtC, srtD and srtE) [14] may also contribute to 
S. suis-host interactions. In S. suis NCTC 10234 strain, three class C sortases genes (srtB, srtC, 
srtD) cluster together and are associated with LPXTG proteins [13]. It is possible that these 
accessory class C sortases, which are present in about 50% of virulent S. suis strains (T. Sekizaki, 
unpublished observations), might specifically anchor the flanking LPXTG-containing proteins. 
Studies are ongoing in our laboratory to verify the role of other S. suis sortases in bacterial 
interactions with host cells and proteins.  
 
We conclude that S. suis SrtA anchors LPXTG-containing surface proteins, thus playing 
an important role in bacterial colonization of host cells and adhesion to ECM proteins. 
However, anchorage of LPXTG proteins alone is not sufficient for virulence in mice. Together, 
these observations suggest that although LPXTG-containing surface proteins participate in 
multiple steps of the pathogenesis of S. suis infection, other non-LPXTG proteins, including 
secreted, membrane-bound and non-proteinaceous components, are likely to be involved in 
cell colonization, ECM binding, and virulence. 
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ANNEX 4. ARTICLE VII. FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. (a) Adhesion to 
PBMEC by mutant SRTΔA 
compared to the wild-type 
strain NCTC 10234. (b) 
Invasion of PBMEC by 
mutant SRTΔA compared to 
the wild-type strain NCTC 
10234. Adhesion and 
invasion are expressed as a 
percentage of the adhesion 
and invasion levels achieved 
by the wild-type strain NCTC 
10234. Asterisk denotes 
values that are significantly 
different (P < 0.05) from 
those of NCTC 10234. 
Fig. 2. Binding to different 
concentrations of plasma 
fibronectin (a) and collagen 
type I (b) by mutant SRTΔA 
compared to the wild-type 
strain NCTC 10234. Asterisk 
denotes values that are 
significantly different (P < 
0.05) between the two 
strains. 
cxviii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Kaplan-Meier survival analysis of CD1 mice infected with the wild-type strain 
NCTC 10234 or the mutant SRTΔA (P = 0.56 for survival times between both groups). 
Six-week-old CD1 mice were inoculated i.p. with 108 bacteria, and survival was 
monitored over a 10-day period. Data are expressed as mean percentage of live 
animals in each group (n=20) 
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1. Introduction 
 
Streptococcus suis serotype 2 is an important bacterial pathogen of swine 
associated mainly with meningitis, but also with other infections such as septicemia, 
endocarditis, arthritis, and pneumonia [1]. Among the 35 serotypes described to date, 
S. suis serotype 2 is the one most frequently recovered from diseased animals [1]. As an 
emerging zoonotic agent, S. suis has been isolated from an increasing number of 
human cases of meningitis, endocarditis, and toxic shock-like syndrome [2, 3]. In 2005, 
an unprecedented outbreak in China resulted in >200 human cases that were directly 
linked to a concurrent outbreak of S. suis infection in pigs. Of these human cases, 20% 
were fatal [2].  
 
Knowledge concerning virulence factors of S. suis is still limited. The capsular 
polysaccharide (CPS) and a recently described opacity factor (OFS) are critical for 
virulence since isogenic mutants lacking either of these factor were markedly less 
virulent [4-6]. Several other virulence candidates, such as a hemolysin (suilysin) [7], a 
fibronectin- and fibrinogen-binding protein (FBPS) [8], adhesins [9], proteases [10], and 
other proteins, such as muramidase-released protein (MRP) [11] and extracellular 
factor (EF) [12], have also been proposed. Recently, a study using a signature-tagged 
mutagenesis system identified a variety of genes potentially involved in virulence of S. 
suis; among them, genes related to capsule biosynthesis and regulation of suilysin 
expression were identified [13].  
 
The multi-step pathogenesis of the infection caused by S. suis is poorly 
understood [14]. Most bacterial infections, including those caused by S. suis, are 
initiated by the attachment of bacteria to host tissues. In particular, interactions of S. 
suis with porcine brain microvascular endothelial cells (PBMEC) from the blood-brain 
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barrier (BBB), which separates the central nervous system (CNS) from the bloodstream 
[15, 16], are thought to be a key step in the pathogenesis of meningitis [14]. We have 
shown that S. suis is able to adhere to and invade PBMEC [17]. In fact, we have recently 
used this interaction model to demonstrate that S. suis preferentially expressed 
particular genes upon interactions with PBMEC using selective capture of transcribed 
sequences (SCOTS) [18]. These genes are involved in cell envelope modification, 
protein sorting, proteolytic activity, regulation, cell division/regulation, 
transport/binding, and metabolism/housekeeping [18]. The objective of this work was 
to find new putative virulence factors of S. suis by screening a Tn917-insertional mutant 
library using bacterial interactions with PBMEC as a reporter system. 
 
2. Results 
 
2.1 Identification of genes involved in S. suis invasion of PBMEC 
 
A qualitative screening assay, adapted from a previously one using group B 
Streptococcus (GBS) [19], successfully allowed the identification of poorly invasive S. 
suis mutants. More than 1000 Tn917 mutants were screened with PBMEC and 89 of 
these were qualitatively less invasive. Following a quantitative invasion assay with 
PBMEC, 19 of these mutants were confirmed to be significantly less invasive showing a 
reduction ranging from 97% to 70% (P < 0.05). Most of the other mutants also revealed 
a decreased adhesion level, but to a lesser extent (between 20 and 65%, data not 
shown). Only one Tn917 insertion occurred in each of these mutants (Figure 1 and data 
not shown). Tn917 insertion sites from these 19 poorly invasive mutants were 
sequenced and characterized, and interrupted genes were identified (Table 1). These 
genes can be divided into the following seven groups: surface protein, 
transport/binding, regulatory functions, metabolism, amino acid synthesis, protein 
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synthesis, and hypothetical proteins. Among them, a gene presenting homologies with 
a cell wall anchor domain of an unknown Leu-Pro-X-Thr-Gly (LPXTG) putative surface 
protein (mutant B8A) was identified. In addition, genes homologous to two genes from 
the same putative ABC-type multidrug transport system were found (mutants F8D and 
H4F). Moreover, a gene from a putative mercuric resistant regulatory protein (mutant 
I10B) downstream of the gene encoding sortase E, which was previously reported to be 
preferentially expressed by S. suis in contact with PBMEC [18], was also identified. 
Finally, a gene similar to a NUDIX hydrolase (mutant E5H) was also found. To the best 
of our knowledge, none of these genes has been previously associated with the 
pathogenesis of S. suis infection. 
 
2.2 Virulence in mice 
 
Five S. suis Tn917 insertion mutants (A8E, B8A, E5H, F8D, I10B) were selected 
for further study on the basis of several considerations including reduced invasion 
(mutants A8E, B8A, E5H, F8D, I10B), previous association in the literature of similar 
genetic regions or genes with interactions with BMEC (mutants B8A, E5H, I10B) or 
biofilm formation (mutant F8D), or because two of the less invasive Tn917 insertion 
mutants were interrupted in the same gene (mutant A8E). The virulence of the five 
selected mutants was assessed in a CD1 mouse model of infection. Median cumulative 
survival times from groups of CD1 mice infected with different mutant strains were 
markedly different from that for the wild-type strain P1/7. As shown in Fig. 2, 
compared to mice infected with the wild-type strain which gave a median survival time 
of 6 days, mice infected with some mutants gave similar (A8E, 5 days) or even lower 
(I10B and E5H, 1 day) survival times. In contrast, animals infected with mutants B8A 
and F8D gave markedly improved median survival times of 10 days. Moreover, 
mortality after 10 days was significantly lower in these two groups, compared to the 
wild-type infected mice (P < 0.05) (Table 2). Notably, zero mortality was recorded in 
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mice infected with mutant F8D. For all groups, mice showing severe clinical signs were 
sacrificed for welfare reasons.  
 
Surviving animals from all groups showed variations in body weight. Animals 
from the group infected with wild-type P1/7 showed maximal mean weight loss of 15% 
on day 2, and recovered their initial body weight by day 7 p.i.. Animals from the group 
infected with I10B showed a constant decrease in body weight which correlated with 
the high mortality observed in this group. Animals from the groups infected by A8E and 
E5H showed maximal mean weight losses of 11% and 10% on days 2 and day 3 p.i., 
respectively (P > 0.05 vs P1/7 group), and recovery to normal body weight was delayed 
in animals infected with each of these mutants. In contrast, at day 2 p.i., animals 
infected with B8A showed less severe loss of body weight than animals infected with 
P1/7 wild-type (9% vs. 15%, P < 0.05). Similarly, animals infected with F8D showed only 
a 5% loss of body weight compared to 14% observed in those infected with wild-type 
P1/7 at day 3 p.i. (P < 0.05). Finally, mice infected with either B8A or F8D recovered 
their initial body weights by day 6 p.i., and showed a weight gain of 6% and 3% at day 
10 p.i, respectively.  
 
The percentages of morbidity and mortality were different among groups of 
mice infected with the mutant strains (Table 2). Mice infected with I10B or E5H showed 
severe clinical signs of disease, severe lethargy and sudden death. These findings 
explain the high levels of mortality observed in mice infected with these two mutants. 
On the other hand, overall morbidity and mortality in animals infected with A8E were 
similar to those infected with the wild-type strain. In contrast, most of the mice 
infected with B8A showed only mild signs of infection such as swollen eyes and rough 
hair coat. This is in agreement with the low mortality compared to relatively high 
morbidity percentages observed in this group (Table 2). Notably, mice infected with 
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F8D showed no mortality and only 20% of them showed mild clinical signs, such as 
rough hair coat.  
 
S. suis were recovered from most organs from the majority of mice infected 
with P1/7, E5H, I10B and A8E between days 1 and 10 (Table 2). However, S. suis was 
detected in only a few mice infected with mutant B8A and F8D (Table 2). Interestingly, 
at the end of the experiment (day 10 p.i.), S. suis was recovered from 60% of surviving 
mice infected with wild-type P1/7, while it was recovered from only 40% of surviving 
mice infected with B8A and 20% of mice infected with F8D. These findings suggest a 
clear reduction in the invasive and/or within-host survival capacities of these two 
mutant strains.  
 
2.3 Virulence in swine 
 
Based on these results, two S. suis Tn917 insertion mutants, B8A and F8D, were 
selected for further evaluation in a pig model of infection. The percentage of morbidity 
of pigs infected with F8D was slightly lower compared to that observed in pigs infected 
with wild-type P1/7 strain and B8A (Figure 3A). In addition, at the end of the 
experiment (day 4), the percentage of surviving pigs was higher in the group infected 
with F8D (Figure 3A). All pigs infected with the wild-type P1/7 strain showed signs of 
infection such as severe depression and lameness (9/10) and severe joint stiffness 
(1/10). Although animals infected with F8D or B8A showed lameness (7/10 and 9/10, 
respectively) and depression (2/10 and 7/10, respectively), presentation of these 
clinical signs was delayed compared to the earlier development of clinical signs in pigs 
infected with the wild-type strain. Furthermore, no significant body weight loss was 
observed in pigs infected with the mutant strains during the experimental period (data 
not shown). According to United Kingdom legislation, the presentation of these clinical 
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signs was considered to be sufficient to require animal euthanasia. Hence, no clinical 
records could be performed after 4 days of infection for welfare reasons.  
 
At the appearance of clinical signs, S. suis levels in blood were significantly 
different (P < 0.05) between groups, with 4.2 ± 2.7 x 103, 1.1 ± 1.8 x 103, and 0.6 ± 0.7 x 
103 CFU/ml of blood from pigs infected with P1/7, B8A and F8D, respectively. S. suis 
bacteria were recovered from most sampled organs from the majority of pigs 
irrespective of the infection group (data not shown). Unfortunately, no comparative 
quantitative analysis could be performed since animals were sampled during post-
mortem examinations. 
 
On the basis of previous observations with pig whole blood cells and in the 
mouse model of infection [20, 21], levels of pro-inflammatory cytokine IL-6, an 
endogenous pyrogen known as a marker for ongoing bacterial infections in pigs [22, 
23], and the chemokine IL-8 were evaluated in plasma samples throughout the 
experiment. No differences were observed in IL-8 levels in plasma from pigs infected 
with wild-type strain P1/7 or either of the mutant strains (data not shown). On the 
other hand, markedly higher levels of pro-inflammatory IL-6 were observed in plasma 
from pigs infected with the P1/7 wild-type (Figure 3B). In contrast, lower (Figure 3B) 
and delayed (data not shown) levels of IL-6 were observed in plasma from pigs infected 
with B8A or F8D, which is in agreement with the lower fever indices [23] shown by 
animals infected with these mutants (Figure 3A).  
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3. Discussion 
 
Despite its importance as a major swine pathogen and as an emerging life-
threatening zoonotic agent, little is known about virulence factors of S. suis [14, 24]. In 
our continued effort to understand the pathogenesis of S. suis infection, we used a 
qualitative invasion assay using PBMEC to screen a mutant library, followed by 
assessment of virulence levels of selected less invasive mutants in mouse and pig 
models of infection. Two mutants, B8A and F8D, were less invasive for PBMEC, 
attenuated in mice as evidenced by decreased colonization of organs, reduced 
mortality and morbidity and, to a considerably lesser extent, also attenuated in pigs as 
indicated by decreased bacterial loads in blood, less severe and delayed clinical signs, 
and lower levels of the pyrogenic cytokine IL-6 in plasma.  
 
In B8A, the Tn917 insertion site is located in a LPXTG-motif cell wall anchor 
domain from an unknown LPXTG protein (Table 1). Many surface proteins possessing a 
LPXTG motif have been reported as mediating the interactions of Gram positive 
bacteria with host tissues, as they often confer the ability to bind to plasma 
components and host proteins from the extracellular matrix, and to adhere to and 
facilitate the invasion of host cells, thus playing important roles in virulence [25]. In S. 
suis, a few important proteins that contain the LPXTG motif have been reported. These 
include OFS, an opacity factor involved in virulence though not in colonization [5], 
surface antigen one (Sao), an immunogenic protein of unknown function conferring 
protection on immunized animals [26, 27], and the virulence marker MRP [11]. In B8A, 
the gene encoding the mutated LPXTG protein (ssu1889) is followed by 4 other genes 
encoding proteins with LPXTG motifs, flanking a cluster of three class C sortase genes: 
srtB, srtC and srtD [28, 29]. Interestingly, this region shows organizational similarity 
with the rlrA island from Streptococcus pneumoniae strain TIGR4 [30, 31]. Moreover, 
ssu1889 gene from S. suis showed 49 % sequence homology to SP_0462 gene (GenBank 
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accession number NC_003028) from rlrA island from S. pneumoniae  TIGR4. LPXTG 
proteins are covalently anchored to the cell wall by sortases [25]. In S. suis, sortase A (a 
class A sortase) plays a critical role in anchoring LPXTG proteins to the cell wall [28]. 
Moreover, we demonstrated recently that a mutant deficient for srtA had reduced 
capacity to adhere to and invade PBMEC and was less adherent to plasma fibronectin, 
cellular fibronectin and collagen type I compared to the wild-type strain [32]. The 
identities of the proteins anchored by class C sortases in S. suis are not yet known as 
their role in virulence. 
 
Pili were very recently described in Gram positive pathogens such as group A, 
group B Streptococcus (GAS, GBS) and S. pneumoniae [33]. Although not completely 
elucidated, pilus assembly in GAS and GBS would occur through covalent 
polymerization by class C sortases of LPXTG pilin subunits encoded by genes within a 
pilus island [33]. Moreover, pili are important for GBS adhesion to and invasion of 
hBMEC [34]. In S. suis, Fittipaldi et al. [18] recently described a putative pilus island 
constituted by a signal peptidase which is followed downstream by the genes for a 
putative ancillary protein and a main pilus subunit and a previously undescribed class C 
sortase. Interestingly, expression of the signal peptidase gene from this island was 
upregulated in presence of PBMEC [18]. This S. suis island presents similar genetic 
organization to GBS pilus island 2b (PI-2b), one of the three identified pilus islands in 
this species [33]. Moreover, Jacques et al. [35] reported the presence of thin and short 
pilus-like structures on the surface of S. suis using electron microscopy. Therefore, it is 
tempting to speculate on a second S. suis putative pilus island, similar to the rlrA island 
from S. pneumoniae, that has been interrupted in B8A and that this region would play a 
role in the invasion of endothelial cells from swine BBB and thus in virulence.  
 
In F8D, the Tn917 insertion site was located in an ATPase component from an 
ABC-type multidrug transport system (Table 1) with homology to the BcrA subfamily of 
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ABC transporters involved in bacitracin resistance [36]. In bacteria, ABC transporters 
are important virulence factors because they play roles in secretion of toxins and 
antimicrobial agents and they are associated with many physiological processes 
(uptake of nutrients, non-classical secretion of signalling molecules, multidrug 
resistance) [37]. Moreover, roles for genes from ABC transport systems in cell-to-
surface and/or cell-to-cell interactions and biofilm development have been proposed 
for different organisms such as Streptococcus gordonii, Pseudomonas fluorescens, and 
Agrobacterium tumefaciens [38-40]. More specifically, in Streptococcus mutans, the 
glrA gene encoding for a bacitracin transport ATP-binding protein plays a role in biofilm 
formation [41]. In Burkholderia cepacia, the multidrug-resistance efflux pump BcrA is 
an immunodominant antigen in cystic fibrosis patients [42]. It is worth noting that 
some strains of S. suis form biofilms [43]. 
 
The genomic region interrupted by Tn917 in F8D seems to be required for S. suis 
interactions with host cells since a second mutant (H4F), in which Tn917 was inserted in 
the second gene located downstream of the gene mutated in F8D (Table 1), was also 
less invasive for PBMEC. In H4F, a putative bacteriocin operon protein (ssu0833) was 
interrupted. Interestingly, S. suis was previously shown to produce bacteriocin-like 
inhibitory substances [44]. Both genes, ssu0835 (mutant F8D) and ssu0833 (mutant 
H4F) share sequence homologies with ABC-transporter forming genes from the GAS 
streptococcin A-FF22 lantibiotic regulon [45], where streptococcin A-FF22 is a 
bacteriocin. Overall, this genetic region seems to be important in S. suis interactions 
with host cells and virulence in in vivo models. Interestingly, a gene homologous to an 
ATP-binding protein from another multidrug ABC transporter was also reported to be 
preferentially expressed by S. suis in contact with PBMEC [18]. However, the actual 
function of the putative ABC transporter reported in the present study, as well as its 
substrate, remain to be determined. 
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The contribution to virulence of a hypothetical protein from mutant A8E was 
studied since two mutants (A8E and E12D, see Table 1) in which this gene was 
interrupted were less able to invade PBMEC. However, A8E showed no significant 
decrease in virulence in mice. In E. coli K1, a NUDIX hydrolase, ygdP, was associated 
with invasiveness of hBMEC [46]. Although the NUDIX hydrolase identified in the 
present study (in mutant E5H) seems also to be involved in S. suis invasiveness of 
PBMEC in vitro, no reduction in virulence was observed in mice. Finally, srtE encoding a 
class C sortase was reported to be preferentially expressed by S. suis in contact with 
PBMEC [18]. The transposon insertion in I10B was located in the merR gene located 
downstream of srtE [28]. However, I10B showed no decrease of virulence in mice. 
Although this region seems to be involved in interactions between S. suis and PBMEC, 
its actual role in S. suis pathogenesis remains to be determined. Hence, a reduction in 
cell invasion level does not always correlate with a significant reduction in virulence in 
vivo. This lack of direct relationship for some mutants tested in this study could be 
explained by the fact that in vivo models of virulence are much more complex and 
involve different parameters.  
 
In conclusion, the qualitative screening PBMEC invasion assay is a good first step 
model to find new putative virulence factor for S. suis since genes coding for a LPXTG 
protein and an ATPase component from an ABC transporter were identified as being 
involved in invasion of swine endothelial cells and in S. suis virulence in mouse and pig 
models of infection in this study. It is worth noting that the PBMEC have been used in 
this study as a model and that these mutations could have also affected the bacterial 
ability to interact not only with these cells but also with different host cells and 
components, with the consequence of a reduced virulence. Finally, we acknowledge 
that transposon insertion polar effects on other genes may be present in some of these 
mutants. Further work using site-directed mutagenesis on each of the most  interesting 
genes identified in this study is granted. In fact, studies focusing on the regions where 
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these two genes are located are under way in our laboratory. 
 
4. Materials and methods 
 
4.1 Bacterial strains 
 
S. suis serotype 2 strain P1/7 [47], isolated from a field case of meningitis, 
harbouring virulence markers MRP, EF, and suilysin, and from which complete genome 
had been sequenced by the S. suis Sequencing Group at the Sanger Institute 
(http://www.sanger.ac.uk/cgi-bin/blast/submitblast/s_suis), was used as wild-type 
strain for this study. A mutant library was created using the pTV408 temperature-
sensitive suicide vector to deliver Tn917 randomly into the chromosomal DNA of S. suis 
strain P1/7 via electroporation [47]. S. suis Tn917 insertion mutants were grown in the 
presence of 1 μg/ml of erythromycin (Sigma-Aldrich, Oakville, ON, Canada) and showed 
similar growth rate to wild-type strain P1/7 (data not shown). 
 
4.2 PBMEC culture 
 
The maintenance of the porcine brain microvascular endothelial cell line 
PBMEC/C1-2 [48] was previously described [17, 49]. A cell suspension of 8 x 104 cells/ml 
in culture medium was distributed in 24-well tissue culture plates (Primaria, BD 
FalconTM; BD Biosciences, Mississauga, ON, Canada) precoated with 1% (w/v) type A 
gelatin from porcine skin (Sigma-Aldrich, Oakville, ON, Canada) and incubated to 
confluence. Before the experiments, medium was removed from plates and replaced 
by medium without antibiotics. 
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4.3 Qualitative screening invasion assay 
 
A qualitative screening assay, previously described [19], and with some 
modifications, was adapted to S. suis. Briefly, S. suis bacteria were grown in Todd-
Hewitt broth (THB, Difco Laboratories, Detroit, MI, USA) for 8 h at 37 °C with agitation. 
Working cultures were obtained by inoculating 100 µl of a 10-1 dilution of these 
cultures in 5 ml of THB and incubating them for 16 h at 37 °C with agitation. Bacteria 
were washed in phosphate-buffered saline (PBS, pH 7.3) and 100 µl aliquots of 
bacterial suspension (approximately 1 x 108 CFU) were used to infect confluent cell 
monolayers from 24-well tissue culture plates containing 900 µl of cell culture medium 
(for an initial inoculum of 1 x 107 CFU/ml corresponding to a multiplicity of infection of 
approximately 40:1). Plates were centrifuged at 800 g for 10 min and incubated for 2 h 
at 37 °C with 5 % CO2. The monolayers were washed twice with PBS, and incubated 
with 1 ml of cell culture medium containing 100 µg/ml of gentamicin and 5 µg/ml of 
penicillin G (Sigma-Aldrich) for 1 h at 37 °C with 5 % CO2. Then, cells were washed three 
times with PBS, and incubated with 200 µl of 0.05% trypsin-0.03% EDTA for 10 min at 
37 °C. Cells were detached and disrupted by scraping the bottom of the well and 
repeated pipetting. This cell lysate was left in the well and mixed with 1 ml of THB 
containing a low concentration of agar (7.5 %, w/v) and incubated overnight at 37 °C. 
The number of S. suis colonies (representing intracellular invading S. suis) in the well 
were visually compared with the number of colonies obtained using the P1/7 wild-type 
strain (non-quantitative assay).  
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4.4 Quantitative invasion assay 
 
The quantitative invasion assay was performed in essentially the same way as 
the qualitative invasion assay described above, but with some modifications. Bacteria 
were grown in THB for 8 h at 37 °C with agitation. Working cultures were obtained by 
inoculating 10 µl of a 10-3 dilution of these cultures into 30 ml of THB and incubating 
them for 16 h at 37 °C with agitation. Then, bacteria were pelleted, washed with PBS, 
and resuspended at 106 CFU/ml in fresh cell culture medium without antibiotics as 
previously described [17, 49]. An accurate determination of the number of colony 
forming units per ml (CFU/ml) in the final suspension was made by plating onto THB 
agar using Autoplate 4000 (Spiral Biotech, Norwood, MA, USA). Confluent cell 
monolayers were infected with 1 ml aliquots of bacterial suspension for 2 h, as 
described above. After incubation with 0.05% trypsin-0.03% EDTA for 10 min at 37 °C, 
800 µl of ice-cold deionised water was added and the cells were scraped from the 
bottom of the well. Serial dilutions of this cell lysate were plated onto THB agar and 
incubated overnight at 37 °C for counts of viable bacteria. 
 
4.5 Plasmid rescue and sequencing of the insertion site 
 
HindIII (Roche) digestions of chromosomal DNA were self-ligated using T4 DNA 
ligase (Quick Ligase kit from New England Biolabs, Pickering, ON, Canada) and then 
transformed into Escherichia coli XL1-Blue Supercompetent cells (Stratagene, La Jolla, 
CA) followed by selection of plasmids by plating onto Luria-Bertani (LB) agar plates 
containing ampicillin (100 µg/ml). Resultant colonies were picked and streaked out, 
and plasmid DNA was purified from liquid cultures using standard methods (QIAprep 
Spin Miniprep Kit, Qiagen, Mississauga, ON, Canada). The plasmids, containing inserts 
cxxxiii 
 
of host chromosomal DNA flanking the transposon insertion site, were sequenced using 
a 373A DNA Sequencing System (Applied Biosystems, Foster City, CA) at the DNA 
Sequencing Facility of the University of Maine (Orono, ME). The primer tn917 seq (5’-
AGAGAGATGTCACCGTCAAGT-3’), designed to read out from the transposon, was used 
for sequencing. S. suis DNA sequences flanking the Tn917 insertion sites. Sequences 
were analysed using the BLAST software package in the GenBank databases 
(http://www.ncbi.nlm.nih.gov/BLAST/). Sequence comparison was also performed 
against data produced by the S. suis Sequencing Group at the Sanger Institute 
(http://www.sanger.ac.uk/cgi-bin/blast/submitblast/s_suis) for European strain P1/7 
and by the Joint Genome Institute Microbial Genomics (http://genome.jgi-psf.org/cgi-
bin/runAlignment?db=strsu&advanced=1) for North American strain 89/1591. 
 
Genomic DNA was isolated from the wild-type P1/7 and mutants strains by the 
guanidium thiocyanathe method [50]. DNA was digested with EcoRI restriction 
endonuclease (GE Healthcare Piscataway, NJ, USA). A digoxigenin (DIG)-labelled probe 
specific for the erm  gene, (which is present in Tn917 but absent from the wild-type 
genome) was generated from pVT408 by PCR using primers ermF 5’-
ACGAGTGAAAAAGTACTCAACC-3’ and ermR 5’-ACCTCTGTTTGTTAGGGAATTG-3’ 
(Invitrogen, Burlington, ON, Canada) and the DIG-PCRlabeling mixture (Roche 
Diagnostics, Laval, QC, Canada). Southern-blots were performed by the procedures 
described previously [51] except that hybridizations were carried out at 68°C. 
 
4.6 Mouse infection  
 
A total of 70 female CD1 6-week-old mice (Charles River Laboratories, 
Wilmington, MA, USA, 5 animals per group) were infected by intraperitoneal injection 
with 1 ml of either S. suis strain P1/7 or the Tn917 insertion mutants A8E, B8A, E5H, 
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F8D, and I10B at approximately 2 x 107 CFU in THB. Mice infected with the vehicle 
solution (sterile THB) were used as controls [20]. This CD1 mouse model is useful to 
study the early septic shock-like syndrome leading to death and, the second late phase 
of S. suis infection that induces evident brain damage [20]. Body weight changes, 
clinical signs of infection (swollen eyes, rough hair coat, lethargy, and neurological 
signs) and survival were recorded daily post-infection (p.i.) over a 10-day (d) period as 
described [20]. In addition, the presence of S. suis in blood (collected by cardiac 
puncture) and homogenized brain and liver samples was determined by plating on 
sheep blood agar plates using Autoplate 4000 at different times post-infection. 
Experiments involving mice were repeated twice (10 animals per group) and were 
conducted in accordance with the guidelines and policies of the Canadian Council on 
Animal Care and the principles set forth in the Guide for the Care and Use of 
Laboratory Animals, Animal Welfare Committee of the Université de Montréal.  
 
4.7 Inoculation of pigs 
 
Thirty Large White four-week-old piglets (from a high health status herd) were 
randomly grouped into 3 different pens one week before infection. Pigs were 
intravenously challenged via the ear vein with 1 ml of either S. suis strain P1/7, mutant 
B8A or mutant F8D at approximately 1 x 107 CFU in THB. Pigs were monitored daily p.i. 
for clinical signs of lameness, joint swelling, prostration, ataxia, recumbency, 
opisthotonus, paddling, and depression. Rectal temperature and body weight changes 
were also recorded. Results of rectal temperatures are expressed as fever index 
representing the percentage of observations for the experimental group of a body 
temperature >40°C. The presence of S. suis in blood samples was monitored when 
clinical signs appeared, and in organs (brain, meninges, liver) at post-mortem 
examinations [1]. Organs samples were homogenized with stainless steel beads 
(Qiagen), diluted in PBS and plated on Columbia agar (Oxoid Ltd., Basingstoke, UK) 
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plates with oxolinic acid (5 µg/ml), colistin sulphate (10 mµg/ml) and 5% (v/v) 
defibrinated horse blood. Pig experiments were conducted in the United Kingdom in 
accordance with the Animal Scientific Procedures Act 1986.  
 
4.8 Determination of cytokine levels in plasma from experimentally infected pigs 
 
Interleukin (IL)-6 and IL-8 were measured by ELISA using porcine-specific pair-
matched antibodies from R&D Systems (Minneapolis, MN, USA), according to the 
manufacturer’s recommendations. Twofold dilutions of recombinant porcine IL-6 (78 to 
5000 pg/ml, R&D Systems) and IL-8 (18 to 1200 pg/ml, R&D Systems) were used to 
generate standard curves. Sample dilutions giving optical density readings in the linear 
portion of the appropriate standard curve were used to quantify the levels of each 
cytokine. Standard and sample dilutions were added in duplicate wells to each ELISA 
plate (Nunc, VWR, Ville Mont Royal, QC, Canada), and all analyses were performed at 
least three times for each plasma sample. Plates were read using a Molecular Devices 
UVmax (Molecular Devices Corp, Sunnyvale, CA, USA) microplate reader.  
 
4.9 Statistical analysis 
 
All data are expressed as means ± standard deviations (error bars). Unless 
specified, data were analyzed by two-tailed, unpaired t test and all assays were 
repeated at least three times. Statistical analysis of the survival and body weight data 
were performed with the LogRank test and the Mann-Whitney Rank Sum test, 
respectively. A P value of < 0.05 was considered as the threshold for significance. 
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ANNEX 5. ARTICLE VIII. TABLES 
Table 1: Genes identified from less invasive S. suis Tn917 insertion mutants with 
PBMEC 
Mutant  Gene a Putative function 
(Organism) 
Adhesio
nb (%) 
Invasio
nb (%) 
GenBank 
identification 
Referen
ce 
Surface protein 
B8A ssu188
9  
LPXTG-motif cell wall 
anchor domain (Bacillus 
cereus subsp. cytotoxis 
NVH 391-98) 
66 21 YP_00137633
1 
 
NA 
       
Transport/binding 
F8D ssu083
5 
ABC-type multidrug 
transport system, ATPase 
component (S. suis 
05ZYH33)  
37 18 ABP89860 [50] 
H4F ssu083
3 
Putative bacteriocin operon 
protein (S. suis 05ZYH33) 
75 7 ABP89858 [50] 
       
Regulatory functions 
B9B ssu082
8 
Response regulator 
consisting of a CheY-like 
receiver domain and a 
winged-helix DNA-
binding domain (S. suis 
98HAH33) 
44 18 ABP92047 [50] 
G7E ssu100
5 
Regulatory protein, GntR 
(S. suis 89/1591) 
37 18 ZP_00875100 NA 
I10B ssu045
5 
Putative mercuric resistant 
regulatory protein merR (S. 
suis)  
50 27 BAB83973 [28] 
       
Metabolism 
B1A ssu019
9 
Phosphotransferase system 
cellobiose-specific 
component IIC (S. suis 
05ZYH33) 
13 29 ABP89180 [50] 
B2D and 
C3A 
ssu089
0 
Aldose 1-epimerase (S. 
suis 89/1591)  
20 4 ZP_00874440 NA 
D12D ssu117
5 
Lactoylglutathione lyase 
and related lyases (S. suis 
05ZYH33)  
65 17 ABP90309 [50]  
E5H ssu099
0 
NUDIX hydrolase (S. suis 
89/1591)  
49 7 ZP_00875084 [46] 
H3H ssu079
7 
Short-chain alcohol 
dehydrogenase (S. suis 
05ZYH33) 
36 3 ABP89821 [50] 
       
Amino acid synthesis 
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E12F ssu083
8 
Carbamoylphosphate 
synthase large subunit (S. 
suis 05ZYH33) 
9 8 ABP89862 [50] 
J7E ssu161
1 
Aspartokinase (S. suis 
05ZYH33) 
48 7 ABP90777 [50] 
H3F ssu041
1 
Shikimate kinase (S. suis 
05ZYH33) 
73 25 ABP89424 [50] 
       
Protein synthesis 
E7A ssu047
0 
Lysyl-tRNA synthetase, 
class-II (S. suis 05ZYH33) 
64 17 ABP89485 [50] 
      
 
Hypothetical proteins 
A8E and 
E12D 
ssu090
6 
Hypothetical protein (S. 
suis 05ZYH33) 
13 30 YP_00119841
5 
[50] 
J2F ssu082
3 
Hypothetical protein (S. 
suis 98HAH33) 
59 7 YP_00120044
1 
[50] 
a Genes are named in accordance with the S. suis strain P1/7 sequencing project 
nomenclature. 
NA: not available 
b
 Levels of adhesion to and invasion of PBMEC obtained with parental strain P1/7 are 
considered as 100%. 
 
Table 2: Virulence of S. suis wild-type strain P1/7 and five Tn917 insertion mutants in 
CD1 mice  
 No. 
of 
mice 
Morbiditya 
(%) 
Mortalityb (%) No. of mice in which S. suis was isolated 
from: 
    blood brain liver 
P1/7 10 100 70 8 9 8 
       
F8D 10 20 0 1 2 1 
B8A 10 90 20 4 4 2 
A8E 10 70 60 7 8 7 
E5H 10 80 80 8 8 8 
I10B 10 100 100 10 10 10 
       
negative 10 0 0 0 0 0 
aPercentage of mice with clinical symptoms.  
bPercentage of mice that died due to infection or were sacrificed for animal welfare 
reasons.  
These measurements were performed over a period of 10 day post-infection.
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ANNEX 5. ARTICLE VIII. FIGURES 
 
 
 
 
Fig. 1. Southern-blot of S. suis 
wild-type P1/7 and Tn917 mutant 
chromosomal DNA digested with 
EcoRI restriction endonuclease 
and hybridized with a DIG-
labelled-probe specific for the 
erm gene. Lane 1, DNA Molecular 
Weight Marker II, DIG-labelled 
(Roche); Lane 2, wild-type S. suis 
P1/7; Lane 3 to 7, 5 individual S. 
suis Tn917 mutants used in mouse 
in vivo experiments  (A8E, B8A, 
E5H, F8D, and I10B, respectively). 
All the mutants presented only 
one insertion of the transposon. 
 
Fig. 2. Survival curves for CD1 
mice infected with the wild-
type strain P1/7 and 5 Tn917 
insertion mutants. Six-week-old 
CD1 mice were inoculated i.p. 
with 2 x 107 bacteria, and mice 
survival was monitored over a 
10-day period. Data are 
expressed as mean percentage 
of live animals in each group 
(n=10). 
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Fig. 3. (A) Virulence of S. suis wild-
type strain P1/7 and two Tn917 
insertion mutants in pigs. 
Morbidity and mortality represent 
the percentage of pigs with clinical 
symptoms and the percentage of 
pigs that were sacrificed for 
animal welfare reasons, 
respectively. Fever indice 
represents the percentage of 
observations for the experimental 
group of a body temperature 
>40°C. (B) Levels of IL-6 in swine 
plasma from pigs infected with S. 
suis wild-type strain P1/7 and two 
Tn917 insertion mutants 24h 
post-infection. Bars indicate mean 
IL-6 level for a group.  
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